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Chapter 2 discusses the synthesis of the arenearylpyrimidylmethanes (AAPMs) series 
was investigated to further develop the structure activity relationships (SAR) of these 
compounds as potential anti-chikungunya virus agents. 1-(4,6-Dichloropyrimidin-5-yl)-
2-methyl-1-(3-nitrophenyl)propan-1-ol was prepared in 50% yield. Subsequent 
dehydration and amination gave the intermediate 4-amino-6-chloro-5-(2-methyl-1-(3-
nitrophenyl)prop-1-en-1-yl)pyrimidine in 90% yield, over two steps. Final amination 





was attempted using several conditions, however, the desired final AAPM derivatives 
were not obtained.  
Further modification of the synthetic protocol was achieved through the replacement of 
the 4,6-dichloropyrimidine with the less hindered 4-chloropyridine. The 4-
chloropyridin-3-yl alcohols were prepared in 42-52% yield. Subsequent dehydration 
afforded the 4-chloropyridine alkenes in 62-85% yield. Final replacement of the 




-diethylpentane-1,4-diamine was attempted under 
different conditions, however, the desired products were not obtained. Instead the 3-
(cyclobutylidene(4-phenoxypyridin-3-yl)methyl)aniline was isolated when using phenol 





diamine with the secondary amine morpholine gave 4-(3-(cyclopropylidene(3-
nitrophenyl)methyl)pyridin-4-yl)morpholine in 65% yield.  
 
Chapter 3 discusses a development of a virtual screening computer model for the 
Chikungunya virus (CHIKV) non-structural protein 3 (nsP3) macro domain, using the 
ADP-ribose binding site as a possible druggable pocket for potential inhibitors. The 
NCI diversity set III of 1990 compounds were screened against the nsP3 using 
Autodock Vina as the virtual screening engine with 17 hits initially identified as 
stronger ligands than the original co-crystallized ligand (ADP-ribose). The hits were 
further screened in a second round docking using Autodock 4 where 7 hits were ranked 





terephthalamide hit achieved a binding energy (ΔGbind) of -11.31 Kcal/mol and a 
predicted inhibitory constant (Ki) value of 5.1 nM and was selected for further in silico 







yl)phenyl)oxalamide was selected as an optimized ligand with ΔGbind of -13.12 
Kcal/mol and Ki value of 0.239 nM, a more than 21 fold improvment in the combined in 
silico binding profile to the nsP3 active site. This optimized ligand was chemically 
accessed in three facile synthetic steps, starting with the synthesis of the 2-(3-
nitrophenyl)-1H-benzo[d]imidazole-5-carbonitrile. Subsequent reduction of the nitro 
group afforded the 2-(3-aminophenyl)-1H-benzo[d]imidazole-5-carbonitrile in 80% 
yield. Reaction with oxalyl chloride finally afforded the target optimized hit in 69% 
yield. Compounds are under anti-chikugunya and cytotoxicity evaluation. 
 
In chapter 4, a series of benzolactone-acid conjugates, benzolactone-tetrazole 
conjugates and isatin-acid conjugates were prepared as mycophenolic acid derivatives to 
be evaluated as potential inhibitors for the CHIKV. The benzolactones were synthesised 
through the Pd catalysed cyclization of benzoic acids. The isatin cores were accessed 
from the corresponding aniline derivatives. Suzuki coupling with 3-(3-
boronophenyl)propanoic acid afforded the acid conjugates. The tetrazole conjugates 
were accessed via two pathways: the formation of the acetonitrile intermediates via a 
Suzuki reaction with either 3-(3-boronophenyl)propanoic acid or 2-(3-(4,4,5,5-
tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)acetonitrile, with subsequent 
cycloaddition reaction with NaN3. The second pathway to access the tetrazole 
conjugates was through a one step Suzuki reaction with the synthesized potassium 5-
((3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)methyl)tetrazol-1-ide. The 
synthesized benzolactones-acid conjugates, benzolactone-tetrazole conjugates and 
isatin-acid conjugates have drug like qualities, as they are water soluble and have 
LogD5.5 values in the range of 1-4. Therefore, this series could be further developed as 
orally bioavailable compounds. These compounds are under anti-chikugunya 
evaluation. 
 
In chapter 5, the crystal structure of the CHIKV nsP2 (the viral protease) was 
investigated for druggable binding sites for the development of possible inhibitors. Two 
sites were detected, one within the proteolytic C domain, and one within the 
NTPase/RTPase N domain. A computer virtual screening model was developed for each 
site, where the Life Chemicals cysteine protease inhibitor library of 28,960 compounds 
was screened in both sites using the FRED virtual screening engine. The interacting 
ix 
 
residues were determined for each hit. A second round of refining docking was 
performed on the top FRED hits, using Autodock. The top 5 hits in each site were 
recorded and purchased for anti-chikungunya evaluation. 
 
Chapter 6 discusses the development of a virtual screening computer model to identify 
novel binding sites for the chikungunya envelope glycoproteins. The model enabled the 
identification of possible antagonists for these sites through virtual screening using two 
successive docking scoring functions; FRED docking for fast precise screening, with 
the top hits then subjected to a ranking scoring using the Autodock algorithm. Both the 
immature and the mature forms of the chikungunya envelope proteins were included in 
the study to increase the probability of finding positive and reliable hits.  Some small 
molecules were identified as good in silico chikungunya virus envelope proteins 
inhibitors, representing templates for drug design targeting this virus.  
 
In chapter 7, three facile synthetic steps were developed to synthesize analogues for the 
lead N-(1-(ethylsulfonyl)-1,2,3,4-tetrahydroquinolin-7-yl)-2-fluorobenzenesulfonamide 
that was discovered through a high throughput screening of 87,926 compounds (WEHI 
2003) library against Trypanosoma brucei. The first step in the synthetic pathway was 
the sulfonation of the secondary amine of the commercially available 7-
nitrotetrahydroquinoline using the appropriate sulfonyl chlorides. Subsequent reduction 
using Raney Nickel and hydrazine hydrate afforded the 7-aminotetrahydroquinoline 
intermediates which were reacted with the appropriate sulfonyl chlorides to afford the 
final bis-sulfonamide analogues. Evaluation of the anti-trypanosoma activity of the 
compounds revealed the activity of some analogues with the IC50 values in the range of 
2-4 µM, with good selectivity indices.  
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CHAPTER 1: Introduction 
 
1.1. Classification, History and Clinical Features 
Chikungunya virus (CHIKV) is an emerging arthrogenic arbovirus that belongs to the 
alphavirus genus, family Togaviridae. It has been responsible for major outbreaks of a 
devastating human arthritis disease during the past five years.
1
 Chikungunya fever 
caused by the virus was first described in 1952,
2
 after an outbreak on the Makonde 
Plateau (named after an ethnic group from East Africa), along the border between 
Tanganyika and Mozambique. During this period, a high proportion of residents of all 
ages were affected by a distinctive disease with a sharp onset of crippling joint pains, 
severe fever, and a conspicuous rash.
2
 The elders of the Makonde tribes could not 
remember any previous, similar epidemics with these symptoms, suggesting that this 
was a new illness. The word ‘‘Chikungunya’’ translates to ‘‘that which bends up’’ 
relating to the stooped posture developed as a result of rheumatologic inflammation.
3
 
After that, only minor outbreaks occurred periodically in Africa, but some major 
epidemics were reported in the 1960s and 70s in India and Southeast Asia.
4
 After the 
1973 outbreak in India, only sporadic activities were detected over the next 30 years, 
with no major recurrence until a large outbreak in Kenya in 2004.
5
 This outbreak 
initiated a spreading epidemic that reached numerous islands of the Indian Ocean, India, 
and parts of Southeast Asia, and was also detected in 18 countries throughout Asia, 
Europe, and North America via imported infectious carriers. Over the course of five 
years, an estimate of more than 2 million cases occurred, with outbreaks in several 
countries where the virus had not been previously documented.
6
 The first European 
detection of CHIKV occurred in Italy in 2007.
7,8
  
Nearly 40 countries have detected chikungunya virus infected cases so far 
(Figure 1.1). The virus was listed in 2008 as a category C priority pathogen by the US 
National Institute of Allergy and Infectious Diseases (NIAID) that include pathogens 
which could be engineered for mass dissemination in the future, because of the high 
morbidity and mortality rates and major health impact.
9,10
 Recent epidemics were 
reported in India (1.4 to 6.5 million cases in 2006-2007), 3,000 – 42,000 cases were 
detected in 2009 in Malaysia and Thailand.
11,12
 The CHIKV mortality rate has been 
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estimated to be 1 in 1000 and most of the deaths occur in neonates, adults with 




Figure 1.1 Chikungunya virus Worldwide distribution,
10
 figure used with permission 
from NPG (Nature publishing group). 
 
CHIKV can be transmitted through an urban cycle, man to mosquito to man, or 
a sylvatic cycle, animal to mosquito to man.
13
 The virus is transmitted to humans by 
mosquitoes of the Aedes genus (Aedes furcifer in Africa and Aedes aegypti in Asia), 
similar to the dengue fever causing virus. However, the Ae. albopictus mosquito was 




The switch of the CHIKV vector from Ae. aegypti to Ae. albopictus was caused 
by the insufficient Ae. aegypti number for its transmission.
14
 A mutation in the E1 
envelope protein, A226V, increased the CHIKV fitness in Ae. albopictus and improved 
the transmissibility of the virus through Ae. albopictus to vertebrate species.
15
 Ae. 
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albopictus has spread to Madagascar, the Indian Ocean nations, Africa, Southern 
Europe and the USA.
16,17
 Virus transmission has been also reported as a result of 




Chikungunya fever (CHIKF): The symptoms of CHIKF infection generally start 4–7 
days after the mosquito bite. Infection tends to present in two phases, the first stage is 
acute, while the second stage is persistent (chronic), causing disabling polyarthritis.
19
 
Acute infection lasts 1–10 days and is characterized by a painful polyarthralgia, high 
fever, asthenia (weakness), headache, vomiting, rash, and myalgia (muscle pain). Rash 
is the least reliable symptom, presenting in as few as 19% of patients. When a rash is 
present, it is typically maculopapular in nature, but recent studies have also noted 
vesiculobullous lesions with desquamation.
20
 The persistent chronic CHIKF phase is 
characterized by polyarthralgia (aches in the joints, joint pains) that can last from weeks 
to years beyond the acute stage.
21
 Eighteen months after disease onset, 40% of patients 
are found to still have anti-CHIKV immunoglobulin M (IgM).
22
  
CHIKV attacks fibroblasts, explaining the involvement of muscles, joints, and 
skin connective tissues. The high number of nerve endings within the joints and muscle 
tissues explains the pain associated with CHIKF. Neurological manifestations have also 
been reported during the most recent epidemics. In India, some neurological disorders 
such as encephalitis, peripheral neuropathy, myelopathy, myeloneuropathy and 
myopathy were reported.
23
 Moreover some cases with multi-organ failure have also 
been reported.
24 Eye infection (Chikungunya neuroretinitis) has also been reported 
where patients suffered from a sudden, painless diminution of vision in both eyes.
25,26
 It 





1.2. Virology of the CHIKV  
The CHIKV genome (Figure 1.2) is a positive sense, single stranded RNA genome of 
about 11.8 Kb in size. It consists of two open reading frames (ORFs),
28
 one in the 5` 
end encoding the non-structural protein (nsP) precursors: 
 nsP1: involved in viral mRNA capping via its guanine-7-methyltransferase and 
guanylyltransferase enzymatic activities,  
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 nsP2: acts as protease and helicase,  
 nsP3: part of the replicase unit and an accessory protein involved in RNA synthesis, 
 nsP4: RNA-dependent-RNA polymerase,  
The nsP123 precursor and nsP4 function in a complex for viral negative-strand 
RNA synthesis. The 3` end ORF encodes the structural proteins, the capsid (C), 
envelope glycoproteins E1 and E2 and two small cleavage products (E3, 6K). The 
untranslated junction region (J) (Figure 1.2) contains its internal promoter, a conserved 





Figure 1.2 Schematic representation for The CHIKV genome showing the RNA 
sequence ORFs. 
 
The CHIKV surface consists of 80 trimeric spikes composed of heterodimers of 
the envelope glycoproteins (E1 and E2) in the lipid bilayer. Similar to other members of 
the alphaviruses, the CHIKV starts its life cycle (Figure 1.3) by entering the target cells 
by pH dependent endocytosis in clathrin coated vesicles via receptor mediated 
interaction,
30
 but the exact mechanism by which it does so remains unclear. CHIKV has 
been shown to replicate in a large number of cell types including epithelial, endothelial 
and fibroblast cells as well as monocyte derived macrophages.
30
 A recent study 
identified prohibitin (PHB) as a microglial cell expressed CHIKV binding protein.
31
 
PHB is an evolutionarily conserved and ubiquitous protein that consists of two highly 
homologous proteins of different molecular weights. PHB1 has a mass of approximately 
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30 kDa while PHB2 is approximately 37 kDa. The two proteins oligomerize, and 
hetero-oligomerization is essential for protein stability.
32
 PHB has been shown to be 
present in multiple cell compartments including the mitochondria, cytoplasm and 
nucleus in addition to its expression on the cell surface.
33
 PHB1 was confirmed as a 
CHIKV E2 binding protein, but not PHB2.
31
 PHB1 was found to be involved in the 
internalization process either on its own or as part of a complex, further suggesting that 
a PHB-virus interaction may be mediated by the specific PHB molecule that interacts 
with the virus. Experimental down-regulation of PHB1 significantly reduced the level 
of infection in tested cell lines. However, it is believed that this mechanism might be 





Figure 1.3 Schematic representation of the Chikungunya virus life cycle. 
 
After entering the cell, the endosome acidic environment triggers conformational 
changes, the viral envelope proteins (E1 and E2 complex) reorganizes, leading to 
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dissociation of the E2-E1 heterodimers, and the formation of E1 homotrimers. E1 
trimerizes and inserts into the target membrane with the hydrophobic fusion peptide 
(fusion loop) and refolds to form a hairpin-like structure. Exposure of the E1 fusion 
peptide mediates virus host cell membrane fusion, releasing the nucleocapsid into the 
cytoplasm.
34,35
 This process depends on low pH and  cholesterol, which is also required 
for budding during  alphavirus infection.
36,37
 
Two non-structural protein precursors are translated from the viral mRNA, and 
then are cleaved generating nsP1, 2, 3 and 4. During translation, nsP123 binds to free 
nsP4 and with some cell proteins, forming the replication complex,
38,39
 which 
synthesizes a full-length negative-strand RNA intermediate required for replication. 
When nsP123 concentration  increases, it is cleaved into nsP1, nsP2, nsP3 and nsP4 
which forms, along with host cell proteins, the positive strand replicase, which produces 
the 26S sub-genomic positive strand RNAs and genomic (49S) RNAs.
39
 Promoters 
present in the negative strand initiate the transcription of 26S sub-genomic positive 
stranded RNA which encodes the structural protein precursors. The later is cleaved by a 
serine protease to yield the capsid (C) which remains in the cytoplasm (Figure 1.3), 
pE2, 6K and E1.
40
  The C protein might be responsible for such autoproteolytic activity 




pE2 and E1 are translated in the endoplasmic reticulum (Figure 1.3) and 
processed in the Golgi, and are moved to the plasma membrane, where pE2 is cleaved 
by furin-like protease activity in the host cell into E2 and E3.
42
 The assembly of virions 
begins in the cytoplasm of the cell, where the formation of the nucleocapsid with 120 
dimers of the C protein starts to occur.
43
 The assembled particle buds at the cell 
membrane as spherical particles of 65 to 70 nm in diameter, composed of genomic RNA 
molecules and the capsid proteins and enveloped in a host-derived lipid membrane.  
1.3. The Development of CHIKV Vaccine  
There is an urgent need to control the spreading CHIKV, however, there is little 
understanding of the interaction between the chronic CHIKV infection and the immune 
system in defending the body against any subsequent reinfection.
10
 The immune 
responses are strongly accepted to induce autoimmunity, by cross reactivity between 
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viral and host antigens. The B cells and T cells might respond to CHIKV and this may 
contribute to the long-term joint disease experienced by many convalescent patients.
44
  
Thus far, there is no licensed CHIKV vaccine. Some vaccine preparations that 
involved either formalin inactivation or Tween-ether extracts of virus
45
 showed high 
immune responses without any adverse effects. In 2000, the US Army carried out a 
Phase II clinical trial examining a live attenuated CHIKV vaccine.
46,47,48
 The vaccine 
was formulated from human MRC-5 cell line. In this study, subjects that received the 
vaccine developed neutralizing antibodies, with few subjects showed mild joint pain 
compared to those who did not.
48
 
In 2009, one study reported a vero cell adapted formalin inactivated prototype 
vaccine with alhydrogel as adjuvant that was prepared using an Indian CHIKV strain 
implicated in the 2006 epidemic. The humoral immune response was characterized by 
high titer antibodies that have been confirmed through microcytotoxicity assay and in 
vivo neutralization tests. Therefore, this could be a promising, safe and effective vaccine 
that can elicit long lasting protective immune response.
49
  
A live CHIKV vaccine was developed in 2011 that elicits a protective immune 
response with no detectable disease in mice. It is also unable to infect mosquito vectors, 
which is an important safety feature for a live virus vaccine that could be used in non 
endemic areas to immunize travellers or laboratory personnel. However, this vaccine 
candidate is still under evaluation in nonhuman primates, before evaluation in humans.
50 
Other promising CHIKV vaccine candidates that depend on virus-like particles are in 
early stages of preclinical development.
51,52 A successful virus-like particle vaccine 
based on viral structural proteins was tested on nonhuman primates and was found to 
produce neutralizing antibodies that protect against viremia after high-dose challenge. 
When these antibodies were transferred into an immunodeficient host (a mouse), the 
host was protected indicating a passive immunity.
53
  
With the ongoing vaccine development research against the CHIKV, the world 
remains under the threat of rapidly spreading CHIKV infections, emphasizing the 
importance of developing chemotherapeutics targeting the virus.  
1.4. Emerging novel CHIKV targets 
As previously mentioned, the CHIKV genome is formed from 2 ORFs, one in the 5` end 
coding for nsP1, nsP2, nsP3 and nsP4. The 3` end ORF encodes capsid (C), envelope 
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proteins E1, E2, E3 and 6k (Figure 1.2). These proteins, which mediate essential steps 
in the lifecycle (Figure 1.3) of the virus,
10
 could be possible targets for drug design.  
1.4.1. Non-Structural Proteins 
1.4.1.1. Non-structural protein 1 
Like in other alphaviruses, CHIKV nsP1 is a palmitoylated 535 amino acid protein. The 
N-terminal region is a methyltransferase and guanylyltransferase involved in capping 
and methylation of the newly formed viral genomic and subgenomic RNAs.
54
 In early 
2013, it was shown that CHIKV nsP1 acts as antagonist for the bone marrow stromal 
antigen 2 (BST-2).
55
 BST-2 is one of the host cell defensive mechanisms, and is 
induced by interferon (INFα). BST-2 expression results in retaining viruses at the 
surface of the infected cells.
56
 BST-2 was found to co-localize with CHIKV E1 and 
nsP1, but only nsP1 is able to down-regulate BST-2 expression and therefore, inhibiting 
the virus tethering on cell surface.
55
  This activity of the CHIKV nsP1 is similar to that 
of the HIV-1 Vpu protein
56
 in that both repress BST-2. This discovery will help in 
developing BST-2 mediated therapeutics targeting the nsP1. 
1.4.1.2. Non-structural protein 2 
The non-structural protein 2 (nsP2) of alphaviruses is a multifunctional protein.
57,58,59,60
 
The proteolytic domain has been allocated to its C-terminal section which forms a 
papain like cysteine protease (also known as thiol protease).
57,61
 The nsP2 proteolytic 




The proteolytic activity of the CHIKV nsP2 has been demonstrated,
64
 and the 
enzymatic activities within the N-terminus have been investigated recently. It was found 
to have RNA triphosphatase activity that performs the first of the viral RNA capping 
reactions. It was also found to have a nucleotide triphosphatase (NTPase) activity, 
fueling the RNA helicase activity performed by the C-terminal domain.
65
 CHIKV-nsP2 
also has 5`-triphosphatase (RTPase) activity that removes the γ-phosphate from the 5` 






Both N and C domains are composed of α-helices and β-strands (Figure 1.4). 
The N terminus is dominated by α-helices, whereas the C-terminal domain contains 
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helices and strands. The central β-sheets are flanked by α-helices. The crystal structure 
of CHIKV nsP2 protease has been solved and comprises 324 residues. Being a cysteine 
protease, the catalytic mechanism involves a nucleophilic cysteine thiol in a catalytic 
dyad.
66
 Analysis of the CHIKV nsP2 crystal structure shows 6 cysteine residues, three 
in the N-terminus (Cys1013, Cys1057 and Cys1121) and three in the C-terminus 
(Cys1233, Cys1274 and Cys1290) as shown in Figure 1.4. Since the proteolytic activity 
is isolated in the C-terminus,
64
 one of the three cysteine residues in the C-domain might 
contribute as the catalytic thiol.  
 
Figure 1.4 CHIKV nsP2 crystal structure showing the N- and C-terminal domains, 
cysteine residues shown in yellow balls and stick form (PDB code: 3TRK
67
, no citation 
was found for the crystal structure). 
 
The first step in the mechanism of cysteine proteases catalysis is usually the 
deprotonation of a thiol group within the enzyme active site by an adjacent amino acid 
containing a basic side chain, often a histidine residue.
68
 Among the three cysteine 
residues in the C-terminus (Figure 1.5), the Cys1274 residue is less likely to be involved 
in the catalytic mechanism because only one His residue (His1314) is nearby, whereas 
the other cysteine residues, four His residues, His1222, His1228, His1229 and His1236 
could be associated in the deprotonation mechanism (Figure 1.5).   




Figure 1.5 Schematic representation of the CHIKV nsP2 C-Domain showing the 
positions of the cysteine residues (yellow) and histidine residues (green). Distances (Å) 
shown in red, generated from the crystal structure PDB file code: 3TRK. 
 
In 2012, Singh Kh et al. reported  the development of a homology model of 
CHIKV nsP2 protein based on the crystal structure of the nsP2 protein of Venezuelan 
equine encephalitis virus (VEEV),
69
 in order to locate the active site of the protease. The 
critical residues in nsP2 were identified by docking three different peptides in order to 
identify the residues responsible for non-structural protein cleavage, nsP1-2, nsP2-3 and 
nsP3-4 peptides. These three peptide sequences represent the substrates for the nsP2 
proteolytic processing with a remarkable preference of nsP3-4>nsP1-2>nsP2-3.
70
 
The active site was investigated and was found to lie in the C-terminal domain
69
 
(Figure 1.5). The key residues Gln1039, Lys1045, Glu1157, Gly1176, His1222, 
Lys1239, Ser1293, Glu1296 and Met1297 were found to interact with the nonstructural 
protein sequence complex to be cleaved, and were considered an individual functional 
unit. Only two residues are located in the N-domain, Gln1039 and Lys1045, all the 
other residues are located in the C-domain. Similar work by Bassetto et al.
71
 reported 
the development of a homology model for the nsP2 protease active site within the C-
domain. 
The predicted active site by Singh Kh et al.
69
 and Bassetto et al.
71
 matches with 
the abovementioned  explanation concerning the poisoning the active site within the C-
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domain, especially, they found that His1222 residue to be lying within the predicted 
active site pocket. Analysis of the enzyme surface shows that the predicted active site is 
located in a major surface groove as shown in Figure 1.6, the major cavity on the 
enzyme surface is more likely to accommodate the substrate polyprotein sequence to be 
cleaved.  
 
Figure 1.6 Electrostatic potential surface of the CHIKV nsP2 and its active site pocket 
within the C-domain, a) The active enzyme surface front view showing the active site as 
a transparent red sphere surrounding the active site with the Cys1233 and His1222 
residues lying within the sphere. b) Side view of the enzyme (rotated left by 90º about 
the vertical axis from the view in a) showing the major accessible cavity to the active 
site with a part of the sphere protruding toward the outer surface, generated from the 
PDB file 3TRK.  
  
This major enzyme groove (Figure 1.6b) may act as the enzyme mouth holding 
the protein to be processed. Therefore, targeting the residues specified above,
69
 as well 
as the residues within the active site, would be an applicable strategy to inhibit the 
enzyme function and consequently inhibiting the virus replication. 
Moreover, the alphaviruses nsP2 proteins have been described as virulence 
factors responsible for the transcriptional and translational shutoff in infected host cells 
and the inhibition of interferon (IFN)-mediated antiviral responses contributing to the 
controlling of translational machinery by viral factors.
72,73
 This controlling comes 
through interactions with cellular RNA binding proteins, including heterogeneous 
nuclear ribonucleoproteins (hnRNPs), ribosomal protein S6 (RpS6), and cellular 
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filament components. Recently, 22 cellular components were hypothesized to interact 
with nsP2 or nsP4 contributing to the CHIKV replication, mainly, heterogeneous 
nuclear ribonucleoprotein K (hnRNP-K) and ubiquilin 4 (UBQLN4). Also, it was noted 
that the interaction of nsP2 with the tetratricopeptide repeat protein 7B (TTC7B) plays a 
significant role in the cellular machinery control induced by the CHIKV infection.
74
 
1.4.1.3. Non-structural protein 3  
The function of alphaviruses nsP3 has remained unknown, although mutations can 
affect different steps of the viral replication machinery.
75
 It is constructed of two 
domains, the first is a unique macro domain in the conserved N-terminal region. The C-
terminal region is less conserved and is phosphorylated in about 16 positions on serines 
and threonines.
76,77
 The function of phosphorylation is not understood, but it was found 
that deletion of these phosphorylated residues decreases the RNA synthesis level.
78
 
Interestingly, viral pathogenicity of Semliki Forest virus (SFV), another alphavirus, is 
decreased in the absence of phosphorylation on nsP3, and the absence of the C terminus 
alters SFV neurovirulence.
79
   
The N-terminus of nsP3 contains a macro domain (known also as X domain), 
which binds to ADP-ribose derivatives and RNA, and is able to hydrolyse ADP-ribose-
1``- phosphate,
80,81
 a side product of cellular pre-tRNA splicing. Therefore, it is 
believed to control the metabolism of ADP-ribose 1``- phosphate and/or other ADP-
ribose derivatives which have regulatory functions in the cell. The ADP ribose–binding 
site within the nsP3 macro domain is solvent-exposed and points away from the other 
domains in the nsP23 polyprotein. Based on sequence conservation in alphaviruses, it 
has been shown that residues just after the nsP3 macro domain play a role in positioning 
of the nsP23 complex cleavage site.
82
 It can be inferred from the crystal structure of the 
nsP23 precursor protein of the closely related alphaviruses, SINV, that the nsP2 is 
connected to the nsP3 through the macro domain of the nsP3.
83
 The nsP23 cleavage site 
is located in a narrow cleft formed between nsP2 and nsP3 that is inaccessible for 
proteolysis, and all the nsP2 noncytopathic mutants lie at the interface between nsP2 
and nsP3.
83
 The inaccessibility of the nsP23 cleavage site indicates that access is tightly 
regulated. It is believed that the activator segment is located in the amino-terminus of 
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In 2010, the crystal structure of the nsP3 macro domain for the CHIKV was 
solved
80
 (Figure 1.7). It is formed of 672 residues and contains six-stranded β sheets 
with three α helices. The intermolecular interactions between the residues in the binding 
pocket of the enzyme and the ADP-ribose,
85
 as analysed from the crystal structure, are 
shown in Figure 1.8. 
 
Figure 1.7 Crystal structure of the CHIKV macro domain with the bound ADP-ribose 
(yellow colour), generated from the PDB file code: 3GPO.  
 
Figure 1.8 2D representation of the interaction of ADP-ribose inside the nsP3 macro 
domain binding pocket showing the other residues inside the active site (Generated 
from the PDB file: 3GPO) 
As shown in Figure 1.8, the key binding residues are: Arg144, Asp10, Ile11 
Thr111, Gly112, Ser110, Tyr114, Val113, Asn24, Asp31 and Val33. The binding 
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showed the strongest interactions with these residues in the enzyme pocket. Also, the 
ribose (with Thr111) and the diphosphate (with Val 33, Ser110, Gly112, Val113, 




Understanding this binding interaction of the ADP-ribose to the macro domain 
of the CHIKV could therefore be a useful element to further assist in drug design and 
development of inhibitors for this virus. Bound inhibitors to the ADP-ribose binding 
pocket will alter the function of the nsP3 either cleaved or in a polyprotein complex, 
and consequently will alter the function of the viral replication machinery.  
Recently, more insights on the molecular function of the nsP3 revealed 
interesting findings, it was reported that the nsP3 of CHKV, as with other alphaviruses, 
use a conserved proline-rich motif to interact with the Src-homology-3 (SH3) domain of 
amphiphysin-1 and amphiphysin-2 proteins of the host cell, two related member 





 the nsP3 has been shown to be the inhibitor of stress granule 
assembly by recruiting G3BP into cytoplasmic foci. The conserved nsP3 SH3 domain-
binding motif (the proline-rich motif) is essential for both nsP3-G3BP interactions and 
viral RNA replication. G3BP (Ras GTPase-activating protein-binding protein) is an 
enzyme in human cells and a member of the heterogeneous nuclear RNA-binding 
proteins.
88
 This protein plays a major role during infection and in the assembly of stress 
granules. Stress granules are membranous cytoplasmic focal structures (foci) that 
immediately aggregate in response to cellular stress, this last action leads to impaired 
translation of most mRNAs.
89
 These stress granules may have antiviral activity that is 
inhibited by CHIKV replication by the nsP3 SH3 domain-binding motif.
87 
1.4.1.4. Non-structural protein 4 
The non-structural protein 4 was identified as the RNA-dependent-RNA 
polymerase,
29,90
 and recently was found to suppress the host cell unfold protein response 
(UPR), also named as endoplasmic reticulum (ER) stress response.
91
 The UPR is a 
mechanism that maintains the cellular protein homeostasis and prevents over-loading of 
unfolded protein in the lumen of the ER during normal and diseased cellular conditions. 
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The UPR involves some steps and some contributing proteins, including the PKR-like 
ER kinases (PERK).
92
 During the UPR, PERK activates by self-dimerization and 
phosphorylation; this activated PERK in turn, phosphorylates the serine 51 position of 
the eukaryotic translation initiation factor 2, alpha subunit (eIF2α), an essential factor 
for protein synthesis. Phosphorylated eIF2α inhibits the general protein synthesis, and 
consequently, will inhibit the pathogen protein replication. The CHIKV nsP4 was found 
experimentally to significantly reduce the phosphorylation (serine 51) of  eIF2α, and 
thus ensuring the translation of the viral protein.
91
 This discovery can be exploited as a 
possible target for anti-CHIKV intervention.  
1.4.2. Structural Proteins 
The invasion of susceptible cells by the CHIKV is performed by two viral 
glycoproteins, E1 and E2. Both carry the basic antigenic determinants and form the 
icosahedral shell of the virion particle. E2 and E3 are produced from furin cleavage of 
p62 (also known as PE2, see Figure 1.2) precursor. E2 is responsible for receptor 
binding whereas E1 mediates the membrane fusion.
10
 E3 contains the 64-amino-
terminal residues of p62.
93
 
E1 and p62 peptide are type I membrane proteins and are derived from a 
structural polyprotein precursor. They are translated in the infected cell endoplasmic 
reticulum, into a p62–E1 heterodimer and processed by the Golgi (Figure 1.3), E3 
protects the E2-E1 heterodimer from premature fusion with cellular membranes.
94
 The 
heterodimers trimerize forming the viral spikes. Cleavage of p62 into E3 and E2 during 
transport to the cell surface prepares the spikes for the fusogenic activation to enter the 
cell. At the plasma membrane, the formed virions bud through interactions between E2 
and genome-containing viral nucleocapsids in the cytoplasm.
95
  
In a recent study, the roles of four amino acid residues (G91, V178, A226, and 
H230) in the CHIKV E1 protein have been linked to the E1 and cell fusion process.
96
 
The study revealed that the highly conserved amino acid residues, G91 and H230, are 
important for membrane fusion functionality. The glycine residue (G91) is critical for 
the fusion process whereas any mutation or substitution in this residue leads to complete 
loss of E1 fusion ability.  The E1 histidine 230 is located outside of the fusion sequence, 
but is still critical for the fusion. Other structural proteins also affect the E1 fusogenic 
capacity. E2 protein facilitates both E1 folding and regulates E1 fusogenic properties. 
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This process is pH and cholesterol dependent.
96
 As an alphavirus family member, the 
hydrophobic fusion peptide of the CHIKV was found to be a trimer of hairpins 
composed of β-sheets in the post fusion state (type II fusion proteins).
97,98
 Figure 1.9 
shows the crystal structure of the CHIKV fusion peptide,
99
 consisting of 18 amino acid 
residues, residues 84−101 in the full-length E1 glycoprotein.95  
 
Figure 1.9 Hydrophobic surface view of the CHIKV fusion peptide showing the residue 
G91 in red label located at the back side (generated from the crystal structure of the 




The crystal structures of the CHIKV p62-E1 (immature) and the E3-E2-E1 
(mature) glycoprotein complexes have been recently solved (Figures 1.10-1.12). E1 is 
folded into three domains I, II and III (Figure 1.11) that are rich in β-sheets. E2 is an 
immunoglobulin β protein, with three domains (A, B and C). Domain A is at the centre, 
domain B is at the membrane upper end whereas domain C is towards the viral 
membrane. The later binds to domain II of E1 by hydrogen bonding due to the 
hydrophilic contact area between them (Figure 1.10). The long β – ribbon of E2 makes 
most of the connection with E3 (Figure 1.12). Furin loop (Figure 1.10) is the E2E3 
junction in the immature complex, and this junction contains a functional proprotein 
convertase motif which is cleaved by the cellular proteases, furin-like proprotein 
convertases, during the maturation (Figure 1.3) of the glycoproteins.
42
 Variations within 
this junction site among the different CHIKV isolates greatly affect the cleavage 
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susceptibility by furin proteases. The amino acid His60 (residue 56 in the crystal 
structure PDB file: 3N40) is the critical residue that determines the spectrum of furin 
and furin-like convertases that process the E2E3 glycoprotein complex.
100
 It can be 
inferred from the comparison between the structures of the immature and the mature 
glycoprotein complex,
95
 that the short peptide sequence (Pro59, His60, Arg63, Glu64, 
Ser65, Thr66, Lys67 and Asp68) is cleaved form the immature complex after furin 
cleavage. 
 
Figure 1.10 Crystal structure of the immature envelope glycoprotein complex of 
Chikungunya virus, E1 formed of domains I, II and III. E2 contains domains A, B and 
C, generated from the PDB file code: 3N40.
95
 E3 stabilizes the E2 β–ribbon connector
94
 
being associated with domain A of E2 and domain II of E1, allowing domain B to 
protect the fusion loop. 
 
The U shaped fusion loop of E1 is inserted in a cavity that lies between E2 
domains A and B that is stabilized by hydrogen bonds (Figure 1.13) with E2 histidine 
side chains.
95
 At neutral pH, E3 maintains the relative orientation of the E2 domain B 
and the domain A, creating the cavity space accommodating the E1 fusion loop. This 
orientation by E3 protects the virus from premature fusion with other cellular 
membranes.
95,101
 The fusogenic activity of the E1 fusion peptide is therefore, highly 
dependent on pH change. The histidine residues of E2 act as the pH sensor for the 
activation of the fusion protein at lower pH
95
 due to the increased probability of 
histidines to become positively charged at lower pH values (acidic endosome), based on 
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the fact that the imidazole ring of the histidine residue is the only amino acid side chain 
whose apparent dissociation constant from protons (pKa; acid dissociation constant at 
logarithmic scale) falls within the physiological range. 
 
Figure 1.11 Crystal structure of E1 glycoprotein formed of 393 residues (residue 402-
residue 794 within the whole complex structure), separated from the complex for 





Figure 1.12 Crystal structure of E2, E3 glycoprotein complex formed of 401 residues 
(residue 1-residue 401 within the whole structural protein complex), separated from the 




Some important locations (transitional epitopes) were identified in both E1 
(domain III) and E2 (domain B) of alphaviruses: these locations become accessible 
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upon exposure to heat or low pH.
102,103
 These locations are also accessible upon the 
contact of the virions with the susceptible cells. This contact leads to conformational 
changes related to cell binding,
104
 e.g. domain B moves out in relation to domain A 
opening the cavity, and the fusion loop now becomes free to release.
95
 This occurs 
without a full dissociation of the E2–E1 heterodimer. Other residues in domain B of E2 
are believed to be associated with cell recognition assuming that several sites on the 
virus surface can interact with different cell receptors and therefore, these residues may 




Figure 1.13 Crystal structure of the CHIKV mature envelope glycoprotein complex. E1 
is viewed as hydrophobic surface with the critical amino acid residue Gly91
99
 of the 
fusion loop labelled in black. E2 and E3 are viewed as solid ribbon, with histidine 
residues on E2 viewed as stick structures in red surrounding the fusion loop and acting 
as the pH sensors
95




1.5. Highlights for the CHIKV emerging targets  
With the recent growing knowledge and available structural information about the 
CHIKV genome, drug design of particular inhibitors targeting individual viral proteins 
has become more real. The most promising targets from a chemical and biological 
standpoint would be the viral protease (nsP2) and the viral envelope proteins. The first 
protein has a complete crystal structure for the protein N and C domains, while the 
critical residues for the proteolytic activity have already been investigated. This nsP2 
Chapter 1  Introduction  
20  
 
protein also functions through the N domain, and therefore, it would be interesting for 
medicinal chemists to investigate all possible options to inhibit the function of this viral 
protein within the two domains. The challenge here is the lack of a tool to validate the 
inhibitory effects of the designed protein antagonists, rather than whole cell assay 
protocols. Therefore, extensive efforts should be devoted to investigate the use of the 
nsP2 as an applicable target for the structure based drug design. The second promising 
protein target is the viral envelope proteins, with several residues identified to be 
essential for the viral fusion process such as the Gly91 and His230 residues. Designing 
specific inhibitors targeting the viral fusion process would be valuable for the inhibition 
of the alphaviruses in general. The viral nsP3 also represents a possible drug design 
target, with the structure of the conserved macro domain already known. However, this 
target requires further investigation, such as the complete protein structure as well as a 
tool to validate the inhibitory activity of the designed antagonists. 
1.6. Development of chemotherapeutics against CHIKV: new medicinal chemistry 
leads  
There is currently no recognised single antiviral treatment for chikungunya. During the 
recent outbreaks that occurred in the Indian Ocean nations, only surface treatments were 
available, based on non-steroidal anti-inflammatory, non-salicylate analgesics and 
fluids. Mild physical exercise is believed to decrease the joint stiffness, but heavy 
exercise may increase the rheumatic pain. During the chronic CHIKV infection, 
corticosteroids may be used to help decrease the inflammation.
105 The status of drug 
discovery for the CHIKV is still in the early stages with no drugs currently in clinical 
trials. The first mouse model to study the pathophysiology of the resulting disease was 
developed in 2008,
106
 after which several animal models were developed to aid the 
understanding of the drug-disease interactions that would facilitate the development of 
an effective therapy.
107 
1.6.1. Protease inhibitors 
Targeting the CHIKV nsP2 protease activity within the C-domain, would have an 
inhibitory effect on viral replication. Using the developed homology model for the 
nsP2, Singh and coworkers screened, in silico, a library of compounds to identify 
potential hits for the predicted active site. Four compounds (1-4) shown in Figure 1.14, 
were identified as potential in silico inhibitors for the nsP2 protease.
69
 Ideally, binding 
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to this active site will block the protein function and will stop the replication cycle. 
However, the actual antiviral activity of these hits (1-4) has not yet been investigated.        
         
Figure 1.14 Chemical structure of the four identified in silico CHIKV nsP2 inhibitors. 
 
In similar work, Bassetto et al.
71
 reported the identification of in silico CHIKV 
nsP2 inhibitors through virtual screening of a large compound library using the 
developed homology model for the CHIKV nsP2. One of the hits, compound 5 (Figure 
1.15) was predicted to bind to the central portion of the nsP2 protease active site, with 
its hydrazone group placed in the region defined by the catalytic dyad. The in vitro 
activity of this hit compound was assessed and it was found to inhibit the virus at EC50 
value of 5 µM and selectivity index (SI) value of 14, through the inhibition of the virus-
induced cytopathic effect.
71
 The central cyclopropyl and the hydrazone moieties were 
found, through a structure activity relationship study, to be important for the anti-
chikungunya activity. A series of derivatives were also designed based on these 
identified pharmacophores of (5). When the cyclopropyl group was replaced with a 
trans-ethenylic moiety maintaining length and geometry of the original linker (6, Figure 
1.15), the antiviral activity was slightly improved. Compound (6) displayed EC50 value 
of 3.2 µM and selectivity index (SI) of 32. The binding modes of both compounds (5, 6) 
inside the nsP2 pocket were similar.
71
 




Figure 1.15 Chemical structure of the CHIKV inhibitors identified from the in silico 
screening, red circles indicates the only difference in the structures responsible for the 
activity change. 
 
1.6.2. Furin inhibitors 
Infection by alphaviruses can be inhibited in vitro by blocking the intracellular furin-
mediated cleavage of viral envelope glycoproteins: the E2E3 or p62 precursors.  This 
blocking was demonstrated by showing the inhibitory effect of an irreversible furin-
inhibiting peptide, decanoyl-RVKR-chloromethyl ketone (dec-RVKR-cmk, 7, Figure 
1.16) on in vitro CHIKV infection.
100
 This peptide significantly reduces the processing 
of E3E2 CHIKV glycoproteins in infected myoblast cultures and led to the formation of 
immature viral particles and impaired viral spreading among cells, but not the 
replication in the already infected cells.
100
 Therefore, the chemical structure of the furin-
inhibiting peptide (7) could be a starting point for generating novel generations of active 
peptidomimetics using the ligand based drug design techniques, targeting the 
intracellular furin cleavage step.  
 
Figure 1.16 Chemical structure of the furin-inhibiting peptide (7). 
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1.6.3. Chloroquine and Quinine 
The in vitro antiviral activity of chloroquine (8, Figure 1.17) was first reported more 
than 35 years ago and has been successfully used as anti-malarial drug.
108,109
 
Concerning the alphaviruses, chloroquine was found to be effective in vitro,
110,111,112
 but 
a few years later, a mouse model revealed that chloroquine may enhance viral 
replication in vivo leading to aggravation of the disease.
113
 Regarding the CHIKF, 
chloroquine and chloroquine phosphate have been used in the treatment of chronic 
chikungunya arthritis,
114
 only for the anti-inflammatory properties of the molecule (used 
in chronic rheumatologic diseases) rather than for the antiviral effect. Some studies 
suggest that chloroquine might interact with the endosome-mediated internalisation 
process during the infection cycle, stating that chloroquine might be classified as an 
entry inhibitor. Chloroquine 8 entered phase 3 clinical trials in France as a therapy for 
the CHIKV in 2006, however, these studies were terminated in 2007 without promising 
results. 
 
Figure 1.17 Chemical structures of chloroquine (8) and quinine (9). 
 
In one clinical study, the effect of chloroquine 8 on CHIKF patients was 
investigated using another placebo treated group of patients, and at the conclusion of the 
study period, there was no statistical difference between the chloroquine and the 
placebo treated groups regarding the mean duration of febrile arthralgia or the decrease 
of viraemia (viral count in plasma). However, these contradicting results casts serious 
doubt as to the effectiveness of chloroquine as an effective chemotherapeutic against 
CHIKV and until resolved, it should be treated with caution as a drug lead.
105
  
Another anti-malarial drug, quinine (9, Figure 1.17), also inhibits the virus in 
vitro in a concentration less than that of chloroquine (IC50 = 0.1 µg/ml for quinine, 1.1 
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µg/ml for chloroquine). Also, quinine is suggested to affect the nsP1 as mutations in this 
protein occur upon growing the virus in a high concentrations of quinine.
105
 
1.6.4. Ribavirin and 6-Azauridine 
The antiviral ribavirin (10, Figure 1.18), is well known to inhibit many RNA viruses in 
vitro, by different mechanisms.
115
 It is being used either alone for treatment of 
Respiratory Syncytial virus, or in combination with alpha-interferon in the treatment of 
hepatitis C virus (HCV) infection. This combination showed a synergistic in vitro 
inhibition of the CHIKV.
116
 A combination of alpha-interferon, at a concentration of 3.9 
IU/ml, and ribavirin at a concentration of 18.75 µg/ml, inhibited CHIKV replication by 
50%, whereas ribavirin 10 alone without interferon, inhibited  CHIKV with EC50 value 
of  83.3 µg/ml. However,  there is no evidence supporting the clinical efficacy of 
ribavirin 10 on CHIKV, and the combination with interferon should be subjected to 
clinical trials for the treatment of CHIKV infections.
105 Furthermore, the exact 
mechanism of ribavirin is still unclear as it may change from one virus to another, 
however, it is believed that ribavirin can interact with the intracellular viral RNA 
production.  
 
Figure 1.18 Chemical structures of ribavirin (10) and 6-azauridine (11).    
 
The broad-spectrum anti-metabolite, 6-azauridine (11, Figure 1.18) inhibits both 
DNA and RNA virus replication, and the activity might be through the inhibition of 
orotidine monophosphate decarboxylase, an enzyme involved in the de novo 
biosynthesis of pyrimidine, cytidine and thymidine.
117
 It showed a significant inhibition 
of CHIKV at a low concentration (0.2 µg/ml) and was more effective against the 
CHIKV compared to ribavirin 10.
116
 6-Azauridine 11 is not approved for human use 
and therefore was not included in a combination study with alpha-interferon. However, 
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6-azauridine triacetate is used for treatment of different diseases without notable 
adverse effects.
118





The antiviral drug arbidol (12, Figure 1.19) was originally developed 20 years ago at the 
Russian Research Chemical and Pharmaceutical Institute.
119
 Since 1990, it has been 
used in Russia for acute respiratory infections including influenza. So far, arbidol shows 
a wide range of activity against many RNA, DNA, enveloped and non-enveloped 
viruses.
120
 This broad spectrum of activity may be attributed to the different modes of 
action including the inhibition of virus mediated fusion,
121
 and blocking of the viral 
entry into the target cells through inhibition of glycoprotein conformational changes that 




In 2011, arbidol 12 and two derived metabolites (Figure 1.19), HZ1 13 and HZ3 
14, were tested in vitro on the chikungunya virus using two cell lines, and in different 
conditions, pre- and post-infection treatments. Arbidol was the only active compound 
with an IC50 value that was much lower than the toxic concentration (IC50 = 12.2 µM, 
CC50 > 200 µg/ml).
124
 HZ1 13 and HZ3 14 were assumed to be responsible for the anti-
viral properties of arbidol, however in this study, HZ1 and HZ3 showed only weak 
effects on CHIKV replication.  
 
Figure 1.19 Chemical structures of arbidol (12), HZ1 (13) and HZ3 (14).                 
 
Arbidol 12 was found not to be viricidal, rather, it blocks the earliest stages of 
the viral replication, virus attachment and/or virus entry as previously reported.
120
 For 
Chapter 1  Introduction  
26  
 
CHIKV, it works by targeting the cellular membrane (E2 viral envelope protein) which 
was confirmed by the use of arbidol resistant CHIKV strain (mutation in the E2 protein, 
G407R).
124
 However, all these studies were performed in vitro and in vivo studies are 
required to validate the activity of arbidol on CHIKV. 
1.6.6. Mycophenolic acid (MPA) 
Mycophenolic acid (15, Figure 1.20) was isolated about one hundred years ago.
125
 It is 
an inhibitor of inosine monophosphate dehydrogenase (IMPDH), an enzyme involved in 
the de novo biosynthesis of guanine nucleotide. It has a very good anti-proliferation 
activity and has been established as an anticancer,
126




                   
Figure 1.20 Chemical structures of mycophenolic acid (15) and trigocherrin A (16). 
 
Recently, MPA was shown to inhibit the CHIKV replication and virus induced 
cell death. The IC50 value was 0.2 µM with a selectivity index of 150.
128
 Mycophenolic 
acid was found to induce CHIKV apoptosis. When the treated CHIKV infected cells 
were provided with exogenous guanosine (GMP), MPA could no more prevent the 
CHIKV induced cell death, indicating that it works by inhibiting IMPDH enzyme. It has 
also been suggested that MPA increases the mutation rate during the viral replication.
128
 
Considered as a good lead compound, the in vivo activity of mycophenolic acid on 
CHIKV should be investigated as it is well known that mycophenolic acid suffers from 
a metabolic drawback associated with rapid conjugation of the C-7 phenolic hydroxyl 
group with glucuronic acid.
129,130  
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1.6.7. Trigocherrin A 
Trigocherrin A (16, Figure 1.20), is a highly oxygenated and chlorinated daphnane 
diterpenoid orthoester, that had been isolated from the bark of Trigonostemon cherrieri 
Veillon (Euphorbiaceae), a tree collected in the sclerophyllous forest of New-Caledonia. 
This genus comprises about 80 species occurring in tropical Asia, from India and Sri 
Lanka to New Guinea.
131





 properties. Recently, this natural product was tested against CHIKV 
and was found to inhibit virus-induced cell death in a virus-cell-based assay with an 
EC50 of 1.5 μM and only caused a significant antimetabolic effects at a concentration 
(CC50) of 35 μM, and the selectivity index (SI) value was 24. Different concentrations 
of 16 were able to protect the host cells from the virus cytopathic effect without any 
adverse effects. Also, it was found to be more potent than the reference compound used 
in this study (chloroquine, 8).
136,137
 The assay protocol suggests that this compound 
might inhibit the viral replicase functions, however, for the drug discovery process, the 
in vivo activity, the precise mode of action as well as the total synthesis of this lead 
compound should be investigated.  
1.6.8. Trigowiin A, Prostratin and 12‑O‑Tetradecanoylphorbol 13-Acetate 
In a recent study (2012), an extract of the bark of Trigonostemon howii  (Euphorbiaceae 
species) from central Vietnam was tested against the CHIKV.
138
 A new tigliane 
diterpenoid, trigowiin A (17, Figure 1.21) was isolated and was found to be structurally 
closely related to the tigliane diterpenes (Figure 1.21), prostratin (a promising adjuvant 
for anti-HIV therapy)
139




Figure 1.21 Chemical structures of trigowiin A (17), prostratin (18) and TPA (19). 
Chapter 1  Introduction  
28  
 
 In the CHIKV assay, trigowiin A 17 showed weak antiviral activity, with an 
EC50 of 43.5 ± 12.8 μM whereas TPA 19 and prostratin 18 proved to be the most potent 
inhibitors, with low EC50 values and higher selectivity indices (SI), for TPA 19, EC50 = 
0.0029 ± 0.0003 μM and SI = 1965 while EC50 for prostratin 18 was 2.6 ± 1.5 μM and 
SI = 30.3 showing that TPA 19 was 65 times more potent than prostratin 18.
138
 At the 
same time, these compounds did not show activity against Sindbis virus (SINV) nor 
Semliki forest virus (SFV) which indicates an excellent selectivity for inhibition of the 
CHIKV. The authors
138
 believe that this selectivity might be due to a specific 
mechanism of virus inhibition through  the activation of the signal transduction enzyme 
protein kinase C (PKC), similar to the proposed mechanism of HIV replication 
inhibition
140
 for TPA 19. However, TPA 19, is currently one of the most potent tumor-
promoting agents known to date,
141
 therefore, the less potent prostratin 18 is more likely 
to be further investigated as a potential candidate, as it does not exhibit
142
 a tumor-
promoting activity. The exact mode of action of these compounds is as yet unknown 
and needs further investigation. 
1.6.9. Lupenone and β-amyrone 
In the continuous effort to identify novel inhibitors of Chikungunya from natural 
sources, a phytochemical study on the leaves of Anacolosa pervilleana (Madagascan 
plant) was performed in a virus-cell-based assay for CHIKV.
143
 Two triterpenoids with 
a moderate anti-CHIKV activity were isolated and identified (Figure 1.22), lupenone 20 
with EC50 = 77 μM and β-amyrone 21 with EC50 value of 86 μM.
143
 However, the weak 
activity of these natural compounds should be improved by medicinal chemistry 
optimization processes before being considered as lead compounds. 
 
Figure 1.22 Chemical structures of lupenone (20) and β-amyrone (21), Me refers to 
methyl groups, simplified to fit within the ring structure.  




Harringtonine (22, Figure 1.23) is an alkaloid from Cephalotaxus harringtonia trees, 
which is native to Japan. The natural product has known antitumor activity and inhibits 
the first cycle of the elongation phase of eukaryotic translation.
144
 Recently, the anti-
CHIKV activity of harringtonine was investigated.
145
 It displayed potent inhibition of 
CHIKV infection (EC50 = 0.24 μM) with minimal cytotoxicity, through the inhibition of 
the early stages of infection after cellular endocytosis. Also, it was found to affect the 
CHIKV RNA production inside the infected cell, as well as viral protein expression 
such as the nsP3 and the E2 proteins.
145
 The in vivo studies of harringtonine are still 
ongoing which could make harringtonine a promising lead towards the discovery of 
anti-CHIKV drugs. 
 
Figure 1.23 Chemical structures of harringtonine (22). 
 
1.6.11. Purine based inhibitors 
In 2012, D’hooghe et al. reported the design and synthesis of a new series of purine-β-
lactam hybrids and purine-aminopropanol hybrids and their evaluation as potential 
antiviral candidates depending on the antiviral templates purines and β-lactams.
146
 
These new scaffolds were screened against nine different viruses including the 
chikungunya virus. Two purine-β-lactam hybrids and one purine-aminopropanol hybrid 
(Figure 1.24) were found to possess promising activity and cytotoxicity profiles, the 
purine-β-lactam 23 with EC50 = 17.11 μM and SI > 5.75, the purine-β-lactam 24 with 
EC50 = 13.01 μM and SI > 4 and the purine-aminopropanol 25 with EC50 = 11.51 μM 
and SI > 6, which displayed relatively stronger inhibition compared to the β-lactam ring 
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analogues, indicating that the β-lactam ring is not essential.
146
 The mode of action has 
not been investigated. The synthesis of this class of compounds is already established 
and therefore, they represent good subject for further medicinal chemistry optimization.  
 
Figure 1.24 Chemical structures of the purine-β-lactams (23, 24) and the purine-
aminopropanol (25) compounds. 
 
1.6.12. Polyinosinic acid 
Polycytidylic acid [Poly (I:C)] (26, Figure 1.25), a synthetic double-stranded RNA 
(dsRNA) analogue, is an immunostimulant that acts as an inducer for the most potent 
interferon (IFN) via interaction with toll-like receptor 3 (TLR3).
147
 It can induce IFN-
α/β production and natural killer (NK) cell activation in vivo after intraperitoneal 
injection.
148
 Activation of the TLR3 contributes to an innate immune response against 
many viruses.
149
 In CHIKV infection, the virus was found to be sensitive to the innate 
immune response induced by Poly (I:C). This sensitivity was noticed as a decreased 
cytopathic effect and inhibition of the virus replication in the infected cell lines. This 
sensitivity has been explained to be a result of the overstimulation of the TLR3 as well 
as the other anti-viral genes by Poly (I:C).
150
 




Figure 1.25 Chemical structures of polycytidylic acid (26). 
 
1.6.13. Gene silencers 
New trends in the CHIKV treatment trials are the use of genes silencers targeting 
specific viral proteins (capsid protein, E1, nsP1 and nsP3). Silencing the target viral 
genes will consequently lead to shutdown of the protein expression process, and thereby 
stopping viral replication. After viral infection, the exogenous small interfering RNA 
(siRNA) induces RNA interference mechanism, resulting in the assembly of RNA-
induced silencing complex (RISC) which inhibits subsequent protein expression. Using 
the siRNA targeting CHIKV E1 and nsP3, was effectively used in suppression of in 
vitro CHIKV replication.
151
 Similarly, a plasmid based small hairpin RNA (shRNA) 
against CHIKV replication targeting the capsid, E1 and nsP1 proteins has been used. 
Simply, the plasmid is first introduced to cell, expressed inside the nucleus, small-
hairpin RNA (shRNA) is formed and processed by cytoplasmic Dicer enzyme to 
siRNAs, leading to activation of the RNA silencing machinery. This silencing 
machinery recognizes and degrades the target CHIKV single strand RNA, consequently 
stopping viral protein expression.
152 However, clinical studies should be able to prove 
the applicability of these trends in developing effective anti-CHIKV therapeutics. 
1.7. Highlights for CHIKV inhibitors 
Several molecules have been tested against the emerging CHIKV with weak to 
moderate activities. Those included drugs already in the market, being used for other 
diseases, such as chloroquine 8, ribavirin 10, arbidol 12 and mycophenolic acid 15. The 
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challenge here would be in finding similar compounds that are structurally unique with 
improved potency and other drug like qualities, also avoiding the metabolic draw backs 
when present. The protease inhibitors 5, 6 that were developed based on an in silico 
study, would be attractive candidates for further development, however, the challenge 
here is to develop a more specific inhibitory assay protocol to confirm the selectivity for 
the inhibition of viral proteins. Protein crystallization with the inhibitor would be a 
useful element to validate such studies. Some of the tested compounds represent 
complex natural products and have good enough activity as antiviral agents, such as 
Trigocherrin A 16, prostratin 18, TPA 19 and harringtonine 22. It will be an arduous 
task to chemically access these structures and to simplify these chemical skeletons to 
more drug like molecules with acceptable ADME properties. 
The anti-CHIKV activity of the tested molecules ranged from strong to weak 
inhibition depending on the type of the assay used, with the TPA 19 being the strongest 
inhibitor with EC50 = 0.0029 μM and β-amyrone 20 which displayed the weakest 
activity with EC50 = 86 μM, similar activity to that of ribavirin 10, EC50 = 83.3 μM. It is 
worth noticing that the active agents, TPA 19 and the less active Trigocherrin A 16, 
shared a common structural feature, the substituted benzo[e]azulene derived structure, 
(Figure 1.26). The TPA structure 19 is simpler than that of Trigocherrin A 16, lacking 
the extra phenyl rings, two chlorine atoms, four oxygen bridges and the alkene side 
chain (Figure 1.26), however, TPA 19 on the other hand has a characteristic long 
tetradecanoic ester moiety which was responsible for the activity over Trigowiin A 17 
and Prostratin 18, two derivatives that were even less active than Trigocherrin A 16. 
These highlights will guide further investigations toward the development of CHIKV 
inhibitors based on that substituted benzo[e]azulene skeleton.  
 




Figure 1.26 Chemical structures of TPA (19) and Trigocherrin A (16), common 
skeleton is highlighted in bold red colour, unique groups to TPA (19) are shown in 
green while the excess groups of Trigocherrin A (16) are shown in blue colour. 
1.8. Concluding remarks 
Chikungunya virus (CHIKV) is an emerging arbovirus virus that has had devastating 
effects in recent years in many areas in the world. Chikungunya virus infection can 
develop into an arthritis disease that remains with the patient for years. The mutations in 
the viral envelope protein genes increased the fitness of the virus in another mosquito 
vector, Ae. albopictus which was responsible for cases reported in temperate zones. 
With no licensed vaccine for immunization against this virus, disease control is 
currently non-existent, and the treatment would be through the development of 
chemotherapeutics. Some promising lead compounds have been discovered recently and 
could be starting points towards effective treatments. The discovery of these leads was 
mostly based on random screening of drugs already on the market, newly discovered 
natural products or the antiviral evaluation of synthetic compounds. Also, in the last two 
years, the molecular functions as well as the crystal structures of a number of critical 
enzymes involved in the virus life cycle are being reported, with no known inhibitor 
thus far. Some in silico models targeting these viral proteins have been developed, with 
some active compounds identified, to initiate the search for effective and selective 
therapy such as targeting the viral protease. This will help the drug discovery and 
development process through designing inhibitors against those targets. The virus has 
been considered neglected for many years and this emphasizes the importance of 
developing highly potent and safe inhibitors. 
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1.9. Project aims 
At the outset of this project (2010), there were no lead compounds reported (including 
those previously mentioned in this chapter 1-26), except for some contradicting 
arguments about the efficacy of chloroquine 8, with limited evidence suggesting the 
efficacy against the chikungunya virus. There were no crystal structures available for 
any of the viral proteins. Therefore, the main aim of the project was to find a hit 
compound that could be taken further via a hit to lead discovery study. The main 
strategies investigated during this project were: 
 Random screening, through the synthesis and evaluation of anti-microbial class 
of compounds that were driven from the current projects within our research 
group. 
 Continuous screening of the literature for emerging viral proteins to develop a 
structure-based drug design approach. 
 Continuous screening of the literature for active lead compounds to conduct a 
ligand-based drug design approach. 
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CHAPTER 2: The Search for Anti-CHIKV Lead Compounds 
 
2.1. Introduction 
At the outset of this project (2010), there were no lead compounds reported, except 
some contradicting arguments about the efficacy of chloroquine 8 against the 
chikungunya virus, as was referred to in chapter 1. Therefore, the goal of this project 
was to search for new lead compounds. Finding a lead compound usually starts with the 
random screening of a compound library against the target virus. One active program 
within our group was the investigation of new structural motifs as potential non-
nucleoside inhibitors of HIV-1 reverse transcriptase (HIV RT)
153
 and developing in 
silico models for the identification of structurally unique inhibitors. While 15 
compounds tested from this in silico screening of these models were inactive against 
HIV RT,
154
 seven possessed good anti-malarial activity. Of these seven compounds, the 
arylarenepyrimidylmethane (AAPM) compound 27 (Figure 2.1) was chosen for further 
investigation as an anti-malarial lead, where it showed an IC50 of 0.88 µM against P. 
falciparum.
155,156 The developed synthetic strategy utilized for the synthesis of 
compound 27 is shown in Figure 2.1. 
 
Figure 2.1 The synthesis of the AAPM derivative, compound 27. 
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When compound 27 was synthesized, no similar derivatives were investigated to 
study structure activity relationships for the anti-malarial activity, nor an optimization 
strategy for the synthetic pathway used to obtain more derivatives. Therefore, our 
research group had focused on developing this series, not only to further develop the 
synthetic methodology, but also accessing analogues to investigate the structure activity 
relationship.  
An attempt to derivatise compound 27 in our laboratory had been performed, 
and only one derivative, the unsubstituted AAPM compound 34 (Figure 2.2) was 





Figure 2.2 The unsubstituted AAPM compound 34, and the two AAPM modified 





 process, some modified AAPM derivatives (without 
the diethylamino-propanol side chain) were synthesized and were tested against dengue 
virus.
157
 The AAPM derivatives 35, 36 showed weak to moderate activity against the 
dengue virus (Figure 2.2). Dengue virus belongs to the family Flaviviridae, and is 
transmitted through the Aedes aegypti mosquito,
158
 the same vector which transmits the 
chikungunya virus. Therefore, this family of heterocycles may also inhibit the CHIKV. 
With an established synthetic strategy, the generation of analogues for testing against 
the CHIKV makes a viable line of research seeking new leads. Consequently, the 
synthesized derivatives would enrich the AAPM library giving strength to the scope of 
Chapter 2  New Leads 
37  
 
developing novel anti-microbial agents in general, and especially, with respect to the 
anti-malarial program. 
2.2. Synthesis of the meta-nitro AAPM derivative 
The synthetic strategy for this AAPM derivative was similar to the procedures described 
in Figure 2.1 replacing the ketone 29 with 38. 
2.2.1. Nitration of isobutyrophenone 37 
The synthesis started with the nitration of isopropyl phenyl ketone 37 under the standard 
nitration conditions of dropwise addition of the cold nitrating mixture to a cold solution 
of the ketone 37 in conc. sulphuric acid (Scheme 2.1). The isopropyl 3-nitro-phenyl 
ketone 38 was isolated in 52% yield, as a yellow oil. 
 
Scheme 2.1 The synthesis of the isopropyl 3-nitrophenyl ketone 38.  
 
2.2.2. Addition of the isobutyrophenone 35 to 4,6-dichloropyrimidine 28 
The next step in the synthetic pathway was the addition of the 4,6-dichloropyrimidine 
28 to the nitro derivative 38. Therefore, a fresh solution of lithium diisopropylamide 
(LDA) solution was prepared by the dropwise addition of n-BuLi solution in hexanes to 
a solution of diisopropyl amine (DIPA) in tetrahydrofuran (THF), pre-cooled to -78 ºC 
(Scheme 2.2), and the solution was allowed to stir at -78 ºC for 45 min to allow the 
complete formation of  LDA.  A solution of 4,6-dichloropyrimidine 28 in THF, pre-
cooled to -78 ºC, was then added dropwise to the LDA solution, producing an instant 
orange colour change which was attributed to the formation of the pyrimidyl anion 39, 
and the solution was stirred at -78 ºC for 45 min. The solution was then cooled to -116 
ºC, and a solution of nitro derivative 38 in THF, pre-cooled to -116 ºC, was added 
dropwise. The mixture was left for 45 min to allow complete addition. The reaction was 
then quenched by addition of NH4Cl. After acidic aqueous workup, the desired alcohol 
40 was isolated in 50% yield as pale yellow crystals, the unreacted starting ketone 38 
was recovered with the remaining outcomes of this reaction being polymeric products 
as analysed from the baseline material on thin layer chromatography (TLC) analysis. 
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The analysis of the 
1
H NMR spectrum of 40 showed a broad singlet peak at 3.38 ppm, 
asssigned to the OH group, and two doublet peaks resonating at 1.11 and 0.93 ppm, that 
were assigned to the two methyl groups. 
 
Scheme 2.2 Addition of 4,6-dichloropyrimidine 28 to the nitro derivative 38, forming 
the alcohol 40. 
 
The proposed mechanism for this reaction starts with the nucleophilic attack of 
LDA onto the 5-pyrimidyl proton resulting in the lithiated dichloropyrimidine anion 39, 
which nucleophilically attacks the electrophilic carbonyl of the ketone 38, to give the 
alcohol after a protic workup (Scheme 2.3). 
  
Scheme 2.3 The proposed mechanism for the formation of alcohol 40. 
 
This reaction (Scheme 2.2) required ultra dry conditions, with all the glassware 
oven dried for at least 12 h prior to reaction, and all the reactants dried overnight under 
vacuum. The 4,6-dichloropyrimidine 28 was crystallized from water. Previous work
157
 
reported the purification of 28 by bulb-to-bulb distillation, however, in this work, 
simple crystallization was effective. The previous best reported yields
157
 of similar 
reactions in our group was 38-47% yield. In this work (Scheme 2.2), the yield was 
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optimized to 50%. The notable increase in yield was attributed to the ultra dry 
conditions, as this reaction was found to be very sensitive to moisture, including from 
the N2 atmosphere used during the reaction. Therefore, in this reaction (Scheme 2.2), 
the needle supplying N2 to the reaction flask, was filled with pre-dried CaCl2 to ensure 
the dry atmosphere inside the reaction flask. The slow rate of addition of the 
electrophile 38, as well as the pre-cooling (-116 ºC) of the electrophile 38 solution prior 
to addition, were found to be important factors for improving the yield (Scheme 2.2). 
2.2.3. Dehydration reaction of the alcohol 38 to the form the alkene 41 
The next synthetic step was the dehydration of alcohol 40. Previous work
157 facilitaed a 
similar transformation by reacting the alcohols with four molar equivalents of thionyl 
chloride (SOCl2) and four molar equivalents of phosphorus pentaoxide (P2O5) in 
dichloromethane with stirring at 50 ºC for 12 h. In this work, when this method was 
carried out on the alcohol 40, the yield of the alkene derivative 41 was low (24%), with 
substantial quantities of un-reacted alcohol (Scheme 2.4), even with the continued 
heating for 48 h at 70 ºC. 
 
Scheme 2.4 Dehydration reaction of the alcohol 40 to the alkene 41, using SOCl2 and 
P2O5 in CH2CH2. 
 
The reaction was then performed using neat pre-distilled SOCl2, by heating the 
alcohol 40 with SOCl2 at reflux under a N2 atmosphere for 48 h (Scheme 2.5). After 
basic aqueous workup, the alkene 41 was isolated in 70% yield. Analysis of the 
1
H 
NMR spectrum of the alkene 41 showed the disappearnce of two peaks at 3.38 ppm and 
3.64-3.58 ppm from 40, indicating the loss of the alcohol functionality. Analysis of the 
13
C NMR spectra showed a shift of the propanol C1 of 40 (81.7 ppm) to 140.1 ppm for 
the propene C1 in 41, indicating the formation of the double bond. 
 




Scheme 2.5 Dehydration of the alcohol 40 using neat SOCl2. 
 
The proposed dehydration mechanism of the reaction begins with the 
nucleophilic attack of the alcohol to the sulfonylchloride. Elimination of HCl results in 
the chlorosulfite intermediate which eliminates to yield SO2 and a second mole of HCl 
and the alkene 41 as shown in Scheme 2.6.  
 
Scheme 2.6 The proposed dehydration mechanism of the alcohol 40 to form 41. 
  
The difference in the yield of the alkene 41 obtained in this work (70%) from the 
yield obtained by the previous other derivatives
156,157
 is attributed to the difference in 
the electronic environment of the aromatic ring carrying the deactivating nitro group 40. 
The electron withdrawing nitro group on the alcohol 40 may be responsible for slowing 
the rate of the reaction (Scheme 2.6), especially the last elimination step of the HCl and 
SO2 in the proposed mechanism.  
The yield of the alkene 41 using SOCl2 dehydration mechanism was 
satisfactory, however, the reaction required 48 h. Therefore, an alternative dehydration 
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method was investigated. Conc. sulphuric acid is a well know dehydrating reagent for 
primary alcohols via an E2 mechanism, and secondary and tertiary alcohols via an E1 
mechanism, to give the corresponding alkenes in both cases.
159
 This sulphuric acid 
dehydration reaction was performed on the alcohol 40 by adding the later, portion-wise, 
to conc. H2SO4 and allowing the mixture to stir at room temperature (Scheme 2.7). The 
reaction was allowed to stir until all the alcohol 40 was consumed. After workup, the 
alkene 41 spot was found to be present in trace (not changing) compared to the major 
product, which was found to be 4-chloro-6,6-dimethyl-5-(3-nitrophenyl)-5,6-
dihydrofuro[2,3-d]pyrimidine 42 derivative (Scheme 2.7). Analysis of the 
1
H NMR 
spectrum showed a singlet peak resonating at 4.55 ppm integrating for one proton, 
which was assigned to H5 of the furo-pyrimidine skeleton. Analysis of the HRMS 
spectrum showed a peak at 306.0648 m/z which was assigned to the molecular formula 
C14H13ClN3O3 (MH+), indicating that the alcohol oxygen atom was still present in the 
structure 
 
Scheme 2.7 Dehydration reaction of the alcohol 40 using H2SO4, producing the furo-
pyrimidine 42. 
  
The proposed mechanism for the formation of the furo[2,3-d]pyrimidine 42 was 
attributed to the rearrangement of the carbocation produced after the E1 elimination step 
(Scheme 2.8), where the positive charge is transferred to carbon 2 of the propyl chain 
(through a hydride shift). The planarity of the benzylic carbocation with the benzene 
and the pyrimidine ring might be responsible for such a rearrangement. This later 
carbocation is further attacked by water giving another tertiary alcohol on C2 of the 
propyl chain. SN2 attack of the OH group to Cl gave the cyclised product 42. This 
reaction (Scheme 2.7) is considered as a new convenient two step synthesis of the 
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furo[2,3-d]pyrimidine heterocycle, which is rarely reported in the literature. Existing 




Scheme 2.8 The proposed mechanism of the formation of furo[2,3-d]pyrimidine 
derivative 42. 
 
2.2.4. Mono-amination of the alkene 41 
The nucleophilic substitution of ammonia onto the pyrimidine ring of the alkene 41 has 
been previously optimized on similar scaffolds using a microwave assisted reaction.
157 
Therefore, the alkene 41 was suspended in ammonia solution (25%), and the mixture 
heated and irradiated in a microwave reactor at two stages; the first stage involved 
heating the mixture at 120 ºC for 50 min, followed by a slight increase in the 
temperature to 130 ºC, for a 30 min (Scheme 2.9). These conditions maximized the 
production of the mono-amino substitution product 43 and minimized the production of 
the di-amino product 44. Analysis of the 
1
H NMR spectrum of 43 showed a broad peak 
at 5.27 ppm, which was assigned to the NH2 group. Analysis of the ESI-MS spectrum 
showed a peak at 307 m/z for the molecular ion (M+, 
37
Cl), indicating the replacement 
of one Cl atom in the alkene 41 by an amino group. 
 




Scheme 2.9 Selective amination of the dichloro-pryrimidine 41. 
 
The reaction proceeded via a SNAr mechanism where the lone pair of electrons 
of ammonia attacked C4 of the pyrimidine ring followed by rearomatisation of the ring 
displacing the chlorine atom resulting in the formation of 43.  
2.2.5. Final amination of 43 for the final AAPM derivative 
The final amination of the amino alkenes had been a challenge in the synthesis of this 
series, in this work as well as the previous work.
157
 Only the lead compound, the chloro-
AAPM 27, and the unsubstituted AAPM 34 were synthesized previously in our group, 
with multiple attempts to generate more derivatives.
156,157
   
The previous synthesis of the AAPM 27 utilised the reaction between the 
racemic, highly viscous, propylamine side-chain 33 in a solvent free reaction with the 





Figure 2.3 The synthesis of the AAPM 27 from the aminochloropyrimidine 32. 
  
When this synthetic strategy was used previously in our group for the synthesis 
of the unsubstituted AAPM 34, the reaction failed with no evidence for the formation of 
the AAPM 34, even after conventional heating of the reactants at 200 ºC for 5 h (Figure 
2.5).
157
 Instead, further investigation of the reaction mixture indicated the 
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polymerization of the poly aminic side chain 33.
157
 However, access to the AAPM 34 
was achieved through an optimization process previously investigated in our group,
157
 




Figure 2.4 Reactions of the aminopyrimidine 45 with the amine 33 for the synthesis of 
the AAPM 34.  
  
Therefore, the aminochloropyrimidine 43 was heated with the amine 33 under 
microwave irradiation at 150 ºC for 5 min (Scheme 2.10). The reaction cycle was 
repeated 5 times until the complete disappearance of the starting aminochloropyrimidine 
43 as indicated by the TLC analysis (90% ethyl acetate in petroleum spirit). Further 
analysis of the reaction revealed the presence of polymeric baseline material and the 
absence of material resembling the AAPM 46. This indicated the disintegration of the 
heterocyclic structure. Although harsh conditions are required to overcome the steric 
barrier of the reaction, prolonged periods of heating result in the destruction of the 
material. Therefore, lower temperature were investigated, Table 2.1 summarises the 
series of microwave reactions attempted using the aminochloropyrimidine 43 and the 
amine 33.  
 
Scheme 2.10 Attempted synthesis of the AAPM 46 using the microwave irradiation. 
Table 2.1 Attempted microwave reactions of 43 with 33. 









1 120 50 0 
2 130 30 0 
3 140 40 0 
 
 For all entries (Table 2.1), TLC analysis was performed to gauge the outcome of 
each reaction. For entry 1, the staring material 43 was the major spot, with the 
additional appearance of the polymeric baseline material. Mass spectrometric analysis 
of the crude reaction mixture did not show any peaks that could be assigned to the 
formation of the AAPM 46. Increasing the temperature to 130 ºC (entry 2) and 140 ºC 
(entry 3) did not produce any differences from the results from entry 1, with the 
exception of increased decomposition. 
 The next attempt to synthesise 46 used solvent in order to solubilise the highly 
viscous amino side chain 33, and for the ease of recovery of the aminochloropyrimidine 
43. In the previous optimized process of the synthesis of AAPM 34, dichlorobenzene 
(DCB) was used, however, it was demonstrated not to improve the reaction, nor the 
recovery of the un-reacted starting material.
157
 Therefore, the reaction was attempted 
here using water as a solvent, because of the amino side chain 33 solubility in water 
reduced the high viscosity of the amine 33 allowing a greater chance of reaction with 
the aminochloropyrimidine 43. Water was also selected as it had been successfully used 
for many microwave assisted reactions.
162
 Therefore, the aminochloropyrimidine 43 
was heated with amino side chain 33 in a microwave tube at 100 ºC for 5 min. TLC 
analysis (90% ethyl acetate in petroleum spirit) indicated the presence of the starting 
materials with polymeric baseline material. The temperature was increased to 150 ºC 
and the reaction was held at this temperature for 10 min. TLC analysis after the 10 min 
at 150 ºC indicated that the concentration of the starting material was decreasing and the 
concentration of the baseline material increased. Furthermore, low resolution mass 
spectrometric analysis did not show any evidence indicating the formation of the 
desired AAPM 46. The aminochloropyrimidine 43 was recovered in 60%. 
 The difficulties in the synthesis of the AAPM derivatives along with the 
previous attempts
157
 were attributed to the polymerization of the amino side chain 33 at 
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the reaction temperatures. The electronic effect of the substituents on the phenyl ring 
(Cl in AAPM 27, H in AAPM 34 and NO2 in the unformed AAPM 46) is also believed 
to play a role in the amination reaction, where the Cl atom might activate the amination 
and the NO2 group may deactivate the amination reaction. No investigations were 




2.3. Modification in the amine side chain of the AAPM derivatives 






 was selected as a 
replacement for the polymeric side chain 33, as it is identical to the amino side chain of 
the antimalarial chloroquine 8. Furthermore, the amine 47 is a liquid with low viscosity 
compared to the amine 33. Therefore, it was thought that it would react more easily with 
the aminochloropyrimidine 43. The later was reacted with amine 47 in different 
conditions (Scheme 2.11) using either conventional heating or microwave irradiation 
(Table 2.2). 
 







                                                             
* Personal communication with Andrew Stevens (ref 157), who synthesized the AAPM 34, and attempted 
in other AAPM derivatives. 
† Was purchased from Aldrich and further distilled under N2 at 70 ºC to provide a colourless liquid. 
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1 Microwave 150 3 min 0 
2 Microwave 150 10 min 0 
3 Microwave 170 5 min Trace 
4 Microwave 200 3 min Trace 
5 Microwave 200 12 min 0 
6 Conventional 150 12 h 0 
7 Conventional 200 48 h 0 
 
 From Table 2.2, the first attempt of the reaction (Scheme 2.11) used microwave 
irradiation (entry 1); this method resulted in no change as indicated by TLC and mass 
spectrometric analyses. Increasing the reaction time to 10 min (entry 2) did not produce 
any change in the reaction. The temperature was then increased to 170 ºC (entry 3) and 
the reaction was held for 5 min. The mass spectrum of the reaction mixture showed a 
weak peak at 427 m/z, indicating a trace of the product 48. Increasing the temperature to 
200 ºC for 3 min (entry 4) to push the reaction to completion did not improve the 
production of 48 but still the weak 427 m/z peak in the mass spectrum could be 
observed. When the hold time was increased to 12 min (entry 5), the weak 427 m/z peak 
of the product 48 could not be seen indicating the decomposition or polymerization of 
the product. In entries 1-4, 70-73% of the starting material was recovered indicating that 
little reaction had taken place, while in entry 5, no starting material was recovered from 
the reaction mixture. The reaction (entry 4) was then repeated on fresh starting 
materials, the content was then subjected to preparative TLC (PTLC) using 10% water 
in acetonitrile, the baseline band was isolated. Analysis of the mass spectrum of this 
band revealed the presence of the 48 peak at 427 m/z and the amine peak 47 at 158 m/z. 
However, analysis of the 
1
H NMR spectrum of this fraction showed mainly complex 
polymeric protons in the aliphatic region (0.6-2.5 ppm) and the compound 48 was not 
separated.  
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 When the reactants were heated using the conventional heating method (entries 
6, 7), no evidence for the formation of 48 was detected by either mass spectrometric or 
NMR analysis, and the starting aminochloropyrimidine 43 was completely decomposed. 
2.4. Decreasing the steric hindrance of the dimethyl groups 
The poor reactivity of the aminochloropyrimidine 43 with either the amine 33 (Scheme 
2.10) or the amine 47 (Scheme 2.11) argued for the difficulties in the reaction being due 
to the steric clashes with the dimethyl group. Therefore, the dimethyl groups in 43 were 
replaced with a cyclopropyl group, in an attempt to give the aminochloropyrimidine 51. 
The cyclopropyl group was selected in order to tether the dimethyl groups together and 
minimize the steric hindrance. The attempted access to 51 was performed in a similar 
synthetic pathway (Scheme 2.12) as that used for 41, using cyclopropylphenyl ketone 
49. 
 
Scheme 2.12 Attempted synthesis of the alkene 51 through the alcohol 50. 
  
The alcohol 50 was isolated in 37% yield compared to 50% of the alcohol 40. 
Analysis of the 
1
H NMR spectrum of 50 showed a broad peak at 2.83 ppm, assigned to 
the OH substituent. The ESI-MS spectrum showed a peak at 295.1 m/z assigned to the 
(M+, 
35
Cl) of the alcohol 50. However, the alcohol 50 was found to be unstable, with 
decomposition occurring immediately after column chromatography (80% ethyl acetate 
in petroleum spirit), as indicated by TLC analysis. These unstable by-products could not 
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be separated and identified. Therefore, the dehydration reaction was carried out 
immediately after the isolation of 50 from the column. Stirring the alcohol 51 with 
SOCl2 at room temperature, or at 80 ºC, caused only charring of the alcohol 51. The 
dehydration reaction using conc. H2SO4, that was carried out on alcohol 40 (Scheme 
2.7), was also attempted on alcohol 50 to investigate the possibility of forming the 
alkene 51, or the furopyrimidine 52 product (Scheme 2.13). However, charring was also 
observed after 5 min of stirring, with no formation of 51 or 52. 
 
Scheme 2.13 Attempted conc. H2SO4 reaction on the alcohol 50. 
  
Compared to alcohol 40, alcohol 50 does not contain a nitro group in the phenyl 
ring. The next investigation was to check whether the presence of the nitro group on the 
phenyl ring of 50 would stabilize the alcohol or not. Therefore, the cyclopropylphenyl 
ketone 49 was first nitrated using conc. H2SO4/HNO3 at -10 ºC to afford the 
cyclopropyl(3-nitrophenyl)methanone 53 in 70% yield (Scheme 2.14).   
 
Scheme 2.14 Nitration of cyclopropylphenyl ketone 49. 
  
The phenone 53 was then subjected to the LDA addition reaction with the 4,6-
dichloropyrimidine 28 (Scheme 2.15). Despite subjecting the substrates to identical 
reaction conditions previously used for the synthesis of the alcohols 40 and 50, the 
alcohol 54 was not formed and the starting phenone 53 was recovered (50%). The 
percentage consumed from the phenone 53 indicated that the reaction may have 
occurred but the product was unstable, and immediately decomposed. 




Scheme 2.14 Attempted LDA addition reaction of the phenone 53 with the 4,6-
dichloropyrimidine 28. 
  
These investigations into the synthesis the AAPM 46, compound 48 and the 
alcohol 54, as well as the instability of the alcohol 50, argued for the importance of 
decreasing the steric hindrance around the Cl atom to be substituted with the amine, and 
also argued for the need of further simplification of the AAPM structure.  
2.5. Replacing the 4,6-dichloropyrimidine with 4-chloropyridine 
One strategy to simplify the core structure of the AAPM precursors involved replacing 
the bulky 4,6-dichloropyrimidine 28 (Scheme 2.2) with the simpler 4-
chloropyridine.HCl 55. Lithiation of the meta position of 4-chloropyridine 55, with 
subsequent addition of aldehydes has been previously reported,
163
 where the 
electrophilic addition was performed at -78 ºC without the need to cool the reaction to -
116 ºC.
163
 This change of the addition temperature would be advantageous, compared to 
the example of 4,6-dichloropyrimidine 28, in avoiding the difficulty of maintaining the 
reaction temperature at -116 ºC. During this modification, the nitro group was kept on 
the phenyl rings of the reacting phenones, ketones 38, 53 and the nitrocyclobutylphenyl 
ketone 57 were investigated in this modification step.  
2.5.1. Synthesis of the nitrocyclobutylphenyl ketone 57 
Ketone 57 was accessed through the nitration of the precursor phenone 56 using a 
nitrating mixture of conc. H2SO4/HNO3 at -15 ºC (Scheme 2.15). After completion of 
the reaction and the aqueous workup, the oil left was subjected to column 
chromatography using 30% ether in petroleum spirit. The desired meta isomer 
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cyclobutyl(3-nitrophenyl)methanone 57 was isolated in 27% yield, and the ortho isomer 
cyclobutyl(2-nitrophenyl)methanone 58 in was isolated 10% yield. 
 
Scheme 2.15 Nitration of the cyclobutylphenyl ketone 56. 
  
The ortho nitration of ketones carrying bulky groups has been previously 
observed as in case of adamantyl bearing aromatic ketones.
164
 Therefore, in the presence 
of the bulky cyclobutyl ring, the formation of the ortho derivative 58 was also possible, 
and could be explained by formation of the nitronium or proton complex with the 
carbonyl of cyclobutylphenyl ketone 56 and establishment of pre-equilibrium included 
both this form and its mutual competition. The increase of the nitronium-carbonyl 
complex concentration leads to an increase of the amount of ortho nitro regioisomer 58 
(Figure 2.5) by the nucleophilic attack of the benzene ring from the ortho position. 
Optimization of this reaction (Scheme 2.15) could be investigated by changing the 
reaction conditions, however, this was out of the scope in this work. 
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2.5.2. Addition reactions of ketones to the 4-chloropyridine.HCl 55 
The first step in the addition reaction was the lithiation of the 4-chloropyridine 55 using 
a freshly prepared LDA solution at -78 ºC as previously discussed (Scheme 2.2). The 
prepared LDA solution was then transferred to the solid 4-chloropyridine HCl 55, and 
the solution was left to react at -78 ºC and to form the lithiated pyridinyl anion (Scheme 
2.16). The completion of the reaction was indicated by the disappearance of the solid 4-
chloropyridine HCl 55, which took almost 45 min. To this anion solution, was added 
dropwise a solution of the appropriate ketone (38, 53 or 57) in dry THF at -78 ºC. The 
reaction temperature was kept at -78 ºC for 45 min, after which the reaction mixture was 
allowed to warm up to room temperature over 12 h. After quenching the reaction and an 
acidic work up, the alcohols 59-61 were obtained after column chromatography in 48-
52% yield. The same dry reaction conditions discussed previously (Scheme 2.2) were 
also utilized. Addition of the ketones at -78 ºC (Scheme 2.16) rather than at -116 ºC 
(Scheme 2.2), was advantageous and could be more easily controlled. Moreover, the 
acidic workup conditions in case of the pyridine based alcohols 59-61 facilitated the 
isolation of relatively pure products. This was indicated by the improved yield and less 
side products observed by TLC analysis, compared to the results obtained before when 
using pyrimidine (Scheme 2.2). Analysis of the 
1
H NMR spectrum of alcohol 59 
showed a broad peak at 3.25 ppm assigned to the OH substituent, whereas the EI-MS 




Scheme 2.16 Addition of the ketones (38, 53, 57) to the 4-chloropyridine HCl 55. 
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The reaction was attempted using 2 molar equivalents of the prepared LDA 
solution, however, this was insufficient to react with the 1 molar equivalent of 4-
chloropyridine HCl 55 and some of the solid remained undissolved. On addition of the 
electrophile (ketones 38, 53 and 57), the reaction proceeded, however, the isolated 
yields were lower than those obtained in Scheme 2.16, due to the presence of a lower 
concentration of the lithiated pyridinyl anion (Scheme 2.16). Using 2.5 molar 
equivellents of LDA was found to completely react with 4-chloropyridine HCl 55. 
2.5.3. Dehydration of the alcohols 59-61 
The first attempted dehydration reaction used the conc. H2SO4 method. Therefore, a 
mixture of the appropriate alcohol (59-61) and conc. H2SO4 was stirred at room 
temperature for 24 h and the reaction was monitored by TLC analysis at 1 h time 
intervals (Scheme 2.17). Although the reactions were clean and complete by TLC 
analysis, in the case of the alcohol 59 and the cyclopropyl alcohol 60, the cyclobutyl 
alcohol 61 underwent charring after 30 min of stirring with conc. H2SO4. The dimethyl 
alkene analogue 62 and the cyclopropyl alkene 63 were isolated after aqueous basic 
workup conditions as yellow oils in 85% and 62% yield, respectively. Analysis of the 
1
H NMR spectrum of the alkene 62 showed the disappearance of the OH substituent of 
the alcohol that was resonating at 3.25 ppm, and the adjacent proton that was resonating 
as a multiplet peak at 3.12-3.09 ppm in 59, indicating the formation of the double bond. 
Analysis of the 
13
C NMR spectrum showed a shift of the propanol C1 in 59 (79.7 ppm) 
to 138.5 ppm for the propene C1 of 62 .Analysis of the EI-MS spectrum of 62 showed a 
peak at 288 m/z, which was assigned to M+. 
 
Scheme 2.17 Dehydration of the alcohols (59-61) using conc. H2SO4. 
 Upon the workup of the charred solution in case the alcohol 61, neither the 
alcohol nor the alkene 64 were detected, instead, a polymeric dark line was present by 
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TLC analysis. Therefore, the SOCl2 dehydration method was attempted, where the 
alcohols 60 or 61 were added to neat SOCl2, and the solutions were heated at 80 ºC 
under N2 atmosphere for 24 h and 36 h, respectively (Scheme 2.18). Upon cooling the 
reactions, ice was added, and the solutions were neutralized with 2 M KOH. After 
CH2CH2 extraction and column chromatography, the oily alkenes 63 and 64 were 
isolated in 75% and 69% yield, respectively. The yield of the alkene 63 was slightly 
improved over using the conc. H2SO4 method (Scheme 2.17).  
 
Scheme 2.18 Dehydration of the alcohols 60 and 61 using neat SOCl2. 
 
2.5.4. Final amination of the alkenes 62-64 
The amine 33 was avoided in this trial based on the results previously discussed 
(Scheme 2.10). The amine 47 was selected for the amination reaction on the alkenes 62-
64 and a series of reactions, using different conditions, were carried out on the alkenes 
62-64 depending on the availability of each. The alkene 62 was mixed neat with the 
amine 47 and the mixture was placed in a microwave tube, followed by irradiation 
under different conditions (Scheme 2.19, Table 2.3). 
Scheme 2.19 Attempted microwave reaction of the alkene 62 with the amine 47. 
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1 135 10 0 0 
2 150 10 0 0 
3 170 20 0 0 
4 200 5 0 0 
5 250 20 0 0 
6 280 20 0 trace 
7 280 60 0 trace 
 
 After each entry (1-7, Table 2.3), a sample of the reaction mixture was taken for 
TLC and low resolution mass analysis. In entries 1-5, TLC analysis indicated no change 
in the reactants. Furthermore, the analysis of EI-MS spectra of the samples showed 
peaks at 288 m/z (M+ of 62) and the amine 47 peak at 158 m/z. The stability of the 
alkene 62 at 250 ºC was encouraging to increase the temperature to 280 ºC. When the 
alkene 62 was heated with the amine 47 at 280 ºC for 20 min (entry 6), TLC analysis 
indicated no change, however, EI-MS spectrum showed a new peak at 269 m/z, which 
corresponded to the (M+) of the amine 66. When the reaction was heated further at 280 
ºC for 60 min (entry 7), the alkene 62 disappeared and the the peak at 269 m/z (amine 
66) was still present in the EI-MS spectrum. TLC analysis of the reaction mixture of 
entry 7 presented a polymeric baseline long spot and the amine 66 was not isolated. 
Formation of the amine 66 at high temperature not only indicated the decomposition of 
the amine 47 releasing the NH2 nucleophile, but also indicated the weak reactivity 
(electrophilicity) of the alkene 62 towards the amine 47. This lack of reactivity towards 
47 and the reactivity with the released nucleophile NH2, can be explained based on 
steric hindrance with the amine 47 being hindered from replacing the 4-chloro on the 
pyridine ring of 62. 
 The instability of the amine 47 and the lack of reactivity of the alkene 62 under 
the normal SNAr conditions required a different strategy. Therefore, the use of a catalyst 
such as palladium [Pd(0)], in mild conditions was attempted to facilitate the reaction 
and to avoid the degradation of the amine 47. The amine 47 was reported to react with 
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4-chloroquinoline 67 in the presence of palladium acetate (4 mol%),  DPEphos
*
 (8 
mol%) and potassium phosphate (K3PO4, 2.5 equivalent) and the mixture was heated in 





Figure 2.6 Reported amination
165
 reaction using the amine 47 with 4-chloroquinoline 
67 using a Pd catalyst.  
  
The presence of the chlorine atom in position 4 of the quinoline 67, makes it 
analogous to the case in the alkene 62, however, there is no steric hindrance around the 
chlorine atom in 67. Therefore, the alkene 62 was placed with the amine 47 in a sealed 
tube, to which was added palladium acetate (4 mol%), DPEphos (8 mol%) and K3PO4 
(2.5 equivalent), and the tube was degassed for 10 min using N2, the tube was sealed 
and then heated at 18 h at 85 ºC (Scheme 2.20). Upon TLC analysis of the mixture, no 
change was observed. Therefore, the content of the tube was transferred to a microwave 
tube and the reaction was irradiated with microwave at 100-160 ºC for 10 min to 1 h. 
No change in the reaction was detected until reaching 160 ºC for 1 h, where the 
reactants decomposed as indicated by the TLC analysis where several minor spots (>7) 
appeared that were difficult to separate.  
                                                             
* (oxydi-2,1-phenylene)bis(diphenylphosphine). 




Scheme 2.20 Attempted Pd catalysed amination of the alkene 62 using the amine 47. 
  
 The failure of the above reactions (Schemes 2.19, 2.20) argued for the difficulty 
of the reactions in the presence of the steric hindrance induced mainly by the methyl 
groups in both 62 and 47. Therefore, the less hindered, alkene 63, with the cyclopropyl 
chain instead of the two methyl groups in 62, was reacted with the amine 47 using the 
same Pd catalysed conditions (Scheme 2.21). At the same time, the alkene 63 was 
reacted with the amine 47 using a conventional heating method in a sealed tube, to test 
the reactivity without the Pd catalyst (Scheme 2.21). 
 
Scheme 2.21 Attempted reactions of the cyclopropyl alkene 63 with the amine 47, using 
the Pd catalysed amination and the free SNAr reaction. 
  
Using the Pd catalysed conditions, the product 69 was not detected and only the 
alkene 63 was recovered. Using the thermal heating method, the reaction was heated 
until the starting material disappeared. No characteristic peaks were identified in the EI-
MS/ESI-MS spectra, therefore, the excess amine 47 was then removed by distillation 
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under vacuum at 120 ºC. Further analysis of the EI-MS and 
1
H NMR spectra of the oily 
residue did not provide any evidence indicating the formation of 69, instead, a 
polymeric material was detected that had complex multiplicity in the aliphatic regions 
(1-3 ppm) with no aromatic protons.  
 Another SNAr reaction of the amine 47 with 9-chloroacridine 70 was reported in 
2009, utilizing phenol as a solvent and heating the reaction at 100 ºC for 15 min, with 
the product 71 isolated in 65% yield
166
 (Figure 2.7). 
 
Figure 2.7 Reported SNAr reaction of the 9-chloroacridine 70 with the amine 47 using 
phenol as a solvent.
166
 
    
Therefore, the alkene 64 was placed in a sealed tube, phenol was added and 
then, the amine 47 was added. The tube was sealed and the reaction was heated at 
100 ºC for 5 min (Scheme 2.22). A sample of the reaction was taken for TLC analysis, 
which indicated no change. The tube was then heated at 120 ºC for 10 min and 140 ºC 
for 1 h, after which, no change was observed in the reaction. Finally, the tube was 
heated at 160 ºC for 14 h. The tube was then cooled and the content was adsorbed onto 
silica and subjected to a flash column chromatography and eluted with 10% methanol in 
CH2Cl2 to give 3-(cyclobutylidene(4-phenoxypyridin-3-yl)methyl)aniline 72 as a 
colourless oil in 43% yield. Analysis of the EI-MS spectrum showed a peak at 328 m/z 
that was assigned to the M+. Analysis of the 
1
H NMR spectrum showed a broad peak at 
3.55 ppm which was assigned to the NH2 group. The IR spectrum of 72 showed the 
disappearance of the NO2 group absorption bands at 1527 and 1340 cm
-1 
from 64, and 
showed an absorption band at 3256 cm
-1
 indicating the presence of an amino group, 
confirming the reduction of the nitro group on the phenyl ring of 64. 




Scheme 2.22 Reaction of the alkene 64 with the amine 47 using phenol as a solvent. 
  
The nucleophilic substitution reaction of the chlorine atom by the phenol is a 
known reaction for the preparation of ethers (Ullmann ether synthesis), where the 
nucleophile (phenol) is heated with a chlorated substrate at elevated temperatures, in the 
presence of a base and copper metal, as in case of 4-phenoxypyridine 74, which was 
prepared via reacting 4-chloropyridine HCl 55 with phenol in the presence of cesium 
carbonate (Cs2CO3), and Cu-source (Figure 2.8).
167
 The same reaction can also occur in 
the absence of the copper metal, where the 4-chloropyridine HCl 55 could be heated 









In our reaction (Scheme 2.22), two transformations are taking place, the solvent 
phenol first serves as a nucleophile and undergoes an SN2 reaction, replacing the Cl 
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leaving group, producing the ether 72. This was surprising because the phenol is a 
weaker nucleophile than the NH2 group of amine 47 or its decomposition product, the 
NH2 nucleophile, as previously noted (Scheme 2.19). This can be explained based on 
the steric hindrance, by the adjacent sp3 carbon in 47, which prevents the nucleophilic 
attack of the amine 47 to give the product 72. At the same time, the amine 47 or its 
decomposition product (at 160 ºC), might serve as base to mediate the reaction of the 
phenol with the alkene 64, as the case mentioned in Figure 2.8. 
 The second transformation that occurred (Scheme 2.22) was the reduction of the 
nitro group of 64 to give the aniline 72. No metal catalyst was present in the reaction to 
catalyse such a reduction, however, the catalyst free reduction of the aromatic nitro 
group is possible and has been reported previously,
169
 where aromatic nitro compounds 
can be heated with a hydrogen source at 110 ºC for 24 h, in a solvent like water or 
water/DMSO mixture.
169
 Amines and hydrazines are well known sources of hydrogen 
in reduction reactions,
170,171
 and therefore, the amine 47 or its decomposition products 
are proposed to be the hydrogen source for the reduction of the nitro group in 64 to the 
amino group in 72, when heated at 160 ºC for 14 h in a sealed tube. The sealed tube also 
provided the pressure required for such a reduction reaction. However, because the 
product 72 is out of the scope in this work, the reaction was not repeated on the other 
alkene 62 or 63, to investigate the scope of this reduction. 
2.5.5. Amination of the alkenes 62-64 using morpholine 75 
Replacing the amine side chain 33 and the amine 47 by morpholine 75 was an 
applicable strategy that was previously used.
157
 The AAPM 36 carrying the morpholine 
side chain (Figure 2.2), displayed a weak to moderate activity against the dengue virus 
(64% inhibition at 25 µM).
157
 The synthesis of the AAPM 36 was also achieved in 62% 
yield.
157
 Therefore, the alkenes 62-64 were reacted with neat morpholine 75, by heating 
the mixture at reflux for 48 h (Scheme 2.23). Excess morpholine 75 was then removed 
by distillation under vacuum, leaving oily residues. Only the cyclopropyl analogue 77 
was isolated after being subjected to alumina column chromatography. Analysis of the 





. Analysis of the 
13
C NMR spectrum of 77 showed a peak at 
66.8 ppm assigned to the morpholine C2 and C6, and two carbon resonating at 53.4 
ppm assigned to C3 and C5 of the morpholine ring in 77. 




Scheme 2.23 Amination reaction of the alkenes 62-64 with morpholine 75. 
  
In case of the alkenes 62 and 64, no reaction was detected and the alkenes were 
fully recovered after the reaction time (Scheme 2.23). The ability of the alkene 63 to 
react with morpholine 75 was related to the less hindrance, in comparison with the more 
hindered alkenes 62 and 64. Therefore, harsher conditions were employed on alkenes 62 
and 64. Neat morpholine 75 was heated with either alkene 62 or alkene 64, in a 
microwave tube (Scheme 2.24). The maximum heat applied was 240 ºC (using the 
maximum microwave power), and the reaction was held for 1 h. The reaction was 
cooled with compressed air for 10 min. TLC and low resolution mass analysis indicated 
no change in the reactants. 
 
Scheme 2.24 Attempted microwave reaction of the alkenes 62, 64 with morpholine 75. 
  
The failure to synthesise 76 and 78 was mainly attributed to the steric hindrance 
by the dimethyl groups in case of alkene 62, and the bulky cyclobutyl of the alkene 64. 
However, the alkenes 62, 64 were found to be stable after heating at 240 ºC for 1 h, and 
were fully recovered. 
Chapter 2  New Leads 
62  
 
2.6. Concluding remarks 
This chapter presented the attempted trials to synthesise the nitro AAPM derivative 46, 
starting from the nitro-isobutyrophenone 38. The sequence of the reaction sequence 
proceeded well until the final amination step with the racemic side chain amine 33. 
Different conditions were tried for this amination, however, the polymerization of the 
side chain and the loss of the starting material, the aminochloropyrimidine 43, provided 
additional difficulties in repeating the reaction. During the optimization of the 
dehydration reaction for the alcohol 40, using conc. H2SO4, a new furopyrimidine 42 
was obtained in an excellent yield. This is considered a novel short synthetic pathway to 
access the furopyrimidine skeleton which has been rarely reported in the literature.  
 The racemic amine 33 was then replaced by the amine 47, which contains 
features present in the anti-malarial chloroquine 8. Final amination using 47 was not 
successful due to the instability of 47, decomposing and releasing NH2 as a nucleophile, 
and also due to the steric hindrance caused mainly by the two methyl groups in the 
aminochloropyrimidine 43. One way to decrease the steric hindrance was by tethering 
the two methyl groups by using the less hindered cyclopropyl group. The replacement 
took place, and the alcohol 50 was isolated, however, it was found to be unstable, and 
the conversion to the alkene 51 was not successful. Another possibility is to use a less 
hindered analogue of 47 that does not have the methyl germinal to the NH2 group.  
 A modification of the AAPM structure was then achieved by replacing the 4,6-
dichloropyrimidine 28 by the simpler 4-chloropyridine HCl 55. The addition and 
dehydration reactions proceeded well and three alcohols 59-61 and the corresponding 
alkenes 62-64 were obtained in good yields. However, the final amination with the 
amine 47 was not successful with any of the alkenes, including the Pd catalysed 
amination chemistry. Instead, the ether-aniline product 72 was obtained when trying the 
amination with the alkene 64, using phenol as a solvent. This product showed that the 
nucleophilic substitution on the alkenes 62-64 was possible, although steric hindrance 
prevented the addition of the amine 47 in the desired position. Product 72 showed also 
the instability of the amine 47 when placed in harsh conditions which might be required 
for such nucleophilic substitution reactions, as can be noted by the reduction of the nitro 
group on alkene 64 to an amino group in 72, depending on the amine as a hydrogen 
source. 
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 Finally, the amination with the secondary amine, morpholine 75, was performed 
on the alkenes 62-64, however, only the cyclopropyl analogue 77 was isolated in good 
yield. This confirmed the difficulties in performing such reactions in the presence of 
hindered systems. 
 In conclusion, the alkene 63, with the less hindered cyclopropyl group, 
represents the most promising alkene to perform more amination reactions under 
moderate conditions. The synthesized compounds, not only represent milestones in the 
optimization process of the AAPM derivative syntheses, but also provide new scaffolds 
for testing against the CHIKV as well as against malaria, to identify new hit 
compounds. 
 Some alternative routes to the AAPM derivatives are to be considered. The 
synthesized new furopyrimidine 42 can be considered for the amination reaction, as it is 
less stericaly hindered than the corresponding alkene 41  (Scheme 2.25). The furan ring 
can then be open using POCl3
160
  to give the final aminated products. 
 
Scheme 2.25 Alternative synthesis of the AAPM 46, 48 and 81 using the 
furopyrimidine 42 intermediate. 
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CHAPTER 3: Modelling Study of the CHIKV nsP3 as a Possible 
Drug Development Target 
 
3.1. Introduction 
The function of alphaviruses nsP3 has remained unknown, although mutations can 
affect different steps of the viral replication machinery.
75
 It is constructed of two 
domains, with the first being a unique macro domain in the conserved N-terminal 
region. The C-terminal region is less conserved and is phosphorylated in about 16 
positions on serines and threonines.
76,77
 The function of phosphorylation is not 
understood, but it was found that deletion of these phosphorylated residues decreases 
the RNA synthesis level in infected cells.
78
  
The N-terminus of nsP3 contains a macro domain (known also as X domain), 
which binds to ADP-ribose derivatives and RNA, and is able to hydrolyse ADP-ribose-
1"- phosphate,
80,81
 a side product of cellular pre-tRNA splicing. Therefore, it is believed 
to control the metabolism of ADP-ribose 1"-phosphate and/or other ADP-ribose 
derivatives which have regulatory functions in the cell. The ADP ribose-binding site 
within the nsP3 macro domain is solvent-exposed and points away from the other 
domains in the nsP23 polyprotein. Based on sequence conservation in alphaviruses, it 
has been shown that residues just after the nsP3 macro domain play a role in positioning 
of the nsP23 complex cleavage site.
82
 It can be inferred from the crystal structure of the 
nsP23 precursor protein of the closely related alphaviruses, SINV, that the nsP2 is 
connected to the nsP3 through the macro domain of the nsP3.
83
  
In 2010, the crystal structure of the nsP3 macro domain for the CHIKV was 
solved
80
 (Figure 3.1). It is formed of 672 residues and contains six-stranded β sheets 
(cyan colour in Figure 3.1) and three α helices (red colour in Figure 3.1). The 2D 
intermolecular interactions between the residues in the binding pocket of the enzyme 
and the ADP-ribose,
85
 as analysed from the crystal structure, are also shown (Figure 
3.2). 
As shown in Figure 3.2, the key binding residues are: Arg144, Asp10, Ile11 
The111, Gly112, Ser110, Tyr114, Val113, Asn24, Asp31 and Val33. The binding 
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showed the strongest interactions with these residues in the enzyme pocket. Also, the 
ribose (with Thr111) and the diphosphate (with Gly112, Ser110, Tyr114, Val113, Val 
33) units were found to play major roles in the CHIKV nsP3 ADP-ribose complex.
85
 
The nsP3 of CHKV uses a conserved proline-rich motif to interact with the Src-
homology-3 (SH3) domain of amphiphysin-1 and amphiphysin-2 proteins, of the host 
cell, which are related members of the BAR (Bin-Amphiphysin-Rvsp) protein 




Figure 3.1 Crystal structure of the CHIKV macro domain with the bound ADP-ribose, 
generated from the PDB file code: 3GPO,
80
 β sheets are shown in cyan, while the three 
α helices are shown in red colour. 
 
Figure 3.2 2D representation of the interaction of ADP-ribose inside the nsP3 macro 
domain binding pocket showing the other residues inside the active site (Generated 
from the PDB file: 3GPO
80
). 





 found that the nsP3 acts as an inhibitor of stress granule 
assembly by recruiting G3BP into cytoplasmic foci. The conserved SH3 domain-
binding motif in nsP3 (the proline-rich motif, not included in the crystal structure) is 
also essential for both nsP3-G3BP interactions and viral RNA replication. G3BP (Ras 
GTPase-activating protein-binding protein) is an enzyme in human cells and a member 
of the heterogeneous nuclear RNA-binding proteins.
88
 This protein plays a major role 
during infection and in the assembly of stress granules. Stress granules are membranous 
cytoplasmic focal structures (foci) that immediately aggregate in response to cellular 
stress; this last action leads to impaired translation of most mRNAs.
89
 These stress 




The crystal structure of the CHIKV nsP3 macro domain represents only one 
domain of the whole protein, however, the main function of the CHIKV nsP3 is located 
within this X domain, through the ADP-ribose binding site. Moreover, like other 
alphaviruses, the nsP2 is connected to the nsP3 through the macro domain of the 
nsP3.
83
 Therefore, targeting the binding site of this domain will have effects on both the 
functions of the whole nsP3 itself, and also, will impair the functions of the polyprotein 
complex (nsP23 cleavage site). Therefore, impairing the functions of the nsP3 macro 
domain would either affect the functions of the whole protein (nsP3) as an individual 
functioning unit, or would impair the functions of the polyprotein complex before being 
cleaved by the protease activity of the nsP2. In either case, the viral replication 
machinery will be impaired.  
This chapter describes the investigation of using of the CHIKV nsP3 as a 
potential drug target by utilizing the ADP-ribose binding site to perform virtual 
screening of a compound library. In this structure-based search approach, the co-
crystallized ligand (ADP-ribose) was used as a control. Ligands which showed higher 
scores within the pocket were considered as potential competitive inhibitors, and 
ligands which showed lower affinities were discarded.   
3.2. Results and discussion: 
3.2.1. The data set library used in the search 
The freely available NCI diversity set III was selected for this virtual screening. The 
diversity set was derived from almost 140,000 compounds available in plates for high 
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throughput screening approaches. Only available compounds were considered. The 
71,756 compounds meeting this criterion were filtered using the program Chem-X 
(Oxford Molecular Group). Chem-X uses defined centres (hydrogen bond acceptor, 
hydrogen bond donor, positive charge, aromatic, hydrophobic, acid, base) and defined 
distance intervals to create a particular finite set of pharmacophores. 3-Point 
pharmacophores were used resulting in almost 1,000,000 possible pharmacophores. The 
Chem-X diverse subset generating function reads through a set of structures and 
determines the acceptable conformations. For each acceptable conformation, it 
determines all the possible pharmacophores. The pharmacophores for the current 
structure are compared to the set of all pharmacophores found in structures already 
accepted into the diverse subset. If the current structure has more than a preset number 
of new pharmacophores, it is added to the diverse subset. The requirements were set as 
5 new pharmacophores and, additionally, 5 or fewer rotatable bonds. This procedure 




3.2.2. Virtual screening with the CHIKV using Autodock Vina  
In this chapter, Autodock Vina (Vina)
172
 was used to perform virtual screening of the 
NCI Diversity Set III into the ADP-ribose binding site within the CHIKV nsP3 macro 
domain crystal structure (pdb: 3GPO
80
). Vina is freely available to the academic 
community. It is two orders of magnitude faster than Autodock 4.0 (Autodock
173
). Vina 
performs well relative to Autodock; while Autodock is slightly better at predicting the 
energy of binding (standard error of 2.2 kcal.mol
-1
 versus 2.8 kcal.mol
-1
 for Vina), Vina 
more accurately reproduces cocrystallized ligand poses.
172,174
 Vina has been used 
successfully for virtual screening with reliable results.
175
  
Table 3.1 shows the top 17 ranked docked poses that achieved lower binding 
energies (ΔGbind) than the co-crystallized ligand (ADP-ribose), with the binding 
energies (Kcal/mol), interacting residues and calculated log (ClogP). The validation of 
the docking accuracy was achieved by docking the native co-crystallized ligand (ADP-
ribose) into its binding site of nsP3 macro domain. The result was satisfactory where the 
docked ligand was exactly superimposed on the native co-crystallized ligand with a 
RMSD value of 0.34 Å, and a binding free energy of -10.4 kcal/mol. The top 10 
compounds were selected for in vitro antiviral evaluation against the CHIKV. 
                                                             
* The diversity set III definition and the preparation procedures were extracted from the NCI website.  
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Table 3.1 Autodock Vina top ranked molecules which scored higher than ADP-ribose, 










Leu108 (H bond, 1.99 Å),  












Arg144 (H bond, 2.15 Å), 
Ser115 (H bond, 2.01 Å), 






Asn24 (H bond, 2.24 Å),  
Cys34 (H bond, 2.08 Å),  
Val113 (H bond, 1.83 Å),  
Leu108 (H bond, 2.47 Å),  
Arg144 (H bond, 1.84 Å),  
Ile11 (H bond, 2.42 Å),  








Trp148 (π-π),  
Val113 (H bond, 2.03 Å),  
Asp31 (H bond, 2.39 Å) 
5.13 
                                                             
* Calculated using ChemBioDraw Ultra 13.0 (2012). 






Arg144 (cation-π, H bond, 2.09 Å),  
Ile11 (H bond, 2.27 Å),  
Tyr142 (H bond, 1.88 Å),  
Thr111 (H bond, 2.19 Å),  





Thr111 (2 H bond, 1.81, 2.48 Å),  





Trp148 (π-π),  
Arg144 (H bond, 1.91 Å),  
Thr111 (H bond, 1.83 Å),  








Arg144 (H bond, 2.13 Å),  
Asp145 (H bond, 2.29 Å),  
Thr111 (H bond, 1.89 Å),  








Arg144 (cation-π, H bond, 2.48 Å),  
Thr111 (H bond, 2.09 Å),  
Gly112 (H bond, 2.17 Å),  





Leu108 (H bond, 1.93 Å),  
Tyr142 (H bond, 2.15 Å),  
Thr111 (H bond, 1.79 Å),  
Gly112 (H bond, 2.33 Å),  
3.78 






Leu108 (H bond, 2.44 Å),  
Val113 (H bond, 2.32 Å),  





Val33 (H bond, 2.47 Å), 
Thr111 (2 H bond, 1.70, 1.88 Å), 
Gly112 (H bond, 2.24 Å), 





Asn24 (H bond, 2.19 Å), 
Thr111 (H bond, 2.16 Å), 




From Table 3.1, it can be seen that all the top ranked poses could interact with 
the key residues inside the CHIKV nsP3 pocket, which interact with ADP-ribose 
(Figure 3.2). The results also revealed the participation of new residues within the 
pocket, where the amino acid Leu108 was found to either accept H-bonds through the 
carbonyl group, or donate H-bonds through the NH group with poses 1, 2, 4, 14 and 15 
(Figure 3.3). The Leu108 residue is located inside the pocket close to the key residues 
Ser110, Thr111, Gly112 and Val113. Interactions with these residues were found to be 
important for the binding of the ADP-ribose ligand.
85
 Therefore, interactions with 
Leu108, should also strengthen the interactions within this site of the pocket. This 
would stabilizes the ligand-enzyme complex at this site, therefore, competing well with 
ADP-ribose (did not show interactions with Leu108) to fit within the pocket inside the 
CHIKV nsP3 macro domain.  
 




Figure 3.3 Leu108 (red colour) interactions within the nsP3 pocket with entries 1, 2, 4, 
14 and 15 (poses are shown in green colour). Leu108 can either accept H-bonds through 
the backbone CO or donate H through the backbone NH group.  
  
Another common residue, Trp148 which is lying on the pocket floor, was found 
to have π-π stacking interactions with entries 2, 3, 6 and 9 (Table 3.1). These poses were 
found to position aromatic systems against the indole ring of Trp148, giving stability of 
the aromatic residues against the pocket mouth (Figure 3.4). The amino acid residue 
Asp145 was also found to form a H-bond only with entry 11 (Table 3.1). Ser115 was 
also found to form a H-bond only with entry 3.  
 
 
Figure 3.4 Trp148 π-π interactions with the aromatic rings of entries 2, 3, 6 and 9. 
Trp148 is shown in blue colour within the transparent surface of the nsP3 pocket. The 
π-π interactions are shown as orange lines. 
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3.2.3. Ranking of the Autodock Vina output using Autodock 
To select the hit to be optimized, the hit list obtained by Autodock Vina (Table 3.1) was 
subjected to ranking using the Autodock algorithm, which was then used for the in 
silico optimization. Re-docking of the hits using Autodock was performed to re-score 
the list with the Autodock scoring function, using the native ligand (ADP-ribose) as a 
control, and excluding those hits which are ranked below the score of ADP-ribose. 
Table 3.2 shows the re-docking results. Autodock 4 results for the ADP-ribose: binding 
energy (ΔGbind = -11.07 Kcal/mol) and predicted inhibition constant (Ki = 7.74 nM).  
 
Table 3.2 Hits which passed the Autodock re-ranking, achieving scores higher than 
(ADP-ribose), their binding energies (ΔGbind), predicted inhibitory constant (Ki) and 
interacting residues. Entries of the table are the same as in Table 3.1. 








-12.66 0.528 Asp31 (H bond, 1.74 Å) 
6 
 
-12.01 1.56  
Asn24 (H bond, 2.32 Å), 
Asp31 (H bond, 2.15 Å), 
Leu108 (H bond, 1.90 Å), 




-11.71 2.59  
Leu108 (H bond, 1.97 Å), 




-11.37 4.62  
Ala22 (H bond, 2.09 Å), 
Cys34 (H bond, 1.71 Å), 
Gly112 (H bond, 2.16 Å), 
Val113 (sigma-π), 
Arg144 (H bond, 2.06 Å) 






Leu108 (H bond, 2.09 Å), 
Val113 (H bond, 2.16 Å), 




-11.31 5.1  
Ala22 (H bond, 2.36 Å), 
Gly112 (H bond, 2.48 Å) 
Val113 (H bond, 2.11 Å), 
Arg144 (2 cation-π, H 
bond 1.97 Å) 
16 
 
-11.14 6.81  
Asp31 (H bond, 2.38 Å), 
Val33 (H bond, 1.78 Å), 
Leu108 (H bond, 1.74 Å), 
Thr111 (H bond, 2.27 Å), 
Gly112 (H bond, 2.09 Å), 
Val113 (H bond, 2.18 Å), 
Tyr114 (H bond, 2.01 Å), 
Agr144 (H bond, 2.23 Å) 
 
Table 3.2 showed that the amino acid residue Asp31 is critical for the ligand-
enzyme interaction complex as demonstrated by entries 12 and 6, where both ere 
predicted to form H-bonding with Asp31 with predicted distances of 1.74 Å and 2.15 Å, 
respectively. Entry 12 also achieved shape matching and therefore was predicted to 
have the highest ΔGbind value. Entry 16 showed the ability to form a H-bonding with 
Asp31 with a predicted distance of 2.38 Å, a greater distance from those observed in 
entries 12 and 6. Although ranked the last pose (Table 3.2), entry 16 showed 8 H-bonds 
with key binding residues within the pocket, ranging from 1.78 to 2.38 Å. 
Entry 3 (benzimidazole derivative) was selected for the docking based 
optimization due to its easy chemical access, high scoring in the first Autodock Vina 
screening, highly optimizable structure and it showed the ability to form 2 cation-π 
interactions with Arg144 (similar to ADP-ribose).  It was also selected in order to 
validate the efficacy of the optimization process (optimizing a lower ranked hit rather 
than a higher ranked one).  
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3.2.4. In silico optimization of entry 3 
Hit 3 (Table 3.2) showed interaction within the CHIKV nsP3 pocket (ΔGbind = -11.31 
Kcal/mol, predicted Ki = 5.1 nM). Figure 3.5 shows the 2D representations of the 
interaction of entry 3 with the nsP3 residues. This hit can be described as two 
benzimidazol-2-yl phenyl units connected to a central phenyl ring through amide 
linkages. One of the benzimidazol-2-yl phenyl forms important interactions with the 
key amino acid residue Arg144, where the benzimidazole moiety forms the π-cation 
stacking interaction with the cationic side chain of Arg144 via the benzo moiety, and 
another π-cation interaction with the phenyl ring, whereas one N atom of the imidazole 
moiety accepts a H-bond from one of the Arg144 NH2 (Figure 3.5). The other 
benzimidazole moiety can donate a H-bond, through the imidazole moiety to the 
backbone carbonyl group of Ala22. One of the amide carbonyl (Figure 3.5) accepts two 
H-bonds from the backbone amide NH of the key residues Gly112 and Val113. 
 
Figure 3.5 2D representations of the interaction of entry 3 within the CHKV nsP3. 
  
Therefore, the important moieties for hit 3 (Table 3.2) appear to be the 
benzimidazol-2-yl phenyl moieties and the amide linkages. The ClogP for this hit is 
6.77, which is due to the presence of 5 phenyl rings in the structure. Removal of the 
central phenyl ring was the first modification performed on hit 3, producing pose_3_1 
(Figure 3.6) which suggested more positive interactions with active site residues (ΔGbind 
= -11.44 Kcal/mol, predicted Ki = 4.08 nM), a slight improvement in the Autodock 
score compared to hit 3. ClogP for pose_3_1 is 4.97, lower than that of the original hit 
3. 




Figure 3.6 2D representations of the pose_3_1 within the CHIKV nsP3. 
  
Figure 3.6 shows that pose_3_1 has the same predicted interactions with the key 
residue Arg144. However, Gly112 also interacted, not through a H-bond as in case of 
hit 3 (Figure 3.5), but through a sigma-π stacking interaction (Figure 3.6). Two amino 
acid residues participated in new H-bonds, the key residue Tyr142 (1.82 Å) and the 
backbone NH of Leu108 (1.88 Å). The other terminal benzimidazole N did not donate a 
H-bond to Ala22 as in hit 3, instead, a H-bonding interaction with the key residue 
Asp31 (Figure 3.6) was predicted. The 3D model of pose_3_1 suggested further 
possibilities of H-bonds with the polar hydrogens of the key amino acid residue Asn24 
(Figure 3.7), through one of the benzimidazole rings. Such H-bond formation will 
require the presence of an acceptor on the terminal benzo moiety of the benzimdazole 
close to Asn24 (Figure 3.7). Moreover, the presence of an acceptor on the other 
benzimidazole moiety (which forms interactions with Arg144), would make possible a 
H-bond with the polar hydrogens of Lys35 (Figure 3.7). 




Figure 3.7 3D representation of pose_3_1 within the nsP3 pocket. Asn24 and Lys35 
polar hydrogens are shown as yellow spheres. 
  
Therefore, the next modification was to insert an acceptor group on the terminal 
benzimidazole rings. This acceptor was to be added on both benzimidazole rings, to 
achieve the two possible interactions with Asn24 and Lys35. Several acceptor groups 
such as NH2, OH, COOH and NO2 could be added on the desired position, however, the 
nitrile group (CN) was selected as an acceptor to be added on the benzimidazole ring. It 
was selected because it is able to form relatively strong H-bonds with the receptor 
residues,
176
 and also, the presence of the carbon atom would act as a spacer, bringing the 
N closer to the receptor residues.
177
 Therefore, pose_3_1 was optimized to give 
Pose_3_2. This modification, not only represented a better in silico binding profile 
(ΔGbind = -13.12 Kcal/mol, predicted Ki = 239.69 pM), but also, it showed interactions 
with 9 key residues within the nsP3 binding pocket (Figure 3.8). Furthermore, the 















Figure 3.8 Pose_3_2 within the CHIKV nsP3 pocket. a) 3D representation, b) 2D 
representation. H-bonds are shown as green dashes, cation-π and sigma-π interactions 
are shown as orange lines. 
  
As predicted, the nitrile group introduced on the benzimidazole rings, not only 
accepted a H-bond from Asn24 (1.90 Å), but also accepted another H-bond from the 
key residue Cys34 (2.19 Å). The nitrile group on the other benzimidazole ring also 
accepted a H-bond from Lys35 (2.35 Å) as predicted. It is envisaged that such 
interactions with Cys34 and Lys35 residues would stabilize the pose within the pocket 
cavity openings (Figure 3.8a). The pocket central residues Gly112, and Val113 were 
able to form sigma-π stacking interactions with a phenyl ring, and the imidazole moiety, 
respectively (Figure 3.8b). The molecular weight of pose_3_2 is 522.5, with ClogP 
value of 3.84, and these drug-like properties made it an attractive candidate for 
synthesis and testing against the CHIKV. 
3.3. Synthesis of pose_3_2 (86) 
The retrosynthetic analysis of pose_3_2 (Figure 3.9) suggested that it could be accessed 
through three synthetic steps; the synthesis of the nitro-benzimidazole, which can be 
then reduced to the amino derivative, and reacted in a final step with oxalyl chloride 
(Figure 3.9) to give the bis-product. 




Figure 3.9 The retrosynthetic analysis for the synthesis of pose_3_2 (86).  
 
 The synthesis of the benzimidazole nucleus can be achieved by a variety of 





 or acid chlorides,
180
 utilizing a variety 
of different solvents and catalysts. In this work, the benzimidazole 84 was synthesized 
via the reaction of the 3,4-diaminobenzonitrile 82 with 3-nitrobenzaldehyde 83 in 
solvent free conditions, where the two solids were mixed together (1:1 molar ratio) and 
the mixture was heated with vigorous stirring at 90 ºC. Both solids melted, giving a dark 
brown oil mixture (Scheme 3.1). After a few minutes of stirring the dark oil at 90 ºC, 
the mixture solidified as a dark brown solid. At this stage, the first step of the reaction 
occurred which was the condensation reaction of the aldehyde 83 with one of the 
amines in 82 giving the Schiff base intermediate (Scheme 3.1). Increasing the 
temperature to 145 ºC initiated the cyclization step, where the 2
nd
 amine attacked the 
electron deficient azomethene carbon, where the dark brown solid condensation 
intermediate melted again giving a dark red oily mixture. Stirring continued for about 3 
min, after which the mixture solidified again as a dark red solid (Scheme 3.1). The solid 
was then extracted into boiling ethanol, and crystallized from a mixture of methanol, 
1,4-dioxane and water to afford the benzimidazole 84 as a yellow crystalline solid. 
 
 




Scheme 3.1 The synthesis of the benzimidazole 84. 
 
Analysis of the ESI-MS spectrum of 84 showed a peak at 264.1 m/z that 
corresponded to (M+). The 
1
H NMR spectrum showed a broad singlet peak resonating 
at 13.8 ppm which was assigned for the NH. This solvent free conditions enabled the 
access to the desired benzimidazole in a short time (less than one hour) and relatively 
good yield (70%). 
 The next synthetic step was the reduction of the nitro group in 84. Therefore, the 
benzimidazole 84 was suspended in methanol, and Raney Nickel catalyst was added 
under N2 atmosphere with vigorous stirring. The hydrogen source for the reduction was 
hydrazine monohydrate in methanol, which was added dropwise. During the addition of 
hydrazine hydrate, hydrogen gas was evolved and upon cessation, the reaction was 
heated to 80 ºC for 2 h (Scheme 3.2). The mixture was then filtered through celite while 
hot, and methanol and excess hydrazine hydrate were removed under reduced pressure 
to give the amine 85 as a dark yellow solid.  
 
Scheme 3.2 Reduction of the benzimidazole 84 to the amino derivative 85. 
 
The analysis of 
1
H NMR spectrum of the product 85 showed a broad peak 
resonating at 5.37 ppm which was assigned as the NH2 group. ESI-MS (negative 
ionization) showed a peak at 233.0 which was assigned for (M-1). 
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The final synthetic step was the dimerization of the amine 81 using oxalyl 
chloride. The amine 85 was dissolved in dry THF in the presence of TEA, and the 
mixture was stirred under N2 atmosphere at 0 ºC. A solution of oxalyl chloride in dry 
THF was then added dropwise with vigorous stirring. After addition, the mixture was 
left to warm to room temperature with stirring for 2 h (Scheme 3.3) after which the 
mixture became turbid. The reaction was then quenched with chilled water and a solid 
precipitated immediately. The solid was filtered and washed with water and methanol, 
recrystallised from DMF to afford the final pose_3_2 (86) in 69% yield. The
 13
C NMR 
spectrum of the product showed a peak at 158.8 ppm which was assigned to the CO 
groups. The 
1
H NMR spectrum showed a peak at 11.08 ppm which was assigned for the 
two oxalamide NH groups. The IR spectrum also showed a band at 2219 cm
-1
 that was 
assigned for the nitrile group. 
 
Scheme 3.3 Reaction of the amino benzimdazole 85 with oxalyl chloride to afford the 
final compound 86. 
  
In this reaction (Scheme 3.3), only the primary amine NH2 group was involved 
in the reaction with oxalyl chloride. The benzimidazole NH is reactive and might react 
with acid chlorides, however, it is known that N-acylbenzimidazoles undergo hydrolysis 
to the free NH again in the presence OH groups or water.
181
 The rate of this hydrolysis 
increases if the imidazole or benzimidazole carries electron withdrawing groups such as 
the nitro group.
182
 The electron withdrawing nitrile group of 85 is therefore believed to 
achieve similar effect, deactivating the acylation of the benzimidazole NH. 
3.4. Concluding remarks 
This chapter discussed the use of the macro domain (domain X) of the CHIKV nsP3 as 
a possible target for the drug design against that virus. The nsP3 is a multifunctional 
viral protein, with the macro domain being the domain which regulates the ADP-ribose 
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substrates within the cellular process. Furthermore, the ADP-ribose binding site within 
the macro domain is close to the connection site with the nsP2. Therefore, occupying 
the ADP-ribose binding pocket with an exogenous ligand (inhibitor) should affect the 
function of the nsP3 either in a polyprotein complex or as an individual functioning 
protein. In this chapter, a virtual screening process of the NCI diversity set III, a library 
that carries drug-like molecules, was performed using the ADP-ribose pocket as the 
target binding site. Autodock Vina, a fast and reliable virtual screening engine, was 
used and 17 hits were identified as potentially stronger enzyme binders compared to the 
original ligand (ADP-ribose) which may serve as inhibitors for the CHIKV nsP3 
functions. The search revealed that the hits made interactions with the identified key 
residues within the pocket, and also with new residues that tended to stabilize the 
ligand-receptor complex, such as Leu108, Trp148, Ser115 and Val22. The top 17 hits 
(Table 3.1) were obtained from the NCI and are currently under antiviral evaluation (at 
Griffith University). 
 The top hits were then subjected to re-ranking against the original ligand (ADP-
ribose) using Autodock 4. This re-ranking resulted in 7 hits achieving higher scores than 
the ADP-ribose. One hit, hit 3 (Table 3.2) was selected for further docking based 
optimization. This optimization resulted in pose_3_2 (86) which showed a significantly 
improved in silico profile compared to the original hit (Figure 3.10). 
a) Hit 3
 
ΔGbind = -11.31 Kcal/mol 
Ki = 5.1 nM 
ClogP = 6.77 
b) Pose_3_2 (optimized hit 3, 86)
 
ΔGbind = -13.12 Kcal/mol 
Ki = 0.239 nM 
ClogP = 3.84 
Figure 3.10 Comparison between (a) hit 3 and (b) the optimized structure 86.  
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 The optimized structure 86 was then accessed through three facile synthetic 
steps. This optimized hit 86 represents an early stage towards the discovery of a lead 
compound, based on the structure-based approach, which can be further optimized using 
in silico and in vitro in-depth studies. 
 The virtual screening hits 4 and 17 (Tables 3.1, 3.2) have the same linear 
skeleton and showed good interactions with the CHIKV nsP3 ADP-ribose pocket. If 
these molecules were demonstrated to be promising in activity, different derivatives can 
be accessed through one step reaction (Figure 3.11), and therefore, they might be a 
subject of both in silico and in vitro optimizations. 
 
Figure 3.11 Possible access of different analogues for hits 4 and 17. 
 
 The inhibitor discovery status for the CHIKV nsP3 is still in the very early 
stages. Thus fare, the enzyme is not even available as a testing kit to validate the 
potential inhibitors. Efforts should be devoted to develop such validation techniques. 





CHAPTER 4: Synthesis of Mycophenolic Acid Analogues as 
Inhibitors of the Chikungunya Virus 
 
4.1. Introduction 
Mycophenolic acid (15, Figure 4.1) was isolated about one hundred years ago 
from the cell culture of  Penicillium brevi-compactum.
125
 It acts as an inhibitor for the 
inosine monophosphate dehydrogenase (IMPDH) enzyme which is involved in the de 
novo biosynthesis of guanine nucleotide. It has good anti-proliferation activity and has 
been established as an anticancer
126





Figure 4.1 Chemical structures of mycophenolic acid 15. 
 
Recently, MPA was shown to inhibit the CHIKV replication and virus induced 
cell death with an IC50 value of 0.2 µM and a selectivity index value of 150 (compared 
to vero cell lines),
128
 and it was found to induce CHIKV apoptosis. It works by 
inhibiting IMPDH, and when the CHIKV infected cells were provided with exogenous 
guanosine (GMP), MPA was prevented from inducing the CHIKV cell death.
128
 
Considered as a good lead compound, the in vivo activity of MPA acid against CHIKV 
should be investigated as it is well known that mycophenolic acid suffers from a 
metabolic drawback associated with rapid conjugation of the C-7 phenolic hydroxyl 
group with glucuronic acid.
183,184,129,130
  
MPA as a lead: Mycophenolic acid 15 has good drug like properties with a molecular 
weight of 320.3, calculated logP (clogP
*
) value of 2.92, calculated LogD
†
 value of 3.56 
                                                             
* Calculated using ACDLabs v.12.0 (ACD/Labs, Toronto, Canada) 
† Calculated using PALLAS3.7.1.2 CompuDrug Chemistry Ltd, USA, LogD is a pH dependent 
distribution coefficient version of the logP. It represents the drug permeability (lipophilicity) at a certain 
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(pH=1-2), 0.67 (pH=7.4) and 2.52 (pH=5.5) indicating good blood solubility and oral 
bioavailability (oral drug absorption occurs in the small intestine at pH ~ 5.5
185,186
). 
With the good CHIKV activity (IC50 = 0.2 µM), MPA 15 is a promising template for 
developing anti-CHIKV drugs, with the metabolic drawbacks to be avoided for better 
bioavailability properties.
183,184,129,130 
The structure of CHIKV IMPDH enzyme is not 
yet available and therefore the structure based drug design for inhibitors is not a 
possibility. Instead, a ligand based drug design approach can be used starting with MPA 
15 as a lead compound. 
4.2. Design of MPA analogues  
Mycophenolic acid consists of three major components (Figure 4.2), an aromatic head 
(the 3-oxo-1,3-dihydroisobenzofuran moiety), a rigid linker (the alkene connection) and 
an acidic tail (the carboxylic acid group). The aromatic head carries two major hydrogen 
bond acceptors (the carbonyl group and the oxygen atom of the lactone ring). The 
aromatic benzo moiety carries a hydroxyl group, a methoxy group and a methyl group.
 In this study, the three components of MPA 15 were investigated as optimizable 
components that could be changed with a variety of similar systems, starting from 
simple cores such as benzoic acids and anilines. Figure 4.2 shows the possible access to 
MPA 15 analogues starting from such derivatives. Both the acids and anilines could be 
converted into the aromatic head groups carrying H-bond acceptor capacity, and then 
could be connected through simple C-C coupling, to the other two cores, the linker and 
the acidic tail. R groups on the acids and anilines were selected to give a similar 
environment as in 15. 
                                                                                                                                                                                  
physiological pH. Oral drugs to be able to be absorbed by passive diffusion through the gut wall, should 
have their lipophilicity within a given range between 1 and 4 on LogD scale. Note that LogD = LogP at 
neutral pH, therefore LogD describes the actual LogP values at different pHs. 




Figure 4.2 Design of MPA 15 analogues starting from benzoic acids and aniline 
derivatives. The red circles indicate the HBA groups, the blue boxes indicate the rigid 
linker and the green circle refers to the acidic tail moiety which could be either COOH 
or the bioisostere tetrazole.  
 
4.2.1. Design Strategy 
The design of alternative and similar cores to MPA 15 was based on: 
1. Changing the aromatic head: the aromatic head was either kept as a 
benzolactone or changed to an isatin moiety (Figure 4.2). The use of benzolactones as 
the aromatic head groups would highlight the importance of this functionality for the 
anti-CHIKV activity. Isatins were also selected as alternative possible replacements for 
the aromatic head group; as they have been showed to possess various pharmacological 
and biological properties including anticholinesterase, anticonvulsant, antiinflammatory, 
antihypertensive, antihypoxic, antimicrobial, and antiviral properties.
187,188 Furthermore, 
the isatin moiety has been found in nature, e.g. as a component of the secretion from the 
parotid gland of Bufo frogs,
187
 and in humans as a metabolic derivative of adrenaline.
189
 
Isatin is also found in the brain.
190
 The structure of isatin participates in the activity, 
where the two carbonyl groups (red circles, Figure 4.2) could accept H-bonds from 
residues in the target receptors, and the NH can donate a H-bond to acceptor 
residues.
191,192
 The aromatic core π-system of isatin was also found to participate 
through aromatic interactions with some target receptor residues.
193
 Therefore, replacing 
Chapter 4  MPA Analogues 
86  
 
the benzolactone head of MPA 15 with isatin, would have some structural similarities, 
with possible similar interactions with the yet unknown viral receptor. 
2. Replacing the rigid linker alkene with the rigid phenyl ring (blue boxes, Figure 
4.2) would be an applicable strategy for obtaining a rigid linker between the aromatic 
head and the acidic tail of MPA analogues. Utilizing the C-C cross coupling 
chemistry
194,195,196
 could facilitate such facile access to the biphenyl system. This phenyl 
aromatic linker may also provide a π-electron system for interaction within the yet 
unknown target site.  
3. The acidic tail was kept as either a carboxylic group or changed to the 
bioisosteric tetrazole
197
 moiety (green, Figure 4.2). The carboxylic group is highly polar 
and can ionize and hinder absorption. The tetrazole ring has similar physiochemical 
properties but offers some advantages over carboxylic acids. Like COOH groups, 
tetrazole rings have an ionisable acidic proton at pH 7.4. They are also planar in 
structure, however, the tetrazole anion is 10 times
198
 more lipophilic than the 
carboxylate anion  and this can enhance drug absorption as a result. Tetrazole rings are 
also resistant to many of the metabolic reactions that occur to the carboxylic 
groups.
199,198
   
This chapter discusses the different synthetic strategies undertaken for the access to 
the aromatic head groups (benzolactones and isatins) and the C-C coupling reactions 
utilized to tether the synthesized head groups to the linker and acidic tails (either COOH 
groups or tetrazoles) producing different conjugates. It also discusses the calculated 
physicochemical properties of the synthesized target compounds as templates for 
developing drug-like candidates. 
4.3. Synthesis of the Aromatic Heads 
4.3.1. Synthesis of the isobenzofuran-1(3H)-one (benzolactones) 
Many procedures have been reported for the synthesis of the isobenzofuran-1(3H)-one 







 and from benzoic acids.
203
 
In this study, benzoic acids were used as starting materials.
203
 Therefore, a 
mixture of benzoic acid derivatives 87-89, palladium acetate, dipotassium phosphate 
and dibromomethane as the solvent and carbon donor was heated in a sealed tube at 140 
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ºC under a N2 atmosphere for 36 h (Scheme 4.1). After dilution of the reaction with 
CH2CH2, filtration through celite, washing with acid and evaporation of the solvent, the 
lactones 90-62 were obtained in 38-58% yield. The obtained compounds were easily 
purified through either flash column chromatography or recrystallization from a mixture 
of chloroform/hexane mixture (1:3, v/v). Analysis of the 
1
H NMR spectra of the 
isobenzofuran-1(3H)-ones 90-92 showed a new singlet peak resonating at 5.17-5.23 
ppm that was assigned to the newly formed lactone CH2 group. Analysis of the 
13
C 
NMR spectra showed one carbon resonating at 68.2-86.7 ppm that was assigned to the 
newly added methylene carbon.  
 
Scheme 4.1 The synthesis of the isobenzofuran-1(3H)-one heads 90-92. 
 
The reaction proceeds via a Pd(II)-catalysed C–H activation where the 
coordination of the cation with the carboxylate group forces the Pd(II) centre to chelate 
in the proximity of the C-H bond ortho to the acid substituent (Figure 4.3), a geometry 
that facilitates C-H cleavage.
203
 The alkylation attacks the less hindered ortho position 
to the carboxylic acid group.  
 




This synthetic procedure was applied either on the brominated benzoic acids, 
which provided the 6-bromobenzolactones with the coupling handles already intact, e.g. 
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the 6-bromo-7-methoxyisobenzofuran-1(3H)-one 90 and the 6-bromo-7-
methylisobenzofuran-1(3H)-one 91, or was applied on the benzoic acid derivative 
without the bromo substituent, which required further attachment of a coupling handle 
for the next step, e.g. 5,7-dimethoxyisobenzofuran-1(3H)-one derivative 92. 
Addition of coupling handle (bromine) to 92: The presence of the coupling handle 
(bromine) on C6 of the 5,7-dimethoxyisobenzofuran-1(3H)-one  92 was previously 
described using a different benzolactone synthesis procedure, starting from either 4,6-
dibromo-5,7-dimethoxyisobenzofuran-1(3H)-one
204
 or from methyl 3-bromo-6-
(bromomethyl)-2,4-dimethoxybenzoate (93, Figure 4.4).
205
 In both cases, the 
benzolactone skeleton was synthesized with the bromine already attached in the desired 
position, prior to the cyclization step. 
 
Figure 4.4 Example of the synthesis of the 6-bromo-5,7-dimethoxyisobenzofuran-
1(3H)-one 94 from methyl 3-bromo-6-(bromomethyl)-2,4-dimethoxybenzoate 93, with 




However, the regioselective bromination on C6 of the unsubstituted phthalide 97 
(benzolactone) has been previously described in acidic medium, using a mixture of 
sulphuric acid and trifluoroacetic acid.
206
 The selective iodination at C6 was also 
previously reported.
207
 Position 6 in 5,7-dimethoxyisobenzofuran-1(3H)-one in 92 is 
more activated than that of the unsubstituted phthalide 97, however, it is more sterically 
hindered by the methoxy groups. In this work, due to the crowding of C6 by the two 
methoxy groups, a different method was used to access the 6-bromo derivative for this 
benzolactone 94 from the corresponding benzolactone 92. A solution of 5,7-
dimethoxyisobenzofuran-1(3H)-one 92 in glacial acetic acid was cooled in an ice bath 
before a solution of bromine in glacial acetic acid was added dropwise and the mixture 
was then stirred at room temperature for 4 h (Scheme 4.2). The resulting solid was 
filtered and subjected to flash column chromatography (60% CH2Cl2 in hexane) to 
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afford the benzofuran 94, which was recrystallised from 1,4-dioxane. The 
isobenzofuran-1(3H)-one 94 was obtained in 84% yield with a melting point of 190 ºC 
(Lit.
205
 m.p 206 ºC). The 
1
H NMR spectrum of 94 showed the disappearance of the C6 
aromatic proton which resonated at 6.42 ppm in 
1
H NMR spectrum of the 
isobenzofuran-1(3H)-one 92. The EI-MS spectrum of 94 showed also a peak at 272 m/z 
which was assigned to the molecular ion (M+, 
79
Br). The addition of the bromine 
solution was carried out at 0 ºC to minimize the production of the 4-bromo isomer 95 
and the 4,6-dibromo derivative 96 side products. These side products were not separated 
due to overlapping bands on the TLC plates, and low mass recovery of this mixture. The 
EI-MS spectrum of the mixture showed peaks at 272 m/z (
79
Br) that was assigned to the 




Br) that was assigned to the 4,6-dibromo 
derivative 96. The reported melting point for the 4,6-dibromo derivative 96 is 136 ºC
204
, 




Scheme 4.2 The synthesis of 6-bromo-5,7-dimethoxyisobenzofuran-1(3H)-one 90. 
 
 The 2D 
1
H NMR NOESY experiment of 94 showed a correlation between the 
aromatic proton H4 with a methoxy group. The methoxy groups appear as singlets 
resonating at 4.02 ppm and integrate for 6 protons
*
. No correlation was seen between 
the aromatic H4 proton and the CH2 in the NOESY experiment. However, the big 
difference in the melting points of 94 and 95 argued the bromination of C6. 
Access to the unsubstituted benzofuran 100: The synthesis of 6-bromoisobenzofuran-
1(3H)-one 100 was performed following the reported short procedure
206
  initially using 
N-bromosuccinimide (NBS) in the H2SO4/TFA mixture and stirring for 3 days (Scheme 
4.3). However, this procedure gave a mixture of the multi-brominated phthalide rather 
                                                             
* Different NMR solvents were used to get better resolution of the methoxy groups, however, they always 
appeared as a singlet peak. 
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than the 6-bromo derivative 100. Therefore, in an alternative procedure
208 (Scheme 4.3), 
phthalide 97 was treated with a nitrating mixture of H2SO4/HNO3 to afford 6-
nitroisobenzofuran-1(3H)-one 98 in 81% yield. Subsequent reduction with iron
209
 in a 
mixture of ethanol, water and acetic acid, followed by standard diazonium formation 
and then treatment with CuBr gave the 6-bromoisobenzofuran-1(3H)-one 100 in 74% 
yield,
210
 which was recrystallised from methanol. 
 
Scheme 4.3 The synthesis of 6-bromoisobenzofuran-1(3H)-one 100. 
 
4.3.2. Synthesis of the isatin aromatic heads  
The desired isatin heads were prepared from the corresponding aniline derivatives with 
or without the bromine coupling handles.  
Access to the bromodimethoxy isatin 103: The synthesis of 4,6-dimethoxyindoline-2,3-
dione 103 (Scheme 4.4) was undertaken using the Stolle procedure.
211
 Therefore, the 
aniline 101 was reacted with oxalyl chloride to form an intermediate chlorooxalylanilide 
with spontaneous cyclization, in the absence of Lewis acid, to yield dimethoxyisatins 









Scheme 4.4 The synthesis of 5-bromo-4,6-dimethoxyindoline-2,3-dione 103. 
 Mono selective bromination of isatins at C5 can be achieved on small scale 
reactions by using N-bromoacetamide in acetic acid medium.
213
  Therefore, a solution of 
the isatin 98 in glacial acetic acid was cooled in an ice bath followed by portion wise 
addition of the NBS at 0 ºC, and the mixture was then left to warm to room temperature 
with stirring for 8 h. The yellow solid was filtered, washed with saturated NaHCO3 
solution, and then with a water/ethanol mixture and then vacuum dried. The residue was 
then recrystallised from 1,4-dioxane to afford the bromoisatin 103 in 60% yield. The EI-




 ion. The 
1
H NMR spectrum showed only one aromatic proton peak resonating at 6.36 ppm 
assigned to H7. This proton correlated to only one methoxy group in the 2D NMR 
(HMBC and NOESY) experiment. This is only possible when the proton is on C7. The 
proton in position 5 must show correlation to both methoxy groups which was not 
observed in 103. This confirmed that the bromination occurred at position 5 of the isatin 
ring. 
Access to the 7-methylisatin 106: The synthesis of 5-bromo-7-methylindoline-2,3-dione 
106 was achieved using Sandmeyer
214
 methodology, starting from 4-bromo-2-
methylaniline 104 which was reacted with chloral hydrate and hydroxylamine 
hydrochloride in aqueous sodium sulphate to form an isonitrosoacetanilide 105 (Scheme 
4.5), which presented as a gummy solid that was difficult to isolate. This gummy solid 
was dried and taken directly to the next cyclization step using concentrated sulphuric 
acid. The mixture was heated gradually to 80 ºC for 10 min. After cooling to room 
temperature, the mixture was poured onto crushed ice and stirred for 1 h, whereby a 
solid precipitated and was filtered. The desired compound was isolated in 75% yield 
over 2 steps. The synthesis of the isatin 106 was previously reported by a different 
method,
215








Scheme 4.5 The synthesis of 5-bromo-7-methylindoline-2,3-dione 106. 
 
Access to methoxymethylisatin 111: The structure of MPA 15 (Figure 4.1) has one 
methyl group in the para position to the OH group on the aromatic head. The isatin 4-
methoxy-7-methylindoline-2,3-dione 111 was selected as a similar derivative with the 
OH group masked as a methoxy functionality, to avoid the metabolic drawback of MPA 
15. The synthesis of this derivative started from the commercially available 4-methyl-3-
nitrophenol 107 which was methylated using methyl iodide
216
 in DMSO with NaOH as 
a base to give 4-methoxy-1-methyl-2-nitrobenzene 108 in 80% yield (Scheme 4.6). The 
5-methoxy-2-methylaniline
217
 109 was then obtained by reducing the nitro group of 108 
over Raney Nickel and using hydrazine monohydrate as hydrogen source, and heating 
in methanol, to afford the aniline 109 in 91% yield. Reaction of the aniline 109 with 
oxalyl chloride in benzene gave the intermediate chlorooxalylanilide 110, without 
spontaneous cyclization as in the case of the dimethoxy derivative 102 (Scheme 4.4). 
This was due to the lower reactivity of the monomethoxy intermediate 110. Therefore, 
the intermediate 110 was directly suspended in dichloroethane (DCE) and aluminium 
chloride was then added as a Lewis acid to promote the cyclization step. Acidic workup, 
followed by extraction with ethyl acetate and concentration of the solvent gave an 
orange residue that was subjected to column chromatography and elution with 30% 
ethyl acetate in petroleum spirit afforded the isatin 111 in 30% yield. The IR spectrum 
of the product showed strong amide absorption peak at 1635 cm
-1
 assigned to the CO 
group. The EI-MS spectrum showed a peak at 191 assigned to the molecular ion mass 
(M+). Analysis of the 
13
C NMR spectrum of 111 showed two additional carbons peaks 
resonating at 180.9 and 160.1 ppm assigned to the two carbonyls C2 and C3, 
respectively.   




Scheme 4.6 The synthesis of 4-methoxy-7-methylindoline-2,3-dione 111. 
  
Addition of the coupling handle (bromine) on 111 for the next synthetic step was 
easily achieved as there was only one dominant bromination site at C5. Therefore, 4-
methoxy-7-methylindoline-2,3-dione 111 was reacted with bromine in glacial acetic 
acid (Scheme 4.7) at 0 ºC to room temperature for 10 h. The resulting solid was 
collected, washed with NaHCO3, water and then recrystallised from acetic acid to yield 
the desired isatin 112 in 84% yield. Analysis of the 
1
H NMR spectrum of the product 
showed the disappearance of the H5 that resonated at 6.61 ppm, and the EI-MS 
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4.4. Coupling of the Aromatic Head groups 
4.4.1. Coupling with the isobenzofuran-1(3H)-one 
4.4.1.1. Coupling to the linker and COOH tail 
Linking of the aromatic head to the acidic tail was accessed utilizing Suzuki C-C cross 
coupling chemistry,
194,195,196
 to access the biphenyl rigid system (Figure 4.2). This facile 
one step synthesis gave the three main components of the MPA designed analogues: the 
aromatic head, the rigid linker (phenyl) and the acidic tail (COOH). The chosen boronic 
acid was the commercially available 3-(3-boronophenyl)propanoic acid 113. Suzuki 
cross coupling for the 6-halo-isobenzofuran-1(3H)-one derivatives was previously 
described
206
 using a diphasic medium of toluene and water as a solvent, disodium 
carbonate as a base and tetrakis(triphenylphosphine)palladium(0) as palladium catalyst 
and heating at reflux temperature.  
In this work, 1,2-dimethoxyethane (DME) was initially used as a solvent 
because of its lower boiling point (~85 ºC) compared to that of toluene (~110 ºC) to 
retain the stability of the lactone ring when heating with water at refluxing temperatures. 
Therefore, the 6-bromo-isobenzofuran-1(3H)-ones 90, 91, 94 and 100 were reacted with 
3-(3-boronophenyl)propanoic 113, potassium phosphate and 
tetrakis(triphenylphosphine)palladium(0) in DME/H2O mixture and the reaction was 
heated in a sealed system at 85 ºC for 8-14 h. After the specified reaction time, the 
solvent was concentrated and the obtained solids were suspended in HCl and were then 
extracted with ethyl acetate. After evaporating the solvent, the resulting residues were 
subjected to PLC (10% methanol in CH2Cl2, 0.5% acetic acid) to afford the acid 
conjugates 114-117. The reaction worked well, however the isolated yields of the final 
product were modest (30-35%). This was due to the poor solubility of the benzolactones 
(90, 91, 94, 100) in DME. Interestingly, replacing the DME with 1,4-dioxane and 
keeping the temperature at 85 ºC (Scheme 4.8), greatly improved the yields up to 78%. 
Table 4.1 shows the optimized reaction conditions. The IR spectra of the obtained 
benzolactone-acid conjugates 114-117 showed broad OH absorption bands at 2972-
2989 cm
-1
 accompnied by C=O absorption bands at 1699-1755 cm
-1 
indicating the 
presence of the COOH functional group. Analysis of the 
1
H NMR spectrum of 3-(3-(4-
methoxy-3-oxo-1,3-dihydroisobenzofuran-5-yl)phenyl)propanoic acid 114 showed a 
peak at 10.54 ppm that was assigned to the COOH group, and the two propanoic CH2 
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groups appeared as two triplets resonating at 2.99 and 2.68 ppm. The purity of the 
compounds 114-117 was found to be >95% as analysed by normal-phase HPLC using 
isopropanol with 0.1% TFA in hexane as the developing solvent. The calculated 
physiochemical properties of this series are shown in Table 4.2. 
 
Scheme 4.8 Coupling procedures for the isobenzofuran-1(3H)-one 90, 91, 94 and 100 
with the boronic acid 113. 
 
Table 4.1 Optimization conditions of the isobenzofuran-1(3H)-ones 114-117 coupling 
reaction with the boronic acid 113. 
Solvent Reaction time (h) Yields (%) 
DME/H2O 8-14 30-35 
Dioxane/H2O 4-6 54-78 
 
The Suzuki coupling is a robust technique for the synthesis of biaryl bonds 
commonly utilising an aryl boronic acid and an aryl halide. The reaction mechanism of 
the Suzuki coupling (Figure 4.5) proceeds in 3 key steps; oxidative addition of the Pd(0) 
complex to the aryl bromide to give the Pd(II) complex, transmetallation of the aryl 
boronate complex to the Pd(II) complex, and reductive elimination to give the biaryl 
and restore the Pd(0) catalyst. 




Figure 4.5 The mechanism of the Suzuki reaction to produce the biaryls. 
 
Table 4.2 Physiochemical properties of the benzolactones-carboxylic acid conjugates 
114-117. 
 





 at pH 
1 5.5 7.4 
114 4-OCH3 312.32 1.96±0.59 2.98 1.97 0.14 
115 4-CH3 296.32 2.83±0.52 2.85 2.08 0.34 
116 4,6-(OCH3)2 342.35 1.67±0.60 2.82 1.84 0.01 
117 H 282.29 2.37±0.52 2.89 1.90 0.07 
                                                             
* Calculated using ACDLabs v.12.0 (ACD/Labs, Toronto, Canada) 
† Calculated using PALLAS3.7.1.2 CompuDrug Chemistry Ltd, USA 
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The introduction of the rigid linker (the phenyl ring) was proposed to increase 
the lipophilicity of the compounds compared to the lead mycophenolic acid which has a 
LogD value of 0.67 at blood pH. Table 4.2 shows that all the synthesized benzolactone-
carboxylic conjugates 114-117 have drug like qualities. This series can ionize in the 
different pH values as can be seen from the change in the LogD values. In acidic pH 
(stomach), they show similar LogD values around 2.85 as the ionization will be 
minimum (unionized), and therefore, 114-117 could be in the absorbable form (can 
cross the lipid layer). At the blood pH (7.4), the acid conjugates showed low LogD 
values indicating good blood solubility, and therefore, may present siutable properties 
for absorbtion from the stomach and distribution through the body with the circulating 
blood. At the intestine pH 5.5, where the oral bioavailable drugs are absorbed,
186
 the 
ionization shifts towards the lipophilic character without returning to the full unionized 
state, where the synthesized compounds have good lipophilicity scale (1.84-2.08, lower 
than that of the lead MPA 15 at the same pH), and therefore, the designed compounds 
might show good oral bioavailability properties. 
 
4.4.1.2. Coupling to the linker and tetrazole tail 
 The first synthesis of the tetrazole ring used the acetonitrile intermediates which 
can then be cyclised to tetrazoles. Therefore, the commercially available boronic acid, 
3-(3-boronophenyl)propanoic acid 118 was utilized in the coupling reaction with the 
bromobenzolactones. Due to the high cost of 118, the ester 2-(3-(4,4,5,5-tetramethyl-
1,3,2-dioxaborolan-2-yl)phenoxy)acetonitrile 119 was also synthesized as an alternative 
to 118 and was used in the coupling reaction (Scheme 4.9). The same coupling 
conditions were used: 1,4-dioxane/H2O mixture, potassium phosphate as a base and 
tetrakis(triphenylphosphine)palladium(0) as a catalyst, and the mixture was heated 
under a N2 atmosphere for 7-15 h. The solvent was then evaporated and the resulting 
residues were suspended in HCl, and extracted with ethyl acetate. After evaporating the 
solvent and subjecting the residues to flash column chromatography, the acetonitrile 
intermediates 120 and 121 were obtained in 50% and 76%, respectively. Analysis of the 
1
H NMR spectra of 120 and 121 showed the CH2 protons adjacent to the CN group, 
resonating as a singlet peak at 4.83 ppm. The IR spectra of these derivatives 120 and 
121 showed strong absorption bands at 2165-2169 cm
-1
 assigned to the CN group. 




Scheme 4.9 The synthesis of the acetonitrile intermediates 120 and 121. 
 
Synthesis of 119: The boronic ester 119 was synthesized starting from the 
commercially available 3-iodophenol 122 where it was dissolved in DMF with NaOH 
and the mixture was stirred until a pale brown solution was obtained (Scheme 4.10). 
Alkylation of the OH group was then achieved using the dropwise addition of 2-
chloroacetonitrile 123 at room temperature and the mixture was stirred for 18 h. The 
mixture was then poured onto ice, where the resulting oil was extracted. Washing the oil 
extract with water and brine, and trituration with charcoal and concentration gave 2-(3-
iodophenoxy)acetonitrile 124 in 80% yield. Analysis of the 
1
H NMR spectrum of the 
intermediate 124 showed a singlet peak at 4.68 ppm assigned to the CH2. Analysis of 
the EI-MS spectrum showed a peak at 259 m/z assigned to the molecular ion (M+).  
 
Scheme 4.10 The synthesis of the acetonitrile boronic ester 119. 
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The intermediate 2-(3-iodophenoxy)acetonitrile 124 was then converted to the 
boronic ester using Miyaura borylation
218
 reaction, using bis(pinacolato)diboron 125, 
potassium acetate and  PdCl2(dppf)
*
 catalyst in THF and the mixture heated at reflux for 
24 h. The solvent was then evaporated, ethyl acetate was added and the resulting residue 
was sonicated for 10 min and filtered. The filtrate was triturated with MgSO4 and 
charcoal, filtered through celite and  then concentrated under vacuum. The resulting 
residue was recrystallised from ethyl acetate/hexane (3:2) to give the boronic ester 119 
as a pink solid in 95% yield. Analysis of the
 1
H NMR spectrum of 119 showed a singlet 
peak resonating at 1.26 ppm integrating for 12 protons assigned to the four methyl 
groups. Analysis of the 
13
C NMR spectrum showed one peak resonating at 83.7 ppm 
integrating for two carbons assigned to the dioxaborolan, and another peak at 25.2 ppm 
(four carbons) that was assigned to the methyl groups. 
The Miyaura borylation reaction proceeds via the oxidative addition of the alkyl 
iodide to the palladium catalyst (Figure 4.6). The acetoxy anion from the base then 
reacts with the palladium complex replacing the iodide ion and forming the 
(acetate)palladium(II) complex. Transmetalation with the bis(pinacolato)diboron and 
subsequent reductive elimination then occurs to afford the boronic ester 119 and 
releasing the ligand complex.  
                                                             
* [1,1'-Bis(diphenylphosphino)ferrocene]dichloropalladium(II) 









The tetrazole ring synthesis: The benzolactone acetonitrile intermediates 120 and 121 
were then used in the tetrazole synthesis step, utilizing the [2 + 3] cycloaddition of 
azides. The nitriles 120 and 121 were allowed to react with 4 equivalents each of NaN3 
and NH4Cl in DMF and the mixture was heated at reflux for 48 h. DMF was then 
evaporated and the resulting residue was dried under vacuum. Ethanol was then added 
to the dry residue and the mixture was sonicated for 10 min, filtered and ethanol was 
concentrated and the residues were subjected to PLC using 90% CH2Cl2, 10% ethanol 
and 0.1% TFA. The isolated yields of the tetrazoles 126 and 127 were below 30%. Acid 
catalysis
219
 for this cycloaddition significantly reduced the reaction time (Scheme 4.11). 
However, the improvement in the yield was not significant (35%). The purity of the 
isolated tetrazoles were analysed by HPLC and was found to be >95%. 




Scheme 4.11 The synthesis of the tetrazoles 126 and 127 from the acetonitrile 




 reported different mechanisms of tetrazole formation using azide 
salts in the presence of ammonium salts. The reaction can either proceed via the known 
[2 + 3] cycloaddition (pathway A, Figure 4.7) or by a two-step sequence where the 
azide, as a nucleophile, attacks the nitrile carbon giving an intermediate compound 
(pathway B, Figure 4.7), followed by ring closure through simple 1,5-cyclization. The 
second mechanistic pathway B depends of the substituent  adjacent to the nitrile group 
(A in Figure 4.7), the more electron-withdrawing group, the intermediate in pathway B 
becomes more stable and mechanism B is more favourable based on calculated energy 
barriers
219
 for the transition states. Also, the presence of a proton in the reaction 
medium can act as an activator to the nitrile group to be attacked. This mechanism is 
similar to the known mechanisms of acid-catalyzed nitrile hydrolysis and the Pinner 
synthesis,
220
 with the difference being that the nucleophile in this case (Figure 4.7) is an 
azide.  
The key to this mechanistic pathway (B) is that the nitrile is activated by a 
proton, provided by the ammonium salts as well as other proton sources. In this reaction 
(Scheme 4.11), the addition of acetic acid catalyst may have provided sufficient 
concentrations of the activating proton, and the reaction proceeded via pathway B, and 
that was the reason for shortening the reaction time (48 h without acid and 12-24 h in 
presence of acid). 
 








Access to the tetrazole via an alternative strategy: The modest yields (35%) of the 
tetrazole formation described above (Scheme 4.11) were not appropriate for the 
synthesis of other tetrazole derivatives. Another synthetic strategy was therefore 
designed to synthesize these derivatives in which the tetrazole moiety was attached to 
the boronic ester, prior to the coupling reaction with the 6-bromobenzolactones. The 
previously synthesized 2-(3-iodophenoxy)acetonitrile 124 was used to access the 
intermediate 128 utilizing the azide tetrazole formation discussed above. Therefore, 124 
was mixed with NaN3 and NH4Cl in DMF containing a few drops of glacial acetic acid 
and the mixture was heated at reflux for 14 h under a N2 atmosphere (Scheme 4.12). 
The solvent was then concentrated and the resulting residue was dried. Ethanol was 
added, and the mixture was sonicated for 10 min, filtered and ethanol was evaporated to 
yield a white fluffy solid of the tetrazole intermediate 128 in good yield (80%). The EI-
MS spectrum for this tetrazole intermediate 128 showed a peak at 302 m/z assigned to 
the molecular ion (M+). This 5-((3-iodophenoxy)methyl)-1H-tetrazole 124 was then 
converted to the boronic ester using the same borylation method discussed in Scheme 
4.10. Therefore, 128 was reacted with bis(pinacolato)diboron 125, potassium acetate 
and  PdCl2(dppf) catalyst in THF and the mixture was heated at reflux temperature for 
18 h under a N2 atmosphere (Scheme 4.12). The solvent was then concentrated and 
ethanol was added to the resulting residue and the mixture was further heated at reflux 
for 10 min, filtered hot and concentrated under vacuum to afford a white solid of 
potassium 5-((3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)methyl)tetrazol-
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1-ide 129 (Scheme 4.12). Analysis of the 
1
H NMR spectrum of this boronic ester 129 
showed a singlet peak resonating at 1.90 ppm and integrating 12 protons assigned to the 
four methyl groups. These four methyl carbons appeared also as a singlet peak in the 
13
C NMR spectrum, resonating at 22.6 ppm. ESI-MS spectrum showed a peak at 301.1 






Scheme 4.12 The synthesis of the tetrazole boronic ester intermediate 129. 
 
The tetrazole synthesis: The synthesized boronic ester-tetrazole conjugate 129 was then 
reacted in the same optimized coupling conditions, using 1,4-dioxane/water mixture, 
with 6-bromo-5,7-dimethoxyisobenzofuran-1(3H)-one 94 and 6-bromoisobenzofuran-
1(3H)-one 100 (Scheme 4.13). The tetrazole rings are known to be stable
198
 in such 
mild coupling conditions as well as many other chemical conditions. Therefore, the 
mixture was heated at 85 ºC for 20-24 h, the solvent then was concentrated and a 
solution of NaHCO3 was added to the resulting residue and sonicated for 15 min. The 
resulting turbid solution was then washed with CH2Cl2 and the aqueous layer was 
filtered, cooled to 0 ºC and neutralized with 2 M HCl. The resulting white solid was 
collected by filtration, washed with chilled methanol and dried under vacuum to afford 
the tetrazoles 130 and 131 in 53% and 57% yield, respectively (Scheme 4.13). The 
HPLC analysis of this series indicated purity >95%. 




Scheme 4.13 Alternative route to access the tetrazole conjugates 130 and 131 via 
reaction with the boronic ester-tetrazole intermediate 129. 
  
Interestingly, using this alternative route (Scheme 4.13) not only allowed the use 
of mild reaction conditions, thereby avoiding unwanted side products, but also 
improved the yield of the final tetrazole conjugate (from 35% in Scheme 4.11 to 56% in 
Scheme 4.13) without further optimization. This reaction (Scheme 4.13) was clean 
compared to the above mentioned cycloaddition tetrazole formation method (Scheme 
4.11) as judged by less side products spots upon TLC analysis.  
 For all the tetrazole conjugates obtained by the two methods, the sodium azide 
cycloaddition, 126 and 127 (Scheme 4.11) and the coupling with the tetrazole-boronic 
ester intermediate, 130 and 131 (Scheme 4.13), the purity was analysed using the 
normal phase HPLC, utilizing a mixture of isopropanol with 0.1% TFA in hexane. This 
system was developed after the failure with the reverse phase HPLC where the tetrazole 
conjugates were eluted first within two minutes, with poor resolution. Table 4.3 showed 
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Table 4.3 Physiochemical properties of the benzolactones-carboxylic acid conjugates. 
 





 at pH 
1 5.5 7.4 
126 5-OCH3 338.32 0.68±0.70 2.33 1.55 -0.16 
127 5-CH3 322.32 1.55±0.68 2.85 2.08 0.34 
130 5,7-(OCH3)2 368.35 0.39±0.72 2.20 1.42 -0.29 
131 H 308.30 1.09±0.68 2.47 1.69 -0.03 
 
 It can be inferred from table 4.3 that the designed and synthesized benzolactone-
tetrazoles conjugates 126, 127, 130 and 131 have good ionization profiles when present 
at physiological pH. Like the synthesized carboxylic acid analogues 114-117, the 
tetrazole conjugates 126, 127, 130 and 131 are nearly non-ionizable in the acidic pH of 
the stomach, however, their LogD values lie in the acceptable scale range (1-4).
186
 The 
noticed increase in the lipophilicity compared to the carboxylic acid conjugates 114-
117, was related to the introduction of the more lipophilic tetrazole moiety. After 
absorption, the tetrazole conjugates 126, 127, 130 and 131 would tend to be strongly 
ionisable in the blood pH as can be indicated by the low LogD values. The methyl 
substituent 127 was the only derivative with a positive LogD value at pH 7.4. This 
argues for the increased blood solubility and also the possibility of conjugation with 
blood soluble proteins. However, at the intestine pH 5.5, the conjugates have relatively 
good LogD values (1.42-2.08), very similar to the carboxylic acid conjugates 114-117 
(Table 4.2), which indicates the possible oral bioavailability of these compounds. 
Synthesis of a β-lactam derivative: During the synthesis of the benzolactone 
derivatives, it was also of interest to synthesize one benzolactone derivative with an 
amino group (NH2) replacing the OH group, which is responsible for the metabolic 
                                                             
*
 Calculated using ACDLabs v.12.0 (ACD/Labs, Toronto, Canada) 
† Calculated using PALLAS3.7.1.2 CompuDrug Chemistry Ltd, USA 
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drawback of the lead MPA 15 (Figure 4.1). Therefore, the synthesis of this amino 
analogue started with the 2-amino-3-bromo-5-methylbenzoic acid 132. The 
benzolactone formation reaction (Scheme 4.1) required protection of the NH2 group in 
the presence of palladium catalyst, and heating at elevated temperature for a long time 
would produce undesired side products that might involve the NH2 group, and therefore, 
a base stable group such as the acetyl or the pivaloyl group, was required. Initial trials 
with mild conditions such as TMA in CH2CH2 were used, however, this method ended 
up with the full recovery of the unprotected amino benzoic acid 132. Instead, an 
alternative method was used (Scheme 4.14) using pivaloyl chloride, excess n-BuLi as 
the base, in THF at -78 ºC. This method was previously described
221
 for the protection 
of the unsubstituted 2-aminobenzoic acid. Therefore, the amino benzoic acid 132 was 
dissolved in THF and the solution was cooled to -78 ºC and was stirred for 20 min. 
Pivaloyl chloride was then added dropwise at -78 ºC and the reaction was allowed to 
warm to room temperature and was stirred for 3 h. The reaction mixture was then 
diluted with ethyl acetate and water and the organic layer was separated and washed 
with water and brine. The combined organic layers were concentrated under vacuum to 
yield a colourless oil (Scheme 4.14). 
 
Scheme 4.14 Attempted reaction to synthesize the protected amino benzoic acid 134. 
  
Surprisingly, analysis of the resulting oil showed that the amino-protected 
compound 134 was not formed, instead, the β-lactam product 133 was obtained in 47% 
yield. The remaining of the reaction mixture was un-reacted starting material 132.  The 
EI-MS spectrum showed a peak at 295 m/z assigned for M+ of 133, rather than a peak at 
313 m/z for 134. This 18 amu unit difference (as H2O) in the molecular ions was an 
indication of the formation of the β-lactam ring system. The HRMS spectrum for the β-
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lactam formula C13H15BrNO2 (calculated; 296.0286 m/z), showed the ion peak at 
296.0294 m/z, confirming the molecular formation of 133.  
This reaction proceeded via nucleophilic attack of the N atom on the carbonyl of 
the carboxylic acid group, forming the β-lactam ring. Figure 4.8 shows suggested 
mechanistic pathways for such reaction. Pathway (A) is the formation of the mixed acid 
anhydride, then the nucleophilic attack of the amino group on the carbonyl group, 
forming the closed ring, and then the less nucleophilic amidic NH attacked another 
pivaloyl group giving the final product 133. The alternative pathway (B) is the 
protection of both functional groups, followed by the nucleophilic attack of the nitrogen 
on the electrophilic carbonyl and ring closure.  
 
Figure 4.8 Suggested mechanistic pathways for the formation of the β-lactam product 
133. 
  
A similar reaction was reported for the synthesis of such β-lactam (Figure 4.9) 
where the reaction occurred after protecting the NH2 with the pivaloyl group.
222
 Such 
evidence might suggest that the second pathway (B) might be the mechanism that 
occurred for 132, especially the reaction (Scheme 4.14) occurred in the presence of 
excess base. 








It was interesting to utilize this β-lactam derivative 133 in the coupling reactions 
with the different boronic acids, especially it has already the coupling handle (bromide) 
attached. Therefore, 133 was heated with 3-(3-boronophenyl)propanoic acid 113, 
tetrakis(triphenylphosphine)palladium(0) and potassium phosphate in dioxane/water 
mixture, at 85 ºC for 18 h (Scheme 4.15). The solvent was then concentrated and the 
flask was cooled to 0 ºC, chilled HCl solution was added dropwise with stirring, the 
resulting solid was extracted with ethyl acetate, washed with water, brine and dried 
(MgSO4), and the solvent was concentrated under vacuum. The resulting residue was 
subjected to a flash column chromatography using 50% CH2Cl2, 50% ethyl acetate and 
1% acetic acid to afford 3-(3-(3-methyl-8-oxo-7-pivaloyl-7-azabicyclo[4.2.0]octa-1,3,5-
trien-5-yl)phenyl)propanoic acid 137 as an oil in 60% yield. Analysis of the 
1
H NMR of 
137 showed a singlet peak at 8.56 ppm assigned to the COOH group. EI-MS spectrum 
showed a peak at 365 assigned to the molecular ion (M+). This oily product was found 
to be > 98% pure by HPLC analysis, with a retention time of 27.9 min. 
 
Scheme 4.15 Coupling reaction of the β-lactam derivative 133 with the boronic acid 
113. 
Chapter 4  MPA Analogues 
109  
 
This β-lactam acid conjugate 137 has a LogD
*
 value of 3.85 (at pH = 1), 2.83 (at 
pH = 5.5) and 0.99 (at pH = 7.4). The relatively unionized (clogP
†
 = 3.75±0.65) form in 
the stomach indicated good lipid solubility that the compound can be found in the 
absorbable form. In the blood, 137 has the tendency to ionize providing good solubility 
and therefore, good distribution within the body. The slight ionization state in the 
jejunum (pH=5.5) makes 137 also a possible orally bioavailable candidiate. 
 The reaction of the β-lactam intermediate 133 with the boronic acid (3-
(cyanomethoxy)phenyl)boronic acid 118 was undertaken utilizing the same coupling 
conditions (Scheme 4.16). The coupling reaction occurred, forming the biphenyl 
system, and the β-lactam was open to give a benzoic acid derivative 138. The IR 
spectrum of 138 showed a broad peak at 3328 cm
-1
 assigned to the NH group. Analysis 
of the 
1
H NMR spectrum showed a peak resonating at 8.61 ppm that was assigned to the 
COOH group. The found mass by the HRMS was 367.1656 that corresponded to the 
formula C21H23N2O4 (MH+; calculated, 367.1658). 
 
Scheme 4.16 Reaction of the β-lactam 133 with (3-(cyanomethoxy)phenyl)boronic acid 
118. 
  
The difference between this reaction (Scheme 4.16) and the previous one 
(Scheme 4.15) was only during the workup, which was the same except the HCl was not 
pre-cooled and was added at room temperature. It is believed that during this thermally 
uncontrolled procedure, the β-lactam ring was hydrolysed to give the COOH group of 
138. The LogD profile for this compound is shown in Table 4.4.  
                                                             
* Calculated using PALLAS3.7.1.2 CompuDrug Chemistry Ltd, USA 
† Calculated using ACDLabs v.12.0 (ACD/Labs, Toronto, Canada) 
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pH 1 pH 5.5 pH 7.4 
4.14±0.74 4.6 3.13 1.30 
  
The presence of a carboxylic acid group within the structure is responsible for 
the unionized state of the compound in acidic pH environment (stomach), and therefore, 
would be present as a lipophilic state that can pass the gut wall. After reaching the blood 
(pH 7.4), the compound ionizes providing blood solubility. At pH 5.5 (jejunum), where 
absorption occurs, the LogD value is within the acceptable range (1-4)
186
 for orally 
bioavailable drugs. 
 
4.4.2. Coupling with the isatin aromatic head groups 
4.4.2.1. Coupling to the linker and COOH tail 
 Synthesis of the 5-aryl isatin derivatives starting from the corresponding 5-halo-
isatin via the cross-coupling Suzuki reaction has been previously described,
223,224
 using 
tetrakis(triphenylphosphine)palladium(0) as a catalyst and potassium phosphate as a 
base. Therefore, the 5-bromoisatin derivatives (103, 106, 112 and the 5-bromoindoline-
2,3-dione 139) were reacted with the 3-(3-boronophenyl)propanoic acid 113, 
tetrakis(triphenylphosphine)palladium(0) and potassium phosphate (Scheme 4.17) in 
either DME or diethylene glycol dimethyl ether (diglyme) based on the solubility of the 
5-bromoisatin used: in case of 5-bromo-4,6-dimethoxyindoline-2,3-dione 103 and 5-
bromo-4-methoxy-7-methylindoline-2,3-dione 112, the solvent used was diglime. The 
reaction was then heated at 85 ºC under nitrogen atmosphere for 4-6 h. After cooling to 
room temperature, the solvent was concentrated and HCl solution was added, and the 
resulting suspended solid was either collected by filtration or extracted with ethyl 
acetate. The combined residues were then dissolved in ethanol and were subjected to 
PLC (10% methanol in CH2Cl2, 0.5% acetic acid) to yield the isatin-acid conjugates 
140-143. Analysis of the 
1
H NMR spectrum for 3-(3-(2,3-dioxoindolin-5-
                                                             
* Calculated using ACDLabs v.12.0 (ACD/Labs, Toronto, Canada) 
† Calculated using PALLAS3.7.1.2 CompuDrug Chemistry Ltd, USA 
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yl)phenyl)propanoic acid 143 showed two triplets resonating at 2.88 and 2.59 ppm, both 
integrating for two protons that were assigned to the two CH2 groups introduced from 
the boronic acid. Analysis of the IR spectrum of 143 showed an absorption band at 2989 
cm
-1
 assigned to the OH of the COOH group. The purity of this series was >95% as 
analysed by HPLC, with retention times 5.34-35.84 min. 
 
Scheme 4.17 The synthesis of the isatin-acid conjugates 140-143. 
  
Table 4.5 shows the calculated physical properties of this series of compounds 
140-143. For all the derivatives, the ionization increases as the pH increases, the LogD 
values at pH 5.5 ranges from 1.13 to 1.71, a good range for oral bioavailability. 
However, the increased solubility in the blood pH, as indicated by the negative LogD 
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Table 4.5 Physiochemical properties of the isatin-carboxylic acid conjugates 
 





 at pH 
1 5.5 7.4 
140 4,6-(CH3)2 355.35 1.49±0.82 2.14 1.13 -0.70 
141 7-CH3 309.32 2.40±0.37 2.53 1.55 -0.28 
142 4-OCH3-7-CH3 339.35 2.06±0.80 2.70 1.71 -0.12 
143 H 295.29 1.94±0.37 2.17 1.19 -0.64 
 
3.4.2.2. Coupling to the linker and tetrazole tail 
 In order to obtain the isatin-tetrazole conjugates, the acetonitrile derivatives 
were synthesized by reacting the 5-bromoisatin derivatives (103, 106, 112 and 139) 
with (3-(cyanomethoxy)phenyl)boronic acid 118 using diglyme/water mixture as a 
solvent in the presence of tetrakis(triphenylphosphine)palladium(0) and potassium 
phosphate and the mixtures were heated at 85 ºC for 5-9 h (Scheme 4.18). The solvent 
was then concentrated and 1 N HCl solution was added, and the suspended solids were 
either collected by filtration or extracted with ethyl acetate. The combined residues were 
adsorbed onto silica and subjected to flash column chromatography (40% ethyl acetate 
in petroleum spirit) to yield the acetonitrile intermediate 144-147 in 35-60% yield. The 
IR spectrum of 2-(3-(2,3-dioxoindolin-5-yl)phenoxy)acetonitrile 147 showed an 
absorption band at 2166 cm
-1
 that was assigned to the CN group. Analysis of the 
1
H 
NMR spectrum of 147 showed a peak resonating at 5.21 ppm and integrating for two 
protons that was assigned to the CH2 group.  
 
                                                             
*
 Calculated using ACDLabs v.12.0 (ACD/Labs, Toronto, Canada) 
† Calculated using PALLAS3.7.1.2 CompuDrug Chemistry Ltd, USA 




Scheme 4.18 The synthesis of the isatin-acetonitrile intermediates 140-143. 
  
Among the isatin-acetonitrile intermediates 144-147, 2-(3-(4,6-dimethoxy-2,3-
dioxoindolin-5-yl)phenoxy)acetonitrile 144 was not isolated from the crude mixture due 
to product instability. The EI-MS spectrum of a sample taken from the reaction mixture 
showed a peak at 338 that assigned to the molecular ion (M+). The HRMS spectrum 
showed a peak at 339.0980 m/z that was assigned to the formula C18H15N2O5 for (MH+; 
calculated, 339.0981 m/z). The reaction for 144 was repeated several times in order to 
isolate a pure compound, however, once the solid was separated from the reaction 
mixture, it was found to decompose to many overlapping spots on the TLC plate. 
Subjecting the solid to a flash column chromatography was not successful and analysis 
of the EI-MS spectra of the isolated fractions did not show any indications of 144. 
Conversion to tetrazoles: The reaction of the isatin-acetonitrile derivatives 145-147 
with sodium azide and ammonium chloride was attempted to afford the isatin-tetrazole 
conjugates (Scheme 4.19). Several attempts were made using different molar ratios of 
the azide/amonium chloride up to 10 equivalents, and heating at elevated temperatures 
for longer times up to 72 h with and without acid catalysis, however, the tetrazole 
conjugates 148-150 were not formed. Upon workup and separation of the oily gummy 
material from the reaction, TLC analysis showed that the starting material disappeared 
and just a polar polymeric spot was found. No evidence indicating the formation of the 
tetrazole conjugate was observed in the mass spectra of these polymerized residues. 




Scheme 4.19 Attempted access to the isatin-tetrazole conjugates 148-150 via the 
cycloaddition reaction with sodium azide/ammonium salts. 
  
Such reaction of the isatin derivatives with the sodium azide has not been 
previously reported. The nucleophilicity of the sodium azide and the electrophilic C3 of 
isatin might be involved in such reaction, however, no evidence was found in the mass 
spectra to support this hypothesis. This reaction was attempted before the design of the 
alternative coupling reaction (Scheme 4.13) with the synthesized tetrazole-boronic ester 
salt 129, and therefore, it would be interesting to try to access the isatin-tetrazole 
conjugates 148-150 utilizing such coupling reaction, in which the electrophilicity of the 
isatin C3 will not interfere with the reaction as in the case of sodium azide. 
 
4.5. Concluding remarks 
This chapter discussed the synthesis of a series of benzolactone-carboxylic acid 
conjugates 114-117, benzolactone-tetrazole conjugates 126, 127, 130, 131 and isatin-
carboxylic acid conjugates 140-143 as analogues of the lead compounds mycophenolic 
acid 15. The designed and synthesized analogues carry the same features as the parent 
lead compound in that they all have the three components: the aromatic head, the rigid 
linker and the acidic tail. All of the synthesized compounds showed good 
physiochemical properties such as the low molecular weight and good LogD profiles, 
having a range of 1-4 in the pH 5.5. Therefore, this series can be further developed as 
promising leads against CHIKV depending on the activities in the preliminary anti-
chikungunya testing. The formation of isatin-tetrazole conjugates 148-151 might be 
possible using the coupling with the designed and synthesized boronic ester 129 
(Scheme 4.20). 




Scheme 4.20 Possible coupling reaction to access the isatin-tetrazole conjugates 148-
151 via reaction with the boronic ester 129. 
A facile and applicable synthetic strategy was developed to access different 
analogues for the mycophenolic acid 15 via the introduction of the widely used cross 
coupling reactions. The obtained carboxylic acid conjugates can be further derivatised 
via the carboxylic acid reactions such as formation of esters or amides as prodrugs. The 
tetrazole conjugates can also be further derivatised via the substitution on the tetrazole 
NH by different alkylation/arylation reactions. The isatin conjugates can also be further 
derivatised utilizing the different nucleophilic reactions on C3 or ring expansion 
reactions (Figure 4.10). This will allow the further investigate the structure activity 
relationship of this series against the CHIKV.  




Figure 4.10 Possible derivatisation of the synthesized conjugates. 
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CHAPTER 5: Computational and Modelling Studies of the CHIKV 
nsP2 as a Possible Drug Development Target 
 
5.1. Introduction 
The CHIKV non-structural protein 2 (nsP2) is a significant enzyme that plays an 
important role during the viral replication cycle. It consists of 324 residues with two 
domains; the N and C domains that have different cellular functions. The nsP2 of 
alphaviruses is a multifunctional protein.
57,58,59,60
 The N-terminus (amino terminal) was 
found to be the RNA triphosphatase that performs the first of the viral RNA capping 
reactions and a nucleotide triphosphatase (NTPase) that fuels the RNA helicase activity 
performed by the other domain.
65
 It also performs 5`-triphosphatase (RTPase) activity 
that removes the γ-phosphate from the 5` end of RNA. Both NTPase and RTPase 




 The proteolytic domain has been 
allocated to its C-terminal (carboxy terminal) section which forms a papain like cysteine 
protease (also known as thiol protease).
57,61
 The nsP2 proteolytic activity is critical for 
virus replication and responsible for the cleavages of the non-structural polyprotein 
complex during the viral life cycle.
62,63
 
During the life cycle, and after entering the host cell, two non-structural protein 
precursors are translated from the viral mRNA, and are then cleaved generating nsP1, 2, 
3 and 4. During translation, nsP123 binds to free nsP4, with some cell proteins forming 
the replication complex,
38,39
 which synthesizes a full-length negative-strand RNA 
intermediate required for replication. When the nsP123 concentration increases, it is 
cleaved into nsP1, nsP2, nsP3 and nsP4 which form, along with host cell proteins, the 
positive strand replicase, which produces the 26S sub-genomic positive strand RNAs 
and genomic (49S) RNAs.
39
 The proteolytic activity of the CHIKV nsP2 is responsible 
for the cleavage of the replication machinery into individual working proteins. The 
alphaviruses nsP2 proteins have also been described as virulence factors responsible for 
the transcriptional and translational shutoff in infected host cells and the inhibition of 
interferon (IFN)-mediated antiviral responses contributing to the controlling of 
translational machinery by viral factors.
72,73,225
 This controlling comes through 
interactions with cellular RNA binding proteins, including heterogeneous nuclear 
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ribonucleoproteins (hnRNPs), ribosomal protein S6 (RpS6), and cellular filament 
components. Recently discovered, 22 cellular components are believed to interact with 
nsP2 or nsP4, contributing to the CHIKV replication, such as heterogeneous nuclear 
ribonucleoprotein K (hnRNP-K) and ubiquilin 4 (UBQLN4). It was also noted that the 
interaction of nsP2 with the tetratricopeptide repeat protein 7B (TTC7B) plays a 
significant role in the cellular machinery control induced by the CHIKV infection.
74
 
These critical functions are associated with nsP2 C domain protease and also the N 
domain that controls some metabolic processes of some cellular substrates, and 
therefore, this enzyme represents an important target in developing drugs against the 
CHIKV virus. 
Both N and C domains are composed of α-helices and β-strands (Figure 5.1). 
The N terminus is dominated by α-helices (red spirals in Figure 5.1) whereas, the C-
terminal domain contains helices and strands (cyan colour in Figure 5.1). The central β-
sheets are flanked by α-helices. The crystal structure of CHIKV nsP2 protease was 
solved in 2012. Being a cysteine protease enzyme (within domain C), the catalytic 
mechanism involves a nucleophilic cysteine thiol in a catalytic dyad.
66
 Analysis of the 
CHIKV nsP2 crystal structure shows 6 cysteine residues; three in the N-terminus 
(Cys1013, Cys1057 and Cys1121) and three in the C-terminus (Cys1233, Cys1274 and 
Cys1290) as shown in Figure 5.1. Since the proteolytic activity is isolated in the C-
terminus,
64
 one of the three cysteine residues in the C-domain might be the catalytic 
head.  
 
Figure 5.1 CHIKV nsP2 crystal structure showing the N- and C-terminal domains, 
cysteine residues shown in yellow balls and stick form (PDB code: 3TRK
67
, no 
reference cited thus far). 
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Generally, the first step in the mechanism of cysteine protease catalysis is the 
deprotonation of a thiol group within the enzyme active site by an adjacent amino 
acid containing a basic side chain, usually a histidine residue.
68
 Among the three 
cysteine residues in the C-terminus (Figure 5.2), the Cys1274 residue is less likely to be 
involved in the catalytic mechanism as only one His residue (His1314) is nearby, 
whereas for the other cysteine residues, four histidine residues (His1222, His1228, 
His1229 and His1236) are nearby and could be associated in the deprotonation 
mechanism (Figure 5.2).   
 
Figure 5.2 Schematic representation of the CHIKV nsP2 C-Domain showing the 
positions of the cysteine residues (in yellow) and histidine residues (in green), generated 
from the crystal structure PDB file code: 3TRK. 
 
For the nsP2 protease activity, the enzyme must hold its substrate at the catalytic 
site to start the cysteine cleavage mechanism. This site can be described as the enzyme 
“mouth”, and will be critical for the enzyme’s function. Blocking this site, will 
therefore, antagonise the enzyme function and will interfere with the viral replication 
cycle inside the infected host cell. 
In 2012, Singh Kh et al. reported  the development of a homology model of 
CHIKV nsP2 protein based on the crystal structure of the nsP2 protein of Venezuelan 
equine encephalitis virus (VEEV),
69
 before the release of the actual nsP2 crystal 
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structure. The critical residues in nsP2 were identified by docking three different 
peptides in order to identify the residues responsible for non-structural protein cleavage; 
nsP1-2, nsP2-3 and nsP3-4 peptides. These three peptide sequences represent the 
substrates for the nsP2 proteolytic processing with a remarkable preference of nsP3-
4>nsP1-2>nsP2-3.
70
 The active site was investigated and was found to lie in the C-
terminal domain.
69
 The key residues Gln1039, Lys1045, Glu1157, Gly1176, His1222, 
Lys1239, Ser1293, Glu1296 and Met1297 were found to interact with the nonstructural 
protein sequence complex to be cleaved, and were considered an individual functional 
unit. Only two residues are located in the N-domain; Gln1039 and Lys1045; all the 
other residues are located in the C-domain. In similar work, Bassetto et al.
71
 reported 
the identification of in silico CHIKV nsP2 inhibitors based also on a homology model 
of CHIKV nsP2 protein, not the actual crystal structure. 
Blocking the protease activity will be an applicable strategy for designing 
inhibitors for that particular enzyme. However, the reported studies
69,71
 only included 
the C domain as the main target site for the enzyme. They also did not describe the 
active proteolytic site in sufficient detail, nor did they discuss the possibility of targeting 
sites in the N domain. Herein, we describe the protease active site revealing some 
important criteria for the future design of inhibitors. We also describe here for the first 
time the binding site within the nsP2 N domain. Blocking the later site might not only 
block the multiple functions of the N domain,
65
 but could affect the C protease domain 
through an allosteric effect, invoking indirect inhibition of the C domain.  
5.2. Results and discussion 
The possible druggable sites at both the C and N domains of the CHIKV nsP2 
were investigated. These sites were then used for the identification of possible inhibitors 
through virtual screenings. 
5.2.1. Protease active site (domain C) 
From the CHIKV nsP2 crystal structure analysis, one major cavity can be 
detected within the enzyme surface lying as a central region between domains C and N. 
It also blocks the access through the two of the cysteine residues within domain C; 
Cys1233, Cys1290. Therefore, this cavity is more likely to be the protease active site 
(Figure 5.3), where the protein holds the peptide segment to be cleaved.  




Figure 5.3 Crystal structure of the CHIKV nsP2 showing the enzyme mouth cavity in 
green space filling lying in the centre between domain N and C. 
 
A closer inspection of the binding site revealed that the cavity looks as a U-
shaped cavity or tunnel (hereafter called site_1) that extends inward from the enzyme 
surface and opens and widens towards the outer surface of the enzyme (Figure 5.4). The 
tunnel itself is narrow and is surrounded by side walls and floor on the exterior side of 
the enzyme. 
 
Figure 5.4 Site_1 U-shaped cavity that is lying between the nsP2 domains N and C. It 
has the two openings on the enzyme surfaces. The cavity mouth is wide and surrounded 
by hydrophobic side wall and a floor.  
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Site_1 makes contact with the residues: Gln1039, Ala1040, Lys1045-Tyr1047, 
Gly1176, Pro1191, Leu1192, Tyr1201, Asn1202, Leu1203, Glu1204, His1222, 
Thr1223, Pro1224, Arg1226, Asp1235, Mes1238, Lys1239, Leu1243. The cavity is 
mainly hydrophobic due to the presence of the residues Ala, Tyr, Gly, Pro and Lys, with 
some amino acids able to form H-bonds such as His, Tyr, Gln, Glu as well as the polar 
part of Lys. The central blue bridge (Figure 5.4) in the middle of the cavity is a 
hydrophilic bridge that is formed by the polar heads of the N domain Lys1045 and the C 
domain Lys1239. Domain C residue Cys1233 is buried in one of the α-helices behind 
this cavity and closer to domain N, confirming the hypothesis that this mouth cavity 
might be the access to the catalytic proteolytic activity of the enzyme. Therefore, 
blocking this cavity might block the proteolytic activity of the enzyme and consequently 
inhibit viral replication.  
5.2.2. N domain binding site  
Lying on the opposite side of the enzyme surface is another hydrophobic pocket 
that extends within the N domain of the enzyme before the junction with domain C 
(Figure 5.5).  
a b 
  
Figure 5.5 Hydrophobic pocket within the N domain of the CHIKV nsP2 a) Front view 
of the pocket, b) side view of the pocket, divided into 3 sections; the narrow linker 
cavity which open towards site_1 side, a middle section and a wide terminal mouth.  
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This pocket (hereafter called site_2) extends under the N domain β-sheet and 
ends with a small cavity that opens on the domain C side surface, just above site_1 
(Figure 5.6). 
 
Figure 5.6 Electrostatic surface of the CHIKV nsP2 showing site_1, site_2 and the 
linker cavity that opens from site_2 towards site_1 
 
Site_2 is mainly lined by residues: Asn1011, Cys1013, Trp1014, Ala1046, 
Tyr1047, Ser1048, Glu1050, Val1077, Tyr1079, Asn1082, Trp1084, Gly1090, 
Lys1091, Leu1205 and Mse1242. It is also a hydrophobic cavity due to the presence of 
hydrophobic residues with some amino acids able to form H-bonds such as Ser, Tyr, 
Trp, Gln, and also the polar moiety of Lys. Targeting this site by inhibitors, might not 
only block the NTPase and RTPase N domain functions, but may also act as an 
allosteric site for the protease binding site on the opposite C domain side of the enzyme; 
small molecules bound to this site may alter the function of the enzyme or change the 
enzyme conformation and consequently block the enzyme function, stopping the viral 
replication.  
5.3. Virtual screening with the CHIKV nsP2 
A virtual screening study was performed on both sites (site_1, site_2) using the Life 
chemicals cysteine protease inhibitors library (28,960 compounds). This library was 
designed using a ligand based approach – first, a set of 585 compounds active in assays 
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related to cysteine proteases was assembled. This Life Chemicals collection was 
searched for compounds similar to the reference dataset using MDL public keys and the 
Tanimoto similarity cut-off of 85% to generate a library of 28,960 compounds.  
The virtual screening was performed using two successive docking scores, 
FRED (fast rigid exhaustive docking) for fast precise screening, with the top hits then 
subjected to a ranking scoring using the AUTODOCK algorithm. The important 
residues within both sites have been identified. Some in silico inhibitors were also 
predicted that could be developed as selective CHIKV nsP2 inhibitors. The results of 
the first Fred screening and the second Audodock re-ranking on both sites are shown in 
tables 5.1-5.6. 
Table 5.1 The top 25 compounds docked by Fred in nsP2_site_1 and their interacting 
















π-cation Lys 1045 
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* VIDA is a visualising software developed by Openeye (OpenEye Scientific Software, Santa Fe, 
NM. http://www.eyesopen.com) 
† Mg ion within the crystal structure 
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Table 5.2 Autodock output for the nsP2_site_1 Fred hit list. Cluster analysis was 











Lowest energy  
cluster poses 
2 -11.36 4.72 4 14 
3 -7.26 4.79 × 103 8 13 
4 -9.83 61.92 13 16 
5 -7.22 5.12 × 103 9 7 
6 -10.5 19.96 7 28 
7 -9.46 116.7 7 22 
8 -10.0 46.58 7 21 
9 -8.68 435.31 17 20 
10 -8.39 709.36 4 10 
11 -9.88 57.32 7 16 
12 -7.13 5.9 × 103 21 5 
13 -10.16 35.58 1 50 
14 -9.03 241.5 21 4 
15 -7.69 2.29 × 103 5 28 
16 -9.37 134.58 10 16 
17 -8.45 644.95 4 22 
18 -9.03 240.22 4 1 
19 -9.18 185.76 2 48 
20 -9.9 55.24 11 15 
21 -9.75 71.74 20 5 
22 -7.92 1.57 × 103 6 20 
23 -8.3 822.33 2 44 
24 -8.63 472.65 41 1 
25 -9.89 56.66 7 12 
26 -10.24 30.98 10 25 
&
 Predicted docked poses are grouped together according to their root-mean-square (RMS) values 
compared to the input ligand structure. Poses that have similar RMS values (within the tolerance value 
selected) are grouped in one cluster.  
 
 
                                                             
* Entries are the same as in Table 5.1, entry 1 was assigned for the Mg ion. 
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Table 5.3 The top 5 poses for the nsP2_site_1 based on Autodock ranking, their ClogP, 












4.08±0.69 -11.36 4.72 
 
Lys 1045 (Hb, 1.9 Å) 
Lys 1239 (2Hb, 1.9, 2.5 Å) 
Lys 1239 (π-cation) 
Leu 1192 (π-sigma) 
6 
 
5.13±0.97 -10.50 19.96 
 
Glu 1043 (2Hb, 2.1, 2.2 Å) 
Lys 1239 (Hb, 1.7 Å) 





5.88±0.94 -10.24 30.98 
 
Glu 1043 (Hb, 1.9 Å) 
Lys 1239 (Hb, 1.7 Å) 
Lys 1239 (π-cation) 
Lys 1239 (π-sigma) 
13 
 
6.07±0.88 -10.16 35.58 
Lys 1045 (Hb, 2.4 Å) 
Lys 1239 (Hb, 2.1 Å) 
Pro 1191 (π-sigma) 
Lys 1045 (π-cation) 
Lys 1239 (π-cation) 
8 
 
5.67±1.05 -10.0 46.58 
Lys 1045 (2Hb, 2.1, 2.2 Å) 
Lys 1239 (Hb, 1.8 Å) 
Lys 1045 (π-cation) 
Lys 1239 (π-sigma) x 2 
Lys 1239 (π-cation) 
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Table 5.4 The top 25 compounds docked by Fred in nsP2_site_2 and their interacting 
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Table 5.5 Autodock output for the nsP2_site_2 Fred hit list. Cluster analysis was 








Number of clusters 
Lowest energy  
cluster poses 
1 -8.32 799.94 13 7 
2 -9.74 72.63 3 42 
3 -9.24 167.47 3 31 
4 -8.97 264.9 11 16 
5 -8.8 353.41 5 2 
6 -7.65 2.47 × 103 9 8 
7 -9.23 170.77 6 10 
8 -9.8 65.79 2 48 
9 -9.76 70.47 4 30 
10 -9.28 156.76 4 20 
11 -8.42 667.9 7 16 
12 -9.9 55.69 3 31 
13 -8.38 722.18 9 20 
14 -8.8 355.69 7 25 
15 -8.88 312.02 10 14 
16 -8.72 404.11 7 28 
17 -8.45 636.79 7 25 
18 -8.82 345.39 6 19 
19 -9.4 129.44 7 27 
20 -8.23 929.53 9 13 
21 -9.67 81.91 1 50 
22 -9.2 180.54 6 36 
23 -8.68 431.68 9 2 
24 -8.15 1.06 × 103 7 16 





                                                             
* Entries are the same as in Table 5.4. 
Chapter 5  CHIKV nsP2 
136  
 
Table 5.6 The top 5 poses in the nsP2_site_2 based on Autodock ranking, their ClogP, 
calculated binding energies, Ki values and interacting residues. 











4.57±0.65 -9.90 55.69 
Ser 1048 (Hb, 1.6 Å) 
Tyr 1079 (Hb, 2.1 Å) 
Trp 1084 (Hb, 1.8 Å) 
Gln 1241 (Hb, 2.4 Å) 
Lys 1091 (π-cation) 
8 
 
4.13±0.68 -9.80 65.79 
 
Trp 1084 (Hb, 1.7 Å) 
Lys 1091 (Hb, 1.8 Å) 
9 
 
3.28±1.00 -9.76 70.47 
Glu 1050 (Hb, 2.3 Å) 
Tyr 1079 (Hb, 2.3 Å) 
Trp 1084 (2Hb, 2.1, 2.2 Å) 
Lys 1091 (Hb, 1.9 Å) 
2 
 
6.12±0.49 -9.74 72.63 
 
Ser 1048 (Hb, 1.7 Å) 
Trp 1084 (Hb, 2.2 Å) 
Lys 1091 (π-cation) 
21 
 
4.86±1.49 -9.67 81.91 
 
Trp 1084 (Hb, 1.8 Å) 
Lys 1091 (π-cation) x2 
*Calculated using ACDLabs v.12.0 (ACD/Labs, Toronto, Canada). 
 
5.3.1. Analysis of the C domain virtual screening results 
The CHIKV nsP2 plays an important role during the replication life cycle, and is 
composed of two domains. Domain C, which is the proteolytic machinery, processing 
the non-structural protein complex into individual functional proteins, and the N 
domain, which performs regulatory cellular functions through the NTPase and RTPase 
activities. These vital roles of the enzyme with the availability of a crystal structure, 
makes it an attractive target for the drug design for this virus. We investigated both 
domains for the possible binding sites. Within domain C which contains 3 cysteine 
residues (Figure 5.2) that might be involved in the proteolytic mechanism, access to 
these residues is most likely to occur through the site_1 (Figure 5.4), a possible site for 
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holding the protein to be cleaved by the protease activity. The site extends between 
domains N and C with residues from both lining the site_1 tunnel. The tunnel opens to 
the outer surface as a wide mouth lined mainly by residues from domain C. Our 
hypothesis is that bound small molecules to this site, not only freezes both domains 
together, preventing its function, but also blocks the sites through π-stacking 
interactions, mostly, hydrophobic/aromatic interactions. Our study did not reveal the 
participation of the cysteine residues (Cys1233, Cys1290), however, other residues have 
been found to strongly participate in the interactions in this site.  Figure 5.7 shows the 




















Figure 5.7 Three and two dimensional representations of the top 5 ranked poses (Table 
5.3) inside the nsP2 site_1 pocket. 
Chapter 5  CHIKV nsP2 
139  
 
Figure 5.7 shows that compounds 2, 13 and 8 were able to insert at least a 
phenyl ring inside the U-shaped tunnel whereas poses 6 and 26 were found to prefer the 
outer surface of the cavity (the outer mouth cavity). All compounds were able to bind to 
Lys1045 or Glu1043 from the N domain and to Lys1239 from the C domain. These 
interactions with residues in the two domains N and C make the compounds good 
possible ligands for this pocket. When bound to the pocket in the predicted way, 
compounds will be able to freeze domain N in relation to domain C, blocking the 
protease cavity of the enzyme, rendering the access to the cysteine residues for the 
catalytic cleavage not possible. 
Poses 2 and 13 were able to form π stacking interactions with the side wall of 
the pocket via interactions with Leu1192 and Pro1191, respectively (Figure 5.7). This 
pocket side wall represents the enzyme outer surface, with this part of the enzyme 
surface being close to the linker cavity of site_2 (see Figure 5.6). 
Poses 2 and 13 were able to orient in such way that they have aromatic rings 
relaxing before the side wall of the pocket forming interactions with Leu1192 and 
Pro1191, respectively. This unique ability for the two ligands (2 and 13) was related to: 
a) the presence of a relatively smaller linear terminal phenyl-furan sequence, such that 
this moiety can insert inside the tunnel, being stabilized by H-bonds with the tunnel 
hydrophilic bridge, b) the flexibility of the other terminal phenyl ring; in the docked 
pose 2, the terminal phenyl is attached to the relatively flexible non-aromatic piperazine 
moiety whereas in the docked pose 13, the terminal phenyl is attached to rigid aromatic 
central moiety via a flexible CH2 linker. This flexibility enables the terminal phenyl 
rings to find the right position for interaction with the amino acid residues Leu1192 and 
Pro1191. These two classes of compounds can be described as relatively small rigid 
aromatic head groups linked in a linear manner through relative flexible joints to small 
aromatic tails. This orientation allows the insertion inside the tunnel forming stacking 
interactions with the cavity residues. 
Poses 6 and 26 are derivatives of the main skeleton of N-aryl-2-((4-oxo-3-aryl-
4,5-dihydro-3H-pyrimido[5,4-b]indol-2-yl)thio)acetamide, with different aryl groups. 
The 3,5-dihydro-4H-pyrimido[5,4-b]indol-4-one head is important in this class of 
compounds as it forms a strong π-stacking interaction with the C domain central 
Lys1239 (Figure 5.7), and is able to insert one the terminal phenyl rings inside the right 
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opening of the tunnel (on the right hand side when looking to front Figure). In both 
derivatives, the 2-mercaptoacetamide linker is important; the carbonyl oxygen can 
accept H-bond from the polar head of Lys1239 of the tunnel central bridge, and the NH 
participates in H-bonding with the N domain Glu1043. The aromatic tail; the relatively 
more flexible benzo[1,4]dioxane in compound 6 and the rigid naphthalene moiety in 
compound 26 blocked the access of the left opening of the tunnel (on the left hand side 
when front looking to the Figure). These three segments, bulky aromatic head, 
mercaptoacetamide linker and the aromatic tail were responsible for the orientation of 
this class in such a way that they block the entrance of the U-shaped tunnel from the 
two openings, and therefore, can be developed as selective blockers for this site. Figure 
5.8 shows the superimposition of compound 6 and 26 inside site_1. 
 
Figure 5.8 Superimposition of pose 6 (violet) and pose 26 (yellow) inside the 
nsP2_site1 binding pocket. 
 
The mercaptoacetamide linker was also important in pose 8 where it connected 
the bulky head the phenylthieno[3,2-d]pyrimidin-4(3H)-one to the tail of the 
tetrahydroquinoline. The terminal phenyl substituent of the head was inserted inside the 
right hand side opening of the tunnel and was stabilized by interaction with the N 
domain tunnel bridge residue Lys1045 (Figure 5.7), whereas the main thieno[3,2-
d]pyrimidin-4(3H)-one moiety was stabilized by interaction with the C domain tunnel 
bridge residue Lys1239 (Figure 5.7). The mercaptoacetamide linker forms H-bonds 
with both residues of the bridge tunnel residues. The benzo moiety of the tail forms an 
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interaction with Lys1045 blocking the left tunnel opening. In comparison with poses 6 
and 26 where the linker is attached to the rigid benzo moiety of the head groups, the 
linker in pose 8 is attached to the relatively flexible moiety of the rigid tail where certain 
flexibility might allow such stabilizing interaction with the tunnel bridge. Such 
stabilization was not possible in case of 6 and 26. 
5.3.2. Analysis of the N domain virtual screening results 
Site_2 is located within the N domain and lies as a channel that is partially 
covered by two of the N domain β-sheets. It represents the main pocket within domain 
N that might be important for the N domain functions. This pocket can also lead to 
access to the cysteine residues within C domain. Therefore, the hypothesis is that 
blocking the pocket will inhibit the enzymatic functions of this domain, and secondly, it 
might be an allosteric site for blocking the enzymatic activity of domain C. Figure 5.9 
shows the 3D and 2D representations of the top ranked docked poses (Table 5.6) within 
the nsP2 site_2 N domain pocket.  
Pose 12 
     
Pose 8 
   










Figure 5.9 Three and two dimensional representations of the top 5 ranked compounds 
(Table 5.6) inside the nsP2 site_2 pocket. 
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Site_2 can be divided into 3 sections (Figure 5.5), the narrow linker cavity 
which opens towards site_1 side, a middle section and a terminal wide mouth. Two 
important interactions emerged in the top ranked poses, one strong H-bond with 
Trp1084 (in the range of 1.7-2.2 Å) which is located in the middle section and another 
interaction with Lys1091 in the terminal wide mouth section (Figure 5.9, the snapshots 
were taken with the wide mouth component in the front). This later interaction was 
either through H-bonds with the polar part of Lys1091 as in poses 8 and 9, or through π-
cation stacking interaction with the positively charged head of Lys1091 as in 
compounds 12, 2 and 21. In poses 12, 8, 9 and 2, the terminal hydrophobic/aromatic 
moiety was inserted inside the narrow linker cavity of the pocket (Figure 5.9, the rear 
part of the snapshots). 
All compounds interacted with residues within domain N without interacting 
with domain C except pose 12, which forms a strong H-bond (2.4 Å, Figure 5.9) with 
the Gln1241 residue, located in one of the α-helices of domain C. This unique 
interaction was responsible for the better binding profile compared to the other docked 
poses as can be inferred from Table 5.6 where pose 12 was predicted to bind to the 
pocket with a binding energy of -9.90 kcal/mol with a predicted inhibition constant (Ki) 
of 55.69 nM.    
The presence of the bi-heterocyclic system in the middle of the pocket, namely 
the benzo[d]thiazole moiety, in poses 12 and 9 was responsible for H-bond formation 
through the sulfur atom with the N domain β-sheet Tyr1079 residue; this β-sheet 
extends outwards like an umbrella over the pocket.  
The presence of a sulfoxide group in the third wide mouth pocket section (front 
view of the snapshots taken in Figure 5.9) is favourable as both oxygens of this group 
can accept H-bonds from the N domain Ser1048 (around 1.6 Å, Table 5.6) as in case of 
poses 12 and 2, or with the near by amino acid Glu1050 (2.3 Å) in case of pose 9. 
Poses 12, 8 and 9 can insert hydrophobic tails within the linker cavity that opens 
on site_1 side. This indicates that this site may affect the other protease site somehow 
through this linker cavity. Figure 5.10 shows a 3D representation of the nsP2 surface 
with pose 12 (Table 5.3, within site_1) and pose 8 (Table 5.6, within site_2). It shows 
the possible clashes between the compounds in the linker cavity. It also shows the 
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possible allosteric effect of ligands in site_2 on the protease active site. This opens other 
possible investigations into using two inhibitors together as an effective inhibitory 
mechanism for that critical enzyme in the viral life cycle. 
 
Figure 5.10 Pose 2 (Table 5.3) within the nsP2 site_1, shown in red colour. Pose 8 
(Table 5.6) within the nsP2 site_2, shown in yellow colour. The hydrophobic tail of 
pose 8 within site_2 is protruding through the linker cavity towards pose 2 in site_1. 
 
5.4. Concluding remarks 
We have examined the CHIKV nsP2, a critical enzyme for the viral life cycle, for 
potential druggable pockets that could be targeted by small molecules. Two major 
pockets where identified within the N and C domains. The hypothesis described here 
investigated the possibility of inhibiting the enzyme multi-functions through blocking 
the active sites of the two domains. A database search on the two hydrophobic pockets 
was performed and this search detected the residues important for significant bindings 
as well as the preferred pharmacophores of the potential in silico inhibitors. Within 
domain C proteolytic site, Lys1239 and Lys1045 were found to interact with most of the 
identified ligands. Both residues represent a hydrophilic bridge in the C domain 
hydrophobic pocket that can form H bonds through their polar heads and stacking 
interactions through their side chains. Within domain N, Trp1084 and Lys1091 were 
found to be interacting with all of the docked poses, with the possibility for interaction 
with the C domain Gln1241. Some small molecules were also identified for each site 
that look promising in silico (nano-molar) inhibitors that might be starting points for 
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lead development targeting this enzyme. Another hypothesis is the possibility of using 
dual inhibitors for the enzyme, targeting both domains at the same time by a 
combination therapy. The CHIKV nsP2 enzyme is unfortunately not available for direct 
binding assays, therefore, the identified compounds were purchased and currently are 
being evaluated for their anti-chikungunya activities. This represents the first study in 
understanding the CHIKV nsP2 enzyme as well as identifying some selective potential 
inhibitors, and this computer model can be further used for screening large libraries to 
identify more hits. Depending on the activities, a retro-synthetic analysis can be 
designed for the active compounds, allowing in-depth in silico with in vitro 




CHAPTER 6: Structure Based Design towards the Identification of 
Novel Binding Sites and Inhibitors for the Chikungunya Virus 
Envelope Proteins 
 
6.1. Introduction  
The CHIKV genome is approximately 11.8 Kb in size and consists of a single stranded, 
positive sense RNA genome with two open reading frames (ORFs),
28
 one in the 5` end 
which encodes two polyproteins, the precursors of the non-structural proteins. The 
second ORF at the 3` end encodes the structural proteins, the capsid (C), envelope 
glycoproteins E1 and E2 and two small cleavage products (E3, 6K). Like the other 
members of the alphaviruses, the CHIKV starts the life cycle by entering the target host 
cells by pH dependent endocytosis via a receptor mediated interaction.
30
 A recent study 
identified prohibitin1 (PHB1) as a microglial cell expressed CHIKV binding protein.
31
 
After entering the cell, the endosome acidic environment triggers conformational 
changes in the viral envelope complex made of E1 and E2 proteins, resulting in 
dissociation of the E2-E1 heterodimers and E1 homotrimers are formed. The E1 trimer 
inserts into the target cell membrane via its hydrophobic fusion peptide (fusion loop) 
and refolds to form a hairpin-like structure. Exposure of the E1 fusion peptide leads to 
releasing of the nucleocapsid into the host cell cytoplasm.
34,35
 During the replication 
cycle inside the host cell, the capsid protein is released, and the pE2 and E1 
glycoproteins are translated in the Golgi and are moved to the plasma membrane, where 
pE2 is cleaved by furin-like protease activity into E2 and E3.
42
  
Glycoprotein E2 is responsible for receptor binding whereas E1 is responsible 
for membrane fusion.
10
 E3 contains the 64-amino-terminal residues of p62 and mediates 
proper folding of pE2 and its subsequent association with E1.
93
 E3 also protects the E2-
E1 heterodimer from premature fusion with cellular membranes.
94
  Furin maturation of 
p62 into E3 and E2 during transport to the cell surface primes the spikes for subsequent 
fusogenic activation for cell entry. Mature virions bud at the plasma membrane via 
interactions between E2 and genome-containing viral nucleocapsids present in the 
cytoplasm,
95
 ready for infecting new cells. The crystal structures of both the immature 
and the mature glycoprotein complexes have recently been solved,
95
 (Figure 6.1). 




Figure 6.1 Crystal structure of the immature envelope glycoprotein complex of 




E1 is folded into three β-sheet rich domains (I, II and III). E2 is an all β protein 
belonging to the immunoglobulin superfamily, with three domains A, B and C. Domain 
B is at the membrane upper end and domain C is towards the viral membrane: Domain 
A is at the centre while domain C binds to the adjacent domain II of E1. The long β – 
ribbon of E2 makes most of the connection with E3. Furin loop is E2-E3 junction in the 
immature complex; this junction contains a functional proprotein convertase motif 
which is cleaved by the cellular porteases; furin-like proprotein convertases during the 
maturation of the glycoproteins.
42
 The amino acid His60 in this junction is the critical 
residue that determines the spectrum of furin and furin-like convertases that process E2-
E3 glycoprotein complex.
100
 The U shaped fusion loop of E1 is inserted in a groove 
between E2 domains A and B being stabilized by hydrogen bonds with E2 histidine side 
chains.
95
 In the neutral pH, E3 maintains E2 domain B in an orientation with respect to 
domain A in such way that it creates the groove accommodating the E1 fusion loop, 
protecting the virus from premature fusion with other cellular membranes.
95,101
 Some 
residues in domain B of E2 are believed to be associated with cell recognition.
94
 The 
fusogenic activity of the E1 fusion peptide is highly dependent on pH change. The 
histidine residues of E2 are believed to be involved as the pH sensor for the activation 
of the fusion protein at lower pH
95
 due to the increased probability of histidines to 
become positively charged at lower pH values, based on the fact that the imidazole ring 
of the histidine residue is the only amino acid side chain whose apparent dissociation 
constant from protons (pKa) falls within the physiological range. Within the E1 fusion 
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peptide sequence, the glycine residue (Gly91) is critical for the fusion process. Also, it 
was found that one histidine residue at E1 230, which is located outside of the fusion 
sequence, is also critical for the fusion.
96
  
Blocking the in vitro CHIKV infection in the host cells targeting the envelope 
proteins has been demonstrated by blocking the intracellular furin-mediated cleavage of 
viral envelope glycoproteins (E2E3 or p62 precursors), this blocking was achieved by 
an irreversible furin-inhibiting peptide which significantly reduce the processing of 
E3E2 CHIKV glycoproteins. This led to the formation of immature viral particles and 
impaired viral spreading through other uninfected cells.
100
 This reflects the importance 
of considering the envelope glycoproteins as an attractive target for selective drug 
development. 
The usage of the three-dimensional structure of the target proteins (crystal 
structures) in the virtual screening (in silico) of chemical libraries has been a powerful 
approach to identify lead compounds with some successful examples in a number of 
systems.
226, 227
 Such structure based drug design techniques, including the identification 
of new binding sites and virtual screening search, have been successfully used for 
identification of lead compounds for the dengue virus envelope protein (E protein).
228, 
229
 Dengue virus is also an arbovirus and is transmitted by the same vector mosquito of 
the CHIKV. Herein, we report for the first time the novel binding sites in the CHIKV 
envelope glycoproteins that can be used as sites for inhibitors that could alter the 
function of the envelope proteins and consequently, inhibit the virus fusion function. To 
increase the chances of possible hits, we examined both the immature and the mature 
glycoprotein crystal structures for possible binding sites. Two sites were chosen that 
were common in both the immature and the mature proteins based on their locations and 
functions. We then used virtual screening combining two different docking algorithms 
with a number of chemical databases to identify suitable compounds predicted to bind 
in these sites. FRED (fast rigid exhaustive docking) was used for fast and precise 
screening using multiple scoring functions, followed by re-docking ranking of the top 
hits using AUTODOCK scoring function. This led to the identification of favoured hits 
that have suitable binding profiles to the CHIKV glycoproteins. This hypothesis 
represents a new strategy for inhibiting this particular virus by targeting the envelope 
proteins which will lead to impaired protein function and thus inhibiting the virus, and 
will help the further synthetic development and optimization of selective inhibitors, as 
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previously and successfully achieved for the dengue virus envelope protein 
inhibitors.
229, 230
   
6.2. Results and discussion 
6.2.1. Identification of novel binding sites 
Both the crystal structure of the immature complex (PDB file: 3N40 
95
) and the mature 
complex (PDB file: 3N42
95
) were used. Binding sites within the receptors were detected 
using the Discovery Studio 3.5 software (Accelrys Software Inc.: San Diego, CA, 
2012). The algorithm is based on a grid search and "eraser" algorithm which derives 
binding sites from cavities in the structure of the receptor. The binding site found is 
displayed as a set of points. The volume of each cavity is defined as the product of the 
number of site points and the cube of the grid spacing. Six main sites were detected in 
both the immature and the mature crystal structures and only one site was detected in 
the mature crystal structure that is not present in the immature form (Figure 6.2). Table 
6.1 shows the identified sites. Suitable cavities were then checked further based on 
functionality, presence of hydrophobic residues, presence of charged residues and 
solvent accessibility.  
 
Figure 6.2 Crystal structure of (a) the immature glycoproteins (generated from file pdb: 
3N40) and (b) the mature glycoproteins (generated from the file pdb: 3N42) showing 
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Table 6.1 The identified receptor cavities in the immature (3N40) and mature (3N42) 
crystal structures, grid coordinates x, y and z, cavity volumes, points count and location 







Site 1 (red) 
x, y, z  -15.381, -1.269, 16.434 -15.687, 2.019, -19.939 Between E1 
domain II and E2 
domain C Volume 687.25 651.375 
Points count 5498 5211 
Site 2 (light green) 
x, y, z -30.631, 17.481, 33.684 -33.937, -18.731, -31.939 Between E1 
domain II and the 
β–ribbon of E2 Volume 395 357.375 
Points count 3160 2859 
Site 3 (dark green) 
x, y, z -30.631, 4.981, 37.934 -33.437, -6.731, -33.189 Adjacent to site 2  
Volume 157.625 156.125 
Points count 1261 1249 
Site 4 (blue) 
x, y, z -38.131, 31.481, 24.934 -42.937, -28.731, -22.939 Behind the fusion 
loop, between E3, 
E2 domain B, E2 
domain A 
Volume 126.25 183.875 
Points count 1010 1471 
Site 5 (black) 
x, y, z -44.631, 14.731, 23.184 -44.437, -14.731, -23.439 between the β–
ribbon of E2 and 
E3 Volume 93.125 124 
Points count 745 992 
Site 6 (yellow) 
x, y, z -57.631, 16.731, 36.184 -16.187, -18.231, -36.439 Within E3 cavity 
Volume 29.5 20.5 
Points count 236 164 
Site 7 (orange) 
x, y, z 
Does not exist 
-59.187, -15.731, -26.189 Replacing the furin 
loop 
Volume 22.25 
Points count 178 
 
6.2.2. Virtual screening with the CHIKV envelope proteins 
Two chemical compounds libraries were used; The NCI set library of 265,242 
compounds and the Life Chemicals protein-protein interactions inhibitors library of 
31,143 compounds. The databases were filtered with the drug-likeness-index; limit the 
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range for Molecular Weight < 500, calculated octanol–water partition coefficient (clogP 
< 5), and hydrogen bond donors, and acceptors (OH’s and NH’s < 5; N’s and O’s < 
10),
231
 using Filter v2.0.2 (OpenEye Scientific Software, Santa Fe, 
NM. http://www.eyesopen.com), producing 55,841 compounds from the NCI library 
and 4,124 compounds from the Life Chemicals library. Fast exhaustive virtual screening 
was performed using FRED v2.2.5 (OpenEye Scientific Software, Santa Fe, 
NM. http://www.eyesopen.com), which is a fast and effective docking application 
whose performance is significantly more reliable, i.e. lower variance, than most other 
programs.
232, 233
 FRED performs a systematic, exhaustive, nonstochastic examination of 
all possible poses within the protein active site, filters for shape complementarily 
234
 and 
pharmacophoric features before selecting and optimizing poses using the Chemgauss 
scoring function. Omega2 (Systematic high-throughput conformer generation, OpenEye 
Scientific Software, Santa Fe, NM. http://www.eyesopen.com),
235, 236
 was used to 
generate multiple conformers for each compound in the database libraries using the 
default settings. Omega2 takes into account the flexibility of a molecule by generating 
all representative conformers. For the NCI library, 2,312,012 conformers were 
generated, and 334,064 conformers were generated from the Life Chemicals 
compounds. The work-flow diagram is shown in (Figure 6.3), the life chemical library 
was screened on site 2 (light green colour in Figure 6.2) in both of the immature and the 
mature glycoproteins. The NCI set compounds were screened on site 4 (blue colour in 
Figure 6.2) of the two envelope protein forms. The binding sites were prepared for 
docking using Fred receptor setup software (OpenEye Scientific Software, Santa Fe, 
NM. http://www.eyesopen.com). The grid boxes were determined based on the x, y and 
z co-ordinates given in Table 1. After the docking calculations, the poses returned were 
scored and ranked with a Gaussian shape function independently by the five available 
scoring functions (PLP, Chemgauss3, Chemscore, OEChemscore, and Screenscore) and 
by a consensus of all. The top ranked poses from the exhaustive docking were then 
optimized using systematic solid body optimization by chemgauss3. VIDA v4.2.0 
(OpenEye Scientific Software, Santa Fe, NM. http://www.eyesopen.com) was used to 
visualise the docked poses within the receptor active site, and to inspect the critical 
interacting residues in each pocket with the individual docked poses. Top 20 hits were 
then recorded for each of the four sites (Tables 6.2, 6.5, 6.8, 6.11). 
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The top 20 docked poses ranked in each of the four binding sites were then 
extracted as PDB files, and were processed with Autodock Tools 1.5.6rc3 (ADT) 
graphical interface.
173
 The Gasteiger charges were calculated and the nonpolar hydrogen 
atoms were merged, torsion angles were defined, they were then saved as pdbqt files for 
Autodock calculations. Crystal structures (3N40, 3N42) were used by Autodock Tools 
1.5.6rc3 to setup the receptor binding sites. The grid box co-ordinates in each site were 
determined based on the co-ordinates in Table 1. AutoGrid 4.2 algorithm was used to 
evaluate the binding energies between the inhibitors and the enzyme and to generate the 
energy maps for the docking run. Fifty runs were generated using Autodock 4.2 
Lamarckian genetic algorithm
173
 for the searches. Cluster analysis was performed on 
docked results, with a root-mean-square tolerance of 2.0 Å, the docked poses were 
ranked according to the binding energies and ligand efficiencies, and finally the five 
lowest energy poses (Tables 6.3, 6.4, 6.6, 6.7, 6.9, 6.10, 6.12, 6.13) were selected as the 
resultant complexes with the enzymes. Compounds are commercially available and 
have drug like qualities and also can be accessed through chemical syntheses for further 
optimization process. 
 
Figure 6.3 Work-flow diagram of the virtual screening procedures used for CHIKV 
envelope proteins. 
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Table 6.2 Fred output virtual screening top 20 hits and their target residues, for the 
immature glycoprotein receptor (3N40) site_2. 
Entry Structure  H-bonding Other interactions 
1 
 
E1 Lys 52 
E1 Thr 53 




 π–sigma (E1 Val 54) 
3 
 
 π–sigma (E2 Arg 100) 
4 
 
E1 Thr 53 
E1 Ile 55 
Lys 52 
π–cation (E1 Lys 52) 
5 
 
E1 Ile 55 π–sigma (E1 Val 54) 
6 
 
E1 Val 231 
E1 His 230 
E1 Ile 55 
π–cation (E1 Lys 52) 
7 
 
E1 His 230 
E1 Val 231 
 





E2 Tyr 301 π–cation (E2 Arg 100) 
9 
 
E1 Ile 55 (2 Bonds) 







E1 Thr 53, Ile 55 




 π–cation (E1 Lys52) 
13 
 
E2 Glu 232  
14 
 
E1 Val 231, His 230  
15 
 
E1 Tyr 301 
E2 Glu 232 
π–sigma (E1 Val 54) 














E1 Val 54, Thr 53 
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Table 6.3 Autodock output for the immature glycoprotein receptor (3N40) site_2 Fred 
hit list, Cluster analysis was performed on docked results, with a root-mean-square 






Number of clusters 
Lowest energy 
cluster poses 
1 -8.37 734.41 6 24 
2 -8.23 930.55 12 19 
3 -8.38 721.49 2 41 
4 -7.67 2.39 × 103 5 24 
5 -9.43 121.87 10 10 
6 -10.06 42.15 10 15 
7 -8.99 255.48 8 19 
8 -8.04 1.29 × 103 13 9 
9 -8.3 819.29 6 31 
10 -9.36 138.19 6 9 
11 -8.8 354.66 16 3 
12 -9.18 187.59 14 3 
13 -8.19 987.11 1 50 
14 -7.91 1.6 × 103 16 3 
15 -7.85 1.75 × 103 4 23 
16 -8.8 357.02 7 11 
17 -8.7 416.95 7 18 
18 -8.43 657.11 4 22 
19 -8.97 267.05 5 33 
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Table 6.4 Top 5 hits identified for site 2 using the immature glycoprotein receptor 
(3N40), showing the molecular weights, calculated logP (clogP), predicted binding 




















































*Calculated using ACDLabs v.12.0 (ACD/Labs, Toronto, Canada).  
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Table 6.5 Fred output virtual screening top 20 hits and their target residues, for the 
mature glycoprotein receptor (3N42) site_2. 
Entry Structure H-bonding Other interactions 
1 
 
E1 Ile 55, Lys 52 
E2 Tyr 237, Arg 36 
π–cation (E2 Arg 36) 
π–cation (E1 Lys 52) 
2 
 
E1 Ile 55, Lys 52, 
Glu112 
E2 Tyr 237, Glu 66 
π–cation (E1 Lys 55) 
π–cation (E2 Arg 36) 




E1 LYS 52 x 2 π–sigma (E1 Val 54) 
4 
 
E1 Lys 52 




E1 Ile 55, Lys 52 
E2 Glu 35, Tyr 237 
π–cation (E1 Lys 52) 
6 
 
E1 Lys 52 




E1 Ile 55 π–sigma (E1 Val 54) 
π–cation (E1 Lys 52) 





E1 Lys 52 π–sigma (E2 Arg 36) 
π–cation (E1 Lys 52) 
9 
 
E1 Ile 55 
E2 Tyr 237 x 2 
π–cation (E1 Lys 52) 
π–cation (E2 Arg 36) 
10 
 
E1 Ile 55, Val 231 
E2 Tyr 237 
π–cation (E1 Lys52) 
11 
 
E1 Ile 55, Lys 52 x 2 π–sigma (E1 Val 54) 
12 
 
E1 Lys 52 π–sigma (E1 Val 54) 
13 
 
E2 Tyr 237 π–cation (E1 Lys 52) 
14 
 
E1 Ile 55  
15 
 
E1 Lys 52 π–cation (E2 Arg 36) 





E1 Lys 52 π–cation (E2 Arg 36) 
17 
 
E1 Lys 52 x 2 π–sigma (E1 Val 54) 
18 
 
E1 Lys 52 x 2 π–cation (E2 Arg 36) 
π–cation (E1 Lys 52) 
19 
 
E1 Lys 52  
20 
 
E1 Lys 52 π–cation (E1 Lys 52) 
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Table 6.6 Autodock output for the mature glycoprotein receptor (3N42) site_2 Fred hit 
list, Cluster analysis was performed on docked results, with a root-mean-square 






Number of clusters 
Lowest energy 
cluster poses 
1 -8.8 357.4 8 15 
2 -8.51 581.05 10 23 
3 -7.63 2.57 × 103 14 11 
4 -9.36 138.07 8 30 
5 -9.17 190.7 18 2 
6 -9.98 48.38 8 22 
7 -9.26 163.4 7 23 
8 -8.05 1.25 × 103 5 13 
9 -8.98 262.77 16 15 
10 -9.71 75.78 8 14 
11 -7.83 1.81 × 103 10 12 
12 -7.97 1.44 × 103 9 28 
13 -8.65 454.1 8 2 
14 -8.29 842.46 8 9 
15 -8.53 554.46 5 22 
16 -8.36 741.07 7 23 
17 -9.12 207.45 4 22 
18 -8.16 1.05 × 103 7 28 
19 -8.19 993.62 6 25 
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Table 6.7 Top 5 hits identified for site_2 using the mature glycoprotein receptor 
(3N42), showing the molecular weights, calculated logP (clogP), predicted binding 























































*Calculated using ACDLabs v.12.0 (ACD/Labs, Toronto, Canada). 
#
Numbers of E2 
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Table 6.8 Fred output virtual screening top 20 hits and their target residues, for the 
immature glycoprotein receptor (3N40) site_4. 
Entry Structure H-bonding Other interactions 
1 
 
E1 Val 229 x 2 
E2 Leu 305 
Sigma–π (E2 His 93, x 
2) 
π–sigma (E2 Leu 80)   
2 
 
E2 His 82, Leu 305 π– π (E2 His 93)        
3 
 
 π–sigma (E2 Leu 80)   
4 
 
E2 Gln 300, 




E1 Fusion Loop Phe 87, 
Val 229 
E2 His 82 




E1 Leu 305  
7 
 
E1 Fusion Loop Phe 87 
E2 His 82, His 93 x 2 
π–sigma (E2 Leu 80) 





E1 Val 229 x 2 
E2 Leu 305 x 2 
π–sigma (E2 Leu 80) 
9 
 
E1 Val 229, Gly 227, 
Fusion Loop Phe 87 




E2 His 93 Cation– π (E2 His93) 
π–sigma (E1 fusion 
loop Met88) 
π–π (E1 fusion loop 
Trp 89) 
π–sigma (E2 Leu 80) 
11 
 
E1 Fusion Loop Phe 87 




E2 His 82, Asn 136 π–sigma (E2 Leu 80) 
13 
 
E2 Leu 305, His 82 
E1 Fusion Loop Phe 87 x 
2 
 





Shape Fitting   
15 
 





E1 Fusion Loop Phe 87 x 
2, Gly 227 




E1 Gly 227, Fusion Loo 
Phe 87 x 2 




E2 Leu 305  
19 
 
E1 Fusion Loop Trp 89, 
Fusion Loop Phe 87, Val 
229 
E2 His 93 
π–sigma (E2 Leu 80) 
20 
 
E1 Fusion Loop Trp 89, 
Val 229 
π–sigma (E2 Leu 80) 
π–sigma (E1 fusion 
loop Met 88) 
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Table 6.9 Autodock output for the immature glycoprotein receptor (3N40) site_4 Fred 
hit list, Cluster analysis was performed on docked results, with a root-mean-square 






Number of clusters 
Lowest energy 
cluster poses 
1 -9.47 114.55 8 29 
2 -10.07 41.32 3 44 
3 -11.23 5.91 4 45 
4 -9.78 67.42 16 6 
5 -9.79 66.16 3 23 
6 -11.2 6.19 4 47 
7 -10.03 44.5 4 42 
8 -8.64 465.62 2 49 
9 -8.39 704.34 3 30 
10 -9.64 85.29 6 31 
11 -10.45 21.98 5 42 
12 -9.49 110.32 6 35 
13 -7.31 4.39 × 103 10 23 
14 -10.69 14.49 5 33 
15 -10.15 36.19 5 26 
16 -7.78 2.0 × 103 6 32 
17 -7.61 2.62 × 103 8 15 
18 -11.3 5.18 6 41 
19 -7.42 3.64 × 103 10 17 
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Table 6.10 Top 5 hits identified for site 4 using the immature glycoprotein receptor 
(3N40), showing the molecular weights, calculated logP (clogP), predicted binding 





















































*Calculated using ACDLabs v.12.0 (ACD/Labs, Toronto, Canada). 
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Table 6.11 Fred output virtual screening top 20 hits and their target residues, for the 
mature glycoprotein receptor (3N42) site_4 
Entry Structure H-bonding Other interactions 
1 
 
E2 His 18, His 29  
2 
 
E2 Leu 16, Leu 241 
E1 Fusion Loop 
Trp 89 




E2 Arg 13, Thr 175, 
Leu 16 x 2 
E1 Fusion Loop 
Trp 89 




E1 Fusion Loop 
Phe 87 x 2 
E2 His 18, His 29 




E1 Fusion Loop 
Trp 89 
E2 Arg 13, Leu 16, 
His 18 








E2 Arg 13, His 18, 
His 29 




E2 His 18, Leu 241 
 
π–cation (E2 His 18) 
π–π (E2 His 29) 





E2 Arg 13, Gln 
236, Leu 16, E2 His 
29 





E2 Arg 13 x 2, 




E2 His 18, Leu 241 π–cation (E2 His 18)  
π–π (E2 His 29) 
π–sigma (E2 Leu 16) 
12 
 
E2 Leu 16 
E2 Arg 13  
π–sigma (E1 fusion 
loop Met 88) 
13 
 
E2 Arg 13, Gln 236 π– sigma (E1 fusion 
loop Met 88) 
14 
 
E1 Val 229 x 2 
E2 His 29, Leu 241 
π–sigma (E2 Leu 16) 
π–sigma (E1 fusion 
loop Met 88) 
Cation–π (E2 His29) 
15 
 
E2 His 29, Thr 228 π–cation (E2 His 29) 
16 
 
E2 Arg 13, Leu 
241, Leu 16 
π–sigma (E2 Thr 175) 





E2 Arg 13, Gln 236 π–sigma (E2 Leu 16) 
18 
 
E1 Fusion Loop 
Trp 89 
E2 Leu 241, Leu 16 
π–sigma (E2 Leu 16) 
19 
 
E2 Arg 13 π–sigma (E2 Thr 175) 
π–cation (E2 His 73) 
π–cation (E2 His 29) 
20 
 
E2 Leu 16 π–cation (E2 His 18) 
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Table 6.12 Autodock output for the mature glycoprotein receptor (3N42) site_4 Fred 
hit list, Cluster analysis was performed on docked results, with a root-mean-square 






Number of clusters 
Lowest energy 
cluster poses 
1 -9.62 88.92 13 17 
2 -8.42 678.5 2 45 
3 -9.58 95.8 3 47 
4 -10.25 30.49 5 36 
5 -8.96 270.32 4 37 
6 -8.76 380.09 10 21 
7 -8.78 368.52 4 31 
8 -9.98 48.35 4 43 
9 -9.63 87.87 1 50 
10 -8.54 551.47 1 50 
11 -10.0 46.61 6 39 
12 -7.75 2.09 × 103 2 49 
13 -8.78 366.14 1 50 
14 -9.48 112.05 7 23 
15 -10.91 10.03 3 43 
16 -7.87 1.72 × 103 4 38 
17 -7.32 4.29 × 103 1 50 
18 -7.51 3.13 × 103 2 2 
19 -9.88 57.61 2 42 
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Table 6.13 Top 5 hits identified for site 4 using the mature glycoprotein receptor 
(3N42), showing the molecular weights, calculated logP (clogP), predicted binding 





















































*Calculated using ACDLabs v.12.0 (ACD/Labs, Toronto, Canada). 
#
Numbers of E2 
residues in the mature form are different than the corresponding residues in the 
immature form. 
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6.3 Analysis of the docking calculations 
The essential role of the CHIKV envelope protein in the fusion process, its location on 
the surface of the mature virus (spikes) and the availability of the crystal structures 
make it a suitable target for structure-based drug design. The CHIKV glycoprotein 
exists in two forms, the immature form and the mature form. The immature form 
represents the early stages of the envelope protein after the replication cycle, translated 
in the endoplasmic reticulum and processed in the Golgi for maturation, moved to the 
plasma membrane, where it is cleaved by furin-like protease activity in the host infected 
cell into E2 and E3.
42
 The furin cleavage occurs at the furin loop, which represents the 
junction between E2-E3. The difference between the two crystal structures is the 
removal of the furin susceptible peptide motif that resulted in slight changes in the 
volumes of the predicted binding sites. We searched for possible binding sites within 
both the immature and the mature crystal structures. Six common sites were detected in 
both structures (Table 1). Among the detected sites, site 2 (the light green colour in 
Figure 6.2) and site 4 (the blue colour in Figure 6.2) were interesting. Site 2 represents a 
surface cavity that lies between the E1 domain II and E2 β–ribbon that connects E2 
domain A to E2 domain C; it also extends downwards as a channel between E1 domain 
II and E2 domain A. E2 domains A and B move relative to each other in the pre- and 
post-fusion structures. Therefore, small molecules that bind to this site may stabilize the 
E1-E2 heterodimer and prevent their dissociation during the fusion process. Another 
hypothesis is that it may also stabilize the orientation of E2 domain A with respect to 
domain B in a way that inhibits the exposure of the fusion peptide in conditions of low 
pH in the endosome, preventing the fusion process. Moreover, being a groove in this 
area looking like the enzyme mouth (Figure 6.4), bound small molecules in this site 
might act as indirect allosteric inhibitors for the furin susceptible peptide motif, and 
therefore, might impair the cleavage step by the furin proteases. The indirect allosteric 
inhibition mechanism might be through the inhibition of the interaction between the 
CHIKV envelope protein, and hence the furin susceptible motif (furin loop), and the 
acting protease (therefore, the Life Chemicals protein-protein inhibitors library was 
used here), or through trapping the glycoprotein conformation in one inactive form 
(relative to the furin cleavage step), which does not interact with the acting proteases. 
The site 2 volume in the immature form is 9.5% bigger than that in the mature form. 
Chapter 6  CHIKV Envelope 
174  
 
Therefore, both structures were included in the virtual screening study in an attempt to 
find positive hits for this site.  
 
Figure 6.4 Surface representation of the location of site 2 (green), parts of E2 and E3 
are shown in orange where the furin loop takes a greyish orange at the top, E1 domain II 
surface is shown in grey. Site 2 is located in a mouth like cavity that might interact 




 Site 2 makes close contact with residues from E1 and E2. The E1 residues are: 
Glu50-Val60, Val229-Pro237; the E2 residues are: Ala97-Arg102 (corresponds to 
Ala33-Arg38 in the mature form), Gln300-Arg308 (Gln236-Arg244 in the mature 
form). Hydrogen bonding within these residues involve E1 Lys52, Thr53, Ile55, 
Val231, His230, and E2 Tyr301 (Tyr237 in the mature form), Glu232 (Glu168 in the 
mature form), and Arg100 (Arg36 in the mature form). Val54, Lys52, Arg100, Ile167 
are able to form other types of strong noncovalent molecular interactions. Generally, 
valine, alanine and proline amino acids within this pocket are also able to participate in 
the hydrophobic interactions.   
Surprisingly, we could not find a common hit ligand that fits in site 2 in both the 
immature and the mature forms. However, inspection of the top 5 docked poses in each 
site reveals that they have the common sequence: heterocycle-S-CH2-CO-N, the amidic 
nitrogen in this sequence might be NH, and also can be a part of another ring system. 
Figure 6.5 shows the 2D representations of the top docked poses in site 2 for both the 
immature and the mature forms of the envelope glycoproteins. The presence of an 
electron rich system results in strong noncovalent molecular interactions such as the π-
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cation interaction with E2 Arg100 (Arg36 in the mature form) and with E1 Lys52. The 
heterocyclic ring adjacent to the sulphur in most of the top ranked poses can accept H-
bonding with E1 Lys52, Ile55, and Thr53. Being able to bind to residues in both E1 and 
E2, the ligands identified for this site are most likely to confirm our hypothesis and 
stabilize the E1-E2 heterodimer and prevent the dissociation. 
 
Figure 6.5 2D representation of the docked poses within the binding site 2. (a) Top 
ranked pose (number 1 in Table 6.4) within the immature glycoprotein complex site 2. 
(b) Top ranked pose (number 1 in Table 6.7) within the mature glycoprotein binding 
site 2. H-bonds are shown in green and blue dashes, while π interactions are shown as 
orange lines. 
 
Site 4 (blue colour in Figure 6.2) can be described as a narrow channel 
extending just behind the fusion loop and surrounded by both E2 domains A and B. 
Comparison between the two sites in the immature and the mature forms indicates that 
the site volume is 31.3% bigger in the mature form (Figure 6.2), and looks like an 
umbrella above this site in the immature form. Small molecules binding to this narrow 
channel will have significant effects; this might not only freeze the relative movement 
of E2 domains A and B, but might also freeze the fusion loop through stabilizing 
interactions, and consequently, prevent the exposure of the fusion loop. The fusion loop 
is stabilized by the histidine residues of E2, which act as the pH sensors for the 
activation of the fusion protein at lower pH.
95
 This site cavity lies in contact with 
several histidine residues of E2. Therefore, blocking this site may also impair the pH 
sensor activation mechanism. All the identified hits were found to bind to both E1 and 
E2 residues, involving the histidine residues of E2, moreover, two hits were found to 
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bind to the fusion loop amino acids, confirming the ability of freezing the fusigenic 
activity of the envelope proteins. 
 Site 4 forms close contact with the E1 fusion loop residues Pro86-Gly91, E1 
Gly227-His230. The fusion loop Gly91 and His230 (outside of the fusion sequence) 
were found to be critical for the fusion.
96
 This emphasizes the importance of our 
hypothesis that binding to this site will impair the fusion process. From E2, residues 
Arg77-His82 (Arg13-His18 in the mature form), Ser91-Val96 (Ser27-Val32 in the 
mature form) and residues Leu305-Ala310 (Leu241-Ala246 in the mature form) form 
close contacts with the binding site. 
 Interestingly, a common hit ligand was found in both the blue sites (ranked 5 in 
Table 6.10, and ranked 2 in Table 6.13). It shows the same interactions within the two 
binding pockets and more importantly, it forms two H-bonds (5.4, 6.3 Å) with E1 fusion 
loop amino acid Phe87 backbone carbonyl, three amino acids away from Gly91, the 
critical
96
 residue for the fusion process. It also binds to E2 His82, His93 (His18, His29 
in the mature form) via H-bonding and π-cation interactions (Figure 6.6). Moreover, the 
predicated binding affinity and inhibitory constant (Ki, in the nano molar range), along 
with the acceptable clogP value of 1.8 (Tables 6.10, 6.13), make it a very attractive 








Figure 6.6 3D representation of the predicted docking pose of compound 2 (Table 6.13) 
within site 4 binding pocket (transparent surface) of the mature chikungunya envelope 
protein showing the H-bonding (green dashes) with the fusion loop amino acid Phe87 
(shown in orange colour). 
 
A further interesting observation is the presence of same chiral skeleton; the (S)-
1-(2-hydroxy-3-phenoxypropyl)-4-phenylpiperazin-1-ium in a series of compounds (1, 
2 and 3 in Table 6.10) and (3, 4 in Table 6.13). The compounds only differ in the 
substituents on the terminal phenyl rings. The chirality of this series indicates the 
selectivity of the compounds and reflects the importance of the stereochemistry in 
designing inhibitors for this site. The enantiomers of these compounds (within the 
library) did not pass the first FRED virtual screening. Within the immature narrow 
binding pocket (site 4), these series were able to form H-bonds with the E1 Val229, E2 
His82, E2 Leu305. However, in case of the 31.3% bigger pocket of the mature site 4, 
this series was able to achieve the H-bonding with E1 Val229, E2 His29 whereas it 
failed to form H-bonds with the E2 Leu241, but was still able to achieve the π stacking 
interaction with E2 His18 and His29 (Figure 6.7). The importance of this stereo-
selectivity in inhibiting the envelope protein, was also noticed recently in the inhibitors 
of the dengue virus envelope proteins mediated fusion, where compounds with certain 
stereochemistry of the OH group (the (S) enantiomers) were shown to have 
stereospecific effects on the activities.
237
 The importance of the (S) configuration of the 
compounds (Figure 6.7) can be related to the ability of the OH groups of the compounds 
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to achieve H-bonds with the E2 histidine residues (His82 of the immature form and 
His29 of the mature form), whereas these H-bonds might not be possible with the other 
enantiomers. Superimposition of the two compounds (number 1 in Table 6.10 and 
number 3 in Table 6.13) within the binding pockets (site 4 in both enzyme forms) 
revealed the positioning of the docked poses in a similar way with slight changes in the 
orientation of the hydroxyl groups and the central piperazinium moiety (Figure 6.8). It 
is also clear that the chlorine atoms seem not essential for interactions. This 
superimposition not only indicates the reliability of the interactions of this class of 
compounds with the residues within this site in the two forms of the enzyme, but also 
confirms our hypothesis that this series might be developed as selective CHIKV 
envelope protein inhibitors. 
Figure 6.7 2D representation of the docked poses within the binding site 4. (a) Top ranked 
pose (number 1 in Table 6.10) within the immature glycoprotein complex site 4. (b) Top 
ranked pose (number 3 in Table 6.13) within the mature glycoprotein binding site 4. H-








Figure 6.8 Superimposition of compound 1 (in Table 6.10) within the immature 
glycoprotein site 4 (compound and residues are shown in violet colour) and compound 3 
(in Table 6.13) within the mature glycoprotein binding site 4 (compound and pocket 
residues are shown in green colour). Slight differences can be observed for the orientation 
of the hydroxyl groups and the central piperazinium ring. 
 
Although ranked 5 in Table 6.13, this ligand shows extraordinary H-bonding 
(2.41 Å) with the fusion peptide amino acid Trp89 backbone (Figure 6.9), just one 
amino acid away from Gly91, the critical
96
 amino acid for the fusion process, The pose 
is also stabilized inside the pocket by the interactions with the E2 His18, His29 and 
Leu16 (Table 6.13). This also emphasizes the possibility of inhibiting the fusion process 
through designing ligands for this pocket.  




Figure 6.9 Pose 5 (Table 6.13) within the mature glycoprotein binding site 4, showing 
the 2.4 Å H-bond interaction (yellow line) with Trp89. Gly91 is shown in orange. 
 
6.4. Concluding remarks  
Thus far, the CHIKV envelope protein has not been investigated as a possible target for 
the drug design against the virus. Therefore, we have investigated for the first time the 
possible binding target sites within the immature and the mature forms of the CHIKV 
envelope proteins. We managed to identify two sites that look critical to the protein 
functions; mainly the fusion process, based on the functionality and the location of the 
sites. A virtual screening search was performed on the two sites in both forms of the 
enzymes to increase the chances of finding reliable positive hits. Five hits for each site 
in both forms of the CHIKV envelope proteins were identified revealing some 
important features for further developing antagonists for these proteins. To test our 
hypothesis, the identified hits need to be evaluated against the CHIKV, which is 
currently under investigation. Our study represents a good template for designing 
selective inhibitors for the chikungunya virus envelope proteins via in silico and in vitro 
optimization process. This developed computer model can be further used for screening 
larger database libraries such as the FDA approved drugs libraries that would facilitate 
the identification of effective therapies against the CHIKV. Our hypothesis might also 
be a useful tool for inhibiting other alphaviruses such as Sindbis virus and Semliki 
Forest virus as well as other fusion mediated viruses. 
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CHAPTER 7: New Leads for African Trypanosomiasis  
 
7.1. Introduction 
Trypanosoma brucei gambiense and T. b. rhodesiense are the causative agents of the 
Human African Trypanosomiasis (HAT), also known as sleeping sickness. Anothere 
neglected disease as the Chikungunya virus, the major topic of this thesis. Trypanosoma 
brucei rhodesiense is found in Eastern and Southern Africa, whereas Trypanosoma 
brucei gambiense occurs in Western and Central Africa and is responsible for over 90% 
of all reported cases of infection.
238
 This disease threatens about 60 million people 
living in sub-Saharan Africa and causes an estimated 25,000 deaths per year.
239
  It has a 
major impact on the affected nations causing suffering and poverty and if left untreated, 
the disease is usually fatal.
240
 The lack of full-scale screening programmes and poor 
diagnostic tools has led to under-reporting of cases, which is likely to be at least 
threefold higher than the measured value.
241
 
Both subspecies are transmitted by the bite of the infected tsetse fly. T. b. 
gambiense HAT is primarily a chronic human disease whereas T. b. rhodesiense HAT is 
primarily zoonotic with a huge animal reservoir, causing the acute form of sleeping 
sickness. After the bite, the parasite starts to multiply in the blood (phase I, febrile 
illness with flu-like symptoms, which can last for several weeks or months). During this 
phase, the parasite lives within the bloodstream and subsequently migrates to other 
areas of the human body, such as the lymph nodes, spleen, and spinal fluid, causing 
symptoms similar to those caused by malaria (rash, fever, shaking chills, body aches, 
and general fatigue). If phase I is left untreated, the parasite then crosses the blood brain 
barrier attacking the central nervous system (phase II) and neurological symptoms start 
to appear, causing progressive mental deterioration, sleep disturbances, long lasting 




Unfortunately, vaccines are not available for this disease. The unavailability of 
vaccines is mainly due to the high degree of antigenic variation expressed by the 
glycoprotein forming their surface coat.
243
 Therefore, the main defence against the 
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parasite would be chemotherapeutics. The treatment options are limited with only few 
drugs available. The four registered drugs to treat HAT, are suramin 152 and 
pentamidine 153 for early stage infections, whereas melarsoprol 154 (contains arsenic) 
and eflornithine 155 are for the late-stage treatment (Figure 7.1).
244,245
 All these drugs 
were developed approximately 30 years ago and suffer high toxicity, the emergence of 
resistance and lack of efficacy. Melarsoprol 154 is the most toxic and causes reactive 




Figure 7.1 Older generation of African sleeping sickness treatment drugs.   
 
Recently, there has been some progress in the treatment of HAT,
247
 with the 
nifurtimox 156−eflornithine 155 (Figure 7.1) combination (NECT) chemotherapy 
developed to reduce resistance frequency.
248,249
 However, these options are still under 
investigation due to inactivity against some trypanosome species or phases of the 




Other trypanocidal agents that are active against the first stage of HAT and are 
orally bioavailable are pafuramidine 157
252
 and fexinidazole 158
253
 (Figure 7.2). 
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Although it was used in phase III clinical trials in 2007, pafuramidine 157 use was 
terminated in 2008 because of hepatic toxicity. More recently, the novel boron-
containing molecule 159 (Figure 7.2) emerged as an orally active drug candidate that 
completed preclinical studies in 2011.
254
 It showed promising activity against the blood 
and the brain parasite. The mechanism by which compound 159 acts as a trypanocidal 
agent is still unknown. It entered phase I clinical trials in France in 2012 for evaluation 
against phase 1 and phase 2 HAT. The present treatment options indicate that new 





Figure 7.2 New generation of African sleeping sickness treatment promising agents.   
 
High throughput screening (HTS) is one approach that can be used to identify 
new lead compounds for such neglected diseases. Therefore, in a previous work,
256
 the 
HTS library of 87,926 compounds (WEHI 2003)
256
 was tested against the related 
trypanosome subspecies, Trypanosoma b. brucei and against a mammalian cell line 
HEK293, to determine a selectivity index for each compound. Cluster analysis, 
considering chemical alerts such as toxicophores, the likelihood of CNS penetration, 
and drug-like structural features yielded a subset of twelve compounds as promising 
medicinal chemistry starting points for drug development. A consortium of Australian 
medicinal chemists was formed among different Australian universities, to optimize the 
obtained hits, and some of these hits were introduced to our group for optimization.  
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This chapter discusses the synthesis and anti-trypanocidal activity of new 
analogues for the bis-sulfonamide hit, WEHI-1203255 (160, Figure 7.3), which showed 
an IC50 1.3 µM, with a selectivity index (SI) of >32. This hit compound 160 has 
excellent physiochemical properties, good calculated aqueous solubility of 100 µM, an 
acceptable polar surface area of 84 Å
2
, and an acceptable CLogP value
231
 of 2.5. The 
analogues were synthesized and tested for their ability to inhibit the growth of T. brucei 
limiting the changes to the two sulfonamide moieties to study the preliminary structure 
activity analysis. The cytotoxicity profiles of the compounds were evaluated using 
(HEK293) cell line and selectivity index was estimated for each analogue. The SI of the 
compounds was determined where possible by directly comparing the IC50 values from 
the T. b. brucei and (HEK 293) assay. If this was not possible, an estimated IC50 value 
was calculated by comparing the dose at which the compound was active >50% in the 
T. b. brucei assay and the highest dose at which there was no activity (<50%) in the 
(HEK 293) assay.  
 
Figure 7.3 Lead compound 160 (WEHI 1203255), IC50= 1.3 µM. 
 
7.2. Results and discussion 
7.2.1. Synthesis of the bis-sulfonamide analogues 
The retro-synthetic analysis of the lead compound 160 (Figure 7.4) revealed that 
it could be accessed through three facile synthetic steps: the sulfonation of the 
commercially available 7-nitrotetrahydroquinoline 161, followed by the reduction of the 
nitro group to afford the aminotetrahydroquinoline 163. A second sulfonation of the 
amino group would result in the final bis-sulfonamide compound 160 (Figure 7.4). This 
strategy enabled us to access 26 separate derivatives in a short timeframe, reliable yields 
and at reasonable cost. 




Figure 7.4 The retro-synthesis analysis for the access of the lead compound 160. 
 
The first step in the synthetic pathway was the sulfonation of the secondary 
amine of commercially available 7-nitrotetrahydroquinoline 161 using the appropriate 
sulfonyl chloride. The reaction (Scheme 7.1) was initially attempted using CH2CH2 as a 
solvent in the presence of TEA as a base and stirring the reaction mixture at room 
temperature for 24 h, however, the yields of the isolated compounds were less than 
40%, with the remaining being un-reacted starting 7-nitrotetrahydroquinoline 161. 
Pyridine behaves as a better solvent and a stronger base for the tetrahydroquinoline 
sulfonation,
257,258
 and was therefore used throughout in this reaction. Therefore, the 7-
nitrotetrahydroquinoline 161 was dissolved in anhydrous pyridine, and the mixture was 
then stirred at 0 ºC. The appropriate sulfonyl chloride (liquid) was then added dropwise 
and the mixture was stirred for 24 h (Scheme 7.1). The reaction mixture was then 
quenched with cold water, after which the resultant oil or solid was extracted using 
ethyl acetate. Column chromatography afforded the desired sulfonamides 162, 164-166 
in 70-88% yield. Analysis of the 
1
H NMR spectrum of 1-(ethylsulfonyl)-7-nitro-1,2,3,4-
tetrahydroquinoline 162 showed quartet peak integrating for two protons and resonating 
at 3.22 ppm, and another triplet peak, integrating three protons, resonating at 2.95 ppm. 
These peaks were assigned to the ethyl CH2 and CH3 groups, respectively. Analysis of 
the EI-MS spectrum of 162 showed a peak at 270 m/z corresponding to the molecular 
ion (M+). 




Scheme 7.1 Sulfonation of the tetrahydroquinoline 161 to afford intermediates 162-165. 
 
The nitro group of the sulfonamides 162, 164-166 was then reduced, initially 
using the reduction methodology developed in our lab, where the sulfonamides 162, 
164-166 were dissolved in a mixture of acetic acid, ethanol and water in the presence of 
iron powder as a catalyst, with sonication at 30 ºC,
209
 however, under these conditions, 
yields of the reduced products were under 50%. Therefore the Raney nickel catalysed 
reduction was performed by dissolving the nitro derivatives in methanol, followed by 
the addition of Raney Nickel (as a suspension in water) under a N2 atmosphere. The 
mixture was then vigorously stirred (Scheme 7.2) and hydrazine monohydrate, as a 
hydrogen source, dissolved in methanol was then added dropwise resulting in the 
production of H2 gas. After the H2 gas evolution ceased, the mixture was heated at 
reflux, filtered hot through celite, and the methanol and excess hydrazine hydrate were 
removed, affording the aniline derivatives 163, 167-169 in 80-90% yields, which were 
easily purified by recrystallization from either methanol or toluene. Analysis of the EI-
MS spectrum of 7-amino-1-(ethylsulfonyl)-1,2,3,4-tetrahydroquinoline 163 showed a 
peak at 240 m/z which was assigned for the molecular ion (M+). Analysis of the 
1
H 
NMR spectrum of 163 showed a broad singlet peak resonating at 3.62 ppm that was 
assigned for the NH2.  




Scheme 7.2 Reduction of the nitrotetrahydroquinolines 162, 164-166. 
 
The amino groups in the sulfonamides 163, 167-169 were then reacted with the 
appropriate sulfonyl chloride (the second sulfonation) in pyridine at room temperature 
(Scheme 7.3). After aqueous workup, extraction, washing with HCl and evaporation of 
the solvents, the bis-sulfonamides compounds 160 and 170-194 were isolated and were 
purified using column chromatography to afford the final analogues in 70-80% yield. 
Analysis of the EI-MS spectrum of N-(1-(ethylsulfonyl)-1,2,3,4-tetrahydroquinolin-7-
yl)-2-fluorobenzenesulfonamide 160 showed a peak at 398 m/z that was assigned as the 
molecular ion (M+). Analysis of the 
13
C NMR spectrum of 160 showed a doublet peak 
at 159.6 ppm (J = 254.9 Hz) that was assigned to the carbon attached to the F atom 
(compound 160, Figure 7.4). HPLC analysis of these bis-sulfonamides showed a purity 
range > 95% for all the synthesized derivatives.  
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7.2.2. Trypanocidal activity and structure activity relationship (SAR) 
The results for the testing against Trypanosoma b. brucei, the calculated ClogP and the 
selectivity index are listed in Table 7.1. The initial activity was screening at 1 µM and 
10 µM and derivatives that showed significant activity were then tested to obtain the 
IC50 values. The first series of derivatives examined the changes in the aromatic sulfonyl 
moiety where the lead compound 160 has a fluorine atom in the ortho position. This 
lead compound was also resynthesised and tested with IC50/SI= 4.1/>20, confirming the 
initial activity results from the (WEHI 2003) compounds library. Changing the ortho-
fluoro substituent to the para (compound 170) and meta (compound 171) positions, did 
not improve the activity where the IC50/SI profile was 7.8 µM/>10 for both derivatives, 
indicating decreased trypanocidal activity and increased toxicity. Increasing the number 
of the fluorine atoms had a negative effect on the activity, where the addition of a 
second fluoro substituent into the adjacent ortho position (compound 172) resulted in a 
decreased activity (82% activity at 10 µM) as did the presence of five fluoro 
substituents (compound 173, 40% activity at 1 µM). This implied the importance of the 
mono-fluoro atom only in the ortho position, with no advantages with the presence of 
the extra fluorine atoms. 
The fluorine atom is the smallest halogen size, therefore, it was interesting to 
test the presence of other halogen atoms. The addition of a bromo substituent at the 
para position (compound 174) resulted in increased toxicity and did not improve the 
activity (IC50/SI= 9.9 µM/>8).  
Replacing the benzene moiety with its bioisostere thiophene
259,260
 (compound 
175) resulted in a similar activity (IC50/SI= 4.0 µM/>20) compared to the lead 160. The 
same activity profile of 160 and the simpler 175 might be attributed to the lipophilic 
nature thiophene ring in 175 that might have the same effect as the fluorine atom in 160. 
The addition of another halogen to this thiophene (Br, compound 176) showed 
improved trypanocidal activity (IC50/SI= 2.6 µM/>7), however, the selectivity index 
value was reduced compared to the unsubstituted thiophene analogue 175. Interestingly, 
replacement of the bulky bromo substituent in 176 by a chloro substituent (compound 
177) was not tolerated, as the activity decreased (IC50/SI= 13.1 µM/>6). The activity of 
177 was 3 fold less than that of 175 and 5 fold less than that of 176. 














Mwt ClogP* IC50 (µM) S.I. 
160  
 
398.47 2.48±0.82 4.1±0.643 20.2 
170  
 
398.47 2.98±0.82 7.8±2.695 10.7 
171  
 
398.47 3.09±0.82 7.8±2.155 10.6 
172  
 
416.46 2.33±0.87 82% @ 10 µM 
173  
 
470.43 3.37±1.07 40% @ 1 µM 
174  
 
477.36 3.50±0.88 9.9±3.319 8.4 
175  
 
386.50 2.27±0.79 4.0±0.625 20.5 
176  
 
465.40 3.49±0.87 2.6±2.573 >7 
177  
 
420.95 3.28±0.88 13.1±4.344 6.3 
178  
 
394.50 3.13±0.77 3.4±0.910 24.4 
179   
332.43 1.57±0.76 IN - 





386.41 2.82±0.96 IN - 
181  
 
408.53 3.66±0.77 4.7 >18 
182  
 
436.58 4.54±0.77 3.9 >22 
183  
 
470.60 4.85±0.79 13.0 >6.6 
184  
 
412.49 3.01±0.82 10.0 >8 
185  
 
400.53 2.80±0.79 IN - 
186  
 
408.53 3.66±0.77 IN - 
187  
 
408.53 3.66±0.77 IN - 
188  
 
422.56 4.12±0.77 16.0 >5 
189  
 
422.56 4.12±0.77 IN - 
190  
 
464.64 5.50±0.78 11.4 >7 
191 
  
440.57 2.26±0.83 IN - 
192 
  
448.57 3.12±0.81 3.1±0.893 2.45 





448.57 3.12±0.81 7.6±2.552 1.5 
194 
  
456.57 3.99±0.79 3.9±0.887 1.9 
*Calculated using ACDLabs v.12.0 (ACD/Labs, Toronto, Canada). 
 
Replacing the aromatic moiety with aliphatic chains as in compounds 179 and 
180 completely abolished the activity which indicates the importance of the aromatic 
ring in that position for the trypanocidal activity. The π system of the aromatic ring may 
be involved in the interaction site, whereas with aliphatic side chains, such interactions 
don’t exist. Interestingly, the introduction of a small hydrophobe such as a methyl group 
on the para position on the phenyl ring of the aromatic sulfonyl moiety (compound 178) 
improved the activity slightly (IC50/SI= 3.4 µM/>24), mostly due to the increased 
difference between the effective and toxic concentrations compared to 160. As the mode 
of action and the target of the compounds are not yet known, the role of this hydrophobe 
methyl group cannot be confirmed, however, it might be involved in a hydrophobic 
interaction within the target site.  
Addition of another hydrophobe (a methyl group) on the ethyl side chain of the 
other sulfonyl group (second changeable moiety) as in compound 181, was also 
tolerated (IC50/SI= 4.7 µM/>18) where no significant difference in the activity 
compared to 178 was observed with a  slight narrowing of the selectivity index 
compared to 178. In the case of compound 185, this extra hydrophobe on the ethyl side 
chain was not tolerated and activity dropped. When the p-tolyl group of 181 was 
replaced by a thiophene ring (compound 185), the activity was completely abolished 
due to this extra hydrophobic methyl (the propyl aliphatic group), compared to 175. 
The para position of the methyl hydrophobe in 181 was important for activity as 
can be indicated by the inactivity of compounds 186 (ortho position) and 187 (meta 
position). The weak activity of 188 and 190 and inactivity of 189 (no p-methyl group) 
also gives indications about the importance of the para position, with no advantages 
with the presence of the extra hydrophobic methyl groups. Figure 7.5 shows the SAR 
for this series of bis-sulfonamides. 




Figure 7.5 Structure activity relationship for the bis-sulfonamides. 
 
Addition of the hydrophobic methyl groups on either the ethyl side chain or on 
the aromatic sulfonyl moieties seemed to act as a tuner for the activity. Compound 185 
was completely inactive whereas compound 184 showed similar activity (IC50/SI= 3.1 
µM/>8) compared to the lead 160, with a narrowing in the selectivity index observed. 
Increasing the bulkiness of compound 181 to 182 (replacing the small methyl 
hydrophobe with the more bulky isopropyl group) resulted in an improved activity 
profile and decreased the toxicity (IC50/SI= 3.9 µM/>22). Increasing the bulkiness by 
replacing the isopropyl in 182 by a phenyl ring (compound 183) decreased the activity 
(IC50/SI= 13 µM/>7) by 3 fold compared to 182, but did not completely abolish the 
activity. This difference can be attributed to the difference of the electronic effect; the 
methyl and isopropyl group have a positive inductive effect on the benzene ring while 
the phenyl ring at the para position has a negative inductive effect. This also confirms 
that the π system of the aromatic ring (directly attached to the sulphonamide group) 
might be involved in the activity. 
When the aliphatic sulfonyl side chain (sulfonyl group attached to the 
tetrahydroquinoline N) was replaced with aromatic ring, the activity was either 
completely abolished as in case of compound 191 or toxicity was increased as in 
compounds 192-194. Interestingly, compound 192 carrying the para methyl group was 
the best in this series (IC50/SI= 3.1 µM/>2), confirming the importance of the para 
Chapter 7  African Sleeping Sickness 
193  
 
position on this aromatic moiety. The aliphatic sulfonyl groups directly attached to the 
tetrahydroquinoline ring is important for activity rather than an aromatic replacment. 
7.3. Concluding remarks 
In this chapter, we synthesized 26 bis-sulfonamide analogues of the lead compound 
160, which had good physiochemical properties and was discovered during the high 
throughput screening (HTS) of the WEHI 2003 library of 87,926 compounds. The 
analogues were accessed through three facile synthetic steps. Some of the analogues 
displayed good activity profile ranging from 2 to 4 µM. The preliminary structure 
activity relationship revealed that the presence of an aliphatic side chain on the 
tetrahydroquinoline 160 is important for activity and should not be replaced by aromatic 
groups. The second sulfonation of the amino group of the sulfonated 
tetrahydroquinoline 166-169 must be with aromatic sulfonyl groups, as when aliphatic 
groups were used, activity was completely abolished. The bis-sulfonamide 176 with the 
bromo-thiophene group, displayed IC50 value of 2.6 µM with a selectivity index >7. The 
para position of the aromatic ring on the bis-sulfonamides 178, was found to be critical 
for tuning the activity, where the activity changed with changing the size of the 
hydrophobe substituents in that position. Small hydrophobe groups were favoured over 
the bulky aromatic groups in that para position. Therefore, this position should be 
investigated more with a variety of possible substitutions. The target site and mode of 
action of the bis-sulfonamides are still yet unknown, and need further investigations.  
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CHAPTER 8: Conclusions and Future Directions  
 
8.1. Chapter 2: The Search for Anti-CHIKV Lead Compounds 
8.1.1. Conclusions  
The modifications in the AAPM series (Figure 8.1) were advantageous in decreasing the 
steric hindrance around the exchangeable chloro substituent, and also in simplification 
of the synthetic steps required throughout the synthesis. The alkene 63, with the less 
hindered cyclopropyl group, represents the most promising alkene to perform more 
amination reactions under moderate conditions, as can be indicated by the formation of 
the morpholine analogue 77. 
 
Figure 8.1 Modifications of the AAPM series by simplification and decreasing the 
steric hindrance.  
  
Different conditions were investigated to synthesize the AAPM with the amines 
33 or 47, however, all attempts failed due to the polymerization of 33 and the 
decomposition of 47 under the reaction conditions. The degradation of 47 was observed 
during the attempted synthesis of 65 (Figure 8.2) where the amine 66 peak was 
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observed in the mass analysis. Furthermore, during the synthesis of 72, the amine 47 is 
believed to decompose providing the hydrogen source for the reduction reaction to 
occur giving the NH2 group in 72 (Figure 8.2). 
 
Figure 8.2 The un-synthesized AAPM 65, the decomposition product 66 and compound 
72 that was produced in a reaction with the amine 47. 
 
8.1.2. Future directions  
Some alternative access routes to the AAPM derivatives are to be considered. The 
synthesized new furopyrimidine 42 can be considered for the amination reaction with 
the original pyrimidine core, as it is less stericaly hindered. The furan ring can then be 
open using POCl3
160
  to give the final aminated products (Scheme 8.1). 
 




Scheme 8.1 Alternative synthesis of the AAPM series using the furopyrimidine 42 
intermediate. 
 
 Using the pyridine core, an alternative synthesis method to access the AAPM 
derivatives can be investigated (Scheme 8.2).  The suggested synthesis starts with the 
reaction of the aminopyridine 196 with the amino-acid chloride 197 to afford the amide 
198. Subsequent addition reaction with the ketone 38 using n-BuLi and N,N,N′,N′-





 at -70 ºC would afford the alcohol 199. 
Finally, a dehydration reaction would afford the alkene 200 as the AAPM derivative. 
 
Scheme 8.2 An alternative synthetic route for the AAPM derivatives starting from 
aminopyridine 196. 
 
8.2. Chapter 3: The CHIKV nsP3 
8.2.1. Conclusions  
The CHIKV nsP3 protein represents an attractive target for developing selective 
inhibitors for the virus. This was illustrated by the virtual screening of the NCI set 
library of 1990 compounds, using the available crystal structure of the macro domain of 
the nsP3. The hits that achieved higher scores than the co-crystallized ligand (ADP-
ribose) were selected for further refining using a second round of docking and scoring. 
This resulted in 7 hits that scored higher than the co-crystallized ligand. Pose_3 (Figure 
8.3) was in silico optimized giving pose_3_2, which achieved higher scoring and 
improved interactions inside the nsP3 macro domain binding pocket. The optimized 
pose_3_2 also has improved drug-like qualities and fits more to Lipinski’s guidelines.
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The optimized hit was the accessed through three facile chemical synthesis steps. The 
compounds are still under antiviral evaluations and the accuracy of the model 
predictions would depend on the biological activity of the compounds. 




Figure 8.3 The virtual screening hit pose_3 that was in silico optimized and 
synthesized. 
 
8.2.2. Future directions  
The parallel virtual screening, in silico optimization and in vitro evaluation of the 
obtained hits, would be an applicable structure-based approach for the drug design of 
selective inhibitors for the CHIKV. Molecular dynamic simulation would also help in 
optimizing the developed computer model, assisting in obtaining more reliable hits. 
 Based on the in vitro activity of the compounds, the retro-synthesis analyses can 
be investigated for the active hits, allowing the generation of more analogues which 
would represent good templates for the discovery of a lead compound, and developing 
the medicinal chemistry against the CHIKV. 
 
8.3. Chapter 4: Mycophenolic acid analogues 
8.3.1. Conclusions 
A series of benzolactone-acid conjugates 114-117, benzolactone-tetrazole conjugates 
126, 127, 130, 131 and isatin-acid conjugates 140-143 was synthesized as 
Chapter 8  Conclusions & Future Directions 
199  
 
mycophenolic acid analogues as inhibitors for the CHIKV (Figure 8.4). Two side 
products were obtained; the β-lactam ring structure and the open β-lactam product. All 
the synthesized analogues have drug-like qualities. The access to the isatin-tetrazole 
conjugates was attempted using the cycloaddition reaction with NaN3, however, no 
compounds were obtained due to the reactivity of the isatin core which is believed to 
interfere with the tetrazole ring formation reaction. 
 
Figure 8.4 Mycophenolic acid derivatives, the coloured features represent the main 
moieties used in the analogues design.  
 
8.3.2. Future directions  
The access to the isatin-tetrazole conjugates could be achieved through the Suzuki 
coupling with potassium 5-((3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-
yl)phenoxy)methyl)tetrazol-1-ide 129. The synthesized conjugates are currently under 
anti-chikungunya evaluation, and based on the derived structure activity relationship, 
further medicinal chemistry derivatisation could be achieved such as formation of esters 
or amides as prodrugs.    
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 The analogues were designed as mycophenolic acid analogues and are assumed 
to inhibit the IMPDH enzyme. Therefore, it would be interesting to evaluate these 
analogues as inhibitors for this enzyme in specific enzyme inhibition tests. Furthermore, 
a number of crystal structures of the IMPDH enzymes with mycophenolic acid are 
available within the protein data bank. Therefore, the ability of the analogues to bind to 
the active site of the enzyme could be in silico evaluated, giving more impact to the 
rational drug design of this series of compounds as spicific enzyme inhibitors. 
 
8.4. Chapter 5: The CHIKV nsP2  
8.4.1. Conclusions 
The CHIKV protease (nsP2) is critical for the viral replication cycle and therefore, 
represents an attractive target for drug design. The druggable binding pockets within the 
nsP2 crystal structure were investigated where two hydrophobic pockets were observed, 
one within the protease C domain and one within the N domain (Figure 8.5). A 
computer virtual screening model was developed combining two virtual screening 
algorithms, FRED and Autodock. The model was used to screen a library of protease 
inhibitors within the two domains and resulted in favoured hit list for each pocket.  
Domain C pocket 
 
Domain N pocket 
 
Figure 8.5 The druggable pockets within the CHIKV nsP2. 
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 Within domain C druggable site, Lys1239 (from domain C) and Lys1045 (from 
domain N) were found to interact with most of the identified ligands, stabilizing them 
within the U-shaped pocket, blocking the protease function. Within domain N pocket, 
Trp1084 and Lys1091 were found to be interacting with all of the docked ligands, with 
the possibility for interaction with the C domain Gln1241. Ligands for this pocket 
would block the enzyme NTPase/RTPase functions, and might act as allosteric 
inhibitors for the domain C protease site. 
 
8.4.2. Future directions  
The anti-CHIKV evaluation of the identified hits is still ongoing. The results of these 
assays would be used evaluate the prediction accuracy of the model. The ongoing 
testing is based on whole cell assays and the ability of the compounds to inhibit the viral 
induced cytopathic effect and viral replication. The CHIKV nsP2 enzyme is not 
available as a testing kit for evaluating the direct binding with the model hits, and this 
would need further investigations and collaborations.  
 Based on the derived model prediction accuracy, it could be used for screening 
more compound libraries, with the in vitro evaluation of the identified hits. Molecular 
dynamic simulation studies on the developed model should reveal more insights for the 
precise molecular interactions with the bound ligands, allowing improved structure-
based drug design approach. 
 
8.5. Chapter 6: The CHIKV envelope proteins 
8.5.1. Conclusions 
The binding sites within the CHIKV envelope proteins (mature and immature 
forms) were identified with two binding sites found common in the two enzyme forms. 
A virtual screening computer model combining two successive docking algorithms was 
developed for these proteins. This model was used for the screening of two chemical 
libraries within the identified sites in the two enzyme forms. The top 5 hits in each 
pocket were selected as promising in silico inhibitors. The green pocket (Figure 8.6) 
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represents a surface cavity that lies between the E1 domain II and E2 β–ribbon that 
connects E2 domain A to E2 domain C, it also extends downwards as a channel 
between E1 domain II and E2 domain A. The blue pocket (Figure 8.6) is a narrow 
channel extending just behind the fusion loop and surrounded by both E2 domains A 
and B. These pockets make contact with residues from E1 and E2 and therefore, ligands 
for these pockets can affect the relative movement of E1 and E2 domains in the pre- and 
post-fusion states. Furthermore, the blue pocket makes contact with the fusion loop 
residues, and therefore, designing antagonists for this pocket would be an applicable 




Figure 8.6 Possible druggable cavities within the CHIKV envelope proteins (parts of 
the whole protein), the blue and the green pockets. E1 is coloured in violet, E2 is 
coloured in orange and E3 is shown in red.  
  
8.5.2. Future directions  
The anti-CHIKV activity of the compounds is to be investigated to evaluate the 
prediction accuracy of the model. To get more insights into the accuracy of the model, 
molecular dynamic simulations are to be developed for these models. This developed 
structure-based computer model can be further used for screening larger database 
libraries such as the FDA approved drugs libraries that would facilitate the 
identification of lead compounds against the CHIKV.  
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 Based on the structural similarities of the CHIKV envelope proteins with the 
other members of alphaviruses, this developed computer model as well as the 
discovered hits could be also evaluated against other viruses.  
 
8.6. Chapter 7: New Leads for African Trypanosomiasis 
8.6.1. Conclusions 
A bis-sulfonamide lead compound was discovered during the high throughput screening 
(HTS) of the WEHI 2003 library of 87,926 compounds that were tested against 
Trypanosoma brucei.
 256
 A series of 26 bis-sulfonamides were synthesized through three 
facile synthetic steps (Scheme 8.3) and were evaluated against Trypanosoma brucei and 
the cytotoxicity profiles of the compounds were evaluated using the HEK293 cell line. 
The lead compound was resynthesized and re-evaluated confirming the activity. 
 
Scheme 8.3 The three facile synthesis steps designed for the synthesis of the bis-
sulfonamides 160, 170-194. 
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 A structure activity relationship was developed for this series based on the 
activities, with some of the analogues displaying good activity profile ranging from 2 to 
4 µM with acceptable selectivity indices from the medicinal chemistry prospective.  
8.6.2. Future directions  
To further assess the structure activity relationship, another possible derivatisation is the 
use of amides instead of the sulfonyl linkages (Figure 8.7) giving a series of compounds 
with the general formula A. Another possibility is the change of the core ring, to 
investigate the importance of the tetrahydroquinoline ring, for example to the indoline 
ring, giving a series of compounds with the general formulas B and C, taking into 
account the preliminary structure activity relationship results. These changes will give a 
full picture for the requirements of activity for this class of the bis-sulfonamide based 
skeleton. More biological evaluation are required to assess the mode of action and the 
target sites for these molecules. 
 
Figure 8.7 Possible derivatisation of the bis-sulfonamide class of compounds.  
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CHAPTER 9: Experimental  
 
9.1. Chemistry  
9.1.1. General experimental 
Unless otherwise stated, chemicals were purchased from Sigma Aldrich (Australia). 
1,2,3,4-Tetrahydro-7-nitroquinoline was purchased from Shanghai Xunxin Chemical 
Co., Ltd. (China). (3-(Cyanomethoxy)phenyl)boronic acid was purchased from Combi-






F NMR spectra were recorded at 500, 125 and 282 
MHz, respectively on a Varian Inova 500 MHz spectrometer. Chemical shifts () are 
reported in parts per million relative to TMS using CDCl3 as a solvent unless otherwise 
noted. The solvents used for 
13
C NMR were the same used for the 
1
H NMR unless 
otherwise noted. Coupling constants (J) are reported in Hertz (Hz). Multiplicities are 
reported as singlet (s), broad (br), doublet (d), doublet of doublets (dd), doublet of 
doublets of doublets (ddd), doublet of triplet (dt), multiplet (m), pentet (p), sextet (sex) 
or septet (sp). Electron impact (EI) and electrospray (ES) mass spectra (MS) were 
recorded on a Shimadzu QP-5000 spectrometer and high resolution (HR) on a VG 
AutoSpec spectrometer. Electrospray (ESI) mass spectra were recorded on a Micromass 
Platform LCZ spectrometer and high resolution on a Micromass QTOF2 spectrometer. 
Ion mass to charge (m/z) values are stated with their relative abundances as a percentage 
in parentheses. Peaks assigned to the molecular ion are denoted by M+ or M- (when 
using the ESI-). Thin Layer Chromatography (TLC) was performed using Merck Silica 
Gel F254 aluminium sheets. Column chromatography purifications were performed 
using flash Silica gel (0.04-0.06 mm, 230 – 400 mesh). Infrared (IR) spectra were 
recorded on a (Shimadzu FT-IR spectrometer) fitted with a Smart Omni-Sampler 
germanium crystal accessory. All IR spectra were recorded as neat samples. In the IR 
spectra, strong, medium and weak peaks are assigned as s, m and w, respectively. 
Melting points were determined using a Gallenkamp (Griffin) melting point apparatus. 
Temperatures are expressed in degrees Celsius (ºC) and are uncorrected. Microwave 
reactions were performed using a Discover CEM Focused Microwave Synthesis System 
in 10 mL closed vessels. HPLC purity check was performed using Waters 1525 HPLC 
pump, Waters
Tm
 486 absorbance detector (using the wavelength, 254 nm) and Nova-
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Pak® Silica 3.9x150 mm C18 column. HPLC solvents used in this work: solvent A was 
hexane, solvent B was isopropanol containing 0.1% TFA, solvent C was isopropanol 
and solvent D is ethyl acetate. Retention times in minutes for the HPLC results are 
expressed as Rt. Reactions performed at -78 °C and -116 °C were cooled using N2 
(l)/EtOAc and N2 (l)/EtOH slush baths, respectively. The concentration of n-BuLi was 
determined by titration using phenanthroline and 2-butanol in toluene (ca. 1 M). Known 
compounds were synthesized either according to the reported procedure (references are 
provided)  or using new methods which were described in detail, and the spectral data 
collected for these reported intermediates matched those reported in the literature. The 
assignments of the protons and carbons in the spectra were based on the given 
nomenclatures, unless otherwise stated. 
 
9.1.2. Experimental for chapter 2 
2-Methyl-1-(3-nitrophenyl)propan-1-one 38 
 
To  conc. H2SO4 (25 mL) cooled to -20 ºC, was added dropwise pre-cooled 2-methyl-1-
phenylpropan-1-one 37 (20 g, 0.135 mol), and the mixture was stirred for 10 min at -20 
ºC. A pre-cooled nitrating mixture of conc. H2SO4 (15 mL) and conc. HNO3 (8.3 g) was 
added dropwise at a rate that the temperature remained at -10 to -5 ºC. After complete 
addition, the reaction mixture was stirred for 1 h at 0 ºC. It was then poured onto 
crushed ice, and extracted with CH2Cl2 (2 x 50 mL). The combined organic layers were 
washed with water (50 mL) and brine (50 mL), dried (MgSO4) and concentrated under 
reduced pressure. The oily residue was then subjected to flash column chromatography 
and elution with 40% CH2Cl2 in petroleum spirit gave the meta-nitro compound 38 
(13.5 g, 52%) as a yellow oil; IR (cm
-1
): υ 1667 (s, C=O), 1528 (s, NO2), 1355 (s, NO2). 
1
H NMR (CDCl3): δ 8.75 (t, J = 1.8 Hz, 1H, phenyl_2 H), 8.40 (ddd, J = 8.3, 2.3, 1.1 
Hz, 1H, phenyl_4), 8.27 (d, J = 7.9 Hz, 1H, phenyl_6 H), 7.68 (t, J = 8.0 Hz, 1H, 
phenyl_5 H), 3.57 (sp, J = 6.8 Hz, 1H, propanone_2 H), 1.17 (d, J = 7.2 Hz, 6H, 
(CH3)2). 
13
C NMR, δ: 202.4 (CO), 149.3 (phenyl C3), 137.7 (phenyl C1), 134.2 (phenyl 
C6), 130.2 (phenyl C5), 127.4 (phenyl C4), 123.4 (phenyl C2), 36.0 (C2), 19.1 (2 CH3). 
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EI-MS m/z 193 (M+, 26), 176 (9), 150 (100%), 134 (19), 121 (22), 104 (70). HRMS 




Under a N2 atmosphere, a fresh solution of LDA was prepared by dropwise addition of 
n-BuLi (1.56 mL of 2 M solution, 3.11 mmol) to a solution of diisopropyl amine (314.7 
mg, 3.11 mmol) in a pre-cooled (-78 ºC) dry THF (20 mL), and the mixture was stired 
for 30 min at -78 ºC. To this solution, was added dropwise, a solution of 4,6-
dichloropyrimidine 28 (385.9 mg, 2.59 mmol) in dry THF (10 mL), also pre-cooled to -
78 
o
C, and the mixture was allowed to stir for 45 min at -78 
o
C. The solution was then 
cooled to -116 
o
C and the mixture was allowed to stir for 10 min, after which, a solution 
of 2-methyl-1-(3-nitrophenyl)propan-1-one 38 (500 mg, 2.59 mmol) in dry THF (10 
mL), pre-cooled to -116 
o
C, was added dropwise over 10 min period. After complete 
addition, the resulting solution was allowed to stir for a further 45 min at -116 to -100 
o
C. The reaction was then quenched with a saturated solution of NH4Cl (25 mL). To the 
resulting biphasic mixture was added H2O (20 mL) before the organic layer was 
partitioned from the reaction mixture. The aqueous layer was further extracted with 
CH2Cl2 (3 x 50 mL) and the combined organic layers were washed with 1 M HCl (25 
mL), dried (MgSO4) and the solvent concentrated under reduced pressure. The resulting 
crude oil was subjected to flash column chromatography and elution with 15% ethyl 
acetate in petroleum spirit gave 1-(4,6-dichloropyrimidin-5-yl)-2-methyl-1-(3-
nitrophenyl)propan-1-ol 40 (442.8 mg, 50%) as pale yellow crystals,  mp:  141-142 ºC; 
IR (cm
-1
): υ 3354 (w, OH), 1556 (w, NO2), 1375 (s, NO2). 
1
H NMR (CDCl3): δ 8.63 (s, 
1H, pyrimidine_2 H), 8.41 (t, J = 1.0 Hz, 1H, phenyl_2), 8.16 (ddd, J = 8.4, 2.1, 1.0 Hz, 
1H, phenyl_4 H), 7.80 (ddd, J = 7.8, 2.0, 0.8 Hz, 1H, phenyl_6 H), 7.52 (t, J = 8.1 Hz, 
1H, phenyl_5 H), 3.64-3.58 (m, 1H, propanol_2 H), 3.38 (br, OH), 1.11 (d, J = 6.6 Hz, 
3H, CH3), 0.93 (d, J = 6.6 Hz, 3H, CH3). 
13
C NMR, δ: 161.4 (pyrimidine C4, C6), 155.1 
(pyrimidine C2), 148.0 (phenyl C3), 145.4 (phenyl C1), 136.3 (pyrimidine C1), 132.5 
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(phenyl C6), 129.1 (phenyl C5), 122.8 (phenyl C4), 121.8 (phenyl C2), 81.7 (propanol 




Cl2, 5), 302 
(20), 300 (70), 298 (100%), 284 (15), 282 (20). HRMS (ESI) calcd for C14H14
35
Cl2N3O3 




A solution of 1-(4,6-dichloropyrimidin-5-yl)-2-methyl-1-(3-nitrophenyl)propan-1-ol 40 
(315 mg, 0.963 mmol) in SOCl2 (10 mL) was heated at reflux for 48 h under a N2 
atmosphere. The mixture was then cooled to room temperature, quenched by the 
dropwise addition of cold H2O (20 mL), and neutralised with 2 M KOH, and was 
extraced with CH2Cl2 (3 x 50 mL). The combined organic layers were dried (MgSO4), 
the solvent concentrated under vacuum and the resulting residue was subjected to flash 
column chromatography (50% CH2Cl2 in petroleum spirit) to yield the alkene 41 (220 
mg, 70%) as a pale yellow crystaline solid, mp:  93-94 °C; IR (cm
-1
): υ 2986 (w, C-H 
aliphatic), 1506 (s, NO2), 1349 (s, NO2). 
1
H NMR (CDCl3): δ 8.74 (s, 1H, pyrimidine_2 
H), 8.17 (s, 1H, phenyl_2 H), 8.14 (d, J = 8.0 Hz, 1H, phenyl_4 H), 7.60 (d, J = 7.5 Hz, 
1H, phenyl_4 H), 7.50 (t, J = 7.5, 1H, phenyl_5 H), 1.94 (s, 3H, CH3), 1.73 (s, 3H, 
CH3). 
13
C NMR, δ: 162.2 (pyrimidine C4, C6), 157.1 (pyrimidine C2), 148.3 (phenyl 
C3), 141.2 (phenyl C1), 140.1 (propene C1), 135.8 (phenyl C6), 134.2 (pyrimidine C5), 
129.4 (phenyl C5), 126.0 (propene C2), 124.8 (phenyl C4), 122.6 (phenyl C2), 22.5 
(CH3), 21.8 (CH3). EI-MS m/z 327 (M+ 
37




Cl, 65), 323 (M+ 
35














A solution of 1-(4,6-dichloropyrimidin-5-yl)-2-methyl-1-(3-nitrophenyl)propan-1-ol 40 
(50 mg, 0.147 mmol) in conc. H2SO4 (5 mL) was stirred for 4 h at room temperature. 
The mixture was then poured onto crushed ice, and a saturated solution of Na2CO3 was 
added dropwise until no more CO2 gas evolved. The mixture was then extracted with 
CH2Cl2 (2 x 20 mL) and the combined organic layers were washed sequentially with 
water (20 mL) and brine (20 mL) and then dried (MgSO4). The solvent was 
concentrated under reduced pressure and the residue was subjected to flash column 
chromatography and elution with 40% ethyl acetate in petroleum spirit gave 42 (38 mg, 
85%) as a pale yellow oil, IR (cm
-1
): υ 2922 (w, C-H aliphatic), 1522 (s, NO2), 1350 (s, 
NO2), 1238 (m, C-O). 
1
H NMR (CDCl3), δ: 8.16 (s, 1H, pyrimidine_2 H), 8.22 (d, J = 
7.5 Hz, 1H, phenyl_4 H), 7.90 (s, 1H, phenyl_2 H), 7.59 (t, J = 7.9 Hz, 1H, phenyl_5 
H), 7.29 (d, J = 7.6 Hz, 1H, phenyl_6 H), 4.55 (s, 1H, C_5 H), 1.73 (s, 3H, CH3), 1.15 
(s, 3H, CH3). 
13
C NMR, δ: 174.1 (pyrimidine C2), 159.8 (O-C-N), 157.8 (phenyl C3), 
148.3 (pyrimidine C4), 138.9 (phenyl C1), 134.1 (phenyl C6), 130.2 (phenyl C5), 123.5 
(phenyl C4), 123.4 (phenyl C2), 119.1 (CCl-C), 90.5 (CH(CH3)2), 55.2 (C5), 29.9 
(CH3), 24.9 (CH3) ppm. EI-MS m/z 305 (M+ 
35
Cl, 50), 288 (100%), 270 (30), 248 (20), 
230 (17). HRMS (ESI) calcd for C14H13
35




A suspension of the alkene 41 (100 mg, 0.306 mmol) in NH4OH (25%, 2 mL) was 
added to a 10 mL microwave reaction vessel, sealed and heated to 120 °C in a 
microwave reactor with a maximum pressure of 15 Bar using a power of 50 W, 
Chapter 9  Experimental 
210  
 
allowing 10 min (ramping) and then held for 50 min. At this time, the pressure regularly 
dropped below the 15 Bar maximum and the temperature was increased to 130 °C for a 
further 30 min. After cooling, the resulting suspension was extracted with ethyl acetate 
(2 x 25 mL), the combined organic layers were washed with brine (25 mL), dried 
(MgSO4) and concentrated under vacuum before being subjected to flash column 
chromatography (80% ethyl acetate in petroleum spirit) to give 4-amino-6-chloro-5-(2-
methyl-1-(3-nitrophenyl)prop-1-en-1-yl)pyrimidine 43 (84.5 mg, 90%) as a yellow 
crystalline solid, mp:  144-145 °C; IR (cm
-1
): υ 3329 (w, NH2), 1562 (s, NO2), 1347 (s, 
NO2). 
1
H NMR (CDCl3): δ 8.31 (s, 1H, pyrimidine_2 H), 8.13-8.11 (m, 2H, phenyl_2,4 
H), 7.57 (d, J = 7.5 Hz, 1H, phenyl_6 H), 7.49 (t, J = 8.0 Hz, 1H, phenyl_5 H), 5.27 (br, 
NH2), 2.17 (s, 3H, CH3), 1.97 (s, 3H, CH3). 
13
C NMR (CDCl3), δ: 162.0 (pyrimidine 
C6), 159.0 (pyrimidine C4), 157.3 (pyrimidine C2), 148.2 (phenyl C3), 141.1 (phenyl 
C1), 140.5 (propene C1), 135.3 (phenyl C6), 129.3 (phenyl C5), 125.3 (propene C2), 
124.1 (phenyl C4), 122.3 (phenyl C2), 116.7 (pyrimidine C5), 22.3 (CH3), 21.9 (CH3). 
ESI-MS m/z 307 (M+ 
37
Cl), 305 (M+ 
35











Under a N2 atmosphere, a fresh solution of LDA was prepared by dropwise addition of 
n-BuLi (1.64 mL of 2.5 M solution, 4.109 mmol) to a solution of diisopropyl amine 
(415.8 mg, 4.109 mmol) in dry THF (20 mL) pre-cooled to -78 ºC, and the mixture was 
stirred for 30 min at -78 ºC. To this solution was added dropwise at -78 
o
C, a solution of 
4,6-dichloropyrimidine 28 (510 mg, 3.424 mmol) in dry THF (10 mL) and the mixture 
was allowed to stir for 45 min at -78 
o
C. The solution was then cooled to -116 
o
C and 
allowed to stir for 10 min, after which a pre-cooled (-116 
o
C) solution of 
cyclopropyl(phenyl)methanone 49 (500 mg, 3.424 mmol) in dry THF (10 mL) was 
                                                             
* Numbers on the structure correspond to the cyclopropyl ring, not related to the compound name. 
  Compound was unstable for HRMS or IR. 
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added dropwise over a 10 min period. After complete addition, the resulting solution 
was allowed to stir for a further 45 min at -116 to -100 
o
C, then quenched with a 
saturated solution of NH4Cl (25 mL). To the resulting biphasic mixture was added H2O 
(20 mL) before the organic layer was partitioned from the reaction mixture. The 
aqueous layer was further extracted with CH2Cl2 (3 x 50 mL) and the resulting organic 
layers were combined and washed with 1 M HCl (25 mL). The organic layer was then 
dried (MgSO4) and the solvent concentrated under reduced pressure. The resulting crude 
oil was subjected to flash chromatography and elution with 15% ethyl acetate in 
petroleum spirit gave the alcohol, cyclopropyl(4,6-dichloropyrimidin-5-
yl)(phenyl)methanol 50 (373 mg,  37%) was obtained as a yellow solid, mp:  146-147 
°C; 
1
H NMR (CDCl3), δ: 8.61 (s, 1H, pyrimidine_2 H), 7.38 (d, J = 7.0 Hz, 2H, 
phenyl_2,6 H), 7.35-7.31 (m, 3H, phenyl_3,4,5 H), 2.83 (s, br, OH), 2.06 (p, J = 7.0 Hz, 
1H, C1_H), 0.90 (q, J = 7.0 Hz, 1H, C_3 H), 0.77 (t, J = 6.5 Hz, 2H, C_3 H, C_2 H), 
0.57 (q, J = 6.5 Hz, 1H, C_2 H). 
13
C NMR, δ: 161.9 (pyrimidine C4, C6), 155.3 
(pyrimidine C2), 145.9 (phenyl C1), 138.1 (pyrimidine C5), 128.9 (phenyl C2, C6), 
128.3 (phenyl C3, C5), 126.2 (pyrimidine C4), 78.3 (methanol C), 20.1 (C1), 4.1 (C3), 
2.3 (C2) ppm. ESI-MS m/z 295.1 (M+ 
35








Cyclopropyl(phenyl)methanone 49 (1.0 g, 6.849 mmol) was added dropwise to a pre-
cooled mixture of conc. H2SO4 (10 mL) and conc. HNO3 (10 mL) at -15 ºC, over 10 
min. The mixture was then allowed to stir at -10 ºC for 2 h before being poured onto 
crushed ice, and extracted with ether (2 x 30 mL). The combined organic layers were 
washed sequentially with water (20 mL), and brine (20 mL) and then dried (MgSO4). 
The solution was passed through short pad of silica gel, and the eluent was evaporated 
to leave a pale yellow oil of cyclopropyl(3-nitrophenyl)methanone 53 (915 mg, 70%). 
IR (cm
-1
): υ 1662 (s, C=O), 1526 (s, NO2), 1350 (s, NO2). 
1
H NMR (CDCl3), δ: 8.84 (s, 
                                                             
* This reference reports only the elemental analysis of 53. 
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1H, phenyl_2 H), 8.42 (d, J = 8.1 Hz, 1H, phenyl_4 H), 8.33 (d, J = 7.8 Hz, 1H, 
phenyl_6 H), 7.70 (t, J = 7.8 Hz, 1H, phenyl_5 H), 2.74-2.69 (m, 1H, CO-CH), 1.32 (t, 
J = 3.7 Hz, 2H, CH2-CH2), 1.16 (p, J = 3.7 Hz, 2H, CH2-CH2). 
13
C NMR, δ: 198.4 
(CO), 139.1 (phenyl C3), 133.9 (phenyl C1), 130.6 (phenyl C6), 129.8 (phenyl C5), 
126.9 (phenyl C4), 122.9 (phenyl C2), 17.5 (cyclopropyl CH), 12.5 (cyclopropyl CH2-
CH2) ppm. EI-MS m/z 191 (M+, 20), 150 (100%), 104 (70), 77 (75). HRMS (ESI) calcd 
for C10H10NO3 (MH+), 192.0661; found, 192.0654. 
 
Nitration of Cyclobutyl(phenyl)methanone 56, formation of 57 and 58 
Cyclobutyl(phenyl)methanone 56 (5 g, 31.25 mmol) was added to a round bottom two-
neck flask fitted with a magnetic stirrer and a thermometer, containing conc. H2SO4 (20 
mL) and the mixture was cooled to -15 ºC in ice/salt bath. A pre-cooled nitrating 
mixture of H2SO4 (10 mL) and conc. HNO3 (10 mL) was added dropwise in a rate that 
the mixture temperature did not exceed 0 ºC. After complete addition, the mixture was 
stirred for 1 h at 0 - 5 ºC. The mixture was then poured onto crushed ice, and extracted 
with CH2Cl2 (2 x 30 mL). The combined organic layers were then washed with a 
saturated solution of NaHCO3 (20 mL), water (20 mL), and brine (20 mL) and then 
dried (MgSO4) and concentrated under reduced pressure. The resulting oil was then 
subjected to flash column chromatography and elution with 30% ether in petroleum 
spirit gave:  




): υ 2989 (w, C-H aliphatic), 1675 (s, C=O), 1527 (s, NO2), 1350 (s, NO2). 
1
H 
NMR (CDCl3), δ: 8.69 (s, 1H, phenyl_2 H), 8.39 (d, J = 7.9 Hz, 1H, phenyl_4 H), 8.23 
(d, J = 7.5 Hz, 1H, phenyl_6 H), 7.67 (t, J = 7.5 Hz, 1H, phenyl_5 H), 4.04 (p, J = 8.3 
Hz, 1H, CO-CH), 2.46-2.33 (m, 4 H, cyclobutyl), 2.19-2.10 (m, 1H, cyclobutyl), 1.99-
1.93 (m, 1H, cyclobutyl). 
13
C NMR, δ: 198.8 (CO), 148.7 (phenyl C3), 137.1 (phenyl 
C1), 134.1 (phenyl C6), 130.1 (phenyl C5), 127.4 (phenyl C4), 123.4 (phenyl C2), 42.5 
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(CO-CH), 25.2 (CH2-CH2-CH2), 18.3 (CH2-CH2-CH2) ppm. EI-MS m/z 205 (M+, 5), 
188 (10), 150 (100%). HRMS (ESI) calcd for C11H12NO3 (MH+), 206.0817; found, 
206.0810. 
Further elution afforded: 
Cyclobutyl(2-nitrophenyl)methanone 58 (640 mg, 10%) as a yellow oil. 
 
Yellow oil, IR (cm
-1
): υ 2990 (w, C-H aliphatic), 1675 (s, C=O), 1528 (s, NO2), 1350 (s, 
NO2). 
1
H NMR (CDCl3), δ: 8.09 (d, J = 8.1 Hz, 1H, phenyl_3 H), 7.70 (t, J = 7.6 Hz, 
1H, phenyl_5 H), 7.59 (t, J = 8.0 Hz, 1H, phenyl_4 H), 7.38 (d, J = 7.6 Hz, 1H, 
phenyl_6 H), 3.66 (p, J = 8.5 Hz, 1H, CO-CH), 2.45-2.38 (m, 2H, cyclobutyl 2H), 2.23-
2.17 (m, 2H, cyclobutyl 2H), 2.05-1.93 (m, 2H, cyclobutyl 2H). 
13
C NMR, δ: 204.1 
(CO), 146.3, (phenyl C2), 137.3 (phenyl C1), 134.3 (phenyl C5), 130.7 (phenyl C4), 
128.0 (phenyl C6), 124.6 (phenyl C3), 45.6 (CO-C), 25.6 (CH2-CH2-CH2), 18.1 (CH2-
CH2-CH2) ppm. EI-MS m/z 205 (M+, 5), 188 (5), 169 (7), 150 (100%). HRMS (ESI) 




Under a N2 atmosphere, diisopropyl amine (400 mg, 3.953 mmol) was added to dry 
TFH (20 mL) in an oven dried 50 mL flask. The flask was then sealed with a rubber 
cap, and the flask was degassed by applying vacuum and flushing with N2 gas. The 
solution was cooled to -78 ºC before n-BuLi (2.47 mL of 1.6 M solution, 3.953 mmol) 
was added dropwise by a syringe, and the mixture was allowed to stir at -78 ºC for 40 
min (Flask A). In a separate oven dried 50 mL flask, 4-chloropyridine.HCl 55 (230 mg, 
1.554 mmol) was added and the flask was sealed with a rubber cap and the flask was 
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flushed with N2 for 10 min and then sealed; the flask was then cooled to -78 ºC (Flask 
B). The LDA solution formed in Flask A was then transferred (under N2) through a 
double sided needle to Flask B, and the resultant mixture was stirred at -78 ºC for 45 
min, where the solution became dark yellow in colour and the 4-chloropyridine.HCl 55 
was completely dissolved as can be indicated from the disappearance of the solid. A 
pre-cooled solution (-78 ºC) of 2-methyl-1-(3-nitrophenyl)propan-1-one 38 (300 mg, 
1.554 mmol) in dry THF (10 mL) was added slowly under N2 to Flask B, using a double 
sided needle, and the reaction was stirred at -78 ºC for another 45 min. The mixture was 
allowed to warm up to room temperature (over 12 h) and was then quenched with a 
mixture of water/THF. The mixture was then acidified with 2 M HCl (20 mL). The 
aqueous acidic layer was separated and the organic layer was further extracted with 2 M 
HCl (2 x 25 mL). The combined acidic extracts were washed with ether (25 mL). The 
acidic extract was then cooled to 0 ºC and conc. ammonia solution was added dropwise 
to give a slightly basic solution (pH paper). The mixture was then extracted with 
CH2Cl2 (2 x 30 mL), the combined organic layers were dried (MgSO4), and then 
concentrated under reduced pressure. The residue was subjected to a flash column 
chromatography and elution with 40% ethyl acetate in petroleum spirit gave 1-(4-
chloropyridin-3-yl)-2-methyl-1-(3-nitrophenyl)propan-1-ol 59 (200 mg, 42%) as a pale 
yellow solid, mp: 132-133 ºC; IR (cm
-1
): υ 3180 (w, OH), 1525 (s, NO2), 1352 (s, NO2). 
1
H NMR (CDCl3), δ: 9.12 (s, 1H, pyridine_2 H), 8.40 (d, J = 5.1 Hz, 1H, pyridine_6 
H), 8.13 (s, 1H, phenyl_2 H), 8.09 (d, J = 7.8 Hz, 1H, phenyl_4 H), 7.69 (d, J = 7.8 Hz, 
1H, phenyl_6 H), 7.47 (t, J = 7.8 Hz, 1H, phenyl_5 H), 7.21 (d, J = 5.1 Hz, 1H, 
pyridine_5 H), 3.25 (s, br, OH), 3.12-3.09 (m, 1H, propanol_2 H), 1.01 (d, J = 6.6 Hz, 
3H, CH3), 0.95 (d, J = 6.9 Hz, 3H, CH3). 
13
C NMR, δ: 149.7 (phenyl C3), 149.6 
(pyridine C6), 149.4 (phenyl C1), 147.9 (pyridine C2), 146.2 (pyridine C3), 142.4 
(pyridine C4), 137.6 (phenyl C6), 133.3 (phenyl C5), 128.8 (pyridine C5), 126.4 
(phenyl C2), 122.2 (phenyl C4), 79.7 (propanol C1), 32.9 (propanol C2), 17.6 (CH3), 
17.4 (CH3) ppm. EI-MS m/z 306 (M+ 
35
Cl, 5), 263 (100%), 217 (50), 182 (20), 140 
(90). HRMS (ESI) calcd for C15H16
35









Under a N2 atmosphere, in an oven dried 50 mL flask, a solution of diisopropyl amine 
(397.4 mg, 3.926 mmol) in dry TFH (20 mL) was prepared, and the flask was then 
sealed with a rubber cap, and the solution was degassed by applying vacuum and 
flushing with N2 gas. The solution was cooled to -78 ºC. n-BuLi (2.62 mL of 1.5 M 
solution, 3.926 mmol) was added dropwise by a syringe, and the mixture was allowed to 
stir at -78 ºC for 40 min (Flask A). In another oven dried 50 mL flask, 4-
chloropyridine.HCl 55 (235 mg, 1.571 mmol) was added and the flask was sealed with a 
rubber cap and flushed with N2, and the flask was then cooled to -78 ºC (Flask B). The 
LDA solution formed in Flask A was then transferred (under N2) through a double sided 
needle to Flask B, and the mixture was stirred at -78 ºC for 45 min, where the solution 
became dark yellow in colour and the 4-chloropyridine.HCl 55 dissolved completely. A 
pre-cooled solution (-78 ºC) of cyclopropyl(3-nitrophenyl)methanone 53 (300 mg, 
1.571 mmol) in dry THF (10 mL) was added slowly under N2 to the content in flask B, 
using a double sided needle, and the reaction was stirred at  -78 ºC for another 45 min. 
The mixture was allowed to warm up to room temperature (over 12 h), and was then 
quenched with a mixture of water/THF. The mixture was then acidified with 2 M HCl. 
The aqueous acidic layer was separated and the organic layer was further extracted with 
2 M HCl (2 x 25 mL). The combined acidic extracts were washed with ether (25 mL). 
The acidic extract was then cooled to 0 ºC and conc. ammonia solution was added 
dropwise to give a slightly basic solution (pH paper). The mixture was then extracted 
with CH2Cl2 (2 x 30 mL), dried (MgSO4) and evaporated under reduced pressure. The 
residue was subjected to a flash column chromatography and elution with 40% ethyl 
acetate in petroleum spirit gave (4-chloropyridin-3-yl)(cyclopropyl)(3-
nitrophenyl)methanol 60 (248 mg, 52%) as a yellow solid, mp: 138-139 ºC; IR (cm
-1
): υ 
3100 (w, OH), 1525 (s, NO2), 1348 (w, NO2). 
1
H NMR (CDCl3), δ: 9.28 (s, 1H, 
pyridine_2 H), 8.50 (d, J = 5.0 Hz, 1H, pyridine_6 H), 8.24 (s, 1H, phenyl_2 H), 8.07 
(d, J = 8.0 Hz, 1H, phenyl_4 H), 7.57 (d, J = 8.0 Hz, 1H, phenyl_6 H), 7.48 (t, J = 8.0 
Hz, 1H, phenyl_5 H), 7.28 (d, J = 5.4 Hz, 1H, pyridine_5 H), 2.98 (s, OH), 1.74 (m, 
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1H, cyclopropyl_CH), 0.81-0.64 (m, 4H, cyclopropyl_CH2). 
13
C NMR, δ: 150.1 (phenyl 
C3), 149.8 (pyridine C6), 148.4 (pyridine C2), 148.1 (phenyl C1), 143.1 (pyridine C4), 
133.9 (phenyl C6), 132.1 (pyridine C3), 129.4 (phenyl C5), 129.1 (phenyl C2), 122.6 
(pyridine C5), 121.0 ( phenyl C4), 89.4 (methanol C), 20.6 (cyclopropyl CH), 2.4 
(CH2), 2.1 (CH2) ppm. ESI-MS m/z 304.8 (MH+ 
35
Cl). HRMS (ESI) calcd for 
C15H14
35




Under a N2 atmosphere, diisopropyl amine (333.2 mg, 3.293 mmol) was added to dry 
THF (20 mL) in an oven dried 50 mL flask. The flask was then sealed with a rubber 
cap, and the flask was degassed by applying vacuum and flushing with N2 gas. The 
solution was cooled to -78 ºC. n-BuLi (2.35 mL of 1.4 M solution, 3.293 mmol) was 
added dropwise by a syringe, and the mixture was allowed to stir at -78 ºC for 40 min 
(Flask A). In another oven dried 50 mL flask, 4-chloropyridine.HCl 55 (197 mg, 1.317 
mmol) was added and the flask was sealed with a rubber cap and flushed with N2, and 
the flask was then cooled to -78 ºC (Flask B). The LDA solution formed in flask A was 
then transferred (under N2) through a double sided needle to flask B, and the mixture 
was stirred at -78 ºC for 45 min, where the solution became dark yellow in colour and 
the 4-chloropyridine.HCl 55 dissolved completely. A pre-cooled solution (-78 ºC) of 
cyclobutyl(3-nitrophenyl)methanone 57 (270 mg, 1.317 mmol) in dry THF (10 mL), 
was added slowly under N2 to Flask B, using a double sided needle, and the reaction 
was stirred at  -78 ºC for another 45 min. The mixture was allowed to warm up to room 
temperature (over 12 h), and then was quenched with a mixture of water/THF. The 
mixture was then acidified with 2 M HCl. The aqueous acidic layer was separated and 
the organic layer was further extracted with 2 M HCl (2 x 25 mL). The combined acidic 
extract was washed with ether (25 mL). The acidic extract was then cooled to 0 ºC and 
conc. ammonia solution was added dropwise to give a slightly basic solution (pH 
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paper). The mixture was then extracted with CH2Cl2 (2 x 30 mL), and dried (MgSO4). 
The solvent was then evaporated under reduced pressure. The residue was subjected to 
flash column chromatography (40% ethyl acetate in petroleum spirit) to give (4-
chloropyridin-3-yl)(cyclobutyl)(3-nitrophenyl)methanol 61 (209 mg, 50%) as a brown 
semi solid, IR (cm
-1
): υ 3094 (w, OH), 1525 (s, NO2), 1341 (s, NO2). 
1
H NMR (CDCl3), 
δ: 8.93 (s, 1H, pyridine_2 H), 8.46 (d, J = 5.1 Hz, 1H, pyridine_6 H), 8.15 (s, 1H, 
phenyl_2 H), 8.09 (d, J = 8.0 Hz, 1H, phenyl_6 H), 7.51 (d, J = 7.8 Hz, phenyl_4 H), 
7.51 (t, J = 8.0 Hz, 1H, phenyl_5 H), 7.25 (d, J = 4.8 Hz, 1H, pyridine_5 H), 3.44 (p, J 
= 8.6 Hz, 1H, cyclobutyl_CH), 3.33 (s, OH), 2.27-2.18 (m, 2H, cyclobutyl_CH2), 2.05-
1.88 (m, 2H, cyclobutyl_CH2), 1.85-1.71 (m, 2H, cyclobutyl_CH2). 
13
C NMR, δ: 150.3 
(phenyl C3), 149.4 (pyridine C6), 148.1 (pyridine C2), 146.7 (phenyl C1), 143.1 
(pyridine C3), 136.9 (pyridine C4), 132.2 (phenyl C6), 129.1 (phenyl C5), 126.4 
(pyridine C5), 122.2 (phenyl C2), 121.1 (phenyl C4), 42.9 (methanol C), 23.2 
(cyclobutyl CH), 22.1 (CH2-CH2-CH2), 21.1 (CH2-CH2-CH2), 16.9 (CH2-CH2-CH2)  
ppm. EI-MS m/z 318 (M+, 7), 301 (5), 263 (100%), 247 (20), 217 (16), 191 (5). HRMS 




A solution of 1-(4-chloropyridin-3-yl)-2-methyl-1-(3-nitrophenyl)propan-1-ol 59 (100 
mg, 0.327 mmol) in conc. H2SO4 (20 mL) was stirred under N2 for 24 h at room 
temperature. The mixture was then poured onto crushed ice, and neutralized with a 
saturated solution of Na2CO3. The mixture was then extracted with CH2Cl2 (2 x 25 mL), 
the combined organic layers were washed with brine (20 mL), dried (MgSO4), and the 
solvent was concentrated under reduced pressure. The residue was subjected to a flash 
column chromatography and elution with 40% ethyl acetate in petroleum spirit gave 4-
chloro-3-(2-methyl-1-(3-nitrophenyl)prop-1-en-1-yl)pyridine 62 (80 mg, 85%) as a 
yellow oil, IR (cm
-1
): υ 2980 (w, C-H aliphatic), 1653 (m, C=C), 1528 (s, NO2), 1465 
(w), 1347 (s, NO2). 
1
H NMR (CDCl3), δ: 8.49 (s, 1H, pyridine_2 H), 8.42 (d, J = 5.4 
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Hz, 1H, pyridine_6 H), 8.09-8.07 (m, 2H, phenyl_2,6 H), 7.51 (d, J = 7.6 Hz, 1H, 
phenyl_4 H), 7.47 (t, J = 7.6 Hz, 1H, phenyl_5 H), 7.35 (d, J = 5.4 Hz, 1H, pyridine_5 
H), 1.92 (s, 3H, CH3), 1.72 (s, 3H, CH3). 
13
C NMR, δ: 151.9 (phenyl C3), 149.3 
(pyridine C6), 148.1 (pyridine C2), 143.6 (phenyl C1), 142.2 (phenyl C6), 138.5 
(propene C1), 136.7 (pyridine C3), 135.7 (pyridine C4), 129.0 (phenyl C5), 128.7 
(pyridine C5), 124.8 (phenyl C4), 124.5 (phenyl C2), 121.7 (propene C2), 22.5 (CH3), 
21.8 (CH3) ppm. EI-MS m/z 288 (M+ 
35
Cl, 100%), 273 (5), 241 (10), 227 (16), 204 (8), 
191 (10). HRMS (ESI) calcd for C15H14
35






Method A: a solution of 4-chloropyridin-3-yl)(cyclopropyl)(3-nitrophenyl)methanol 60 
(100 mg, 0.329 mmol) in conc. H2SO4 (10 mL) was stirred under N2 for 24 h at room 
temperature. The mixture was then poured onto crushed ice, and neutralized with a 
saturated solution of Na2CO3. The mixture was then extracted with CH2Cl2 (2 x 25 mL), 
the combined organic layers were washed with brine (15 mL), dried (MgSO4), and the 
solvent was removed under reduced pressure. The residue was subjected to a flash 
column chromatography and elution with 40% ethyl acetate in petroleum spirit gave the 
alkene 63 (58.3 mg, 62%) as a yellow oil, IR (cm
-1
): υ 2990 (w, C-H aliphatic), 1676 
(w, C=C), 1527 (s, NO2), 1347 (s, NO2). 
1
H NMR (CDCl3), δ: 8.57 (d, J = 5.1 Hz, 1H, 
pyridine_6 H), 8.50 (s, 1H, pyridine_2 H), 8.17-8.07 (m, 2H, phenyl_2,4 H), 7.49-7.45 
(m, 2H, phenyl_6 H, pyridine_5 H), 6.54 (t, J = 7.2 Hz, 1H, phenyl_5 H), 3.63 (t, J = 
6.6 Hz, 2H, CH2-CH2), 2.52 (q, J = 6.6 Hz, 2H, CH2-CH2). 
13
C NMR, δ: 151.7 (phenyl 
C3), 150.5 (pyridine C6), 148.5 (pyridine C2), 143.8 (phenyl C1), 141.2 (C*), 136.3 
(phenyl C6), 132.2 (pyridine C4), 131.4 (phenyl C5), 129.5 (pyridine C3), 124.9 
(pyridine C5), 124.0 (phenyl C4), 122.5 (phenyl C2), 121.0 (C**), 43.2 (CH2), 32.9 
(CH2) ppm. EI-MS m/z 286 (M+ 
35
Cl, 25), 227 (100%), 204 (10), 191 (70), 164 (60). 
HRMS (ESI) calcd for C15H12
35
ClN2O2 (MH+), 287.0587; found, 287.0576. 
                                                             
 Asterisks on the structures are for peak assignments. 
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Method B: Under a N2 atmosphere, (4-chloropyridin-3-yl)(cyclopropyl)(3-
nitrophenyl)methanol 60 (100 mg, 0.329 mmol) was added to SOCl2 (15 mL) in a 25 
mL round bottom flask. The flask was then heated at 80 ºC under N2 atmosphere for 24 
h. The mixture was cooled to room temperature, and the solution was poured onto 
crushed ice (50 mL) with vigorous stirring. KOH solution (2 M) was added dropwise 
until neutral solution obtained (pH paper). The mixture was then extracted with CH2Cl2 
(2 x 25 mL), washed with water (2 x 20 mL), brine (20 mL) and dried (MgSO4). The 
organic fraction was then concentrated under reduced pressure and the residue subjected 
to flash column chromatography (40% ethyl acetate in petroleum spirit) to afford 4-
chloro-3-(cyclopropylidene(3-nitrophenyl)methyl)pyridine 63 (70.6 mg, 75%) as a 







Under a N2 atmosphere, a solution of (4-chloropyridin-3-yl)(cyclobutyl)(3-
nitrophenyl)methanol 61 (90 mg, 0.283 mmol) in SOCl2 (15 mL) was then heated at 80 
ºC under N2 atmosphere for 36 h. The mixture was cooled, and the solution was poured 
onto crushed ice (50 mL) with vigorous stirring. KOH solution (2 M) was added 
dropwise to neutral (pH paper). The mixture was then extracted with CH2Cl2 (2 x 25 
mL), the combined organic extracts were washed sequentially with water (2 x 20 mL), 
brine (20 mL), and then dried (MgSO4). The solvent was removed under reduced 
pressure. The resulting residue was subjected to a flash column chromatography and 
elution with 40% ethyl acetate in petroleum spirit gave 4-chloro-3-(cyclobutylidene(3-
nitrophenyl)methyl)pyridine 64 (58.6 mg, 69%) as a brown oil, IR (cm
-1
): υ 2989 (w, C-
H aliphatic), 1657 (m, C=C), 1527 (s, NO2), 1340 (s, NO2). 
1
H NMR (CDCl3), δ: 8.51 
(d, J = 5.1 Hz, 1H, pyridine_6 H), 8.49 (s, 1H, pyridine_2 H), 8.04 (d, J = 8.1 Hz, 1H, 
                                                             
 Asterisks on the structures are for peak assignments. 
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phenyl_4 H), 8.01 (s, 1H, phenyl_2 H), 7.44 (t, J = 8.1 Hz, 1H, phenyl_5 H), 7.40 (d, J 
= 5.6 Hz, 1H, pyridine_5 H), 7.34 (d, J = 8.0 Hz, 1H, phenyl_6 H), 3.12 (t, J = 7.2 Hz, 
2H, cyclobutyl CH2), 2.68 (t, J = 7.2 Hz, 2H, cyclobutyl CH2), 2.17 (p, J = 7.2 Hz, 2H, 
CH2-CH2-CH2). 
13
C NMR, δ: 152.4 (phenyl C3), 149.9 (pyridine C6), 149.2 (pyridine 
C2), 148.6 (phenyl C1), 144.1 (C**), 140.3 (C*), 133.9 (phenyl C6), 133.0 (phenyl C5), 
129.4 (pyridine C4), 125.7 (pyridine C3), 125.2 (pyridine C5), 121.9 (phenyl C4), 121.5 
(phenyl C2), 32.9 (CH2-CH2-CH2), 31.9 (CH2-CH2-CH2), 17.4 (CH2-CH2-CH2) ppm. 
EI-MS m/z 300 (M+ 
35
Cl, 100%), 285 (5), 253 (20), 218 (20), 164 (22). HRMS (ESI) 
calcd for C16H14
35




4-Chloro-3-(cyclobutylidene(3-nitrophenyl)methyl)pyridine 64 (100 mg, 0.333 mmol) 





diethylpentane-1,4-diamine 47 (105 mg, 0.666 mmol). The tube was sealed and heated 
at 100 ºC for 5 min, 120 ºC for 10 min, 140 ºC for 1 h, and then at 160 ºC for 14 h. The 
tube was then cooled to room temperature, the mixture was then adsorped onto silica 
and subjected to a flash column chromatography and elution with 10% methanol in 
CH2Cl2 gave 3-(cyclobutylidene(4-phenoxypyridin-3-yl)methyl)aniline 72 (46.9 mg, 
43%) as a colourless oil, IR (cm
-1
): υ 3256 (w, NH2), 1452 (s, C-N), 1237 (w, C-O). 
1
H 
NMR (CDCl3), δ: 8.41-8.35 (m, 2H, pyridine_2,6 H), 7.33 (t, J = 7.8 Hz, 2H, 
phenoxy_3,5 H), 7.17 (t, J = 7.3 Hz, 1H, aniline_5 H), 7.06 (t, J = 7.8 Hz, 1H, 
phenoxy_4 H), 6.90 (d, J = 7.8 Hz, 2H, phenoxy_2,6 H), 6.65-6.59 (m, 2H, aniline_4,6 
H), 6.50 (d, J = 7.8 Hz, 1H, pyridine_5 H), 6.84 (s, 1H, aniline_2 H), 3.55 (br, NH2), 
3.08 (t, J = 7.0 Hz, 2H, CH2-CH2-CH2), 2.75 (t, J = 7.0 Hz, 2H, CH2-CH2-CH2), 2.06 
(p, J = 7.4 Hz, 2H, CH2-CH2-CH2).
13
C NMR, δ: 162.8 (phenoxy C1), 154.9 (pyridine 
C4), 153.3 (pyridine C2), 150.1 (pyridine C6), 146.4 (aniline C1), 144.6 (aniline C3), 
140.9 (C*), 130.2 (phenoxy C3, C5), 129.3 (phenoxy C4), 126.1 (C**), 125.2 (aniline 
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C5), 120.9 (pyridine C3), 120.8 (phenoxy C2, C6), 118.5 (aniline C4), 114.5 (aniline 
C2), 113.6 (pyridine C5), 111.8 (aniline C6), 33.1 (CH2), 32.1 (CH2), 17.6 (CH2-CH2-
CH2) ppm. EI-MS m/z 328 (M+, 100%), 313 (20), 299 (17), 235 (23), 219 (15). HRMS 






In a 25 mL round bottom flask fitted with a reflux condenser, 4-chloro-3-
(cyclopropylidene(3-nitrophenyl)methyl)pyridine 63 (100 mg, 0.349 mmol) was 
dissolved in morpholine 75 (15 mL), and the mixture was heated at reflux for 48 h. The 
excess morpholine was then removed by distillation under vacuum to leave a dark 
brown oily residue, which was subjected to alumina column chromatography using 40% 
CH2Cl2 and 60% ethyl acetate. 4-(3-(Cyclopropylidene(3-nitrophenyl)methyl)pyridin-4-
yl)morpholine 77 was isolated as a red oil (76.4 mg, 65%). IR (cm
-1
): υ 2957 (w, C-H 
aliphatic), 1525 (s, NO2), 1457 (m), 1346 (s, NO2). 
1
H NMR (CDCl3), δ: 8.56 (d, J = 
5.3 Hz, 1H, pyridine_6 H), 8.48 (s, 1H, pyridine_2 H), 8.10 (s, 1H, phenyl_2 H), 7.48-
7.43 (m, 3H, phenyl_4,6 H, pyridine_5 H), 6.53 (t, J = 7.4 Hz, 1H, phenyl_5 H), 3.69 (t, 
J = 4.3 Hz, 4H, morpholine_2,6 H), 2.42 (t, J = 7.3 Hz, 2H, cyclopropyl_2H), 2.26 (br, 
apparent s, 4H, morpholine_3,5 H), 2.08 (ddd, J = 14.3, 7.3, 7.3 Hz, 2H, 
cyclopropyl_2H). 
13
C NMR, δ: 151.7 (pyridine C6), 150.1 (phenyl C3), 148.4 (pyridine 
C4), 143.7 (pyridine C2), 141.5 (C*), 134.5 (phenyl C6), 133.7 (phenyl C5), 133.3 
(phenyl C1), 131.9 (phenyl C4), 129.3 (phenyl C2), 124.9 (pyridine C3), 122.1 (C**), 
120.8 (pyridine C5), 66.8 (morpholine C2, C6), 57.7 (cyclopropyl CH2), 53.4 
(morpholine C3, C5), 27.3 (cyclopropyl CH2) ppm. ESI-MS m/z 336.9 (M-). HRMS 
(ESI) calcd for C19H19N3O3 (MH+), 338.1505; found, 338.1506. 
 
                                                             
 Asterisks on the structures are for peak assignments. 
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9.1.3. Experimental for chapter 3 
2-(3-Nitrophenyl)-1H-benzo[d]imidazole-5-carbonitrile 84 
 
In a 50 mL round bottom flask, 3,4-diaminobenzonitrile 82 (1.0 g, 7.519 mmol) was 
added to 3-nitrobenzaldehyde 83 (1.13 g, 7.519 mmol), and the mixture was triturated 
until homogenous mixture obtained. The flask was then fitted with a CaCl2 tube, and 
heated in an oil bath at 90 ºC with vigorous stirring. The mixture started to melt to a 
brown oily solution before the mixture solidified into dark brown gummy solid. The oil 
bath temperature was then increased to 145 ºC where the brown gummy solid started to 
melt to give dark red oil. After stirring of this red oil for 3 min, the mixture then 
solidified to give a gummy dark red solid. The flask was then cooled to room 
temperature and excess ethanol was added and the mixture was heated at 80 ºC for 10 
min and filtered hot. The filtrate was concentrated under reduced pressure and the solid 
residue was recrystallised from a mixture of methanol/1,4-dioxane/water (3:1:1) to give 
2-(3-nitrophenyl)-1H-benzo[d]imidazole-5-carbonitrile 84 as a yellow crystalline solid 
(1.38 g, 70%), mp: 239-240 ºC, IR (cm
-1
): υ 3294 (w, NH), 2224 (m, CN), 1623 (w, 
C=N), 1517 (s, NO2), 1348 (s, NO2). 
1
H NMR (DMSO-d6), δ: 13.8 (br, NH), 9.02 (s, 
1H, phenyl_2 H), 8.62 (d, J = 7.8 Hz, 1H, phenyl_4 H), 8.37 (d, J = 7.8 Hz, 1H, 
phenyl_6 H), 8.21 (s, 1H, benzimidazole_4 H), 7.89 (t, J = 7.8 Hz, 1H, phenyl_5 H), 
7.80 (d, J = 8.3 Hz, 1H, benzimidazole_6 H), 7.63 (d, J = 8.3 Hz, 1H, benzimidazole_7 
H). 
13
C NMR, δ: 152.1 (benzimidazole C2), 148.3 (phenyl C3), 135.4 (benzimdazole 
C3a), 132.9 (benzimidazole C7a), 132.8 (phenyl C6), 130.8 (phenyl C1), 130.7 (phenyl 
C5), 126.1 (benzimidazole C6), 124.9 (phenyl C4), 123.9 (benzimidazole C4), 121.3 
(phenyl C2), 119.8 (CN), 116.6 (benzimidazole C7), 104.5 (benzimidazole C5) ppm. 









To a solution of 2-(3-nitrophenyl)-1H-benzo[d]imidazole-5-carbonitrile 84 (200 mg, 
0758 mmol) in methanol (20 mL) in a 100 mL round bottom flask, was added under a 
N2 atmosphere, Raney Nickel (0.1 mol%) with vigorous stirring. Under a N2 
atmosphere, a solution of hydrazine monohydrate (75.6 mg, 1.5 mmol) in methanol (5 
mL) was added dropwise over 10 min at room temperature. The mixture was then 
heated at 80 ºC for 2 h, and filtered hot through a short pad of celite. Methanol and 
excess hydrazine hydrate were concentrated under reduced pressure to give a brown 
residue. The residue was then subjected to a flash column chromatography and elution 
with 10% methanol in CH2Cl2 gave 2-(3-aminophenyl)-1H-benzo[d]imidazole-5-
carbonitrile 85 (141 mg, 80%) as a dark yellow solid, mp:  69-70 ºC, IR (cm
-1
): υ 3174 
(m, NH), 2219 (m, CN), 1616 (m, C=N). 
1
H NMR (DMSO-d6), δ: 8.08 (s, 1H, 
phenyl_2 H), 7.70 (d, J = 8.3 Hz, 1H, phenyl_4 H), 7.56 (d, J = 8.3 Hz, 1H, phenyl_6 
H), 7.46 (s, 1H, benzimidazole_4 H), 7.32 (d, J = 7.2 Hz, 1H, benzimidazole_6 H), 7.19 
(d, J = 8.0 Hz, 1H, phenyl_5 H), 6.72 (d, J = 7.0 Hz, 1H, benzimidazole_7 H), 5.37 (br, 
NH2). 
13
C NMR, δ: 155.4 (benzimidazole C2), 149.2 (phenyl C3), 149.1 (benzimidazole 
C7a), 140.0 (benzimidazole C3a), 129.8 (phenyl C5), 129.5 (phenyl C1), 125.4 
(benzimidazole C6), 120.2 (benzimidazole C4), 116.3 (phenyl C6), 115.9 (CN), 115.5 
(phenyl C4), 114.3 (benzimidazole C7), 112.2 (phenyl C2), 103.6 (benzimidazole C5) 
















To a solution of 2-(3-aminophenyl)-1H-benzo[d]imidazole-5-carbonitrile 85 (100 mg, 
0.427 mmol) in dry THF (20 mL) In an oven dried 25 mL flask, was added TEA (43 
mg, 0.427 mmol) and the mixture was stirred under N2 at 0 ºC for 30 min. A solution of 
oxalyl chloride (27.1 mg, 0.213 mmol) in dry THF (5 mL) was added dropwise over 15 
min. The mixture was left to warm up to room temperature with stirring for 2 h. Chilled 
water (10 mL) was added to the reaction mixture with vigorous stirring. The separated 
solid was filtered, washed with water and methanol, and was recrystallised from DMF 
to give the bis product 86 (153.8 mg, 69%) as a brown solid, mp:  >250 ºC; IR (cm
-1
): υ 
3259 (w, NH), 2224 (m, CN), 1684 (s, C=O). 
1
H NMR (DMSO-d6), δ: 11.08 (s, br, 
oxalamide NH), 8.85 (s, 2H, phenyl_2 H), 8.18 (s, 2H, benzimidazole_6 H), 7.99-7.96 
(m, 4 H, phenyl_4 H, benzimidazole_7 H), 7.78 (d, J = 8.2 Hz, 2 H, benzimidazole_6 
H), 7.64-7.60 (m, 4H, phenyl_5,6 H). 
13
C NMR, δ: 158.8 (CO), 153.9 (benzimidazole 
C2), 141.4 (benzimidazole C7a), 139.9 (phenyl C1), 138.3 (benzimidazole C3a), 129.6 
(phenyl C3), 126.5 (benzimidazole C6), 125.9 (benzimidazole C4), 123.2 (phenyl C6), 
123.1 (phenyl C5), 120.7 (phenyl C4), 119.9 (CN), 119.5 (phenyl C2), 115.7 
(benzimidazole C7), 104.3 (benzimidazole C5) ppm. ESI-MS m/z 521.4 (M-H). HRMS 
(ESI) calcd for C30H17N8O2 (M-H), 521.1474; found, 521.1453. 
 
9.1.4. Experimental for chapter 4 
General procedure 1: synthesis of isobenzofuran-1(3H)-one derivatives 90-92: 
Under a N2 atmosphere, a sealed tube was charged with the appropriate benzoic acid (1 
mmol), palladium acetate (22.4 mg, 0.1 mmol), dipotassium phosphate (K2HPO4, 522.5 
mg, 3 mmol) and dibromomethane (4 mL). The content of the tube was degassed by 
flushing N2 through a needle for 10 min. The tube was then sealed, and heated in an oil 
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bath at 140 ºC for 36 h. The tube was then allowed to cool to room temperature, the 
content was diluted with CH2Cl2 (20 mL), and then filtered through celite. The filtrate 
was washed with 1 M HCl (20 mL) and brine (2 x 15 mL), and was dried (MgSO4). The 
solvent was evaporated under reduce pressure and the residue was either subjected to 
flash column chromatography (10% methanol in chloroform) or recrystallised from 




Following the general procedure 1using 3-bromo-2-methoxybenzoic acid 87 (231 mg), 
the benzofuran 90 was isolated after column chromatography, as a white solid (92 mg, 
38%), mp: 102-103 ºC; IR (cm
-1
): υ 1752 (s, C=O), 1288 (m, C-O), 1064 (w, C-O), 
1111 (w, C-Br). 
1
H NMR (CDCl3), δ: 7.84 (d, J = 7.9 Hz, 1H, H5), 7.06 (d, J = 7.9 Hz, 
1H, H4), 5.23 (s, 2H, CH2), 4.16 (s, 3H, OCH3). 
13
C NMR, δ: 167.5 (C=O), 156.3 (C7), 
148.3 (C3a), 139.3 (C5), 118.6 (C4), 117.9 (C7a), 117.2 (C6), 68.7 (CH2), 62.9 (CH3) 




Br, 30), 213 (33), 198 (100%), 183 (15). HRMS (ESI) 
calcd for C9H8
79




Following the general procedure 1using 3-bromo-2-methylbenzoic acid 88 (215 mg), 
the benzofuran 91 was isolated after recrystallisation, as a pale yellow solid (124 mg, 
55%), mp: 91-92 ºC; IR (cm
-1
): υ 1739 (s, C=O), 1358 (w, C-O), 1069 (w, C-Br). 
1
H 
NMR (CDCl3), δ: 7.79 (d, J = 8.0 Hz, 1H, H5), 7.18 (d, J = 8.0 Hz, 1H, H4), 5.20 (s, 
2H, CH2), 2.74 (s, 3H, CH3). 
13
C NMR, δ: 170.1 (C=O), 146.1 (C3a), 139.8 (C5), 137.7 
(C4), 126.3 (C7), 124.7 (C7a), 120.6 (C6), 68.2 (CH2), 16.6 (CH3) ppm. EI-MS m/z 226 







Br, 55), 197 (100%), 169 (30). HRMS (ESI) calcd for C9H8
79
BrO2 (MH+), 




  92 
 
This compound is reported but prepared in this work by a different method, following 
the general procedure 1 using 2,4-dimethoxybenzoic acid 89 (182 mg). The benzofuran 
92 was isolated after column chromatography as a white solid (112.5 mg, 58%). 








   
In a round bottom flask (50 mL), 5,7-dimethoxyisobenzofuran-1(3H)-one 92 (150 mg, 
0.773 mmol) was dissolved in glacial acetic acid (20 mL) with vigorous stirring and the 
flask was cooled to -5 : 0 ºC using an ice bath. A solution of bromine (136 mg, 0.851 
mmol) in glacial acetic acid (10 mL) was added dropwise over 20 min. The reaction was 
allowed to warm up slowly to room temperature and was then allowed to stir for 4 h. 
The formed solid was filtered and washed with dilute acetic acid, and was then 
subjected to column chromatography (60% CH2Cl2 in hexane) to afford the benzofuran 
94 (176.7 mg, 84%) as a white solid. It could also be recrystallised from 1,4-dioxane, 
mp: 189-190 ºC; IR (cm
-1
): υ 1700 (s, C=O), 1316 (w, C-O), 1071 (w, C-O), 1036 (w, 
C-Br). 
1
H NMR (CDCl3), δ: 6.46 (s, 1H, H4), 5.07 (s, 2H, CH2), 4.02 (s, 6H, OCH3). 
13
C NMR, δ: 168.4 (C=O), 162.2 (C7), 159.5 (C5), 150.5 (C3a), 107.8 (C7a), 96.2 (C6), 
95.1 (C4), 69.3 (CH2), 57.1 (C7-OCH3), 56.6 (C5-OCH3) ppm. EI-MS m/z 272 (M+ 
                                                             
* This reference reports only the elemental analysis and 1H NMR.  






Br, 40), 254 (20), 243 (30), 228 (100%), 213 (20). HRMS (ESI) calcd for 
C10H10
79






This compound was prepared following the reported procedure.
208
 The nitro-phthalide 






Reduction of the nitro group of the 6-nitroisobenzofuran-1(3H)-one 98 to the 6-
aminoisobenzofuran-1(3H)-one 99 was achieved following the reported reduction 
procedure developed in our laboratory.
209
 by sonicating a suspension of the nitro 
derivative 98 (172 mg, 0.961 mmol) in a mixture of ethanol (2 mL), acetic acid (2 mL) 
and water (1 mL) and with iron powder (0.27 g, 5 mmol) for 1 h at 35 ºC. The reaction 
mixture was filtered to remove the iron residue. The filtrate was partitioned with 2 M 
KOH, and the basic layer was further extracted with ethyl acetate (3 x 25 mL). The 
combined organic extracts were washed with brine (2 x 25 mL) and water (3 x 50 mL), 
dried (MgSO4), and concentrated under reduced pressure. The solid residue was then 
crystallized from toluene to give the amino derivative 99 in 88% yield (126 mg) as a 
white solid. The spectral data obtained for this compound 99 using this reduction 









This compound was prepared following the reported procedure.
210
 The 6-
bromoisobenzofuran-1(3H)-one 100 was isolated as a pale yellow solid (106 mg, 74%). 







This compound was prepared following the reported procedure.
212
 The 4,6-




In a 100 mL round bottom flask, a solution of 4,6-dimethoxyindole-2,3-dione 102 (143 
mg, 0.5 mmol) in acetic acid (10 mL) was stirred at room temperature until all the isatin 
was dissolved completely before being cooled to 0 ºC using an ice bath. N-
Bromosuccinimide (97.9 mg, 0.55 mmol) was added portion wise over 15 min. After 
addition of the NBS, the reaction mixture started to solidify, and the flask was removed 
from the ice bath and was allowed to warm to room temperature and then stirred for 8 h. 
The yellow solid was filtered from the mother liquor to which cold water (10 mL) was 
added to precipitate the remaining soluble product. The combined solids were washed 
with saturated NaHCO3 solution (2 x 15 mL) and with 1:1 water ethanol mixture (25 
mL) and then vacuum dried. Recrystallisation from 1,4-dioxane yielded the 5-bromo-
4,6-dimethoxyindoline-2,3-dione 103 as a yellow solid (118 mg, 60%), mp: >250 ºC; IR 
(cm
-1
): υ 3195 (m, NH), 1718 (s, C=O), 1264 (m, C-O). 
1
H NMR (DMSO-d6), δ: 11.14 
(s, NH), 6.36 (s, H7), 3.99 (s, 3H, C6-OCH3), 3.94 (s, 3H, C4-OCH3). 
13
C NMR, δ: 
178.4 (C3), 165.5 (C2), 161.7 (C4), 160.4 (C6), 151.4 (C7a), 102.7 (C3a), 91.8 (C7), 





257 (100%), 213 (7). HRMS (ESI) calcd for C10H9N
79
BrNO4 (MH+), 285.9715; found, 
285.9719. 
 







This compound is reported by a different method than the method described here.
215
 In 
this work, 4-bromo-2-methylaniline 104 (6.88 g, 37 mmol) was added to a 500 mL flask 
and was reacted with chloral hydrate (7.35 g, 44.4 mmol), hydroxylamine hydrochloride 
(9.25 g, 133 mmol), sodium sulfate (42 g, 295 mmol) in water (250 mL) and 2 M HCl 
(12.5 mL), by heating the mixture at 55 ºC with vigorous stirring for 14 h. After cooling 
to room temperature, the aqueous layer was decanted from the formed the gummy 
residue which was further washed with cold water and dried under vacuum. The flask 
was then cooled to -5 : 0 ºC using ice/salt bath before adding cold sulphuric acid (22.5 
mL). The flask was allowed to warm to room temperature before heating the reaction 
mixture gradually to 70 ºC where the mixture started to get darker in colour. When the 
colour change became stable after almost 30 min, the reaction was heated to 80 ºC for 
10 min. After cooling to room temperature, the mixture was poured onto crushed ice 
(150 mL) and stirred for 1 h. The separated solid was then filtered and washed with 
water (3 x 100 mL) to give a red solid of 5-bromo-7-methylindoline-2,3-dione 106 (6.65 
g, 75%) and was sufficiently pure for the next step. The spectral data were consistent 








This compound was synthesized following the reported procedure from 4-methyl-3-
nitrophenol 107.
216
 The 4-methoxy-1-methyl-2-nitrobenzene 108 was isolated as a 
white crystalline solid (5.34 g, 80%). 
 







The synthesis of this compound is reported by a different method.
217
 In this work, it was 
prepared by dissolving 4-methoxy-1-methyl-2-nitrobenzene 108 (5.1 g, 30.5 mmol) in 
methanol (35 mL) under a N2 atmosphere. Raney Nickel (0.1 mol %) was added and the 
mixture was vigorously stirred at room temperature until the H2 ceased to evolve. 
Hydrazine monohydrate (2.0 g, 41 mmol) in methanol (10 mL) was added through a 
syringe slowly over 10 min. The mixture was then heated at reflux for 4 h. The reaction 
mixture was filtered hot through celite, and the filtrate was concentrated under reduced 
pressure. The obtained residue was recrystallised from petroleum spirit to yield 5-
methoxy-2-methylaniline 109 as white solid (3.8 g, 91%). Spectral data for this aniline 








In a 250 mL round bottom flask, 5-methoxy-2-methylaniline 109 (2.0 g, 15 mmol) was 
dissolved in anhydrous benzene (20 mL), and oxalyl chloride (4.12 g, 2.8 mL, 32.4 
mmol) was added dropwise. When the HCl ceased to evolve, the reaction was heated at 
reflux for 3 h. The benzene and oxalyl chloride were then removed by distillation, and 
the residue was quickly suspended in dichloroethane (20 mL) and then cooled to 0 ºC in 
an ice bath. Aluminium chloride (2.1 g, 15.5 mmol) as a suspension in dichloroethane 
(10 mL) was added portion wise with vigorous stirring and the reaction mixture was 
allowed to warm to room temperature over 3 h. The reaction mixture was then heated at 
reflux for 40 min. After cooling to room temperature, the mixture was poured onto 
                                                             
* This compound is commercially available but with no synthesis reference. 
Chapter 9  Experimental 
231  
 
crushed ice, portioned between 0.1 M HCl and ethyl actetate. The aqueous layer was 
further extracted with ethyl acetate (2 x 100 mL). The combined organic layers were 
washed with brine (100 mL), dried (MgSO4) and evaporated under reduced pressure. 
The resulting orange solid was subjected to a flash column chromatography and elution 
with 30% ethyl acetate in petroleum spirit yielded 4-methoxy-7-methylindoline-2,3-
dione 111 as an orange solid (0.84 g, 30%), mp: 235-236 ºC; IR (cm
-1
): υ 3195 (m, NH), 
1635 (s, C=O), 1250 (m, C-O). 
1
H NMR (DMSO-d6), δ: 10.99 (s, NH), 7.36 (d, J = 8.7, 
1H, H6), 6.61 (d, J = 8.7, 1H, H5), 3.83 (s, 3H, OCH3), 2.09 (s, 3H, CH3). 
13
C NMR, δ: 
180.9 (C2), 160.1 (C3), 156.4 (C4), 149.1 (C7a), 141.8 (C6), 112.9 (C7), 106.5 (C5), 
105.8 (C3a), 55.8 (OCH3), 14.6 (CH3) ppm. EI-MS m/z 191 (M+, 100%), 163 (50), 149 





In a 100 mL round bottom flask, 4-methoxy-7-methylindoline-2,3-dione 111 (440 mg, 
2.3 mmol) was dissolved in glacial acetic acid (15 mL) and the mixture was stirred until 
the solid dissolved completely. The flask was then cooled to 0 ºC using an ice bath. A 
solution of bromine (405 mg, 2.5 mmol) in glacial acetic acid (5 mL) was then added 
dropwise over 10 min. The flask was allowed to warm to room temperature and was 
stirred for 2 h. The resulting solid was filtered and cold water (15 mL) added to the 
filtrate and the resulting solid was filtered. The combined solids were washed with 
saturated NaHCO3 (2 x 25 mL) and water (2 x 25 mL), and recrystallised from acetic 
acid to yield 5-bromo-4-methoxy-7-methylindoline-2,3-dione 112 as an orange solid 
(520.5 mg, 84%), mp: >250 ºC; IR (cm
-1
): υ 3162 (m, NH), 1696 (s, C=O), 1248 (w, C-
O). 
1
H NMR (DMSO-d6), δ: 11.20 (s, NH), 7.67 (s, H6), 3.97 (s, 3H, OCH3), 2.12 (s, 
3H, CH3). 
13
C NMR, δ: 180.7 (C2), 159.2 (C3), 152.6 (C4), 148.9 (C7a), 142.6 (C6), 
117.7 (C7), 110.1 (C3a), 108.1 (C5), 61.8 (OCH3), 14.6 (CH3) ppm. EI-MS m/z 271 







Br, 90), 241 (100%), 228 (20), 185 (80). HRMS (ESI) calcd for 
C10H9
79
BrNO3 (MH+), 269.9766; found, 269.9773. 
 
General procedure 2: Suzuki coupling of 6-bromobenzolactone derivatives 90, 91, 
94 and 100 with 3-(3-boronophenyl)propanoic acid 113: 
Under a N2 atmosphere, a 25 mL flask was charged with the bromoisobenzofuran-
1(3H)-one (1 equiv), 3-(3-boronophenyl)propanoic acid 113 (1.2 equiv), 
tetrakis(triphenylphosphine)palladium(0) (5 mol%) and 1,4-dioxane (5 mL). The flask 
was sealed with a rubber cap. The reaction mixture was degassed by flushing N2 
through a needle for 10 min. The flask was heated in an oil bath at 85 ºC. When the 
solid dissolved, a N2 degassed solution of potassium phosphate (3 equiv) in water (3 
mL) was added to the reaction mixture and heating at 85 ºC continued for 4-6 h. After 
cooling to room temperature, the solvent was concentrated under reduced pressure, and 
2 M HCl (15 mL) was added to the residue. The suspended solid was either collected by 
filtration or extracted with ethyl acetate (2 x 25 mL). The combined ethyl acetate 
extracts were dried (MgSO4) and evaporated under reduced pressure. The obtained 
residues were dissolved in ethanol and were subjected PLC (10% methanol in CH2Cl2, 
0.5% acetic acid).  
 
3-(3-(4-Methoxy-3-oxo-1,3-dihydroisobenzofuran-5-yl)phenyl)propanoic acid 114 
 
Following the general procedure 2 using 6-bromo-7-methoxyisobenzofuran-1(3H)-one 
90 (110 mg, 0.453 mmol), 3-(3-boronophenyl)propanoic acid 113 (105.5 mg, 0.544 
mmol), tetrakis(triphenylphosphine)palladium(0) (26.2 mg, 0.023 mmol) and potassium 
phosphate (288.5 mg, 1.359 mmol) and heating for 5 h, the acid 114 was isolated as a 
white solid  (87.5 mg, 62%), mp: 116-117 ºC; IR (cm
-1
): υ 2989 (m, OH), 1755 (s, 
C=O), 1718 (s, C=O), 1216 (m, C-O). 
1
H NMR (CDCl3), δ: 10.54 (s, 1H, COOH), 7.73 
(d, 1H, J = 7.5 Hz, isobenzofuran_6 H), 7.45 (s, 1H, phenyl_2 H), 7.41 (d, 1H, J = 7.7 
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Hz, phenyl_4 H), 7.40-7.37 (m, 2H, phenyl_5,6 H), 7.30 (d, 1H, J = 7.5 Hz, 
isobenzofuran_7 H), 5.37 (s, 2H, isobenzofuran CH2), 3.88 (s, 3H, OCH3), 2.99 (t, 2H, J 
= 6.7 Hz, COOH-CH2-CH2), 2.68 (t, 2H, J = 6.7 Hz, COOH-CH2-CH2). 
13
C NMR, δ: 
175.6 (COOH), 168.9 (C=O), 156.9 (isobenzofuran C4), 148.4 (phenyl C1), 140.5 
(isobenzofuran C7a), 137.8 (phenyl C5), 137.1 (isobenzofuran C6), 135.7 (phenyl C6), 
129.5 (phenyl C3), 128.7 (phenyl C2), 127.9 (isobenzofuran C5), 127.5 (phenyl C4), 
118.0 (isobenzofuran C3a), 117.1 (isobenzofuran C7), 68.9 (isobenzofuran C1), 62.7 
(OCH3), 47.4 (COOH-CH2-CH2), 30.8 (COOH-CH2-CH2) ppm. EI-MS m/z 312 (M+, 
75), 295 (20), 266 (17), 239 (100%), 223 (50), 208 (15), 195 (51). HRMS (ESI) calcd 
for C18H17O5 (MH+), 313.1076; found, 313.1078. HPLC purity: 97.4%, Rt=8.245 (1% 
solvent B in solvent A). 
 
3-(3-(4-Methyl-3-oxo-1,3-dihydroisobenzofuran-5-yl)phenyl)propanoic acid 115 
 
Following the general procedure 2 using 6-bromo-7-methylisobenzofuran-1(3H)-one 91 
(95 mg, 0.418 mmol), 3-(3-boronophenyl)propanoic acid 113 (97.3 mg, 0.502 mmol), 
tetrakis(triphenylphosphine)palladium(0) (24.2 mg, 0.021 mmol) and potassium 
phosphate (266.2 mg, 1.254 mmol) and heating for 4 h, the acid 115 was isolated as a 
white solid (66.8 mg, 54%), mp: 110-111 ºC; IR (cm
-1
): υ 2989 (m, OH), 1731 (s, 
C=O), 1696 (s, C=O). 
1
H NMR (CDCl3), δ: 7.55 (d, 1H, J = 7.8 Hz, isobenzofuran_6 
H), 7.50 (d, 1H, J = 7.3 Hz, phenyl_4 H), 7.37 (t, 1H, J = 7.3 Hz, phenyl_5 H), 7.26 (d, 
1H, J = 7.3 Hz, phenyl_6 H), 7.20 (s, 1H, phenyl_2 H), 7.16 (d, 1H, J = 7.3 Hz, 
isobenzofuran_7 H), 5.28 (s, 2H, isobenzofuran CH2), 3.02 (t, 2H, J = 7.3 Hz, COOH-
CH2-CH2), 2.74 (t, 2H, J = 7.3 Hz, COOH-CH2-CH2), 2.59 (s, 3H, CH3). 
13
C NMR, δ: 
185.4 (COOH), 171.6 (C=O), 146.3 (phenyl C1), 143.5 (isobenzofuran C7a), 140.5 
(phenyl C3), 140.3 (isobenzofuran C4), 137.6 (phenyl C2), 135.7 (isobenzofuran C5), 
132.3 (phenyl C5), 129.5 (phenyl C6), 128.7 (isobenzofuran C6), 127.6 (phenyl C4), 
123.8 (isobenzofuran C3a), 119.1 (isobenzofuran C7), 68.5 (isobenzofuran C1), 35.7 
(COOH-CH2-CH2), 30.7 (COOH-CH2-CH2), 14.9 (CH3) ppm. EI-MS m/z 296 (M+, 
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100%), 278 (54), 260 (46), 250 (80), 136 (60), 223 (40). HRMS (ESI) calcd for 
C18H17O4 (MH+), 297.1127; found, 297.1129. HPLC purity: 97.9%, Rt=5.571 (1% 
solvent B in solvent A). 
 
3-(3-(4,6-Dimethoxy-3-oxo-1,3-dihydroisobenzofuran-5-yl)phenyl)propanoic acid 116 
 
Following the general procedure 2 using 6-bromo-5,7-dimethoxyisobenzofuran-1(3H)-
one 94 (80 mg, 0.293 mmol), 3-(3-boronophenyl)propanoic acid 113 (68.2 mg, 0.352 
mmol), tetrakis(triphenylphosphine)palladium(0) (16.9 mg, 0.015 mmol) and potassium 
phosphate (186.6 mg, 0.879 mmol) and heating for 6 h, the acid 116 was isolated as a 
pale yellow oil in (56 mg, 56%), IR (cm
-1
): υ 2989 (m, OH), 1750 (s, C=O), 1739 (s, 
C=O), 1208 (w, C-O). 
1
H NMR (CDCl3), δ: 7.33 (t, 1H, J = 7.9 Hz, phenyl_5 H), 7.18 
(d, 1H, J = 7.9 Hz, phenyl_4 H), 7.12-7.10 (m, 2H, phenyl_2,6 H), 6.50 (s, 1H, 
isobenzofuran_7 H), 4.98 (s, 2H, isobenzofuran CH2), 4.03 (s, 3H, isobenzofuran_4 
OCH3), 3.85 (s, 3H, isobenzofuran_6 OCH3), 2.97 (t, 3H, J = 7.6 Hz, COOH-CH2-
CH2), 2.66 (t, 3H, J = 7.6 Hz, COOH-CH2-CH2). 
13
C NMR, δ: 177.2 (COOH), 169.0 
(C=O), 162.8 (isobenzofuran C6), 159.4 (isobenzofuran C4), 149.3 (phenyl C1), 140.7 
(isobenzofuran C7a), 133.8 (phenyl C3), 129.3 (phenyl C2), 128.7 (phenyl C5), 127.7 
(phenyl C4), 127.4 (phenyl C6), 117.5 (isobenzofuran C3a), 106.1 (isobenzofuran C5), 
95.5 (isobenzofuran C7), 68.3 (isobenzofuran C1), 56.3 (isobenzofuran_6 OCH3), 56.2 
(isobenzofuran_4 OCH3), 35.1 (COOH-CH2-CH2), 30.7 (COOH-CH2-CH2) ppm. EI-
MS m/z 342 (M+, 100), 326 (25), 296 (26). HRMS (ESI) calcd for C19H18O6 (MH+), 
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3-(3-(3-Oxo-1,3-dihydroisobenzofuran-5-yl)phenyl)propanoic acid 117 
 
Following the general procedure 2 using 6-bromoisobenzofuran-1(3H)-one 100 (90 mg, 
0.422 mmol), 3-(3-boronophenyl)propanoic acid 113 (98.2 mg, 0.506 mmol), 
tetrakis(triphenylphosphine)palladium(0) (24.4 mg, 0.021 mmol) and potassium 
phosphate (268.7 mg, 1.266 mmol) and heating for 4 h, the acid 117 was isolated as a 
white solid (92.8 mg, 78%), mp: 118-119 ºC; IR (cm
-1
): υ 2972 (m, OH), 1743 (s, 
C=O), 1699 (s, C=O). 
1
H NMR (CDCl3), δ: 8.11 (s, 1H, isobenzofuran_4 H), 7.90 (d, 
1H, J = 8.0 Hz, phenyl_4 H), 7.55 (d, 1H, J = 7.9 Hz, phenyl_6 H), 7.47 (s, 1H, 
phenyl_2 H), 7.46 (d, 1H, J = 6.2 Hz, isobenzofuran_6 H), 7.41 (t, 1H, J = 8.0 Hz, 
phenyl_5 H), 7.27 (d, 1H, J = 6.7 Hz, isobenzofuran_7 H), 5.37 (s, 2H, isobenzofuran 
CH2), 3.05 (t, 2H, J = 7.6 Hz, COOH-CH2-CH2), 2.75 (t, 2H, J = 7.6 Hz, COOH-CH2-
CH2). 
13
C NMR, δ: 178.3 (COOH), 171.4 (C=O), 145.5 (phenyl C1), 142.8 
(isobenzofuran C7a), 141.4 (phenyl C2), 139.9 (isobenzofuran C5), 133.4 (phenyl C3), 
129.6 (phenyl C5), 128.3 (phenyl C6), 127.6 (isobenzofuran C6), 126.7 (isobenzofuran 
C3a), 125.6 (phenyl C4), 124.3 (isobenzofuran C4), 122.7 (isobenzofuran C7), 69.9 
(isobenzofuran C1), 35.6 (COOH-CH2-CH2), 30.8 (COOH-CH2-CH2) ppm. EI-MS m/z 
282 (M+, 70), 253 (20), 237 (100%), 223 (16). HRMS (ESI) calcd for C17H15O4 (MH+), 





Under a N2 atmosphere, an oven dried 100 mL flask was charged with 2-(3-
iodophenoxy)acetonitrile 124 (1.16 g, 4.479 mmol), bis(pinacolato)diboron 125 (4.55 g, 
17.916 mmol), potassium acetate (17.916 mmol, 1.76 g) and [1,1′-
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bis(diphenylphosphino)ferrocene]dichloropalladium(II) (PdCl2(dppf)) (32.8 mg, 1 
mol%). Dry THF (50 mL) was added to the mixture, and the flask was heated at reflux 
for 18 h under N2 atmosphere. The solvent was then evaporated under reduced pressure, 
ethyl acetate (30 mL) was added and the mixture was sonicated for 10 min and filtered. 
The filtrate was triturated with MgSO4 and charcoal (0.5 g), and filtered through a short 
pad of celite. The filtrate was then concentrated under reduced pressure and the 
resulting residue was recrystallised from a mixture of ethyl acetate/hexane (3:2) to give 
the boronic ester 119 as a pink solid (1.1 g, 95%), mp: 40-41 ºC; IR (cm
-1
): υ 2980 (m, 
C-H aliphatic), 2152 (m, CN), 1128 (w, C-O). 
1
H NMR (CDCl3), δ: 7.43 (d, 1H, J = 7.6 
Hz, phenoxy_6 H), 7.39 (s, 1H, phenoxy_2 H), 7.08 (t, 1H, J = 7.9 Hz, phenoxy_5 H), 
6.96 (d, 1H, J = 8.0 Hz, phenoxy_4 H), 4.76 (s, 2H, CH2), 1.26 (s, 12H, 4CH3). 
13
C 
NMR, δ: 157.1 (phenoxy C1), 132.6 (phenoxy C3), 131.4 (phenoxy C5), 124.7 
(phenoxy C4), 114.8 (CN), 114.6 (phenoxy C2), 94.6 (phenoxy C6), 83.7 (dioxaborolan 
C4, C5), 53.9 (CH2), 25.2 (4CH3) ppm. ESI-MS m/z 259 (M+). HRMS (ESI) calcd for 
C14H19BNO3 (MH+), 260.1458; found, 260.1462. 
 
General procedure 3: Suzuki coupling of 6-bromobenzolactone derivatives 90 and 
91 with (3-(cyanomethoxy)phenyl)boronic acid 118 or ester 119: 
A round bottom 25 mL flask was charged with the appropriate dihydroisobenzofuran 
derivative  (1 equiv), (3-(cyanomethoxy)phenyl)boronic acid 118 (1 equiv) or 2-(3-
(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)acetonitrile 119 (1.2 equiv), 
tetrakis(triphenylphosphine)palladium(0) (5 mol%), 1,4-dioxane (10 mL) was added 
and the flask was sealed with a rubber cap. The reaction mixture was degassed by 
flushing N2 through a needle for 10 min. The flask was heated in an oil bath at 85 ºC. 
When all the solid was dissolved, potassium phosphate (3 mmol, 636.8 mg) dissolved in 
water (5 mL) was added to the reaction via a needle. The flask was then heated at 85 ºC 
for 7-15 h. The solvent was concentrated under reduced pressure, and was added 1M 
HCl (10 mL), the reaction mixture turned to a white turbid solution which was then 
extracted with ethyl acetate (2 x 30 mL), washed with brine (2 x 10 mL) and dried 
(MgSO4). The solvent was evaporated and the residue was subjected to flash column 
chromatography (40% ethyl acetate in petroleum spirit). 





Following the general procedure 3 using 6-bromo-7-methoxyisobenzofuran-1(3H)-one 
90 (100 mg, 0.411 mmol), (3-(cyanomethoxy)phenyl)boronic acid 118 (72 mg, 0.411 
mmol),  tetrakis(triphenylphosphine)palladium(0) (23.7 mg, 0.021 mmol) and heating 
for 15 h, the acetonitrile intermediate 120 was isolated as a white solid (60.7 mg, 50%), 
mp: 103-104 ºC; IR (cm
-1
): υ 2920 (w, C-H aliphatic), 2165 (m, CN), 1759 (s, C=O), 
1212 (w, C-O). 
1
H NMR (CDCl3), δ: 7.74 (d, 1H, J = 7.7 Hz, isobenzofuran_6 H), 7.43 
(t, 1H, J = 8.0 Hz, phenyl_5 H), 7.25-7.23 (m, 2H, phenyl_4 H, isobenzofuran_7 H), 
7.19 (s, 1H, phenyl_2 H), 7.02 (d, 1H, J = 8.2 Hz, phenyl_6 H), 5.30 (s, 2H, 
isobenzofuran CH2), 4.83 (s, 2H, CN-CH2), 3.90 (s, 3H, OCH3). 
13
C NMR, δ: 168.5 
(C=O), 156.7 (phenyl C1), 156.4 (isobenzofuran C4), 148.7 (isobenzofuran C7a), 138.7 
(isobenzofuran C6), 137.4 (phenyl C5), 134.7 (isobenzofuran C5), 129.8 (phenyl C4), 
124.1 (phenyl C3), 117.9 (phenyl C6), 117.1 (phenyl C2), 116.1 (CN), 115.1 
(isobenzofuran C3a), 114.5 (isobenzofuran C7), 68.7 (isobenzofuran C1), 62.7 (CN-
CH2), 53.7 (OCH3) ppm. EI-MS m/z 295 (M+, 15), 255 (100%), 237 (13), 208 (10), 180 
(16). HRMS (ESI) calcd for C17H14NO4 (MH+), 296.0914; found, 296.0913. HPLC 




Following the general procedure 3 using 6-bromo-7-methoxyisobenzofuran-1(3H)-one 
91 (100 mg, 0.358 mmol), 2-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy) 
acetonitrile 119 (111.4 mg, 0.430 mmol), tetrakis(triphenylphosphine)palladium(0) 
(20.7 mg, 0.018 mmol)  and heating for 7 h, the acetonitrile intermediate 121 was 
isolated as white solid (93.4 mg, 76%), mp: 99-100 ºC; IR (cm
-1
): υ 2972 (w, C-H 
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aliphatic), 2169 (m, CN), 1743 (s, C=O). 
1
H NMR (CDCl3), δ: 7.74 (d, 1H, J = 7.7 Hz, 
isobenzofuran_6 H), 7.43 (t, 1H, J = 7.9 Hz, phenyl_5 H), 7.32 (d, 1H, J = 7.7 Hz, 
isobenzofuran_7 H), 7.02 (d, 2H, J = 8.0 Hz, phenyl_4,6 H), 6.93 (s, 1H, phenyl_2 H), 
5.28 (s, 2H, isobenzofuran CH2), 4.83 (s, 2H, CN-CH2), 2.60 (s, 3H, CH3). 
13
C NMR, δ: 
171.4 (C=O), 156.7 (phenyl C1), 146.7 (isobenzofuran C7a), 142.8 (isobenzofuran C4), 
142.1 (isobenzofuran C5), 137.6 (phenyl C3), 135.6 (phenyl C5), 130.1 (isobenzofuran 
C3a), 124.4 (phenyl C4), 124.1 (isobenzofuran C6), 119.4 (isobenzofuran C7), 116.4 
(phenyl C2), 115.3 (CN), 114.1 (phenyl C6), 68.6 (isobenzofuran C1), 53.9 (CN-CH2), 
15.0 (CH3) ppm. EI-MS m/z 279 (M+, 90), 239 (100%), 223 (15), 195 (12), 165 (24). 
HRMS (ESI) calcd for C17H14NO3 (MH+), 280.0974; found, 280.0966. HPLC purity: 





A solution of 3-iodophenol 122 (2.0 g, 9.09 mmol) and NaOH (0.91 g, 22.73 mmol) in 
dry DMF (25 mL) was stirred vigorously for 30 min until the solution became pale 
brown. 2-Chloroacetonitrile 123 (1.03 g, 0.86 mL, 13.64 mmol) was then added 
dropwise through a syringe and the mixture was further stirred for 18 h at room 
temperature. The resulting brown solution was then poured onto crushed ice (100 mL), 
stirred for 30 min, and the resulting oil was extracted with ethyl acetate (2 x 25 mL). 
The combined organic layers were washed with water (2 x 25 mL), brine (2 x 25 mL) 
and dried (MgSO4). The organic fraction was then triturated with charcoal (0.5 g) and 
filtered through celite, and evaporated under reduced pressure to afford 2-(3-
iodophenoxy)acetonitrile 124 as a yellow oil (1.88 g, 80%), IR (cm
-1
): υ 2942 (m, C-H 
aliphatic), 2246 (s, CN), 1203 (w, C-O). 
1
H NMR (CDCl3), δ: 7.37 (d, 1H, J = 7.7 Hz, 
phenoxy_6 H), 7.29 (s, 1H, phenoxy_2 H), 7.02 (t, 1H, J = 7.9 Hz, phenoxy_5 H), 6.90 
(d, 1H, J = 8.0 Hz, phenoxy_4 H), 4.68 (s, 2H, CH2). 
13
C NMR, δ: 157.1 (phenoxy C1), 
132.5 (phenoxy C5), 131.6 (phenoxy C4), 124.7 (phenoxy C2), 115.3 (CN), 114.6 
                                                             
* This reference was published in 2013 after the synthesis of 124 in this work, and it only reports the 1H 
NMR, 13C NMR and LRMS. 
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(phenoxy C6), 94.9 (phenoxy C3), 54.0 (CH2) ppm. EI-MS m/z 259 (M+, 100%), 219 
(27), 203 (5). HRMS (ESI) calcd for C8H7INO (MH+), 259.9572; found, 259.9565. 
 
General procedure 4: synthesis of the benzolactone-tetrazole conjugates 126 and 
127 using sodium azide method: 
Under a N2 atmosphere, a round bottom flask (25 mL) was charged with the appropriate 
acetonitrile derivative 120-121 (0.186 mmol), sodium azide (48.4 mg, 0.744 mmol), 
amonium chloride (39.4 mg, 0.744 mmol), DMF (10 mL) and a catalytic amount of 
glacial acetic acid (5-10 drops), and the reaction mixture was then heated at reflux for 
24 h. DMF was concentrated under reduced pressure and the residue was dried by 
vacuum. Ethanol was added to the resulting dry residue and the mixture was sonicated 
for 10 min, filtered and the ethanol solution was concentrated and subjected to PLC 





Following the general procedure 4 using 2-(3-(4-methoxy-3-oxo-1,3-
dihydroisobenzofuran-5-yl)phenoxy)acetonitrile 120 (55 mg), the tetrazole conjugate 
126 was isolated as a pale yellow solid (21.4 mg, 34%), mp: 130-131 ºC; IR (cm
-1
): υ 
3404 (w, NH), 2907 (w, C-H aliphatic), 1751 (s, C=O), 1660 (m, C=N), 1134 (w, C-O). 
1
H NMR (CD3OD), δ: 7.72 (d, 1H, J = 7.7 Hz, isobenzofuran_5 H), 7.42 (t, 1H, J = 7.9 
Hz, phenyl_5 H), 7.37 (d, 1H, J = 7.7 Hz, isobenzofuran_4 H), 7.22-7.17 (m, 2H, 
phenyl_2,4 H), 7.10 (d, 1H, J = 8.2 Hz, phenyl_6 H), 5.50 (s, 2H, isobenzofuran CH2), 
5.34 (s, 2H, O-CH2), 3.78 (s, 3H, OCH3). 
13
C NMR, δ: 169.7 (C=O), 157.9 (phenyl C3), 
156.5 (isobenzofuran C7), 149.6 (tetrazole C), 138.7 (isobenzofuran C3a), 137.7 
(isobenzofuran C5), 135.1 (phenyl C5), 129.5 (isobenzofuran C6), 129.4 (phenyl C6), 
123.0 (phenyl C1), 117.6 (phenyl C4), 117.5 (phenyl C2), 115.9 (isobenzofuran C7a), 
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113.9 (isobenzofuran C4), 69.3 (isobenzofuran C3), 61.7 (tetrazole-CH2-O), 59.9 
(OCH3) ppm. EI-MS m/z 338 (M+, 14), 255 (100%), 239 (10), 211 (12), 195 (11). 
HRMS (ESI) calcd for C17H15N4O4 (MH+), 339.1093; found, 339.1107. HPLC purity: 




Following the general procedure 4 using 2-(3-(4-methyl-3-oxo-1,3-
dihydroisobenzofuran-5-yl)phenoxy)acetonitrile 121 (51.9 mg), the final tetrazole 
conjugate 127 was isolated as a pale yellow gummy solid (21 mg, 35%), IR (cm
-1
): υ 
3392 (m, NH), 2988 (w, C-H aliphatic), 1741 (s, C=O), 1668 (m, C=N), 1212 (w, C-O). 
1
H NMR (CD3OD), δ: 7.58 (d, 1H, J = 7.7 Hz, isobenzofuran_5 H), 7.48 (d, 1H, J = 7.7 
Hz, isobenzofuran_4 H), 7.44 (t, 1H, J = 7.9 Hz, phenyl_5 H), 7.12 (d, 1H, J = 7.9 Hz, 
phenyl_6 H), 7.03 (s, 1H, phenyl_2 H), 6.99 (d, 1H, J = 7.5 Hz, phenyl_4 H), 5.51 (s, 
2H, isobenzofuran CH2), 5.36 (s, 2H, O-CH2), 2.55 (s, 3H, CH3). 
13
C NMR, δ: 170.9 
(C=O), 162.4 (phenyl C3), 157.3 (tetrazole C), 147.2 (isobenzofuran C3a), 142.1 
(isobenzofuran C7), 141.1 (isobenzofuran C6), 135.7 (phenyl C5), 135.4 (isobenzofuran 
C5), 129.7 (phenyl C1), 122.9 (isobenzofuran C7a), 122.7 (phenyl C6), 120.8 
(isobenzofuran C4), 115.8 (phenyl C2), 114.1 (phenyl C4), 68.5 (isobenzofuran C3), 
59.3 (tetrazole-CH2-O), 14.4 (CH3) ppm. EI-MS m/z 322 (M+, 50), 239 (75), 223 (26), 
195 (60), 165 (100%). HRMS (ESI) calcd for C17H15N4O3 (MH+), 323.1144; found, 











In a round bottom 50 mL flask, a solution of 2-(3-iodophenoxy)acetonitrile 124 (1.6 g, 
6.18 mmol), sodium azide (1.6 g, 24.7 mmol) and amonium chloride (1.3 g, 24.7 mmol) 
in dry DMF (25 mL), containing few drops of glacial acetic acid, was heated at reflux 
for 14 h under a N2 atmosphere. The solvent was then concentrated under reduced 
pressure, and the resulting residue was dried under vacuum. Ethanol (25 mL) was added 
to the residue and the mixture was sonicated for 10 min, filtered and ethanol was 
evaporated under reduced pressure resulting in a white fluffy solid of the tetrazole 
intermediate 128 (1.5 g, 80%), mp: 99-100 ºC ; IR (cm
-1
): υ 2995 (w, NH), 1589 (m, 
C=N), 1240 (w, C-O). 
1
H NMR (CD3OD), δ: 7.46 (s, 1H, phenoxy_2 H), 7.39 (t, 1H, J 
= 7.0 Hz, phenoxy_5 H), 7.09-7.08 (m, 2H, phenoxy_4,6 H), 5.47 (s, 2H, CH2). 
13
C 
NMR, δ: 159.7 (phenoxy C1), 155.3 (tetrazole C), 132.4 (phenoxy C4), 132.2 (phenoxy 
C5), 125.4 (phenoxy C2), 115.3 (phenoxy C6), 94.9 (phenoxy C3), 61.1 (CH2) ppm. EI-
MS m/z 302 (M+, 100%), 220 (80), 203 (10). HRMS (ESI) calcd for C8H8IN4O (MH+), 





Under a N2 atmosphere, an oven dried 100 mL flask was charged with 5-((3-
iodophenoxy)methyl)-1H-tetrazole 128 (960 mg, 3.179 mmol), bis(pinacolato)diboron 
125 (3.2 g, 12.716 mmol), potassium acetate (1.25 g, 12.716 mmol) and PdCl2(dppf) 
(23.3 mg, 1 mol%). Dry THF (30 mL) was added to the mixture, and the flask was 
heated at reflux for 18 h under a N2 atmosphere. The solvent was then concentrated 
under reduced pressure. Ethanol (30 mL) was added to the resulting residue and the 
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mixture was further heated at reflux for 10 min, filtered hot and concentrated under 
reduced pressure to afford a white solid of the boronic ester potassium salt 129 (1.1 g, 
99%), mp: >250 ºC ; IR (cm
-1
): υ 2983 (s, C-H aliphatic), 1680 (m, C=N), 1233 (w, C-
O). 
1
H NMR (CD3OD), δ: 7.38 (s, 1H, phenoxy_2 H), 7.28 (d, 1H, J = 7.1 Hz, 
phenoxy_6 H), 7.04-6.99 (m, 2H, phenoxy_4,5 H), 5.25 (s, 2H, CH2), 1.90 (s, 12H, 
4CH3). 
13
C NMR, δ: 178.5 (phenoxy C1), 159.5 (tetrazole C), 158.3 (phenoxy C3), 
130.8 (phenoxy C5), 130.2 (phenoxy C4), 124.2 (phenoxy C6), 114.2 (phenoxy C2), 




General procedure 5: synthesis of the benzolactone-tetrazole conjugates 130 and 
131 using the coupling method: 
Under a N2 atmosphere, a mixture of the appropriate bromoisobenzofuran-1(3H)-one 
derivative (1 mmol) and potassium 5-((3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-
yl)phenoxy)methyl)tetrazol-1-ide 129 (374 mg, 1.1 mmol),  
tetrakis(triphenylphosphine)palladium(0) (80.9 mg, 7 mol%) and potassium phosphate 
(636.8 mg, 3 mmol) was added to a solvent mixture of 1,4-dioxane (25 mL) and water 
(10 mL) in a 50 mL round bottom flask. The reaction mixture was degassed by flushing 
N2 through a needle for 10 min, the flask was then sealed with a rubber cap, heated at 85 
ºC for 20-24 h. The solvent was then concentrated under reduced pressure. Saturated 
NaHCO3 (25 mL) was added to the resulting residues, and the mixture sonicated for 15 
min, before the turbid solution was washed with CH2Cl2 (25 mL). The aqueous layer 
was filtered, cooled to 0 ºC using an ice bath, and the filtrate was then neutralized with 
2 M HCl. The resulting white solid was collected by vacuum filtration, washed with 











Following the general procedure 5 using 6-bromo-5,7-dimethoxyisobenzofuran-1(3H)-
one 90 (1 mmol, 273 mg) and heating for 24 h, the final tetrazole conjugate 130 was 
isolated as a white solid (195 mg, 53%), mp: charring; IR (cm-1): υ 3204 (w, NH), 1740 
(s, C=O), 1614 (m, C=N), 1218 (w, C-O). 
1
H NMR (CD3OD), δ: 7.37 (t, 1H, J = 7.9 
Hz, phenyl_5 H), 7.05 (d, 1H, J = 8.0 Hz, phenyl_6 H), 7.02 (s, 1H, phenyl_2 H), 6.98 
(d, 1H, J = 7.7 Hz, phenyl_4 H), 6.78 (s, 1H, isobenzofuran_4 H), 5.48 (s, 2H, 
isobenzofuran CH2), 5.09 (s, 2H, O-CH2), 4.04 (s, 3H, isobenzofuran_7 OCH3), 3.89 (s, 
3H, isobenzofuran_5 OCH3). 
13
C NMR, δ: 167.9 (C=O), 162.6 (isobenzofuran C5), 
158.9 (phenyl C3), 157.4 (isobenzofuran C7), 153.6 (tetrazole C), 149.2 (isobenzofuran 
C3a), 134.9 (phenyl C5), 129.5 (phenyl C6), 122.8 (phenyl C4), 115.9 (phenyl C10), 
115.7 (phenyl C11), 114.1 (isobenzofuran C7a), 104.7 (isobenzofuran C4), 96.2 
(isobenzofuran C6), 67.8 (isobenzofuran C3), 59.2 (tetrazole-CH2-O), 56.6 
(isobenzofuran_7 OCH3), 56.1 (isobenzofuran_5 OCH3) ppm. ESI-MS m/z 367.1 (M-
H). HRMS (ESI) calcd for C18H15N4O5 (M-H
+
), 367.1042; found, 367.1038. HPLC 




Following the general procedure 5 using 6-bromoisobenzofuran-1(3H)-one 91 (213 mg, 
1 mmol) and heating for 20 h, the final tetrazole conjugate 131 was isolated as a white 
solid (181 mg, 59%), mp: charring; IR (cm
-1
): υ 3195 (w, NH), 1751 (s, C=O), 1653 (m, 
C=N). 
1
H NMR (CD3OD), δ: 8.07 (s, 1H, isobenzofuran_7 H), 7.99 (d, 1H, J = 8.0 Hz, 
isobenzofuran_5 H), 7.67 (d, 1H, J = 8.0 Hz, isobenzofuran_4 H), 7.38 (t, 1H, J = 7.9 
Hz, phenyl_5 H), 7.33 (s, 1H, phenyl_2 H), 7.24 (d, 1H, J = 7.5 Hz, phenyl_6 H), 7.09 
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(d, 1H, J = 8.0 Hz, phenyl_4 H),  5.42 (s, 2H, isobenzofuran CH2), 5.37 (s, 2H, O-CH2). 
13
C NMR, δ: 171.9 (C=O), 159.3 (phenyl C3), 146.3 (tetrazole C), 142.4 (isobenzofuran 
C3a), 140.9 (isobenzofuran C6), 133.2 (phenyl C1), 129.7 isobenzofuran C5), 125.9 
(phenyl C5), 122.9 (phenyl C6), 122.7 (isobenzofuran C7), 122.6 (isobenzofuran C7a), 
119.7 (phenyl C2), 114.4 (isobenzofuran C4), 113.7 (phenyl C4), 69.9 (isobenzofuran 
C3), 61.1 (tetrazole-CH2-O) ppm. ESI-MS m/z 307.1 (M-H). HRMS (ESI) calcd for 
C16H11N4O3 (M-H
+
), 307.0831; found, 307.0826. HPLC purity: 98.8%, Rt=13.175 (5% 




In an oven dried 50 mL flask and under a N2 atmosphere, 2-amino-3-bromo-5-
methylbenzoic acid 132 (750 mg, 3.26 mmol) was dissolved in dry THF (20 mL), and 
the flask was then sealed with a rubber cap with fitted with a N2 balloon, and cooled to -
78 ºC. n-BuLi (4.08 mL of 2 M solution, 8.15 mmol) was added dropwise through a 
needle and the mixture was stirred for 20 min at -78 ºC before adding pivaloyl chloride 
(0.48 mL, 3.91 mmol) dropwise. The reaction was then allowed to warm to room 
temperature and stirred for 3 h. The reaction mixture was then diluted with ethyl acetate 
(10 mL) and water (10 mL), the organic layer was separated and washed with water (2 x 
20 mL), brine (2 x 10 mL) and dried (MgSO4). The combined organic layers were 
concentrated under reduced pressure to yield the β-lactam derivative 133 as a colourless 
oil (452 mg, 47%), IR (cm
-1
): υ 1745 (s, C=O), 1634 (s, C=O), 1465 (w, C-N), 1059 (w, 
C-Br). 
1
H NMR (CDCl3), δ: 7.94 (s, 1H, H4), 7.86 (s, 1H, H2), 2.45 (s, 3H, CH3), 1.42 
(s, 9H, pivaloyl 3CH3). 
13
C NMR, δ: 168.1 (pivaloyl C=O), 159.7 (C6), 142.3 (C=O), 
140.9 (C4), 139.3 (C1), 127.4 (C2), 121.8 (C3), 117.8 (C5), 38.3 (C(CH3)3), 27.6 
(pivaloyl  3CH3), 20.9 (CH3) ppm. EI-MS m/z 295 (M+, 35), 280 (100%), 253 (20), 238 
(37). HRMS (ESI) calcd for C13H15BrNO2 (MH+), 296.0286; found, 296.0294. 
 




yl)phenyl)propanoic acid 137  
 
Under a N2 atmosphere, a 25 mL round bottom flask was charged with the β-lactam 
derivative 133 (100 mg, 0.339 mmol), 3-(3-boronophenyl)propanoic acid 113 (72.3 mg, 
0.372 mmol), tetrakis(triphenylphosphine)palladium(0) (19.6 mg, 0.016 mmol) and 
potassium phosphate (215.9 mg, 1.02 mmol). A mixture of 1,4-dioxane (10 mL) and 
water (3 mL) was added and the reaction mixture was degassed by flushing N2 through 
a needle for 10 min. The flask was then sealed with a rubber cap, heated at 85 ºC for 18 
h. The solvent was then concentrated under reduced pressure and the flask was cooled 
to 0 ºC. Chilled 1 N HCl (10 mL) was added dropwise with stirring, and the resulting 
solid was extracted with ethyl acetate (2 x 15 mL). The combined organic layers were 
washed with water (15 mL), brine (15 mL) and dried (MgSO4) and concentrated under 
reduced pressure. The resulting residue was subjected to a flash column 
chromatography (50% CH2Cl2, 50% ethyl acetate and 1% acetic acid) to afford 137 as a 
pale yellow oil (74.2 mg, 60%), IR (cm
-1
): υ 2959 (m, OH), 1696 (s, C=O), 1662 (s, 
C=O), 1481 (m, C-N). 
1
H NMR (CDCl3), δ: 8.56 (s, 1H, COOH), 7.77 (s, 1H, H4), 
7.32-7.29 (m, 2H, phenyl_5 H, H2), 7.20 (d, 1H, J = 7.5 Hz,  phenyl_6 H), 7.19 (s, 1H, 
phenyl_2 H), 7.15 (d, 1H, J = 7.7 Hz, phenyl_4 H), 2.97 (t, 2H, J = 7.5 Hz, COOH-
CH2-CH2), 2.68 (t, 2H, J = 7.6 Hz, COOH-CH2-CH2), 2.37 (s, 3H, CH3), 1.03 (s, 9H, 
pivaloyl 3CH3). 
13
C NMR, δ: 178.4 (pivaloyl C=O), 176.9 (COOH), 171.9 (azabicyclo 
C=O), 140.4 (phenyl C1), 140.1 (azabicyclo C6), 139.8 (phenyl C3), 136.4 (phenyl C5), 
135.8 (azabicyclo C4), 133.1 (azabicyclo C2), 130.9 (azabicyclo C3), 128.8 (azabicyclo 
C1), 128.7 (phenyl C2), 127.3 (phenyl C6), 126.8 (azabicyclo C5), 124.8 (phenyl C4), 
39.3 (C(CH3)3), 35.8 (COOH-CH2-CH2), 30.9 (COOH-CH2-CH2), 27.2 (pivaloyl  
3CH3), 21.0 (CH3) ppm. EI-MS m/z 365 (M+, 60), 350 (70), 320 (50), 299 (25), 277 
(100%), 235 (26), 220 (23), 193 (52). HRMS (ESI) calcd for C22H24NO4 (MH+), 
366.1705; found, 366.1717. HPLC purity: 98.9%, Rt=27.924 (3% solvent B in solvent 
A). 
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3'-(Cyanomethoxy)-5-methyl-2-pivalamido-[1,1'-biphenyl]-3-carboxylic acid 138 
 
Under a N2 atmosphere, a 25 mL round bottom flask was charged with the β-lactam 
derivative 133 (100 mg, 0.339 mmol), (3-(cyanomethoxy)phenyl)boronic acid 118 (66.0 
mg, 0.373 mmol), tetrakis(triphenylphosphine)palladium(0) (19.6 mg, 0.016 mmol) and 
potassium phosphate (215.9 mg, 1.02 mmol). A mixture of 1,4-dioxane (10 mL) and 
water (3 mL) was added and the reaction mixture was degassed by flushing N2 through 
a needle for 10 min. The flask was then sealed with a rubber cap, heated at 85 ºC for 12 
h. The solvent was then concentrated under reduced pressure and 1 N HCl (10 mL) was 
added dropwise to the resulting residue which was extracted with ethyl acetate (2 x 15 
mL). The combined organic layers were washed with water (15 mL), brine (15 mL) and 
dried (MgSO4). The mixture was then concentrated under reduced pressure, and the 
resulting residue was subjected to a flash column chromatography and elution with 90% 
CH2Cl2, 10% ethanol and 0.1% TFA yielded 138 as a pale yellow oil (59.4 mg, 48%), 
IR (cm
-1
): υ 3328 (m, NH), 2967 (m, OH), 2200 (m, CN), 1646 (w, NH), 1411 (w, C-
N). 
1
H NMR (CDCl3), δ: 8.61 (s, 1H, COOH), 7.53 (s, 1H, phenyl_6 H), 7.32 (t, 1H, J = 
7.7 Hz, phenyl_5' H), 7.15 (s, 1H, phenyl_4 H), 7.01 (d, 1H, J = 7.5 Hz, phenyl_6' H), 
6.92-6.90 (m, 2H, phenyl_2', 4'), 6.47 (s, 1H, NH), 4.73 (s, 2H, CH2), 2.28 (s, 3H, CH3), 
0.97 (s, 9H, pivaloyl 3 CH3). 
13
C NMR, δ: 177.7 (pivaloyl C=O), 176.7 (COOH), 173.8 
(C3'), 156.4 (C2), 141.7 (C5), 137.8 (C1), 135.7 (C6'), 133.2 (C4), 130.5 (C6), 129.7 
(C1'), 129.6 (C6'), 123.4 (C4'), 115.6 (CN), 115.1 (C3), 113.3 (C2'), 53.5 (CH2), 38.9 
(C(CH3)3), 26.9 (pivalamido 3 CH3), 20.8 (CH3) ppm. ESI-MS m/z 365.0 (M-H). 
HRMS (ESI) calcd for C21H23N2O4 (MH+), 367.1658; found, 367.1656. HPLC purity: 
99.4%, Rt=17.599 (2% solvent B in solvent A). 
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General procedure 6: Suzuki coupling of 5-bromoisatin derivatives 103, 106, 112 
and 139 with 3-(3-boronophenyl)propanoic acid 113: 
Under a N2 atmosphere, a 25 mL flask was charged with the 5-bromoisatin derivative (1 
equiv), 3-(3-boronophenyl)propanoic acid 113 (1.2 equiv), 
tetrakis(triphenylphosphine)palladium(0) (5 mol%) and DME (3 mL) or diglyme (3 
mL), was sealed with a rubber cap. The reaction mixture was degassed by flushing N2 
through a needle for 10 min, and was then heated in an oil bath at 85 ºC. When the solid 
dissolved, a N2 degassed solution of potassium phosphate (3 equiv) in water (3 mL) was 
added to the reaction mixture and heating continued at 85 ºC for 4-6 h. After cooling to 
room temperature, the solvent was concentrated under reduced pressure. A solution of 
HCl 2 M (15 mL) was added, and the resulting suspended solid was either collected by 
filtration or extracted with ethyl acetate (2 x 25 mL). The combined organic layers were 
dried (MgSO4) and evaporated under reduced pressure. The combined residues were 
then dissolved in ethanol and were subjected to PLC (10% methanol in CH2Cl2, 0.5% 
acetic acid) to yield the isatin-acid conjugates 140-143.  
 
3-(3-(4,6-Dimethoxy-2,3-dioxoindolin-5-yl)phenyl)propanoic acid 140 
 
Following the general procedure 6 using 5-bromo-4,6-dimethoxyindoline-2,3-dione 103 
(100 mg, 0.349 mmol), 3-(3-boronophenyl)propanoic acid 113 (81.2 mg ,0.419 mmol), 
tetrakis(triphenylphosphine)palladium(0) (20.2 mg, 0.017 mmol) and potassium 
phosphate (222.2 mg, 1.047 mmol) and heating for 6 h, the acid 140 was isolated as a 
yellow solid (49.5 mg, 40%), mp: 175-176 ºC; IR (cm
-1
): υ 3185 (m, NH), 2978 (m, 
OH), 1718 (s, C=O), 1696 (s, C=O), 1290 (w, C-O). 
1
H NMR (DMSO-d6), δ: 12.09 (s, 
1H, COOH), 10.36 (s, NH), 7.31 (t, J = 7.5 Hz, 1H, phenyl_5 H), 7.20 (d, J = 7.5 Hz, 
1H, pheny_4 H), 7.08-7.06 (m, 2H, phenyl_2,6 H), 6.35 (s, 1H, isatin_7 H), 3.97 (s, 3H, 
isatin_4 OCH3), 3.84 (s, 3H, isatin_C6 OCH3), 2.85 (t, J = 7.5 Hz, 2H, COOH-CH2-
CH2), 2.58 (t, J = 7.5 Hz, 2H, COOH-CH2-CH2). 
13
C NMR, δ: 178.1 (COOH), 174.0 
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(isatin C2), 166.6 (isatin C3), 161.5 (isatin C6), 160.1 (isatin C4), 149.2 (phenyl C1), 
141.0 (isatin C7a), 131.2 (phenyl C3), 130.3 (phenyl C5), 128.3 (phenyl C6), 127.4 
(phenyl C2), 120.9 (phenyl C4), 108.2 (isatin C7), 100.6 (isatin C5), 90.1 (isatin C3a), 
56.7 (isatin_4 OCH3), 56.3 (isatin_6 OCH3), 35.0 (COOH-CH2-CH2), 30.3 (COOH-
CH2-CH2) ppm. EI-MS m/z 355 (M+, 40), 299 (4), 254 (100%), 191 (45). HRMS (ESI) 
calcd for C19H18NO6 (MH+), 356.1134; found, 356.1116. HPLC purity: 99.3%, 
Rt=35.814 (3% solvent B in solvent A). 
 
3-(3-(7-Methyl-2,3-dioxoindolin-5-yl)phenyl)propanoic acid 141 
 
Following the general procedure 6 using 5-bromo-7-methylindoline-2,3-dione 106 (100 
mg, 0.416 mmol), 3-(3-boronophenyl)propanoic acid 113 (96.8 mg, 0.499 mmol), 
tetrakis(triphenylphosphine)palladium(0) (24 mg, 0.021 mmol) and potassium 
phosphate (264.9 mg, 1.248 mmol) and heating for 4 h, the acid 141 was isolated as a 
red solid (70 mg, 55%), mp: 238-239 ºC; IR (cm
-1
): υ 3172 (m, NH), 2989 (m, OH), 
1731 (s, C=O), 1696 (s, C=O). 
1
H NMR (Acetone-d6), δ: 9.94 (s, NH), 7.81 (s, 1H, 
isatin_4 H), 7.66 (s, 1H, phenyl_2 H), 7.60 (s, 1H, isatin_6 H), 7.50 (d, J = 7.6 Hz, 1H, 
pheny_6 H), 7.40 (t, J = 7.6 Hz, 1H, phenyl_5 H), 7.29 (d, J = 7.6 Hz, 1H, phenyl_4 H), 
3.03 (t, J = 7.3 Hz, 2H, COOH-CH2-CH2), 2.71 (t, J = 7.3 Hz, 2H, COOH-CH2-CH2), 
2.41 (s, 3H, CH3). 
13
C NMR (DMSO-d6), δ: 184.8 (COOH), 173.9 (isatin C3), 160.1 
(isatin C2), 148.5 (isatin C7a), 141.7 (phenyl C3), 138.7 (phenyl C1), 137.6 (isatin C6), 
134.8 (isatin C5), 128.9 (phenyl C5), 127.4 (phenyl C6), 126.5 (phenyl C2), 123.8 
(phenyl C4), 122.1 (isatin C4), 119.8 (isatin C3a), 118.1 (isatin C7), 35.3 (COOH-CH2-
CH2), 30.4 (COOH-CH2-CH2), 15.5 (CH3) ppm. EI-MS m/z 309 (M+, 100%), 277 (25), 
253 (80), 207 (79), 193 (30). HRMS (ESI) calcd for C18H16NO4 (MH+), 310.1079; 
found, 310.1071. HPLC purity: 98.1%, Rt=5.339 (1% solvent B in solvent A). 
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3-(3-(4-Methoxy-7-methyl-2,3-dioxoindolin-5-yl)phenyl) propanoic acid 142 
 
Following the general procedure 6 using 5-bromo-4-methoxy-7-methylindoline-2,3-
dione 112 (100 mg, 0.370 mmol), 3-(3-boronophenyl)propanoic acid 113 (86.1 mg, 
0.444 mmol), tetrakis(triphenylphosphine)palladium(0) (21.4 mg, 0.019 mmol) and 
potassium phosphate (235.6 mg, 1.11 mmol) and heating for 5 h, the acid 142 was 
isolated as a red solid (60 mg, 48%), mp: 219-220 ºC; IR (cm
-1
): υ 3182 (m, NH), 2982 
(m, OH), 1749 (s, C=O), 1692 (s, C=O), 1287 (w, C-O). 
1
H NMR (DMSO-d6), δ: 11.16 
(s, NH), 7.40 (s, 1H, isatin_6 H), 7.13 (t, J = 7.4 Hz, 1H, phenyl_5 H), 7.26 (s, 1H, 
phenyl_2 H), 7.22 (d, J = 7.4 Hz, 1H, pheny_6 H), 7.19 (d, J = 7.4 Hz, 1H, phenyl_4 
H), 3.81 (s, 3H, OCH3), 2.86 (t, J = 7.4 Hz, 2H, COOH-CH2-CH2), 2.56 (t, J = 7.4 Hz, 
2H, COOH-CH2-CH2), 2.41 (s, 3H, CH3). 
13
C NMR, δ: 182.8 (COOH), 174.5 (isatin 
C2), 160.5 (isatin C3), 154.6 (isatin C4), 149.3 (isatin C3a), 142.6 (phenyl C1), 141.5 
(isatin C6), 137.4 (phenyl C3), 129.5 (phenyl C2), 129.1 (phenyl C5), 128.8 (isatin C7), 
127.7 (phenyl C6), 127.3 (phenyl C4), 116.5 (isatin C5), 110.3 (isatin C3a), 62 (OCH3), 
35.9 (COOH-CH2-CH2), 31.0 (COOH-CH2-CH2), 15.6 (CH3) ppm. EI-MS m/z 339 
(M+, 100%), 311 (75), 293 (10), 277 (77). HRMS (ESI) calcd for C19H18NO5 (MH+), 
340.1185; found, 340.1187. HPLC purity: 99.4%, Rt=5.579 (1% solvent B in solvent 
A). 
 
3-(3-(2,3-Dioxoindolin-5-yl)phenyl)propanoic acid 143 
 
Following the general procedure 6 using 5-bromoindoline-2,3-dione 139 (100mg, 0.442 
mmol), 3-(3-boronophenyl)propanoic acid 113 (102.9 mg, 0.530 mmol), 
tetrakis(triphenylphosphine)palladium(0) (25.5 mg, 0.022 mmol) and potassium 
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phosphate (281.5 mg, 1.326 mmol) and heating for 4 h, the acid 143 was isolated as an 
orange solid (84.8 mg, 65%), mp: 182-183 ºC; IR (cm
-1
): υ 3185 (m, NH), 2989 (m, 
OH), 1714 (s, C=O), 1684 (s, C=O). 
1
H NMR (DMSO-d6), δ: 11.14 (s, NH), 7.89 (dd, J 
= 8.2, 1.8 Hz, 1H, isatin_6 H), 7.77 (d, J = 1.4 Hz, 1H, isatin_4 H), 7.53 (s, 1H, 
phenyl_2 H), 7.46 (d, J = 7.6 Hz, 1H, phenyl_4 H), 7.35 (t, J = 7.5 Hz, 1H, phenyl_5 
H), 7.21 (d, J = 7.5 Hz, 1H, phenyl_6 H), 6.99 (d, J = 7.9 Hz, 1H, isatin_7 H), 2.88 (t, J 
= 7.6 Hz, 2H, COOH-CH2-CH2), 2.59 (t, J = 7.5 Hz, 2H, COOH-CH2-CH2). 
13
C NMR, 
δ: 184.9 (COOH), 174.4 (isatin C3), 160.0 (isatin C2), 150.4 (isatin C7a), 142.2 (phenyl 
C3), 139.1 (phenyl C1), 136.9 (isatin C6), 135.4 (isatin C 5), 129.4 (phenyl C5), 127.9 
(phenyl C6), 126.7 (phenyl C2), 124.4 (phenyl C4), 122.9 (isatin C4), 118.9 (isatin 
C3a), 113.1 (isatin C7), 35.7 (COOH-CH2-CH2), 30.9 (COOH-CH2-CH2) ppm. EI-MS 
m/z 295 (M+, 40), 267 (100%), 250 (95), 207 (20), 193 (25). HRMS (ESI) calcd for 
C17H14NO4 (MH+), 296.0914; found, 296.0912. HPLC purity: 98.2%, Rt=7.237 (1% 
solvent B in solvent A). 
 
General procedure 7: Suzuki coupling of the 5-bromoisatin derivatives 103, 106, 
112 and 139 with (3-(cyanomethoxy)phenyl)boronic acid 118: 
Under a N2 atmosphere, a 25 mL flask was charged with the 5-bromoisatin derivative (1 
equiv), (3-(cyanomethoxy)phenyl)boronic acid 118 (1 equiv), 
tetrakis(triphenylphosphine)palladium(0) (5 mol%), potassium phosphate (3 equiv) and 
a mixture of diglyme (3 mL) and  water (3 mL), and the reaction mixture was degassed 
by flushing N2 through a needle for 10 min. The flask was then sealed and heated at 85 
ºC for 5-9 h. After cooling to room temperature, the solvent was concentrated under 
reduced pressure, and 1 N HCl (15 mL) was added. The suspended solid was either 
collected by filtration or extracted with ethyl acetate (2 x 25 mL). The combined 
organic layers were dried (MgSO4) and evaporated under reduced pressure. The 
combined residues were adsorbed onto silica and subjected to flash column 









Following the general procedure 7 using 5-bromo-4,6-dimethoxyindoline-2,3-dione 103 
(40 mg, 0.139 mmol), (3-(cyanomethoxy)phenyl)boronic acid 118 (24.6 mg, 0.139 
mmol), tetrakis(triphenylphosphine)palladium(0) (8 mg, 0.007 mmol), potassium 
phosphate (88.5 mg, 0.417 mmol) and heating for 9 h, the acetonitrile intermediate 144 
could not be isolated. Analysis of the crude mixture: EI-MS m/z 338 (M+, 17), 309 (7), 
382 (66), 257 (100%), 225 (25). HRMS (ESI) calcd for C18H15N2O5 (MH+), 339.0981; 
found, 339.0980. This sample was collected from the reaction mixture before 
purification trial. Could not purify and was not stable enough to get NMR data.  
 
2-(3-(7-Methyl-2,3-dioxoindolin-5-yl)phenoxy)acetonitrile  145 
 
Following the general procedure 7 using 5-bromo-7-methylindoline-2,3-dione 106 (100 
mg, 0.416 mmol), (3-(cyanomethoxy)phenyl)boronic acid 118 (73.6 mg, 0.416 mmol), 
tetrakis(triphenylphosphine)palladium(0) (24 mg, 0.021 mmol), potassium phosphate 
(264.9 mg, 1.248 mmol) and heating for 5 h, the acetonitrile intermediate 145 was 
isolated as a red solid (63.2 mg, 52%), mp: 208-209 ºC; IR (cm
-1
): υ 3185 (w, NH), 
2365 (m, CN), 1750 (s, C=O), 1587 (s, C=O). 
1
H NMR (Acetone-d6), δ: 10.13 (s, NH), 
7.83 (s, 1H, isatin_4 H), 7.68 (s, 1H, isatin_C6), 7.47 (t, J = 7.8 Hz, 1H, phenoxy_5 H), 
7.40-7.38 (m, 2H, phenoxy_2,4 H), 7.09 (d, J = 8.0 Hz, 1H, phenoxy_6 H), 5.21 (s, 2H, 
CH2), 2.39 (s, 3H, CH3). 
13
C NMR, δ: 185.1 (isatin C3), 160.5 (phenoxy C1), 158.6 
(isatin C2), 149.8 (isatin C7a), 142.4 (phenoxy C3), 138.9 (isatin C7), 136.4 (isatin C6), 
131.3 (isatin C5), 123.3 (phenoxy C5), 121.8 (isatin C4), 121.2 (phenoxy C4), 119.5 
(phenoxy C2), 116.7 (phenoxy C6), 115.3 (CN), 114.1 (isatin C3a), 54.7 (CH2), 15.8 
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(CH3) ppm. EI-MS m/z 292 (M+, 93), 264 (80), 236 (100%), 196 (17), 180 (11). HRMS 
(ESI) calcd for C17H13N2O3 (MH+), 293.0926; found, 293.0931. HPLC purity: 97.9%, 
Rt=13.070 (2.5% solvent C in solvent A). 
 
2-(3-(4-Methoxy-7-methyl-2,3-dioxoindolin-5-yl)phenoxy) acetonitrile 146 
 
Following the general procedure 7 using 5-bromo-4-methoxy-7-methylindoline-2,3-
dione 112 (100 mg, 0.370 mmol), (3-(cyanomethoxy)phenyl)boronic acid 118 (65.5 mg, 
0.370 mmol), tetrakis(triphenylphosphine)palladium(0) (21.4 mg, 0.019 mmol), 
potassium phosphate (235.6 mg, 1.11 mmol) and heating for 8 h, the acetonitrile 
intermediate 146 was isolated as a red solid (41.7 mg, 35%), mp: 179-180 ºC; IR (cm
-1
): 
υ 3190 (m, NH), 2166 (w, CN), 1706 (s, C=O), 1611 (s, C=O), 1294 (w, C-O). 
1
H NMR 
(CD3OD), δ: 7.40 (s, 1H, isatin_6 H), 7.38 (t, J = 8.2 Hz, 1H, phenoxy_5 H), 7.12 (d, J 
= 8.2 Hz, 1H, phenoxy_4 H), 7.11 (s, 1H, phenoxy_2 H), 7.01 (d, J = 8.3 Hz, 1H, 
phenoxy_6 H), 5.00 (s, 2H, CH2), 3.91 (s, 3H, OCH3), 2.22 (s, 3H, CH3). 
13
C NMR, δ: 
160.2 (isatin C3), 156.7 (phenoxy C1), 154.9 (isatin C2), 148.6 (isatin C4), 142.1 (isatin 
C7a), 138.9 (isatin C6), 137.8 (phenoxy C3), 129.2 (phenoxy C5), 123.4 (isatin C5), 
120.5 (isatin C7), 115.9 (phenoxy C4), 115.7 (phenoxy C6), 115.5 (phenoxy C2), 113.7 
(CN), 109.5 (isatin C3a), 61.13 (CH2), 53.3 (OCH3), 13.7 (CH3) ppm. EI-MS m/z 322 
(M+, 74), 294 (68), 280 (4), 254 (7), 226 (100%), 211 (11). HRMS (ESI) calcd for 
C18H15N2O4 (MH+), 323.1032; found, 323.1018. HPLC purity: 99.5%, Rt=11.766 (2.5% 










Following the general procedure 7 using 5-bromoindoline-2,3-dione 139 (100 mg, 0.442 
mmol), (3-(cyanomethoxy)phenyl)boronic acid 118 (78.2 mg, 0.442 mmol), 
tetrakis(triphenylphosphine)palladium(0) (25.5 mg, 0.022 mmol), potassium phosphate 
(281.5 mg, 1.326 mmol) and heating for 5 h, the acetonitrile intermediate 147 was 
isolated as a red solid (73.7 mg, 60%), mp: 205-206 ºC; IR (cm
-1
): υ 3168 (w, NH), 
2166 (m, CN), 1732 (s, C=O), 1621 (s, C=O). 
1
H NMR (Acetone-d6), δ: 10.04 (s, NH), 
7.95 (d, J = 8.2, 1H, phenoxy_4 H), 7.83 (s, 1H, phenoxy_2 H), 7.47 (t, J = 8.2 Hz, 1H, 
phenoxy_5 H), 7.39-7.38 (m, 2H, isatin_4,7  H), 7.14 (d, J = 8.2 Hz, phenoxy_6 H), 
7.09 (d, J = 8.6 Hz, 1H, isatin_6 H), 5.21 (s, 2H, CH2). 
13
C NMR, δ: 184.1 (isatin C3), 
159.6 (phenoxy C1), 157.8 (isatin C2), 150.4 (isatin C7a), 141.5 (phenoxy C3), 137.0 
(phenoxy C4), 135.7 (phenoxy C2), 130.6 (phenoxy C5), 123.1 (isatin C5), 121.0 (isatin 
C7), 118.9 (phenoxy C6), 116.0 (CN), 114.6 (isatin C3a), 113.1 (isatin C4), 112.9 
(isatin C6), 53.8 (CH2) ppm. EI-MS m/z 278 (M+, 46), 250 (100%), 207 (5), 182 (49). 
HRMS (ESI) calcd for C16H11N2O3 (MH+), 279.0770; found, 279.0759. HPLC purity: 
99.7%, Rt=20.046 (2.5% solvent C in solvent A). 
 
9.1.5. Experimental for chapter 7 
General procedure 8: synthesis of compounds 162, 164-166  
A solution of 7-nitro-1,2,3,4-tetrahydroquinoline 161 (1.0 g, 5.62 mmol) in dry pyridine 
(3 mL) was cooled to 0 ºC. The appropriate sulfonyl chloride (6.18 mmol) was then 
added dropwise over 10 min with stirring and the mixture was then allowed to warm to 
room temperature and stirred for 24 h. Cold water (20 mL) was added, the resulting 
solid or oil was extracted with ethyl acetate (2 x 25 mL). The combined organic layers 
were washed with 1 M HCl (2 x 20 mL), brine (10 mL) and dried (MgSO4). The solvent 
was then removed under reduced pressure. The resulting residue was subjected to flash 
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column chromatography and elution with 20% ethyl acetate in petroleum spirit yielded 




Following general procedure 8 using ethanesulfonyl chloride (794 mg, 6.18 mmol) gave 
the intermediate 162 (1.1 g, 70%) as a yellow solid, mp: 64-65 ºC; IR (cm
-1
): υ 3139 (w, 
C-H aromatic), 2944 (w, C-H aliphatic), 1517 (s, NO2), 1345 (m, SO2), 1333 (m, NO2), 
1147 (w, C-N). 
1
H NMR, δ: 8.49 (s, 1H, H8), 7.86 (d, J = 8.3 Hz, 1H, H6), 7.28 (d, J = 
8.3 Hz, 1H, H5), 3.83 (t, J = 6.0 Hz, 2H, H2), 3.22 (q, J = 7.5 Hz, 2H, ethyl CH2), 2.95 
(t, J = 6.5 Hz, 2H, H4), 2.07 (p, J = 6.0 Hz, 2H, H3), 1.41 (t, J = 7.5 Hz, 3H, CH3). 
13
C 
NMR, δ: 146.7 (C8a), 137.9 (C7), 135.7 (C5), 130.4 (C4a), 118.3 (C6), 116.8 (C8), 47.1 
(ethyl CH2), 46.4 (C2), 27.6 (C4), 22.1 (C3), 8.0 (CH3) ppm. EI-MS m/z 270 (M+, 55), 





Following general procedure 8 using propane-1-sulfonyl chloride (880.5 mg, 6.18 
mmol) gave the intermediate 164 (1.28 g, 80%) as a yellow solid, mp: 79-80 ºC; IR (cm
-
1
): υ 3128 (w, C-H aromatic), 2972 (w, C-H aliphatic), 1517 (s, NO2), 1346 (m, SO2), 
1332 (m, NO2), 1143 (w, C-N). 
1
H NMR, δ: 8.51 (s, 1H, H8), 7.86 (d, J = 8.3 Hz, 1H, 
H6), 7.28 (d, J = 8.4 Hz, 1H, H5), 3.83 (t, J = 5.8 Hz, 2H, H2), 3.13 (t, J = 7.7 Hz, 2H, 
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propyl_1 CH2), 2.95 (t, J = 6.4 Hz, 2H, H4), 2.07 (p, J = 5.9 Hz, 2H, H3), 1.89 (sex, J = 
7.6 Hz, 2H, propyl_2 CH2), 1.06 (t, J = 7.4 Hz, 3H, CH3). 
13
C NMR, δ: 146.7 (C8a), 
137.9 (C7), 135.8 (C5), 130.4 (C4a), 118.3 (C6), 116.8 (C8), 54.3 (propyl C1), 46.3 
(C2), 27.6 (C4), 22.1 (C3), 17.1 (propyl C2), 12.9 (CH3) ppm. EI-MS m/z 284 (M+, 54), 





Following general procedure 8 using thiophene-2-sulfonyl chloride (1.13 g, 6.18 mmol) 
gave the intermediate 165 (1.52 g, 84%) as an orange solid, mp: 130-131 ºC; IR (cm
-1
): 
υ 3139 (w, C-H aromatic), 2966 (w, C-H aliphatic), 1515 (s, NO2), 1341 (m, SO2), 1292 
(m, NO2), 1160 (w, C-N). 
1
H NMR, δ: 8.72 (s, 1H, H8), 7.91 (d, J = 8.4 Hz, 1H, H6), 
7.56 (d, J = 4.8 Hz, 1H, thiophene_5 H), 7.52 (d, J = 3.1 Hz, 1H, thiophene_3 H), 7.21 
(d, J = 8.4 Hz, 1H, H5), 7.06 (t, J = 4.4 Hz, 1H, thiophene_4 H), 3.89 (t, J = 6.2 Hz, 2H, 
H2), 2.66 (t, J = 6.5 Hz, 2H, H4), 1.80 (p, J = 6.2 Hz, 2H, H3). 
13
C NMR, δ: 146.7 
(C8a), 138.9 (thiophene C1), 137.5 (C7), 137.2 (C5), 133.0 (thiophene C3), 132.9 
(C4a), 129.9 (thiophene C4), 127.6 (thiophene C5), 119.4 (C6), 119.3 (C8), 46.6 (C2), 
27.3 (C4), 21.2 (C3) ppm. EI-MS m/z 324 (M+, 10), 243 (9), 214 (17), 177 (15), 131 











Following general procedure 8 using 4-methylbenzenesulfonyl chloride (1.18 g, 6.18 
mmol) gave the intermediate 166 (1.64 g, 88%) as a yellow crystalline solid, mp: 133-
134 ºC; IR (cm
-1
): υ 3136 (m, C-H aromatic), 2949 (m, C-H aliphatic), 1510 (s, NO2), 
1340 (m, SO2), 1334 (w, NO2), 1163 (w, C-N). 
1
H NMR, δ: 8.68 (s, 1H, H8), 7.87 (dd, 
J = 8.4, 2.1 Hz, 1H, H6), 7.57 (d, J = 8.3 Hz, 2H, tosyl_2,6 H), 7.25 (d, J = 8.1 Hz, 2 H, 
tosyl_3,5 H), 7.17 (d, J = 8.4 Hz, 1H, H5), 3.85 (t, J = 6.0 Hz, 2H, H2), 2.64 (t, J = 6.5 
Hz, 2H, H4), 2.40 (s, 3H, CH3), 1.75 (p, J = 6.5 Hz, 2H, H3). 
13
C NMR, δ: 146.6 (C8a), 
144.4 (C7), 137.8 (tosyl C4), 137.0 (tosyl C1), 136.1 (C5), 129.93 (C4a), 129.90 (tosyl 
C3, C5), 127.2 (tosyl C2, C6), 118.9 (C6), 118.8 (C8), 46.3 (C2), 27.2 (C4), 21.6 (C3), 
21.1 (CH3) ppm. EI-MS m/z 332 (M+, 70), 268 (46), 251 (49), 177 (70), 130 (100%). 
HRMS (ESI) calcd for C16H17N2O4S (MH+), 333.0909; found, 333.0900. 
 
General procedure 9: synthesis of compounds 163, 167-169 
A solution of the appropriate sulfonamide 162, 164-166 (1 equiv) and Raney Ni (0.05 
equiv) in methanol (20 mL) was stirred at room temperature under a N2 atmosphere. A 
solution of hydrazine hydrate (1.2 equiv) in methanol (10 mL) was then added dropwise 
and stirring continued for 10 min, after which the H2 gas ceased to evolve, and the 
reaction mixture was then heated at reflux for 4-6 h. The mixture was then filtered hot 
through a short pad of celite, and the filterate was concentrated under reduced pressure. 









Following the general procedure 9 using 1-(ethylsulfonyl)-7-nitro-1,2,3,4-
tetrahydroquinoline 162 (1.1 g, 4.07 mmol), hydrazine hydrate (244 mg, 4.884 mmol) 
and heating for 4 h, the amine intermediate 163 was obtained by recrystallisation from 
methanol as a  white solid (763 mg, 78%), mp: 65-66 ºC; IR (cm
-1
): υ 3358 (w, C-H 
aromatic), 2943 (w, C-H aliphatic), 1323 (m, SO2), 1143 (w, C-N). 
1
H NMR, δ: 7.07 (s, 
1H, H8), 6.88 (d, J = 8.0 Hz, 1H, H6), 6.40 (d, J = 8.0 Hz, 1H, H5), 3.78 (t, J = 6.0 Hz, 
2H, H2), 3.62 (s, br, NH2), 3.10 (q, J = 7.3 Hz, 2H, ethyl CH2), 2.73 (t, J = 6.4 Hz, 2H, 
H4), 1.95 (p, J = 6.0 Hz, 2H, H3), 1.33 (t, J = 7.3 Hz, 3H, CH3). 
13
C NMR, δ: 145.4 
(C7), 137.9 (C8a), 130.6 (C5), 118.7 (C4a), 111.7 (C6), 108.3 (C8), 46.9 (ethyl C1), 
46.2 (C2), 26.7 (C4), 23.1 (C3), 8.2 (CH3) ppm. EI-MS m/z 240 (M+, 30), 147 (100%), 




Following the general procedure 9 using 7-nitro-1-(propylsulfonyl)-1,2,3,4-
tetrahydroquinoline 164 (1.2 g, 4.22 mmol), hydrazine hydrate (253 mg, 5.064 mmol) 
and heating for 4 h, the amine intermediate 167 was obtained by recrystallisation from 
methanol as an orange solid (808 mg, 75%), mp: 86-87 ºC; IR (cm
-1
): υ 3358 (m, NH2), 
2941 (w, C-H aliphatic), 1327 (m, SO2), 1139 (m, C-N). 
1
H NMR, δ: 7.07 (s, 1H, H8), 
6.88 (d, J = 8.1 Hz, 1H, H6), 6.40 (d, J = 7.8 Hz, 1H, H5), 3.77 (t, J = 5.8 Hz, 2H, H2), 
3.65 (s, br, NH2), 3.02 (t, J = 7.4 Hz, 2H, propyl_1 CH2), 2.71 (t, J = 6.3 Hz, 2H, H4), 
1.93 (p, J = 6.0 Hz, 2H, H3), 1.83 (sex, J = 7.5 Hz, 2H, propyl_2 CH2), 1.00 (t, J = 7.4 
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Hz, 3H, CH3). 
13
C NMR, δ: 145.2 (C8), 137.6 (C8a), 130.4 (C5), 118.4 (C4a), 111.5 
(C6), 108.2 (C8), 53.3 (propyl C1), 46.6 (C1), 26.5 (C4), 22.8 (C3), 17.0 (propyl C2), 
13.0 (CH3) ppm. ESI-MS m/z 255.2 (M+H). HRMS (ESI) calcd for C12H19N2O2S 




Following the general procedure 9 using 7-nitro-1-(thiophen-2-ylsulfonyl)-1,2,3,4-
tetrahydroquinoline 165 (1.0 g, 3.09 mmol), hydrazine hydrate (185 mg, 3.708 mmol) 
and heating for 6 h, the amine intermediate 168 was obtained by recrystallisation from 
toluene as a yellow solid (762 mg, 84%), mp: 78-79 ºC; IR (cm
-1
): υ 3363 (w, NH2), 
3092 (w, C-H aromatic), 2937 (w, C-H aliphatic), 1337 (m, SO2), 1153 (w, C-N). 
1
H 
NMR, δ: 7.49 (d, J = 4.4 Hz, 1H, thiophene_5 H), 7.38 (d, J = 3.8 Hz, 1H, thiophene_3 
H), 7.19 (s, 1H, H8), 6.99 (t, J = 4.5 Hz, 1H, thiophene_4 H), 6.80 (d, J = 8.0 Hz, 1H, 
H5), 6.46 (dd, J = 8.0, 2.1 Hz, 1H, H6), 3.80 (t, J = 6.0 Hz, 2H, H2), 3.67 (s, br, NH2) 
2.38 (t, J = 6.5 Hz, 2H, H4), 1.63 (p, J = 6.3 Hz, 2H, H3). 
13
C NMR, δ: 144.9 (C7), 
139.6 (C8a), 136.8 (thiophene C1), 131.9 (thiophene C3), 131.8 (C4a), 129.8 (C5), 
127.2 (thiophene C4), 120.7 (thiophene C5), 112.8 (C6), 111.4 (C8), 47.1 (C2), 25.9 
(C4), 21.5 (C3) ppm. EI-MS m/z 294 (M+, 47), 230 (100%), 145 (52), 130 (65). HRMS 











Following the general procedure 9 using 7-nitro-1-tosyl-1,2,3,4-tetrahydroquinoline 166 
(1.0 g, 3.01 mmol), hydrazine hydrate (180.6 mg, 3.612 mmol) and heating for 6 h, the 
amine intermediate 169 was obtained by recrystallisation from toluene as a yellow 
crystalline solid (773 mg, 85%), mp: 89-90 ºC (Lit.
266
 m.p: 109-110 ºC); IR (cm
-1
): υ 
3353 (w, NH2), 2949 (w, C-H aliphatic), 1339 (m, SO2), 1156 (w, C-N). 
1
H NMR, δ: 
7.50 (d, J = 8.1 Hz, 2H, tosyl_3,5 H), 7.20 (s, 1H, H8), 7.18 (d, J = 8.1 Hz, 2H, 
tosyl_2,6 H), 6.76 (d, J = 8.1 Hz, 1H, H5), 6.44 (dd, J = 8.0, 2.1 Hz, 1H, H6), 3.76 (t, J 
= 5.9 Hz, 2H, H2), 3.64 (s, br, NH2), 2.37 (s, 3H, CH3),  2.33 (t, J = 6.4 Hz, 2H, H4), 
1.55 (p, J = 6.1 Hz 2H, H3). 
13
C NMR, δ: 144.9 (C7), 143.4 (C8a), 137.4 (tosyl C4), 
136.9 (tosyl C1), 129.5 (C5), 127.13 (C4a), 127.07 (tosyl C3, C5), 120.4 (tosyl C2, C6), 
112.5 (C6), 111.2 (C8), 46.7 (C2), 25.8 (C4), 21.59 (C3), 21.51 (CH3) ppm. EI-MS m/z 
302 (M+, 55), 238 (46), 147 (100%), 130 (75). HRMS (ESI) calcd for C16H19N2O2S 
(MH+), 303.1167; found, 303.1156. 
 
General procedure 10: synthesis of compounds 160, 170-194 
A solution of the appropriate amine intermediate 163, 167-169 (1 mmol) in dry pyridine 
(2 mL) was cooled at 0 ºC. The appropriate sulfonyl chloride (1.2 mmol) was added 
portion wise over a 10 min period with stirring. The reaction mixture was then allowed 
to warm to room temperature and stirred for 6 h. Cold water (5 mL) was then added and 
the resulting solid or oil was extracted with ethyl acetate (2 x 10 mL). The combined 
organic layers were washed with 1 M HCl (2 x 10 mL), brine (10 mL) and dried 
(MgSO4). The solvent was then concentrated under reduced pressure and the resulting 
residues were subjected to flash column chromatography (30% ethylacetate in 
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Following the general procedure 10 using 1-(ethylsulfonyl)-1,2,3,4-tetrahydroquinolin-
7-amine 163 (240 mg, 1.0 mmol), 2-fluorobenzenesulfonyl chloride (233.5 mg), 160 
was isolated as a colourless solid (282.6 mg, 71%), mp: 108-109 ºC; IR (cm
-1
): υ 3223 
(m, NH), 2949 (w, C-H aliphatic), 1472 (w, C-F), 1329 (m, SO2), 1135 (w, C-N). 
1
H 
NMR, δ: 7.86 (t, J = 6.9 Hz, 1H, benzene_4 H), 7.53 (q, J = 6.8 Hz, 1H, benzene_3 H), 
7.42 (s, br, NH), 7.26-7.17 (m, 2H, benzene_5,6 H), 6.96 (d, J = 8.2 Hz, 1H, 
tetrahydroquinoline_6 H), 6.92 (s, 1H, tetrahydroquinoline_8 H), 6.86 (d, J = 8.2 Hz, 
1H, tetrahydroquinoline_5 H), 3.73 (t, J = 6.0 Hz, 2H, tetrahydroquinoline_2 CH2), 
3.03 (q, J = 7.5 Hz, 2H, ethyl CH2), 2.73 (t, J = 6.4 Hz, 2H, tetrahydroquinoline_4 
CH2), 1.92 (p, J = 6.3 Hz, 2H, tetrahydroquinoline_3 CH2), 1.27 (t, J = 7.4 Hz, 3H, 
CH3). 
13
C NMR, δ: 159.6 (d, J = 254.9 Hz, benzene C2), 137.7 (tetrahydroquinoline 
C8a), 135.4 (d, J = 8.4 Hz, benzene C3), 134.4 (tetrahydroquinoline C7), 131.1 
(tetrahydroquinoline C5), 130.1 (benzene C5), 126.4 (d, J = 13.0 Hz, benzene C1), 
125.6 (benzene C6), 124.5 (d, J = 3.7 Hz, benzene C4), 117.1 (tetrahydroquinoline 
C4a), 116.7 (tetrahydroquinoline C6), 114.2 (tetrahydroquinoline C8), 46.5 
(tetrahydroquinoline C2), 46.4 (ethyl CH2), 26.7 (tetrahydroquinoline C4), 22.4 
(tetrahydroquinoline C3), 8.0 (CH3) ppm. EI-MS m/z 398 (M+, 50), 305 (45), 159 (15), 
145 (100%). HRMS (ESI) calcd for C17H20FN2O4S2 (MH+), 399.0849; found, 









Following the general procedure 10 using 1-(ethylsulfonyl)-1,2,3,4-tetrahydroquinolin-
7-amine 163 (240 mg 1.0 mmol), 4-fluorobenzenesulfonyl chloride (233.5 mg), 170 was 
isolated as a colourless solid (286.6 mg, 72%), mp: 90-91 ºC; IR (cm
-1
): υ 3276 (m, 
NH), 2955 (w, C-H aliphatic), 1456 (w, C-F), 1327 (m, SO2), 1166 (w, C-N). 
1
H NMR, 
δ: 7.84 (dd, J = 8.2, 5.2 Hz, 2H, benzene_3,5 H), 7.35 (s, 1H, tetrahydroquinoline_8 H), 
7.12 (s, br, NH), 7.09 (d, J = 8.2 Hz, 2H, benzene_2,6 H), 6.99 (d, J = 8.2 Hz, 1H, 
tetrahydroquinoline_5 H), 6.86 (d, J = 8.1 Hz, 1H, tetrahydroquinoline_6 H), 3.75 (t, J 
= 6.0 Hz, 2H, tetrahydroquinoline_2 H), 3.05 (q, J = 7.4 Hz, 2H, ethyl CH2), 2.76 (t, J 
= 6.4 Hz, 2H, tetrahydroquinoline_4 H), 1.96 (p, J = 6.0 Hz, 2H, tetrahydroquinoline_3 
H), 1.27 (t, J = 7.4 Hz, 3H, CH3). 
13
C NMR, δ: 165.5 (d,  J = 266.4 Hz, benzene C4), 
138.1 (tetrahydroquinoline C8a), 135.4 (d, J = 13.8 Hz, benzene C2, C6), 135.2 
(tetrahydroquinoline C7), 130.9 (tetrahydroquinoline C4a), 130.6 (d, J = 10.1 Hz, 
benzene C1), 125.8 (tetrahydroquinoline C5), 117.0 (d, J = 90.3 Hz, benzene C3, C5), 
116.5 (tetrahydroquinoline C8), 114.6 (tetrahydroquinoline C6), 46.9 
(tetrahydroquinoline C2), 46.8 (ethyl CH2), 27.0 (tetrahydroquinoline C4), 22.8 
(tetrahydroquinoline C3), 8.3 (CH3) ppm. EI-MS m/z 398 (M+, 17), 305 (10), 159 (20), 
145 (65), 95 (100%). HRMS (ESI) calcd for C17H20FN2O4S2 (MH+), 399.0849; found, 












Following the general procedure 10 using 1-(ethylsulfonyl)-1,2,3,4-tetrahydroquinolin-
7-amine 163 (240 mg, 1.0 mmol), 3-fluorobenzenesulfonyl chloride (233.5 mg), 171 
was isolated as a pale yellow solid (274 mg, 69%), mp: 91-92 ºC; IR (cm
-1
): υ 3272 (m, 
NH), 2955 (m, C-H aliphatic), 1451 (w, C-F), 1327 (m, SO2), 1144 (w, C-N). 
1
H NMR, 
δ: 7.64 (d, J = 7.6 Hz, 1H, benzene_2 H), 7.50 (d, J = 7.6 Hz, 1H, benzene_6 H), 7.44-
7.40 (m, 2H, benzene_4,5 H), 7.37 (s, 1H, tetrahydroquinoline_8 H), 7.21 (t, J = 8.1 
Hz, 1H, benzene_5 H), 6.99 (d, J = 8.2 Hz, 1H, tetrahydroquinoline_5 H), 6.89 (d, J = 
8.1 Hz, 1H, tetrahydroquinoline_6 H), 3.74 (t, J = 5.5 Hz, 2H, tetrahydroquinoline_2 
H), 3.06 (q, J = 7.2 Hz, 2H, ethyl CH2), 2.75 (t, J = 5.9 Hz, 2H, tetrahydroquinoline_4 
H), 1.95 (p, J = 5.5 Hz, 2H, tetrahydroquinoline_3 H), 1.27 (t, J = 7.2 Hz, 3H, CH3). 
13
C NMR, δ: 162.5 (d, J = 251.2 Hz, benzene C3), 141.3 (d, J = 6.5 Hz, benzene C1), 
137.8 (tetrahydroquinoline C8a), 135.1 (tetrahydroquinoline C7), 131.2 (d, J = 7.5 Hz, 
benzene C5), 130.8 (tetrahydroquinoline C5), 125.8 (tetrahydroquinoline C4a), 123.5 
(d, J = 3.7 Hz, benzene C6), 120.4 (d, J = 21.4 Hz, benzene C4), 117.5 
(tetrahydroquinoline C6), 115.0 (d, J = 25.1 Hz, benzene C2), 114.7 
(tetrahydroquinoline C8), 46.8 (tetrahydroquinoline C2), 46.7 (ethyl CH2), 26.9 
(tetrahydroquinoline C4), 22.7 (tetrahydroquinoline C3), 8.2 (CH3) ppm. EI-MS m/z 
398 (M+, 33), 305 (33), 159 (10), 145 (80), 118 (60), 95 (100%). HRMS (ESI) calcd for 
C17H20FN2O4S2 (MH+), 399.0849; found, 399.0837. HPLC purity: 99.3%, Rt=10.956 











Following the general procedure 10 using 1-(ethylsulfonyl)-1,2,3,4-tetrahydroquinolin-
7-amine 163 (240 mg, 1.0 mmol), 2,6-difluorobenzenesulfonyl chloride (255 mg), 172 
was isolated as a white solid (295 mg, 71%), mp: 118-119 ºC; IR (cm
-1
): υ 3245 (m, 
NH), 2942 (w, C-H aliphatic), 1467 (w, C-F), 1318 (m, SO2), 1139 (w, C-N). 
1
H NMR 
(CD3OD), δ: 7.62-7.54 (m, 1H, benzene_4 H), 7.47 (s, 1H, tetrahydroquinoline_8 H), 
7.07 (t, J = 9.0 Hz,  2H, benzene_3,5 H), 7.02 (d, J = 8.2 Hz,  1H, 
tetrahydroquinoline_5 H), 6.87 (d, J = 8.2 Hz, 1H, tetrahydroquinoline_6 H), 3.71 (t, J 
= 5.8 Hz, 2H, tetrahydroquinoline_2 H), 3.09 (q, J = 7.4 Hz, 2H, ethyl CH2), 2.75 (t, J 
= 6.5 Hz, 2H, tetrahydroquinoline_4 H), 1.93 (p, J = 6.4 Hz, 2H, tetrahydroquinoline_3 
H), 1.23 (t, J = 7.3 Hz, 3H, CH3). 
13
C NMR (CD3OD), δ: 160.0 (dd, J = 256.5, 3.8 Hz, 
benzene C2, C6), 139.5 (tetrahydroquinoline C8a), 137.9 (tetrahydroquinoline C7), 
135.2 (t, J = 10.9 Hz, benzene C1), 130.2 (benzene C4), 125.7 (tetrahydroquinoline 
C5), 117.1 (tetrahydroquinoline C4a), 116.5 (tetrahydroquinoline C6), 114.0 
(tetrahydroquinoline C8), 113.0 (dd, J = 23.3, 3.4 Hz, benzene C3, C5), 46.4 
(tetrahydroquinoline C2), 46.0 (ethyl CH2), 26.4 (tetrahydroquinoline C4), 22.4 
(tetrahydroquinoline C3), 7.0 (CH3) ppm. EI-MS m/z 416 (M+, 30), 323 (27), 177 (20), 
145 (100%), 118 (82). HRMS (ESI) calcd for C17H19F2N2O4S2 (MH+), 417.0754; 












Following the general procedure 10 using 1-(ethylsulfonyl)-1,2,3,4-tetrahydroquinolin-
7-amine 163 (240 mg, 1.0 mmol), 2,3,4,5,6-pentafluorobenzenesulfonyl chloride (319.8 
mg), 173 was isolated as a white solid (348 mg, 74%), mp: 122-123 ºC; IR (cm
-1
): υ 
3201 (m, NH), 2947 (w, C-H aliphatic), 1464 (m, C-F), 1324 (m, SO2), 1143 (w, C-N). 
1
H NMR, δ: 7.39 (s, br, NH), 7.32 (s, 1H, tetrahydroquinoline_8 H), 7.06 (d, J = 8.2 Hz, 
1H, tetrahydroquinoline_5 H), 6.92 (dd, J = 8.5, 1.9 Hz, 1H, tetrahydroquinoline_6 H), 
3.74 (t, J = 5.7 Hz, 2H, tetrahydroquinoline_2), 3.12 (q, J = 7.4 Hz, 2H, ethyl CH2), 
2.79 (t, J = 6.6 Hz, 2H, tetrahydroquinoline_4 H), 1.97 (p, J = 6.1 Hz, 2H, 
tetrahydroquinoline_3 H), 1.34 (t, J = 7.4 Hz, 3H, CH3). 
13
C NMR, δ: 145.1 (ddd, J = 
259.2, 12.1, 4.7 Hz, benzene C4), 144.6 (dt, J = 263.3, 13.1 Hz, benzene C2, C6), 138.3 
(dt, J = 258.6, 12.1 Hz, benzene C3, C5), 138.2 (tetrahydroquinoline C8a), 137.5 (d, J 
= 117.2  Hz, benzene C1), 133.4 (tetrahydroquinoline C7), 131.2 (tetrahydroquinoline 
C5), 127.2 (tetrahydroquinoline C4a), 117.8 (tetrahydroquinoline C6), 115.0 
(tetrahydroquinoline C8), 47.2 (tetrahydroquinoline C2), 46.7 (ethyl CH2), 27.0 
(tetrahydroquinoline C4), 22.7 (tetrahydroquinoline C3), 8.2 (CH3) ppm. 
19
F NMR, δ: -
136.6 (2F), -145.0, -158.6 (2F). ESI-MS m/z 469.2 (M-H). HRMS (ESI) calcd for 
C17H16F5N2O4S2 (MH+), 471.0472; found, 471.0452. HPLC purity: 95.3%, Rt=6.211 











Following the general procedure 10 using 1-(ethylsulfonyl)-1,2,3,4-tetrahydroquinolin-
7-amine 163 (240 mg, 1.0 mmol), 4-bromo-2-fluorobenzenesulfonyl chloride (328.2 
mg), 174 was isolated as a red solid (328 mg, 69%), mp: 138-139 ºC; IR (cm
-1
): υ 3244 
(w, NH), 2967 (w, C-H aliphatic), 1471 (w, C-F), 1314 (m, SO2), 1130 (w, C-N). 
1
H 
NMR, δ: 7.73 (t, J = 7.9 Hz, 1H, benzene_3 H), 7.40-7.37 (m, 3H, benzene_5,6, 
tetrahydroquinoline_8 H), 6.99 (d, J = 8.1 Hz,  1H, tetrahydroquinoline_5 H), 6.87 (s, 
br, NH), 6.84 (d, J = 8.2 Hz, 1H, tetrahydroquinoline_6 H), 3.74 (t, J = 5.7 Hz, 2H, 
tetrahydroquinoline_2 H), 3.03 (q, J = 7.4 Hz, 2H, ethyl CH2), 2.75 (t, J = 6.4 Hz, 2H, 
tetrahydroquinoline_4 H), 1.94 (p, J = 6.1 Hz, 2H, tetrahydroquinoline_3 H), 1.29 (t, J 
= 7.3 Hz, 3H, CH3). 
13
C NMR, δ: 157.5 (d, J = 259.6 Hz, benzene C2), 138.0 
(tetrahydroquinoline C8a), 134.1 (tetrahydroquinoline C7), 132.3 (tetrahydroquinoline 
C5), 130.7 (tetrahydroquinoline C4a), 129.0 (d, J = 9.3 Hz, benzene C6), 128.2 (d, J = 
3.7 Hz, benzene C5), 126.2 (d, J = 14.0 Hz, benzene C1), 126.1 (benzene C5), 120.8 (d, 
J = 24.2 Hz, benzene C3), 117.3 (tetrahydroquinoline C6), 114.5 (tetrahydroquinoline 
C8), 46.6 (tetrahydroquinoline C2, ethyl CH2), 26.9 (tetrahydroquinoline C4), 22.5 
(tetrahydroquinoline C3), 8.1 (CH3) ppm. EI-MS m/z 476 (M+
79
Br, 9), 385 (8), 237 
(11), 189 (6), 173 (12), 145 (100%). HRMS (ESI) calcd for C17H19
79
BrFN2O4S2 (MH+), 












Following the general procedure 10 using 1-(ethylsulfonyl)-1,2,3,4-tetrahydroquinolin-
7-amine 163 (240 mg, 1.0 mmol), thiophene-2-sulfonyl chloride (219 mg), 175 was 
isolated as a red solid (247 mg, 64%), mp: 80-81 ºC; IR (cm
-1
): υ 3276 (w, NH), 2942 
(m, C-H aliphatic), 1332 (m, SO2), 1123 (w, C-N). 
1
H NMR, δ: 7.58 (d, J = 3.5 Hz, 1H, 
thiophene_5 H), 7.54 (d, J = 4.9 Hz, 1H, thiophene_3 H), 7.38 (s, 1H, 
tetrahydroquinoline_8 H), 7.04-7.01 (m, 2H, thiophene_4 H, tetrahydroquinoline_5 H), 
6.91 (d, J = 7.5 Hz, 1H, tetrahydroquinoline_6 H), 6.65 (s, br, NH), 3.76 (t, J = 6.0 Hz, 
2H, tetrahydroquinoline_2 H), 3.06 (q, J = 7.5 Hz, 2H, ethyl CH2), 2.78 (t, J = 6.4 Hz, 
2H, tetrahydroquinoline_4 H), 1.94 (p, J = 6.0 Hz, 2H, tetrahydroquinoline_3 H), 1.30 
(t, J = 7.5 Hz, 3H, CH3). 
13
C NMR, δ: 139.4 (thiophene C2), 137.5 (tetrahydroquinoline 
C8a), 134.9 (tetrahydroquinoline C7), 133.1 (tetrahydroquinoline C5), 132.4 (thiophene 
C4), 130.5 (thiophene C3), 127.4 (thiophene C5), 125.6 (tetrahydroquinoline C4a), 
117.2 (tetrahydroquinoline C6), 114.4 (tetrahydroquinoline C8), 46.5 
(tetrahydroquinoline C2), 46.4 (ethyl CH2), 26.7 (tetrahydroquinoline C4), 22.4 
(tetrahydroquinoline C3), 7.9 (CH3) ppm. EI-MS m/z 386 (M+, 20), 322 (20), 293 (11), 
229 (29), 145 (96), 118 (100%), 99 (33). HRMS (ESI) calcd for C15H19N2O4S3 (MH+), 














Following the general procedure 10 using 1-(ethylsulfonyl)-1,2,3,4-tetrahydroquinolin-
7-amine 163 (240 mg, 1.0 mmol), 5-bromothiophene-2-sulfonyl chloride (313.8 mg), 
176 was isolated as red solid (315 mg, 68%), mp: 82-83 ºC; IR (cm
-1
): υ 3192 (w, NH), 
2958 (m, C-H aliphatic), 1326 (m, SO2), 1152 (w, C-N), 635 (w, C-Br). 
1
H NMR, δ: 
7.41 (d, J = 1.5 Hz, 1H, tetrahydroquinoline_8 H), 7.33 (d, J = 4.1 Hz, 1H, thiophene_4 
H), 7.27 (s, br, NH), 7.04 (d, J = 8.2 Hz, 1H, tetrahydroquinoline_5 H), 6.98 (d, J = 3.9 
Hz, 1H, thiophene_3 H), 6.94 (dd, J = 8.4, 1.6 Hz, 1H, tetrahydroquinoline_6 H), 3.77 
(t, J = 5.7 Hz, 2H, tetrahydroquinoline_2 H), 3.10 (q, J = 7.4 Hz, 2H, ethyl CH2), 2.79 
(t, J = 6.5 Hz, 2H, tetrahydroquinoline_4 H), 1.98 (p, J = 5.9 Hz, 2H, 
tetrahydroquinoline_3 H), 1.31 (t, J = 7.4 Hz, 3H, CH3). 
13
C NMR, δ: 140.2 (thiophene 
C2), 137.7 (tetrahydroquinoline C8a), 134.5 (tetrahydroquinoline C7), 133.3 (thiophene 
C4), 130.7 (tetrahydroquinoline C5), 130.5 (thiophene C3), 125.9 (tetrahydroquinoline 
C4a), 120.3 (tetrahydroquinoline C6), 117.3 (thiophene C5), 114.4 (tetrahydroquinoline 
C8), 46.5 (tetrahydroquinoline C2, ethyl CH2), 26.8 (tetrahydroquinoline C4), 22.5 




Br, 10), 400 (12), 
321 (12), 307 (11), 227 (35), 145 (97), 118 (100%), 91 (32). HRMS (ESI) calcd for 
C15H18
79
BrN2O4S3 (MH+), 464.9612; found, 464.9617. HPLC purity: 98.0%, Rt=3.968 












Following the general procedure 10 using 1-(ethylsulfonyl)-1,2,3,4-tetrahydroquinolin-
7-amine 163 (240 mg, 1.0 mmol), 5-chlorothiophene-2-sulfonyl chloride (260.4 mg), 
177 was isolated as a yellow oil (277 mg, 66%), IR (cm
-1
): υ 3195 (w, NH), 2941 (w, C-
H aliphatic), 1328 (s, SO2), 1155 (w, C-N). 
1
H NMR, δ: 7.48 (s, br, NH), 7.43 (s, 1H, 
tetrahydroquinoline_8 H), 7.38 (d, J = 3.8 Hz, 1H, thiophene_4 H), 7.04 (d, J = 8.3 Hz, 
1H, tetrahydroquinoline_5 H), 6.94 (d, J = 7.9 Hz, 1H, tetrahydroquinoline_6 H), 6.83 
(d, J = 3.8 Hz, 1H, thiophene_3 H), 3.77 (t, J = 5.7 Hz, 2H, tetrahydroquinoline_2 H), 
3.12 (q, J = 7.4 Hz, 2H, ethyl CH2), 2.79 (t, J = 6.3 Hz, 2H, tetrahydroquinoline_4 H), 
1.97 (p, J = 5.8 Hz, 2H, tetrahydroquinoline_3 H), 1.30 (t, J = 7.3 Hz, 3H, CH3). 
13
C 
NMR, δ: 137.7 (thiophene C2), 137.5 (tetrahydroquinoline C8a), 137.4 
(tetrahydroquinoline C7), 134.6 (thiophene C3), 132.7 (thiophene C4), 130.7 
(tetrahydroquinoline C5), 126.9 (tetrahydroquinoline C4a), 125.9 (thiophene C5), 117.3 
(tetrahydroquinoline C6), 114.4 (tetrahydroquinoline C8), 46.6 (tetrahydroquinoline C2, 
ethyl CH2), 26.8 (tetrahydroquinoline C4), 22.5 (tetrahydroquinoline C3), 8.0 (CH3) 
ppm. EI-MS m/z 420 (M+ 
35
Cl, 10), 356 (12), 263 (30), 227 (27), 181 (24), 145 (97), 
118 (100%). HRMS (ESI) calcd for C15H18
35
ClN2O4S3 (MH+), 421.0117; found, 












Following the general procedure 10 using 1-(ethylsulfonyl)-1,2,3,4-tetrahydroquinolin-
7-amine 163 (240 mg, 1.0 mmol), 4-methylbenzenesulfonyl chloride (228.7 mg), 178 
was isolated as a colourless solid (287 mg, 73%), mp: 74-75 ºC; IR (cm
-1
): υ 3274 (m, 
NH), 2939 (w, C-H aliphatic), 1320 (s, SO2), 1124 (w, C-N). 
1
H NMR, δ: 7.71 (d, J = 
7.5 Hz, 2H, benzene_2,6 H), 7.33 (s, 1H, tetrahydroquinoline_8 H), 7.23 (d, J = 7.9 Hz, 
2H, benzene_3,5 H), 6.98 (d, J = 5.5 Hz, 1H, tetrahydroquinoline_5 H), 6.87 (d, J = 5.5 
Hz, 1H, tetrahydroquinoline_6), 6.85 (s, br, NH), 3.74 (t, J = 5.5 Hz, 2H, 
tetrahydroquinoline_2 H), 3.03 (q, J = 7.5 Hz, 2H, ethyl CH2), 2.75 (t, J = 6.4 Hz, 2H, 
tetrahydroquinoline_4 H), 2.37 (s, 3H, p-CH3), 1.94 (p, J = 6.1 Hz,  2H, 
tetrahydroquinoline_3 H), 1.27 (t, J = 7.1 Hz, 3H, CH3). 
13
C NMR, δ: 144.1 
(tetrahydroquinoline C8a), 137.9 (benzene C4), 136.6 (benene C1), 135.5 
(tetrahydroquinoline C7), 130.8 (tetrahydroquinoline C5), 130.0 (benzene C3, C5), 
127.8 (benzene C2, C6), 125.4 (tetrahydroquinoline C4a), 117.3 (tetrahydroquinoline 
C6), 114.3 (tetrahydroquinoline C8), 46.8 (tetrahydroquinoline C2), 46.7 (ethyl CH2), 
27.1 (tetrahydroquinoline C4), 22.8 (tetrahydroquinoline C3), 21.9 (benzene_4 CH3), 
8.3 (CH3) ppm. EI-MS m/z 394 (M+, 15), 301 (9), 237 (5), 145 (90), 118 (55), 91 
(100%). HRMS (ESI) calcd for C18H23N2O4S2 (MH+), 395.1099; found, 395.1096. 




Following the general procedure 10 using 1-(ethylsulfonyl)-1,2,3,4-tetrahydroquinolin-
7-amine 163 (240 mg, 1.0 mmol), ethanesulfonyl chloride (154.2 mg), 179 was isolated 
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as a colourless oil (199 mg, 60%), IR (cm
-1
): υ 3260 (m, NH), 2943 (w, C-H aliphatic), 
1322 (s, SO2), 1139 (w, C-N). 
1
H NMR, δ: 7.50 (d, J = 1.7 Hz, 1H, 
tetrahydroquinoline_8 H), 7.32 (s, br, NH), 7.06 (d, J = 8.2 Hz, 1H, 
tetrahydroquinoline_5 H), 6.98 (dd, J = 8.2, 1.9 Hz, 1H, tetrahydroquinoline_6 H), 3.78 
(t, J = 5.7 Hz, 2H, tetrahydroquinoline_2 H), 3.21 (q, J = 7.4 Hz, 2H, ethylsulfonyl 
CH2),  3.15 (q, J = 7.4 Hz, 2H, ethanesulfonamide CH2), 2.80 (t, J = 6.5 Hz, 2H, 
tetrahydroquinoline_4 H), 2.00 (p, J = 6.4 Hz,  2H, tetrahydroquinoline_3 H), 1.36 (t, J 
= 7.3 Hz, 3H, ethylsulfonyl CH3), 1.35 (t, J = 7.4 Hz, 3H, ethanesulfonamide CH3). 
13
C 
NMR, δ: 137.8 (tetrahydroquinoline C8a), 135.6 (tetrahydroquinoline C7), 130.6 
(tetrahydroquinoline C5), 124.9 (tetrahydroquinoline C4a), 116.0 (tetrahydroquinoline 
C6), 113.5 (tetrahydroquinoline C8), 46.9 (tetrahydroquinoline C2), 46.5 (ethylsulfonyl 
CH2), 45.9 (ethanesulfonamide CH2), 26.6 (tetrahydroquinoline C4), 22.6 
(tetrahydroquinoline C3), 8.1 (ethylsulfonyl CH3), 8.0 (ethanesulfonamide CH3) ppm. 
ESI-MS m/z 331.1(M-H). HRMS (ESI) calcd for C13H20N2O4S2 (M-H), 331.0786; 





Following the general procedure 10 using 1-(ethylsulfonyl)-1,2,3,4-tetrahydroquinolin-
7-amine 163 (240 mg, 1.0 mmol), 2,2,2-trifluoroethane-1-sulfonyl chloride (219 mg), 
180 was isolated as a pale yellow solid (247 mg, 64%), mp: 78-79 ºC; IR (cm
-1
): υ 3236 
(m, NH), 2951 (m, C-H aliphatic), 1244 (w, C-F), 1322 (s, SO2), 1126 (w, C-N). 
1
H 
NMR, δ: 7.16 (s, 1H, tetrahydroquinoline_8 H), 7.24 (s, br, NH), 7.11 (d, J = 8.2 Hz, 
1H, tetrahydroquinoline_5 H), 6.99 (d, J = 8.2 Hz, 1H, tetrahydroquinoline_6 H), 3.85 
(q, J = 8.8 Hz, 2H, CF3CH2),  3.79 (t, J = 5.7 Hz, 2H, tetrahydroquinoline_2 H), 3.19 
(q, J = 7.4 Hz, 2H, ethyl CH2), 2.83 (t, J = 6.4 Hz, 2H, tetrahydroquinoline_4 H), 2.02 
(p, J = 5.5 Hz, 2H, tetrahydroquinoline_3 H), 1.36 (t, J = 7.4 Hz, 3H, CH3). 
13
C NMR, 
δ: 138.3 (tetrahydroquinoline C8a), 134.1 (tetrahydroquinoline C7), 131.3 
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(tetrahydroquinoline C5), 126.8 (tetrahydroquinoline C4a), 121.8 (q, J = 276.5 Hz, 
CF3), 117.3 (tetrahydroquinoline C6), 114.9 (tetrahydroquinoline C8), 52.6 (q, J = 31.7 
Hz, CF3CH2), 47.2 (tetrahydroquinoline C2), 46.8 (ethyl CH2), 27.1 
(tetrahydroquinoline C4), 22.8 (tetrahydroquinoline C3), 8.3 (CH3) ppm. ESI-MS m/z 
385.1 (M-H). HRMS (ESI) calcd for C13H18F3N2O4S2 (MH+), 387.0660; found, 












Following the general procedure 10 using 1-(propylsulfonyl)-1,2,3,4-
tetrahydroquinolin-7-amine 167 (254 mg, 1.0 mmol), 4-methylbenzenesulfonyl chloride 
(228.7 mg), 181 was isolated as a pale yellow solid (310 mg, 76%), mp: 112-113 ºC; IR 
(cm
-1
): υ 3276 (w, NH), 2976 (m, C-H aliphatic), 1320 (s, SO2), 1125 (w, C-N). 
1
H 
NMR, δ: 7.72 (d, J = 7.8 Hz, 2H, benzene_2,6 H), 7.54 (s, br, NH), 7.42 (s, 1H, 
tetrahydroquinoline_8 H), 7.20 (d, J = 7.9 Hz,  2H, benzene_3,5 H), 6.95 (d, J = 8.0 
Hz, 1H, tetrahydroquinoline_5 H), 6.86 (d, J = 8.0 Hz, 1H, tetrahydroquinoline_6 H), 
3.72 (t, J = 5.6 Hz, 2H, tetrahydroquinoline_2 H), 2.99 (t, J = 7.4 Hz, 2H, propyl_1 H), 
2.72 (t, J = 6.4 Hz, 2H, tetrahydroquinoline_4 H), 2.34 (s, 3H, p-CH3), 1.92 (p, J = 5.7 
Hz, 2H, tetrahydroquinoline_3 H), 3.74 (sex, J = 7.4 Hz, 2H, propyl_2 H), 0.97 (t, J = 
7.3 Hz, 3H, propyl_3 H). 
13
C NMR, δ: 143.9 (tetrahydroquinoline C8a), 137.8 (benzene 
C4), 136.5 (benzene C1), 135.6 (tetrahydroquinoline C7), 130.6 (tetrahydroquinoline 
C5), 129.8 (benzene C3, C5), 127.6 (benzene C2, C6), 125.1 (tetrahydroquinoline C4a), 
116.9 (tetrahydroquinoline C6), 114.0 (tetrahydroquinoline C8), 53.9 
(tetrahydroquinoline C2), 46.6 (propyl C1), 26.9 (tetrahydroquinoline C4), 22.7 
(tetrahydroquinoline C3), 21.7 (benzene_4 CH3), 17.2 (propyl C2), 13.2 (propyl C3) 
ppm. EI-MS m/z 408 (M+, 48), 301 (46), 237 (10), 145 (100%), 118 (45), 91 (81). 
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HRMS (ESI) calcd for C19H25N2O4S2 (MH+), 409.1256; found, 409.1258. HPLC purity: 





Following the general procedure 10 using 1-(propylsulfonyl)-1,2,3,4-
tetrahydroquinolin-7-amine 167 (254 mg, 1.0 mmol), 4-isopropylbenzenesulfonyl 
chloride (555.7 mg), 182 was isolated as pale yellow solid (344 mg, 79%), mp: 108-109 
ºC; IR (cm
-1
): υ 3273 (m, NH), 2967 (m, C-H aliphatic), 1324 (s, SO2), 1126 (w, C-N). 
1
H NMR, δ: 7.77 (d, J = 8.2 Hz, 2H, benzene_2,6 H), 7.42 (s, 1H, 
tetrahydroquinoline_8 H), 7.28 (d, J = 8.0 Hz,  2H, benzene_3,5 H), 7.21 (s, br, NH), 
6.96 (d, J = 8.2 Hz, 1H, tetrahydroquinoline_5 H), 6.85 (d, J = 8.2 Hz, 1H, 
tetrahydroquinoline_6 H), 3.74 (t, J = 5.7 Hz, 2H, tetrahydroquinoline_2 H), 3.02 (t, J 
= 7.6 Hz, 2H, propyl_1 H), 2.95-2.89 (m, 1H, CH(CH3)2), 2.74 (t, J = 6.4 Hz, 2H, 
tetrahydroquinoline_4 H), 1.94 (p, J = 6.1 Hz, 2H, tetrahydroquinoline_3 H), 1.77 (sex, 
J = 7.6 Hz, 2H, propyl_2 H), 1.22 (d, J = 6.8 Hz, 6H, CH(CH3)2), 0.98 (t, J = 7.5 Hz, 
3H, propyl_3 H). 
13
C NMR, δ: 154.5 (benzene C4), 137.7 (tetrahydroquinoline C8a), 
136.8 (benzene C1), 135.5 (tetrahydroquinoline C7), 130.5 (tetrahydroquinoline C5), 
127.6 (benzene C3, C5), 127.2 (benzene C2, C6), 124.9 (tetrahydroquinoline C4a), 
116.6 (tetrahydroquinoline C6), 113.8 (tetrahydroquinoline C8), 53.9 
(tetrahydroquinoline C2), 46.5 (propyl C1), 34.2 (CH(CH3)2), 26.8 (tetrahydroquinoline 
C4), 23.7 (CH(CH3)2), 22.6 (tetrahydroquinoline C3), 17.1 (propyl C2), 13.1 (propyl 
C3) ppm. EI-MS m/z 436 (M+, 33), 329 (30), 265 (8), 145 (100%), 119 (60), 91 (47). 
HRMS (ESI) calcd for C21H29N2O4S2 (MH+), 437.1569; found, 437.1550. HPLC purity: 
99.4%, Rt=5.180 (15% solvent D in solvent A). 
 








Following the general procedure 10 using 1-(propylsulfonyl)-1,2,3,4-
tetrahydroquinolin-7-amine 167 (254 mg, 1.0 mmol), [1,1'-biphenyl]-4-sulfonyl 
chloride (303.2 mg), 183 was isolated as a reddish white solid (362 mg, 77%), mp: 118-
119 ºC; IR (cm
-1
): υ 3265 (m, NH), 2971 (w, C-H aliphatic), 1325 (s, SO2), 1125 (w, C-
N). 
1
H NMR, δ: 7.90 (d, J = 8.3 Hz, 2H, H2, H6), 7.57 (d, J = 8.3 Hz,  2H, H3, H5), 
7.50 (d, J = 7.5 Hz, 2H, H8, H12), 7.46 (d, J = 1.3 Hz, 1H, tetrahydroquinoline_8 H), 
7.42 (s, br, NH), 7.40 (d
†
, J = 7.7 Hz, 2H, H9, H11), 7.36 (t, J = 7.0 Hz, 1H, H10), 6.97 
(d, J = 8.3 Hz, 1H, tetrahydroquinoline_5 H), 6.90 (dd, J = 8.2, 1.4 Hz, 1H, 
tetrahydroquinoline_6 H), 3.71 (t, J = 5.8 Hz, 2H, tetrahydroquinoline_2 H), 3.00 (t, J 
= 7.6 Hz, 2H, propyl _1 H), 2.70 (t, J = 6.4 Hz, 2H, tetrahydroquinoline_4 H), 1.91 (p, 
J = 6.1 Hz, 2H, tetrahydroquinoline_3 H), 1.72 (sex, J = 7.6 Hz, 2H, propyl_2 H), 0.90 
(t, J = 7.5 Hz, 3H, propyl_3 H). 
13
C NMR, δ: 145.9 (C7), 139.4 (C4), 138.2 
(tetrahydroquinoline C8a), 138.0 (C1), 135.6 (tetrahydroquinoline C7), 130.7 (C3, C5), 
129.2 (tetrahydroquinoline C5), 128.7 (C2, C6), 128.2 (C9, C11), 127.8 
(tetrahydroquinoline C4a), 127.5 (C10), 125.5 (C8, C12), 117.1 (tetrahydroquinoline 
C6), 114.4 (tetrahydroquinoline C8), 54.1 (tetrahydroquinoline C2), 46.7 (propyl C1), 
27.0 (tetrahydroquinoline C4), 22.8 (tetrahydroquinoline C3), 17.3 (propyl C2), 13.1 
(propyl C3) ppm. EI-MS m/z 470 (M+, 45), 363 (33), 299 (29), 253 (10), 207 (11), 145 
(100%), 118 (62), 91 (31). HRMS (ESI) calcd for C24H27N2O4S2 (MH+), 471.1412; 
found, 471.1407. HPLC purity: 98.8%, Rt=6.716 (20% solvent D in solvent A). 
 
                                                             
* Numbering of the 1,1'-biphenyl  carbons doesn’t correspond to the compound name.  
† Apparent doublet. 






Following the general procedure 10 using 1-(propylsulfonyl)-1,2,3,4-
tetrahydroquinolin-7-amine 167 (254 mg, 1.0 mmol), 2-fluorobenzenesulfonyl chloride 
(233.5 mg), 184 was isolated as red solid (284 mg, 69%), mp: 102-103 ºC; IR (cm
-1
): υ 
3245 (w, NH), 2958 (m, C-H aliphatic), 1472 (w, C-F), 1331 (s, SO2), 1126 (w, C-N). 
1
H NMR, δ: 7.55 (t, J = 7.6 Hz, 1H, benzene_4 H), 7.53 (q, J = 7.4 Hz, 1H, benzene_3 
H), 7.42 (s, 1H, tetrahydroquinoline_8 H), 7.23-7.17 (m, 2H, benzene_5,6 H), 6.97 (d, J 
= 8.2 Hz, 1H, tetrahydroquinoline_5 H), 6.94 (s, br, NH), 6.86 (d, J = 8.2 Hz, 1H, 
tetrahydroquinoline_6 H), 3.72 (t, J = 5.7 Hz, 2H, tetrahydroquinoline_2 H), 2.95 (t, J 
= 7.7 Hz, 2H, propyl_1 H), 2.73 (t, J = 6.4 Hz, 2H, tetrahydroquinoline_4 H), 1.92 (p, J 
= 6.2 Hz, 2H, tetrahydroquinoline_3 H), 1.75 (sex, J = 7.7 Hz, 2H, propyl_2 H), 0.99 
(t, J = 7.6 Hz, 3H, propyl_3 H). 
13
C NMR, δ: 159.0 (d, J = 254.96 Hz, benzene C2), 
137.9 (tetrahydroquinoline C8a), 135.6 (d, J = 8.38 Hz, benzene C4), 134.6 
(tetrahydroquinoline C7), 131.3 (tetrahydroquinoline C5), 130.7 (tetrahydroquinoline 
C4a), 127.1 (d, J = 13.07 Hz, benzene C1), 125.9 (tetrahydroquinoline C6), 124.7 (d, J 
= 3.77 Hz, benzene C6), 117.3 (benzene C5), 117.1 (d, J = 20.47 Hz, benzene C3), 
114.5 (tetrahydroquinoline C8), 53.9 (tetrahydroquinoline C2), 46.6 (propyl C1), 27.0 
(tetrahydroquinoline C4), 22.6 (tetrahydroquinoline C3), 17.2 (propyl C2), 13.2 (propyl 
C3) ppm. EI-MS m/z 412 (M+, 42), 305 (44), 145 (100%), 118 (60). HRMS (ESI) calcd 
for C18H22FN2O4S2 (MH+), 413.1005; found, 413.1000. HPLC purity: 99.7%, Rt=8.117 










Following the general procedure 10 using 1-(propylsulfonyl)-1,2,3,4-
tetrahydroquinolin-7-amine 167 (254 mg, 1.0 mmol), thiophene-2-sulfonyl chloride 
(219 mg), 185 was isolated as an orange solid (268 mg, 67%), mp: 96-97 ºC; IR (cm
-1
): 
υ 3288 (w, NH), 2976 (w, C-H aliphatic), 1335 (s, SO2), 1125 (w, C-N). 
1
H NMR, δ: 
7.58 (d, J = 3.7 Hz, 1H, thiophene_5 H), 7.52 (d, J = 4.9 Hz, 1H, thiophene_3 H), 7.43 
(s, 1H, tetrahydroquinoline_8 H), 7.18 (s, br, NH), 7.03 (d, J = 7.9 Hz, 1H, 
tetrahydroquinoline_5 H), 7.00 (t, J = 4.2 Hz, 1H, thiophene_4), 6.92 (d, J = 8.1 Hz, 
1H, tetrahydroquinoline_6), 3.75 (t, J = 5.7 Hz, 2H, tetrahydroquinoline_2 H), 3.02 (t, J 
= 7.8 Hz, 2H, propyl_1 H), 2.77 (t, J = 6.4 Hz, 2H, tetrahydroquinoline_4 H), 1.96 (p, J 
= 6.1 Hz, 2H, tetrahydroquinoline_3 H), 1.78 (sex, J = 7.6 Hz, 2H, propyl_2 H), 1.00 
(t, J = 7.5 Hz, 3H, propyl_3 H).
 13
C NMR, δ: 139.6 (thiophene C2), 137.6 
(tetrahydroquinoline C8a), 134.8 (tetrahydroquinoline C7), 133.1 (thiophene C4), 132.4 
(tetrahydroquinoline C5), 130.5 (thiophene C3), 127.4 (thiophene C5), 125.6 
(tetrahydroquinoline C4a), 117.3 (tetrahydroquinoline C6), 114.5 (tetrahydroquinoline 
C8), 53.7 (tetrahydroquinoline C2), 46.4 (propyl C1), 26.8 (tetrahydroquinoline C4), 
22.5 (tetrahydroquinoline C3), 17.0 (propyl C2), 12.9 (propyl C3) ppm. EI-MS m/z 400 
(M+, 24), 335 (25), 293 (17), 229 (61), 145 (100%), 118 (76). HRMS (ESI) calcd for 
C16H21N2O4S3 (MH+), 401.0663; found, 401.0646. HPLC purity: 99.9%, Rt=8.586 












Following the general procedure 10 using 1-(propylsulfonyl)-1,2,3,4-
tetrahydroquinolin-7-amine 167 (254 mg, 1.0 mmol), 2-methylbenzenesulfonyl chloride 
(228.7 mg), 186 was isolated as an orange oil (302 mg, 74%), IR (cm
-1
): υ 3244 (m, 
NH), 2936 (m, C-H aliphatic), 1326 (s, SO2), 1130 (w, C-N). 
1
H NMR, δ: 7.98 (d, J = 
7.7 Hz, 1H, benzene_6 H), 7.41 (t, J = 7.7 Hz, 1H, benzene_5 H), 7.35 (d,  J = 2.0 Hz, 
1H, tetrahydroquinoline_8 H), 7.27-7.24 (m, 3H, NH, benzene_3,4 H), 6.93 (d, J = 8.2 
Hz, 1H, tetrahydroquinoline_5 H), 6.81 (dd, J = 8.2, 2.0 Hz, 1H, tetrahydroquinoline_6 
H), 3.70 (t, J = 5.8 Hz, 2H, tetrahydroquinoline_2 H), 2.94 (t, J = 7.9 Hz, 2H, propyl_1 
H), 2.70 (t, J = 6.4 Hz, 2H, tetrahydroquinoline_4 H), 2.65 (s, 3H, o-CH3), 1.90 (p, J = 
6.2 Hz, 2H, tetrahydroquinoline_3 H), 1.72 (sex, J = 7.6 Hz, 2H, propyl_2 H), 0.96 (t, J 
= 7.4 Hz, 3H, propyl_3 H). 
13
C NMR, δ: 137.8 (benzene C1), 137.7 
(tetrahydroquinoline C8a), 137.5 (benzene C2), 135.4 (benzene C4), 133.2 (benzene 
C5), 132.8 (tetrahydroquinoline C7), 130.7 (benzene C3), 130.4 (tetrahydroquinoline 
C5), 126.4 (benzene C6), 124.9 (tetrahydroquinoline C4a), 116.2 (tetrahydroquinoline 
C6), 113.5 (tetrahydroquinoline C8), 53.8 (tetrahydroquinoline C2), 46.6 (propyl C1), 
26.9 (tetrahydroquinoline 4), 22.7 (tetrahydroquinoline C3), 20.6 (benzene_2 CH3), 
17.2 (propyl C2), 13.2 (propyl C3) ppm. EI-MS m/z 408 (M+, 40), 301 (36), 237 (10), 
145 (96), 118 (55), 91 (100%). HRMS (ESI) calcd for C19H25N2O4S2 (MH+), 409.1256; 











Following the general procedure 10 using 1-(propylsulfonyl)-1,2,3,4-
tetrahydroquinolin-7-amine 167 (254 mg, 1.0 mmol), 3-methylbenzenesulfonyl chloride 
(228.7 mg), 187 was isolated as a yellow oil (306 mg, 75%), IR (cm
-1
): υ 3256 (m, NH), 
2934 (m, C-H aliphatic), 1324 (s, SO2), 1123 (m, C-N). 
1
H NMR, δ: 7.69 (s, 1H, 
benzene_2 H), 7.61 (d, J = 6.4 Hz, 1H, benzene_6 H), 7.38 (s, 1H, 
tetrahydroquinoline_8 H) 7.31-7.28 (m, 2H, benzene_4,5 H), 7.22 (s, br, NH), 6.96 (d, J 
= 8.2 Hz, 1H, tetrahydroquinoline_5 H), 6.86 (dd, J = 8.2, 1.8 Hz, 1H, 
tetrahydroquinoline_6 H), 3.72 (t, J = 5.9 Hz, 2H, tetrahydroquinoline_2 H), 2.98 (t, J 
= 7.6 Hz, 2H, propyl_1 H), 2.73 (t, J = 6.6 Hz, 2H, tetrahydroquinoline_4 H), 2.34 (s, 
3H, m-CH3), 1.92 (p, J = 6.2 Hz, 2H, tetrahydroquinoline_3 H), 1.74 (sex, J = 7.6 Hz, 
2H, propyl_2 H), 0.97 (t, J = 7.6 Hz, 3H, propyl_3 H). 
13
C NMR, δ: 139.3 
(tetrahydroquinoline C8a), 139.0 (benzene C3), 137.5 (benzene C1), 135.3 
(tetrahydroquinoline C7), 133.7 (benzene C4), 130.4 (tetrahydroquinoline C5), 128.8 
(benzene C5), 127.7 (tetrahydroquinoline C4a), 124.9 (benzene C6), 124.5 (benzene 
C2), 116.8 (tetrahydroquinoline C6), 113.9 (tetrahydroquinoline C8), 53.7 
(tetrahydroquinoline C2), 46.4 (propyl C1), 26.7 (tetrahydroquinoline C4), 22.5 
(tetrahydroquinoline C3), 21.2 (benzene_3 CH3), 17.0 (propyl C2), 12.9 (propyl C3) 
ppm. EI-MS m/z 408 (M+, 43), 301 (37), 237 (11), 145 (100%), 118 (60), 91 (95). 
HRMS (ESI) calcd for C19H25N2O4S2 (MH+), 409.1256; found, 409.1236. HPLC purity: 










Following the general procedure 10 using 1-(propylsulfonyl)-1,2,3,4-
tetrahydroquinolin-7-amine 167 (254 mg, 1.0 mmol), 2,4-dimethylbenzenesulfonyl 
chloride (245.5 mg), 188 was isolated as an orange oil (320 mg, 76%), IR (cm
-1
): υ 3277 
(m, NH), 2973 (m, C-H aliphatic), 1322 (s, SO2), 1139 (m, C-N). 
1
H NMR, δ: 7.88 (d, J 
= 8.0 Hz, 1H, benzene_6 H), 7.35 (d, J = 2.0 Hz 1H, tetrahydroquinoline_8 H), 7.33 (s, 
1H, benzene_3 H), 7.06 (s, br, NH), 7.05 (d, J = 8.0 Hz, 1H, benzene_5 H), 6.92 (d, J = 
8.2 Hz, 1H, tetrahydroquinoline_5 H), 6.80 (dd, J = 8.5, 2.0 Hz, 1H, 
tetrahydroquinoline_6 H), 3.72 (t, J = 5.8 Hz, 2H, tetrahydroquinoline_2 H), 2.95 (t, J 
= 7.7 Hz, 2H, propyl_1 H), 2.71 (t, J = 6.5 Hz, 2H, tetrahydroquinoline_4 H), 2.61 (s, 
3H, benzene_2 CH3), 2.31 (s, 3H, benzene_4 CH3),  1.91 (p, J = 6.0 Hz,  2H, 
tetrahydroquinoline_3 H), 1.75 (sex, J = 7.7 Hz, 2H, propyl_2 H), 0.97 (t, J = 7.5 Hz, 
3H, propyl_3 H). 
13
C NMR, δ: 143.9 (benzene C1), 137.8 (benzene C2), 137.3 
(tetrahydroquinoline C8a), 135.6 (benzene C4), 134.8 (benzene C5), 133.5 
(tetrahydroquinoline C7), 130.6 (benzene C6), 130.6 (tetrahydroquinoline C5), 127.0 
(tetrahydroquinoline C4a), 124.7 (benzene C3), 116.0 (tetrahydroquinoline C6), 113.3 
(tetrahydroquinoline C8), 53.8 (tetrahydroquinoline C2), 46.6 (propyl C1), 26.9 
(tetrahydroquinoline C4), 22.7 (tetrahydroquinoline C3), 21.5 (benzene_2 CH3), 20.5 
(benzene_4 CH3), 17.2 (propyl C2), 13.2 (propyl C3) ppm. EI-MS m/z 422 (M+, 32), 
315 (26), 251 (29), 145 (100%), 118 (33), 105 (30), 91 (17). HRMS (ESI) calcd for 
C20H27N2O4S2 (MH+), 423.1412; found, 423.1399. HPLC purity: 99.9%, Rt=5.799 
(20% solvent D in solvent A). 
 
 






Following the general procedure 10 using 1-(propylsulfonyl)-1,2,3,4-
tetrahydroquinolin-7-amine 167 (254 mg, 1.0 mmol), 3,5-dimethylbenzenesulfonyl 
chloride (245.5 mg), 189 was isolated as an orange oil (324 mg, 77%), IR (cm
-1
): υ 3246 
(m, NH), 2968 (m, C-H aliphatic), 1324 (s, SO2), 1146 (w, C-N). 
1
H NMR, δ: 7.48 (s, 
2H, benzene_2,6 H), 7.42-7.40 (m, 2H, tetrahydroquinoline_8 H, benzene_4 H), 7.11 (s, 
br, NH), 6.95 (d, J = 8.3 Hz, 1H, tetrahydroquinoline_5 H), 6.85 (dd, J = 8.2, 1.70 Hz, 
1H, tetrahydroquinoline_6 H), 3.72 (t, J = 5.8 Hz, 2H, tetrahydroquinoline_2 H), 2.99 
(t, J = 7.7 Hz, 2H, propyl_1 H), 2.73 (t, J = 6.5 Hz, 2H, tetrahydroquinoline_4 H), 2.29 
(s, 6H, benzene_3,5 CH3), 1.92 (p, J = 6.0 Hz,  2H, tetrahydroquinoline_3 H), 1.75 
(sex, J = 7.6 Hz, 2H, propyl_2 H), 0.97 (t, J = 7.5 Hz, 3H, propyl_1 H). 
13
C NMR, δ: 
138.9 (tetrahydroquinoline C8a), 138.8 (benzene C3, C5), 137.5 (benzene C1), 135.3 
(tetrahydroquinoline C7), 134.5 (benzene C4), 130.3 (tetrahydroquinoline C5), 124.9 
(tetrahydroquinoline C4a), 124.7 (benzene C2, C6), 116.5 (tetrahydroquinoline C6), 
113.6 (tetrahydroquinoline C8), 53.6 (tetrahydroquinoline C2), 46.3 (propyl C1), 26.6 
(tetrahydroquinoline C4), 22.5 (tetrahydroquinoline C3), 21.1 (benzene_3,5 CH3), 16.9 
(propyl C2), 12.9 (propyl C3) ppm. EI-MS m/z 422 (M+, 40), 315 (38), 251 (20), 207 
(17), 145 (100%), 118 (27), 105 (29). HRMS (ESI) calcd for C20H27N2O4S2 (MH+), 











Following the general procedure 10 using 1-(propylsulfonyl)-1,2,3,4-
tetrahydroquinolin-7-amine 167 (254 mg, 1.0 mmol), 2,3,4,5,6-
pentamethylbenzenesulfonyl chloride (296 mg), 190 was isolated as a yellow solid (371 
mg, 80%), mp: 128-129 ºC;  IR (cm
-1
): υ 3266 (m, NH), 2937 (m, C-H aliphatic), 1315 
(s, SO2), 1130 (w, C-N). 
1
H NMR, δ: 7.21 (s, 1H, tetrahydroquinoline_8 H), 6.92 (d, J 
= 8.2 Hz, 1H, tetrahydroquinoline_5 H), 6.92 (s, br, NH), 6.70 (d, J = 8.2, 1H, 
tetrahydroquinoline_6 H), 3.71 (t, J = 5.7 Hz, 2H, tetrahydroquinoline_2 H), 2.84 (t, J 
= 7.8 Hz, 2H, propyl_1 H), 2.71 (t, J = 6.5 Hz, 2H, tetrahydroquinoline_4 H), 2.58 (s, 
6H, benzene_2,6 CH3), 2.24 (s, 3H, benzene_4 CH3), 2.21 (s, 6H, benzene_3,5 CH3), 
1.91 (p, J = 6.1 Hz,  2H, tetrahydroquinoline_3 H), 1.67 (sex, J = 7.6 Hz, 2H, propyl_2 
H), 0.93 (t, J = 7.4 Hz, 3H, propyl_3 H). 
13
C NMR, δ: 139.8 (benzene C2, C6), 137.5 
(tetrahydroquinoline C8a), 135.9 (benzene C3, C5), 135.4 (benzene C4), 134.9 
(tetrahydroquinoline C7), 134.4 (tetrahydroquinoline C5), 130.4 (tetrahydroquinoline 
C4a), 124.6 (benzene C1), 116.4 (tetrahydroquinoline C6), 113.6 (tetrahydroquinoline 
C8), 53.4 (tetrahydroquinoline C2), 46.4 (propyl C1), 26.8 (tetrahydroquinoline C4), 
22.5 (tetrahydroquinoline C3), 19.0 (benzene_2,6 CH3), 17.8 (benzene_3,5 CH3), 17.1 
(benzene_4 CH3), 16.9 (propyl C2), 12.9 (propyl C3)  ppm. EI-MS m/z 464 (M+, 29), 
293 (66), 254 (16), 147 (100%). HRMS calcd for C23H33N2O4S2 (MH+), 465.1882; 










Following the general procedure 10 using 1-(thiophen-2-ylsulfonyl)-1,2,3,4-
tetrahydroquinolin-7-amine 168 (294 mg, 1.0 mmol), thiophene-2-sulfonyl chloride 
(219 mg), 191 was isolated as a white solid (264 mg, 60%), mp: 108-109 ºC; IR (cm
-1
): 
υ 3259 (m, NH), 2965 (w, C-H aliphatic), 1339 (s, SO2), 1122 (w, C-N). 
1
H NMR, δ: 
7.60 (d, J = 3.4 Hz, 1H, thiophen-2-yl_5 H), 7.55 (d, J = 4.9 Hz, 1H, thiophene_5 H), 
7.50 (d, J = 4.9 Hz, 2H, thiophen-2-yl_3 H, thiophene_3 H), 7.35 (d, J = 3.3 Hz, 1H, 
thiophen-2-yl_4 H), 7.26 (s, br, NH), 7.06-6.96 (m, 3H, tetrahydroquinoline_5,6 H, 
thiophene_4 H), 6.76 (s, 1H, tetrahydroquinoline_8H), 3.79 (t, J = 5.8 Hz, 2H, 
tetrahydroquinoline _2 H), 2.46 (t, J = 6.5 Hz, 2H, tetrahydroquinoline_4 H), 1.66 (p, J 
= 6.0 Hz, 2H, tetrahydroquinoline _3 H). 
13
C NMR, δ: 139.5 (tetrahydroquinoline C8a), 
139.2 (thiophene C1), 136.9 (thiophen-2-yl C1), 134.6 (tetrahydroquinoline C7), 133.3 
(tetrahydroquinoline C5), 132.5 (thiophene C4), 132.4 (thiophen-2-yl C3), 132.3 
(thiophene C3), 130.1 (thiophen-2-yl C4), 128.0 (thiophen-2-yl C5), 127.5 (thiophene 
C5), 127.4 (tetrahydroquinoline C4a), 118.9 (tetrahydroquinoline C6), 117.7 
(tetrahydroquinoline C8), 46.8 (tetrahydroquinoline C2), 26.4 (tetrahydroquinoline C4), 
21.3 (tetrahydroquinoline C5) ppm. EI-MS m/z 440 (M+, 29), 376 (26), 312 (38), 229 
(80), 145 (100%), 118 (78), 91 (55). HRMS (ESI) calcd for C17H17N2O4S4 (MH+), 




















Following the general procedure 10 using 1-(thiophen-2-ylsulfonyl)-1,2,3,4-
tetrahydroquinolin-7-amine 168 (294 mg, 1.0 mmol), 4-methylbenzenesulfonyl chloride 
(228.7 mg), 192 was isolated as a yellow solid (291 mg, 65%), mp: 119-120 ºC; IR (cm
-
1
): υ 3236 (m, NH), 2948 (w, C-H aliphatic), 1318 (s, SO2), 1129 (w, C-N). 
1
H NMR, δ: 
7.74 (d, J = 8.1 Hz, 2H, benzene_2,6 H), 7.50 (s, 1H, tetrahydroquinoline_8 H), 7.48 (d, 
J = 4.8 Hz, 1H, thiophene_5 H), 7.28 (d, J = 3.1 Hz, 1H, thiophene_3 H), 7.23 (d, J = 
8.0 Hz, 2H, benzene_3,5 H), 6.97-6.91 (m, 3H, tetrahydroquinoline_5,6 H, thiophene_4 
H), 6.89 (s, br, NH), 3.77 (t, J = 6.1 Hz, 2H, tetrahydroquinoline_2 H), 2.43 (t, J = 6.4 
Hz, 2H, tetrahydroquinoline_4 H), 2.36 (s, 3H, p-CH3), 1.65 (p, J = 6.1 Hz, 2H, 
tetrahydroquinoline_3 H). 
13
C NMR, δ: 143.8 (tetrahydroquinoline C8a), 139.2 
(thiophene C2), 136.8 (benzene C4), 136.2 (benzene C1), 135.0 (tetrahydroquinoline 
C7), 132.3 (tetrahydroquinoline C5), 132.1 (thiophene C3), 129.9 (thiophene C4), 129.5 
(thiophene C5), 127.3 (benzene C3, C5), 127.3 (tetrahydroquinoline C4a), 127.2 
(benzene C2, C6), 118.3 (tetrahydroquinoline C6), 117.2 (tetrahydroquinoline C8), 46.8 
(tetrahydroquinoline C2), 26.3 (tetrahydroquinoline C4), 21.6 (tetrahydroquinoline C3), 
21.3 (benzene_4 CH3) ppm. EI-MS m/z 448 (M+, 24), 384 (17), 319 (26), 229 (99), 146 
(100%), 118 (53), 91 (80). HRMS (ESI) calcd for C20H21N2O4S3 (MH+), 449.0663; 











Following the general procedure 10 using 1-tosyl-1,2,3,4-tetrahydroquinolin-7-amine 
169 (302 mg, 1.0 mmol), thiophene-2-sulfonyl chloride (219 mg), 193 was isolated as  a 
pale yellow solid  (287 mg, 64%), mp: 68-69 ºC; IR (cm
-1
): υ 3255 (m, NH), 2951 (w, 
C-H aliphatic), 1329 (s, SO2), 1132 (w, C-N). 
1
H NMR, δ: 7.60 (d, J = 3.8 Hz, 1H, 
thiophene_5 H), 7.55 (d, J = 4.9 Hz, 1H, thiophene_3 H), 7.51 (d, J = 1.7 Hz, 1H, 
tetrahydroquinoline_8 H), 7.41 (d, J = 8.0 Hz, 2H, tosyl_2,6 H), 7.18 (d, J = 8.1 Hz, 
2H, tosyl_3,5 H), 7.02 (t, J = 4.0 Hz, 1H, thiophene_4 H), 7.00 (dd, J = 7.9, 1.7 Hz, 1H, 
tetrahydroquinoline_6 H), 6.92 (d, J = 8.2 Hz, 1H, tetrahydroquinoline_5 H),  6.83 (s, 
br, NH), 3.75 (t, J = 5.9 Hz, 2H, tetrahydroquinoline_2 H), 2.42 (t, J = 6.6 Hz, 2H, 
tetrahydroquinoline_4 H), 2.38 (s, 3H, p-CH3), 1.59 (p, J = 6.2 Hz, 2H, 
tetrahydroquinoline_3 H). 
13
C NMR, δ: 143.8 (thiophene C2), 139.5 
(tetrahydroquinoline C8a), 137.5 (tosyl C4), 136.5 (tetrahydroquinoline C7), 134.5 
(tosyl C1), 133.3 (tetrahydroquinoline C5), 132.4 (thiophene C4), 129.9 (thiophene C3), 
129.7 (tosyl C3, C5), 127.6 (thiophene C5), 127.4 (tosyl C2, C6), 127.1 
(tetrahydroquinoline C4a), 118.5 (tetrahydroquinoline C6), 117.5 (tetrahydroquinoline 
C8), 46.5 (tetrahydroquinoline C2), 26.3 (tetrahydroquinoline C4), 21.6 
(tetrahydroquinoline C3), 21.3 (CH3) ppm. EI-MS m/z 448 (M+, 16), 320 (19), 229 
(18), 207 (22), 145 (100%) 118 (60), 91 (85). HRMS (ESI) calcd for C20H21N2O4S3 











Following the general procedure 10 using 1-tosyl-1,2,3,4-tetrahydroquinolin-7-amine 
169 (302 mg, 1 mmol), 4-methylbenzenesulfonyl chloride (228.7 mg), 194 was isolated 
as a white solid (296 mg, 65%), mp: 148-149 ºC; IR (cm
-1
): υ 3232 (m, NH), 2921 (w, 
C-H aliphatic), 1326 (s, SO2), 1157 (w, C-N). 
1
H NMR, δ: 7.75 (d, J = 8.1 Hz, 2H, 
benzene_2,6 H), 7.51 (d, J = 2.1 Hz, 1H, tetrahydroquinoline_8 H), 7.37 (d, J = 8.1 Hz, 
2H, benzene_3,5 H), 7.23 (d, J = 8.1 Hz, 2H, tosyl_2,6 H), 7.14 (d, J = 8.1 Hz, 2H, 
tosyl_3,5 H), 7.01 (s, br, NH), 6.93 (dd, J = 8.0, 1.9 Hz, 1H, tetrahydroquinoline_6 H), 
6.86 (d, J = 8.2 Hz, 1H, tetrahydroquinoline_5 H), 3.73 (t, J = 5.9 Hz, 2H, 
tetrahydroquinoline_2 H), 2.39-2.36 (m, 5H, tetrahydroquinoline_4 H, benzene_4 CH3), 
2.35 (s, 3H, tosyl_CH3), 1.57 (p, J = 5.9 Hz, 2H, tetrahydroquinoline_3 H). 
13
C NMR, 
δ: 143.7, 143.6, 137.4, 136.5, 136.2, 134.9, 129.9 (tetrahydroquinoline C5), 129.7, 
129.6, 127.5, 127.1, 126.9 (tetrahydroquinoline C6), 117.9 (tetrahydroquinoline C8), 
116.9, 46.5 (tetrahydroquinoline C2), 26.2 (tetrahydroquinoline C4), 21.6 
(tetrahydroquinoline C3), 21.5 (benzene_4 CH3), 21.3 (tosyl_CH3) ppm. EI-MS m/z 456 
(M+, 30), 327 (27), 301 (33), 237 (24), 207 (19), 145 (100%), 118 (37), 91 (73). HRMS 
(ESI) calcd for C23H25N2O4S2 (MH+), 457.1256; found, 457.1242. HPLC purity: 99.4%, 
Rt=13.965 (15% solvent D in solvent A). 
 
9.2. In Silico experiments  
9.2.1. CHIKV non-structural protein 2 (nsP2) 
The CHIKV nsP2 crystal structure (PDB: 3TRK) was used for the virtual screening 
study. The virtual screening study was performed on both nsP2 sites (the domain C 
site_1 and the domain N site_2) using the Life chemicals cysteine protease inhibitors 
library (28,960 compounds). This cysteine protease inhibitors library was designed 
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using Ligand based approach – first, a set of 585 compounds active in assays related to 
cysteine proteases was assembled. And then, Life Chemicals collection was searched 
for compounds similar to the reference dataset using MDL public keys and the 
Tanimoto similarity cut-off of 85% to generate a library of 28,960 compounds. Omega2 
(OpenEye Scientific Software, Santa Fe, NM. http://www.eyesopen.com),
235, 236
 was 
used to generate multiple conformers for each compound in the cysteine protease 
inhibitors library, using the default settings, generating 3,349,162 conformers. The 
binding sites were prepared for docking using Fred receptor setup software (OpenEye 
Scientific Software, Santa Fe, NM. http://www.eyesopen.com). The binding sites were 
detected using the molecular detection method within Fred receptor setup software, 
where the method detection uses multiple molecular probes rather than a single carbon 
probe to determine areas of the protein where docking is likely to occur. These probes 
are docked using a shape based potential, and regions where multiple probes dock are 
considered favourable. This type of site based detection is slow, it can take several 
minutes, but detects few sites that are in general of higher quality than atomic probe 
detection method.  
For the C domain site_1, the binding site detected within the C domain had a 
size of 8321 Å
3
, an inner contour of 119 Å
3
 and an outer contour of 2023 Å
3
. For the N 
domain site_2, the binding site had a box size of 9394 Å
3
, an inner contour of 69 Å
3
 and 
an outer contour of 2748 Å
3
. As a blind docking, no constraints were enabled within 
these sites, with any of the amino acid residues. 
Fast exhaustive virtual screening was performed using FRED v2.2.5 (OpenEye 
Scientific Software, Santa Fe, NM. http://www.eyesopen.com). During the docking 
calculations, chemgauss3 scoring functions was enabled. After the docking calculations, 
the poses returned were scored and ranked with a Gaussian shape function 
independently by the five available scoring functions (PLP, Chemgauss3, Chemscore, 
OEChemscore, and Screenscore) and by a consensus of all. The top ranked poses from 
the exhaustive docking were then optimized using systematic solid body optimization 
by chemgauss3. VIDA v4.2.0 (OpenEye Scientific Software, Santa Fe, 
NM. http://www.eyesopen.com) was used to visualise the docked poses within the 
receptor active site, and to inspect the critical interacting residues in each pocket with 
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the individual docked poses. Top 25 hits were then recorded for each of the two sites 
(Tables 5.1, 5.4). 
The top 25 docked poses ranked in each of the two binding sites (site_1, site_2) 
were then extracted as PDB files, and were processed with AutoDock Tools 1.5.6rc3 
(ADT) graphical interface.
173
 The Gasteiger charges were computed and the nonpolar 
hydrogen atoms were merged, torsion angles were defined, they were then saved as 
pdbqt files for Autodock calculations. The crystal structure 3TRK was used by ADT to 
setup the binding sites. For the C domain site_1, the grid box x, y and z coordinates 
were 11.779, 31.511 and 29.546, respectively. The grid spacing was set to 0.375 Å. The 
grid box size was set to 42 x 42 x 42 points in x, y, and a z direction. For the N domain 
site_2, the grid box x, y and z coordinates were 3.366, 28.678 and 21.482 respectively. 
The grid box size was set to 42 x 42 x 42 points in x, y, and a z direction, with grid 
spacing of 0.375 Å. AutoGrid 4.2 algorithm was used to evaluate the binding energies 
between the inhibitors and the enzyme and to generate the energy maps for the docking 
run. Fifty runs were generated by using Autodock 4.2 Lamarckian genetic algorithm
173
 
for the searches. Cluster analysis was performed on docked results, with a root-mean-
square tolerance of 1.0, 2.0 and 3.0 Å, the docked poses were ranked according to the 
binding energies and ligand efficiencies, and finally the five lowest energy poses 
(Tables 5.2, 5.3, 5.5, 5.6) were selected as the resultant complexes with the enzymes. 
The complexes were then typed with the CHARMm forcefield with Discovery Studio 
3.5 software (Accelrys Software Inc.: San Diego, CA, 2012) to relax the obtained poses 
within the enzyme pockets, and visualized. 
 
9.2.2. CHIKV envelope proteins 
9.2.2.1. Identification of novel binding sites 
Both the crystal structure of the immature complex (PDB file: 3N40
95
) and the mature 
complex (PDB file: 3N42
95
) were used. Binding sites within the receptors were detected 
using the Discovery Studio 3.5 software (Accelrys Software Inc.: San Diego, CA, 
2012). The algorithm is based on a grid search and "eraser" algorithm which derives 
binding sites from cavities in the structure of the receptor. The binding site found is 
displayed as a set of points. The volume of each cavity is defined as the product of 
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number of site points and the cube of the grid spacing. Six main sites were detected in 
both the immature and the mature crystal structures and only one site were detected in 
the mature crystal structure that is not present in the immature form (Figure 6.2). Table 
1 shows the identified sites with their characters. Suitable cavities were then checked 
further based on functionality, presence of hydrophobic residues, presence of charged 
residues and solvent accessibility.  
9.2.2.2. Virtual screening with the CHIKV envelope proteins 
Two chemical compounds libraries were used; The NCI set library of 265,242 
compounds and the Life chemicals protein-protein interactions inhibitors library of 
31,143 compounds. The databases were filtered with the drug-likeness-index; limit the 
range for Molecular Weight < 500, calculated octanol–water partition coefficient (clogP 
< 5), and hydrogen bond donors, and acceptors (OH’s and NH’s < 5; N’s and O’s < 
10),
231
 using Filter v2.0.2 (OpenEye Scientific Software, Santa Fe, 
NM. http://www.eyesopen.com), producing 55,841 compounds from the NCI library 
and 4,124 compounds from the Life Chemicals library. Fast exhaustive virtual screening 
was performed using FRED v2.2.5 (OpenEye Scientific Software, Santa Fe, 
NM. http://www.eyesopen.com). FRED is a fast and effective docking application 
whose performance is significantly more reliable, i.e. lower variance, than most other 
programs.
232, 233
 FRED performs a systematic, exhaustive, nonstochastic examination of 
all possible poses within the protein active site, filters for shape complementarily 
234
 and 
pharmacophoric features before selecting and optimizing poses using the Chemgauss 
scoring function. Omega2 (Systematic high-throughput conformer generation, OpenEye 
Scientific Software, Santa Fe, NM. http://www.eyesopen.com),
235, 236
 was used to 
generate multiple conformers for each compound in the database libraries using the 
default settings. Omega2 takes into account the flexibility of a molecule by generating 
all representative conformers. For the NCI library, 2,312,012 conformers were 
generated, and 334,064 conformers were generated from the Life Chemicals 
compounds. The work-flow diagram is shown in (Figure 6.3), the life chemical library 
was screened on site 2 (light green, Figure 6.2) in both of the immature and the mature 
glycoproteins. The NCI set compounds were screened on site 4 (blue, Figure 6.2) of the 
two envelope protein forms. The binding sites were prepared for docking using Fred 
receptor setup software (OpenEye Scientific Software, Santa Fe, 
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NM. http://www.eyesopen.com). The grid boxes were determined based on the x, y and 
z co-ordinates given in Table 1. For site 2 in the 3N40 receptor, the box size was set to 
6153 Å
3
 and was assigned an inner contour of 99 Å
3
 and an outer contour of 1886 Å
3
. 
Site 4 in the 3N40 receptor has a box size of 6580 Å
3
 and was assigned an inner contour 
of 116 Å
3
 and an outer contour of 1071 Å
3
. Site 2 in 3N42 receptor has a box size of 
7578 Å
3
 and was assigned an inner contour of 66 Å
3
 and an outer contour of 1816 Å
3
. 
Site 4 in 3N42 receptor was assigned a box size of 6482 Å
3
, an inner contour of 45 Å
3
 
and an outer contour of 1547 Å
3
. No constraints were enabled in any of the prepared 
receptors. During the docking calculations, both chemgauss3 and shapeguass scoring 
functions were enabled. After the docking calculations, the poses returned were scored 
and ranked with a Gaussian shape function independently by the five available scoring 
functions (PLP, Chemgauss3, Chemscore, OEChemscore, and Screenscore) and by a 
consensus of all. The top ranked poses from the exhaustive docking were then 
optimized using systematic solid body optimization by chemgauss3. VIDA v4.2.0 
(OpenEye Scientific Software, Santa Fe, NM. http://www.eyesopen.com) was used to 
visualise the docked poses within the receptor active site, and to inspect the critical 
interacting residues in each pocket with the individual docked poses. Top 20 hits were 
then recorded for each of the four sites (Tables 6.2, 6.5, 6.8, 6.11). 
The top 20 docked poses ranked in each of the four binding sites were then 
extracted as PDB files, and were processed with AutoDock Tools 1.5.6rc3 (ADT) 
graphical interface.
173
 The Gasteiger charges were computed and the nonpolar hydrogen 
atoms were merged, torsion angles were defined, they were then saved as pdbqt files for 
Autodock calculations. Crystal structures (3N40, 3N42) were used by AutoDock Tools 
1.5.6rc3 to setup the receptor binding sites. The grid box co-ordinates in each site were 
determined based on the co-ordinates in Table 6.1. The grid box size was set to 46 x 46 
x 46 points in x, y, and a z direction in each of the four sites and a grid spacing of 0.375 
Å was used. AutoGrid 4.2 algorithm was used to evaluate the binding energies between 
the inhibitors and the enzyme and to generate the energy maps for the docking run. Fifty 
runs were generated by using Autodock 4.2 Lamarckian genetic algorithm
173
 for the 
searches. Cluster analysis was performed on docked results, with a root-mean-square 
tolerance of 2.0 Å, the docked poses were ranked according to the binding energies and 
ligand efficiencies, and finally the five lowest energy poses (Tables 6.3, 6.4, 6.6, 6.7, 
6.9, 6.10, 6.12, 6.13) were selected as the resultant complexes with the enzymes. The 
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complexes were then typed with the CHARMm forcefield with Discovery Studio 3.5 
software (Accelrys Software Inc.: San Diego, CA, 2012) to relax the obtained poses 
within the enzyme pockets, and visualized.  
 
9.2.3. CHIKV non-structural protein 3 (nsP3) 
9.2.3.1. Virtual screening with Autodock Vina 
The CHIKV nsP3 macro domain crystal structure was downloaded from the protein 
data bank (RCSB), PDB code: 3GPO.
80
 Autodock Tools 1.5.6rc3 (ADT) graphical 
interface
173
 was used to prepare the receptor, where waters were removed, non-polar 
hydrogens were merged and polar hydrogens were added. The Kollman charges were 
added and the Gasteiger charges were calculated for the receptor. The grid box co-
ordinates were determined according to the co-crystallized ligand (ADPribose) where x, 
y and z values were 29.642, 29.232 and 21.592, respectively. The grid box size was set 
to 32 x 32 x 32 Å, with a grid spacing of 0.375 Å. The receptor was then saved as a 
pdbqt file, and was ready for the virtual screening run. 
The NCI Diversity Set III 1990 compounds’ library was downloaded from the 
NCI website (http://cactus.nci.nih.gov/download/nci/). Compounds were energy 
minimized using the Uff forcefield
267
 embedded within the Open Babel of PyRx 
(Scripps research institute, http://pyrx.sourceforge.net/), with 100,000 steps where the 
minimization stopped when the energy difference was less than 0.001. The minimized 




Autodock Vina was used to dock each compound in the library within the nsP3 
binding site, using an exhaustiveness (number of runs) value of 125. The docked poses 
were then ranked according to the Vina binding energies (Kcal/mol). Top poses ranked 
that achieved better binding energies than the co-crystallized ligand (ADP-ribose), were 
extracted, complexed with the receptor (nsP3). The complexes were then typed with the 
CHARMm forcefield with Discovery Studio 3.5 software (Accelrys Software Inc.: San 
Diego, CA, 2012) to relax the obtained poses within the enzyme pocket, and visualized.  
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9.2.3.2. Re-ranking using Autodock 4 
The Autodock Vina hit list poses (Table 3.1) were extracted as pdbqt files by (ADT). 
The CHIKV nsP3 receptor that was prepared for Autodock Vina was re-used for 
Autodock 4. AutoGrid 4.2 algorithm was used to evaluate the binding energies between 
the inhibitors and the enzyme and to generate the energy maps for the docking run. Fifty 
runs were generated by using Autodock 4.2 Lamarckian genetic algorithm
173
 for the 
searches. Cluster analysis was performed on docked results, with a root-mean-square 
tolerance of 1.0, 2.0 and 3.0 Å, the docked poses were ranked according to the binding 
energies and ligand efficiencies, and finally, the survived lowest energy poses (Table 
3.2) were selected as the resultant complexes with the enzyme. The complexes were 
then typed with the CHARMm forcefield with Discovery Studio 3.5 software (Accelrys 
Software Inc.: San Diego, CA, 2012) to relax the obtained poses within the enzyme 
pocket, and visualized. 
 
9.3. Biological evaluation 
9.3.1. Anti-Chikungunya evaluations  
Currently, the synthetic compounds 114-117, 120, 121, 126, 127, 130, 131, 137, 138, 
140-143 and 145-147, along with the CHIKV nsP2 data base searching hits (Tables 5.3 
and 5.6) are being evaluated for their anti-CHIKV activity including virus-cell-based 
CPE reduction and cytotoxicity assays (with the standard deviations). Testing is being 
conducted at Rega Institute for Medical Research, University of Leuven (KU Leuven), 
Belgium, with Prof. Johan Neyts and Dr. Peiter Leyssen. 
The NCI hits (Table 3.1) are being evaluated against the CHIKV by Professor Suresh 
Mahalingam, Emerging Viruses and Inflammation Research Group, Institute for 
Glycomics, Griffith University, Gold Coast, QLD, Australia, 4222. 
9.3.2. Trypanocidal activity evaluation 
9.3.2.1. Initial screen 
The bis-sulfonamide compounds 160, 170-194 were resuspended in the appropriate 
volume of 100% DMSO to give a stock solution of 21 mM. Initially all compounds 
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were screened at doses of 10.43 µM and 1.4 µM against T. b. brucei, to give an 
indication of the compounds trypanocidal activity. The compounds were screened once 
against two separate trypanosome populations, designated culture A and culture B. 
Compounds with >80% activity at 10.43 µM and >50% activity at 1.4 µM were 
classified as active. Using these selection criteria, active compounds were selected for 
IC50 and selectivity index (SI) determination.  
 
9.3.2.2. Assay controls 
Positive in-plate controls in wells G2-O23 contained 0.417% final DMSO 
concentration. The in-plate controls were used to calculate the activity of compounds 
whilst taking into account any plate-to-plate variability in the signal of the assay.  Two 
types of external control plates were included for each trypanosome population. To 
calculate the assay Z’, a plate containing minimum and maximum assay signals was 
used. For calculation of the minimum signal, or 100% inhibition of cell growth, 36.45 
μM final concentration puromycin was placed in half of the plate. To calculate the 
maximum signal, 0.42% DMSO was placed in the second half of the plate. The Z’ 
prime was 0.57 and 0.72 for culture A and B respectively.  
As a measure of the sensitivity of each assay, a plate containing dose response 
dilutions of the reference compounds pentamidine, diminazene aceturate and puromycin 
was used. Puromycin gave IC50 values of 54.78 nM and 73.69 nM for culture A and B, 
respectively. Pentamidine exhibited an IC50 value of 1.6 nM and 2.44 nM for culture A 
and B respectively. Diminazene aceturate had an IC50 value of 103.8 nM and 155.2 nM. 
9.3.2.3. IC50 and selectivity index determination 
The compounds were screened against T. b. brucei and HEK 293 in 20 point dose CRC 
format. The highest dose of 83.33 μM was only used in the HEK293 assay. This 
allowed the selectivity index of the compounds to be estimated. The compounds were 
screened in duplicate against two separate cultures (designated A and B) of both T. 
brucei and HEK 293. The IC50 and SI was determined for compounds with greater than 
>80% activity at 41.67 μM in the T. b. brucei assay. The SI of the compound was 
determined where possible by directly comparing the IC50 values between the two 
assays. If this was not possible, an estimated IC50 value was calculated by comparing 
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the dose at which the compound was active >50% in the T. brucei assay and the lowest 
dose at which there was no activity (<50%) in the HEK293 assay.  
Assay controls: Positive in-plate controls in column 23 (rows B-O) contained 0.417% 
final DMSO concentration. The in-plate controls were used to calculate the activity of 
compounds whilst taking into account any plate-to-plate variability in the signal of the 
assay. Two types of external control plates were included for each of the two cell 
populations in the T. b. brucei and HEK 293 assay. To calculate the assay Z’, a plate 
containing minimum and maximum assay signals was used. For calculation of the 
minimum signal, or 100% inhibition of cell growth, 36.45 μM final puromycin was 
placed in half of the plate. To calculate the maximum signal, 0.42% DMSO was placed 
in the second half of the plate. The Z’ prime was 0.63 and 0.72 for culture A and B in 
the T. brucei assay respectively. In the HEK 293 assay the Z’ prime was 0.69 for culture 
A and 0.56 for culture B. As a measure of the sensitivity of each assay, a plate 
containing dose response dilutions of the reference compounds pentamidine, 
diminazene aceturate and puromycin was used. In the T. brucei assay Puromycin gave 
IC50 values of 43.6 nM and 47.62 nM for culture A and B, respectively. Pentamidine 
exhibited an IC50 value of 1.58 nM and 1.78 nM for culture A and B respectively. 
Diminazene aceturate had an IC50 value of 94.6 nM and 88.9 nM. In the HEK 293 
assay, Puromycin gave IC50 values of 165.3 nM and 225.7 nM for culture A and B, 
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